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A B S T R A C T
Background
This review is the third update of the Cochrane review “Selenium for preventing cancer”. Selenium is a naturally occurring element
with both nutritional and toxicological properties. Higher selenium exposure and selenium supplements have been suggested to protect
against several types of cancer.
Objectives
To gather and present evidence needed to address two research questions:
1. What is the aetiological relationship between selenium exposure and cancer risk in humans?
2. Describe the efficacy of selenium supplementation for cancer prevention in humans.
Search methods
We updated electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 2), MEDLINE (Ovid,
2013 to January 2017, week 4), and Embase (2013 to 2017, week 6), as well as searches of clinical trial registries.
Selection criteria
We included randomised controlled trials (RCTs) and longitudinal observational studies that enrolled adult participants.
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Data collection and analysis
We performed random-effects (RE) meta-analyses when two or more RCTs were available for a specific outcome. We conducted RE
meta-analyses when five or more observational studies were available for a specific outcome. We assessed risk of bias in RCTs and in
observational studies using Cochrane’s risk assessment tool and the Newcastle-Ottawa Scale, respectively.We considered in the primary
analysis data pooled from RCTs with low risk of bias. We assessed the certainty of evidence by using the GRADE approach.
Main results
We included 83 studies in this updated review: two additional RCTs (10 in total) and a few additional trial reports for previously
included studies. RCTs involved 27,232 participants allocated to either selenium supplements or placebo. For analyses of RCTs with
low risk of bias, the summary risk ratio (RR) for any cancer incidence was 1.01 (95% confidence interval (CI) 0.93 to 1.10; 3 studies,
19,475 participants; high-certainty evidence). The RR for estimated cancer mortality was 1.02 (95% CI 0.80 to 1.30; 1 study, 17,444
participants). For the most frequently investigated site-specific cancers, investigators provided little evidence of any effect of selenium
supplementation. Two RCTs with 19,009 participants indicated that colorectal cancer was unaffected by selenium administration (RR
0.99, 95% CI 0.69 to 1.43), as were non-melanoma skin cancer (RR 1.16, 95% CI 0.30 to 4.42; 2 studies, 2027 participants), lung
cancer (RR 1.16, 95% CI 0.89 to 1.50; 2 studies, 19,009 participants), breast cancer (RR 2.04, 95% CI 0.44 to 9.55; 1 study, 802
participants), bladder cancer (RR 1.07, 95% CI 0.76 to 1.52; 2 studies, 19,009 participants), and prostate cancer (RR 1.01, 95% CI
0.90 to 1.14; 4 studies, 18,942 participants). Certainty of the evidence was high for all of these cancer sites, except for breast cancer,
which was of moderate certainty owing to imprecision, and non-melanoma skin cancer, which we judged as moderate certainty owing
to high heterogeneity. RCTs with low risk of bias suggested increased melanoma risk.
Results for most outcomes were similar when we included all RCTs in the meta-analysis, regardless of risk of bias. Selenium supple-
mentation did not reduce overall cancer incidence (RR 0.99, 95% CI 0.86 to 1.14; 5 studies, 21,860 participants) nor mortality (RR
0.81, 95% CI 0.49 to 1.32; 2 studies, 18,698 participants). Summary RRs for site-specific cancers showed limited changes compared
with estimates from high-quality studies alone, except for liver cancer, for which results were reversed.
In the largest trial, the Selenium and Vitamin E Cancer Trial, selenium supplementation increased risks of alopecia and dermatitis,
and for participants with highest background selenium status, supplementation also increased risk of high-grade prostate cancer. RCTs
showed a slightly increased risk of type 2 diabetes associated with supplementation. A hypothesis generated by theNutritional Prevention
of Cancer Trial - that individuals with low blood selenium levels could reduce their risk of cancer (particularly prostate cancer) by
increasing selenium intake - has not been confirmed. As RCT participants have been overwhelmingly male (88%), we could not assess
the potential influence of sex or gender.
We included 15 additional observational cohort studies (70 in total; over 2,360,000 participants). We found that lower cancer incidence
(summary odds ratio (OR) 0.72, 95% CI 0.55 to 0.93; 7 studies, 76,239 participants) and lower cancer mortality (OR 0.76, 95%
CI 0.59 to 0.97; 7 studies, 183,863 participants) were associated with the highest category of selenium exposure compared with the
lowest. Cancer incidence was lower in men (OR 0.72, 95% CI 0.46 to 1.14, 4 studies, 29,365 men) than in women (OR 0.90,
95% CI 0.45 to 1.77, 2 studies, 18,244 women). Data show a decrease in risk of site-specific cancers for stomach, colorectal, lung,
breast, bladder, and prostate cancers. However, these studies have major weaknesses due to study design, exposure misclassification,
and potential unmeasured confounding due to lifestyle or nutritional factors covarying with selenium exposure beyond those taken
into account in multi-variable analyses. In addition, no evidence of a dose-response relation between selenium status and cancer risk
emerged. Certainty of evidence was very low for each outcome. Some studies suggested that genetic factors might modify the relation
between selenium and cancer risk - an issue that merits further investigation.
Authors’ conclusions
Well-designed andwell-conducted RCTs have shown no beneficial effect of selenium supplements in reducing cancer risk (high certainty
of evidence). Some RCTs have raised concerns by reporting a higher incidence of high-grade prostate cancer and type 2 diabetes in
participants with selenium supplementation. No clear evidence of an influence of baseline participant selenium status on outcomes has
emerged in these studies.
Observational longitudinal studies have shown an inverse association between selenium exposure and risk of some cancer types, but null
and direct relations have also been reported, and no systematic pattern suggesting dose-response relations has emerged. These studies
suffer from limitations inherent to the observational design, including exposure misclassification and unmeasured confounding.
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Overall, there is no evidence to suggest that increasing selenium intake through diet or supplementation prevents cancer in humans.
However, more research is needed to assess whether selenium may modify the risk of cancer in individuals with a specific genetic
background or nutritional status, and to investigate possible differential effects of various forms of selenium.
P L A I N L A N G U A G E S U M M A R Y
Selenium for preventing cancer
Review question
We reviewed the evidence investigating the relation between selenium intake and cancer prevention. This review updates the most
recent Cochrane review on this topic (Vinceti 2014), which was an update of Dennert 2011.
Background
Selenium is a naturally occurring element that individuals are exposed to mainly through food consumption, although exposure can
also occur through air, drinking water, and dietary supplements. Small amounts of selenium are essential for certain biological functions
in humans, but slightly higher amounts can pose a toxicity risk, making selenium an element with a narrow, but as yet not well-defined,
safe range of exposure. Selenium occurs in many different chemical forms with different biological activity. From the late 1960s, a few
observational studies reported that people with high levels of selenium in their diet or in their body tissues had lower risk of cancer,
and some laboratory studies showed that selenium could inhibit the growth of cancer cells. This led to widespread interest in selenium
supplements and claims that taking such supplements could prevent cancer. Since that time, many more observational studies have
been conducted to compare cancer rates among individuals with high and low selenium exposure. More recently, several randomised
controlled trials designed to assess whether selenium supplementation can prevent cancer have been carried out. These trials played a
major role in enhancing our understanding of the relation between selenium and cancer risk as a result of their stronger study design
as compared with observational studies. The most recent trials in particular have shown high methodological quality and statistical
power. Several trials focused on whether selenium could prevent prostate cancer.
Study characteristics
This review includes 10 trials in which adults were randomly assigned to receive selenium supplements or placebo, and 70 observational
studies in which adults were followed over time to determine whether their baseline selenium status was associated with their risk of
cancer. The evidence is current to January 2017.
Key results
All of the high-quality randomised trials reported no effect of selenium on reducing overall risk of cancer or risk of particular cancers,
including the most investigated outcome - prostate cancer. Some trials unexpectedly suggested that selenium may increase risks of high-
grade prostate cancer, type 2 diabetes, and dermatological abnormalities.
Observational studies have yielded inconsistent evidence of a possible effect of selenium exposure on cancer risk, with no evidence of a
dose-response relation. When we pooled results of these studies, overall they suggested an inverse relation between cancer exposure and
subsequent incidence of any cancer or some specific cancers, such as colon and prostate cancer. However, observational studies have
major weaknesses. The selenium exposure status of participants could have been misclassified owing to limitations of the indicators of
selenium exposure used, as well as to uncertainty regarding the particular selenium species contributing to overall exposure. In addition,
unmeasured confounding from lifestyle or nutritional factors - a major and well-known source of bias in nutritional epidemiology
studies of observational design - could have been present. Therefore, the internal validity of these studies is limited.
Currently, the hypothesis that increasing selenium intakemay reduce cancer risk is not supported by epidemiological evidence. Additional
research is needed to assess whether seleniummay affect the risk of cancer in individuals with specific genetic backgrounds or nutritional
status, and to determine how the various chemical forms of selenium compounds may have different effects on cancer risk.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Highest compared with lowest selenium exposure for preventing cancer in randomised controlled studies with low risk of bias
Patient or population: Part icipants in trials with low risk of bias
Setting: out-pat ient
Intervention: highest selenium exposure
Comparison: lowest selenium exposure
Outcomes Relative effect
(95% CI)
Anticipated absolute effects* (95% CI) Quality of the evidence
(GRADE)
Comments
Without highest With highest Difference
Any cancer risk
No. of part icipants: 19,
475
(3 RCTs)
RR 1.01
(0.93 to 1.10)
Study populat ion ⊕⊕⊕⊕
HIGH
SELECT study had the
strongest inf luence on
the ef fect est imate. The
RR in all RCTs is 0.99
(95%CI 0.86 to 1.14)
10.0% 10.1%
(9.3 to 11.0)
0.1%more
(0.7 fewer to 1 more)
Colorectal cancer risk
No. of part icipants: 19,
009
(2 RCTs)
RR 0.99
(0.69 to 1.43)
Study populat ion ⊕⊕⊕⊕
HIGH
SELECT study had the
strongest inf luence on
the ef fect est imate. The
RR in all RCTs is 0.74
(95%CI 0.41 to 1.33)
0.7% 0.7%
(0.5 to 1.0)
0.0% fewer
(0.2 fewer to 0.3 more)
Non-melanoma skin
cancer risk
No. of part icipants:
2027
(2 RCTs)
RR 1.16
(0.30 to 4.42)
Study populat ion ⊕⊕⊕©
MODERATEa
Pooled est imate is im-
precise owing to high
heterogeneity. The RR in
all RCTs is 1.23 (95% CI
0.73 to 2.08)
2.9% 3.4%
(0.9 to 12.9)
0.5%more
(2 fewer to 10 more)
Lung cancer risk
No. of part icipants: 19,
009
(2 RCTs)
RR 1.16
(0.89 to 1.50)
Study populat ion ⊕⊕⊕⊕
HIGH
The RR in all RCTs is 1.
03 (95%CI 0.78 to 1.37).
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1.0% 1.2%
(0.9 to 1.5)
0.2%more
(0.1 fewer to 0.5 more)
Breast cancer risk
No. of part icipants: 802
(1 RCT)
RR 2.04
(0.44 to 9.55)
Study populat ion ⊕⊕⊕©
MODERATEb
The RR in all RCTs is 1.
44 (95%CI 0.96 to 2.17).
0.7% 1.5%
(0.3 to 7.0)
0.8%more
(0.4 fewer to 6.3 more)
Bladder cancer risk
No. of part icipants: 19,
009
(2 RCTs)
RR 1.07
(0.76 to 1.52)
Study populat ion ⊕⊕⊕⊕
HIGH
SELECT study had the
strongest inf luence on
the ef fect est imate. The
RR in all RCTs is 1.10
(95%CI 0.79 to 1.52)
0.6% 0.7%
(0.5 to 1.0)
0.0% fewer
(0.2 fewer to 0.3 more)
Prostate cancer risk
No. of part icipants: 18,
942
(4 RCTs)
RR 1.01
(0.90 to 1.14)
Study populat ion ⊕⊕⊕⊕
HIGH
SELECT study had the
strongest inf luence on
the ef fect est imate. The
RR in all RCTs is 0.91
(95%CI 0.75 to 1.12)
5.4% 5.4%
(4.8 to 6.1)
0.1%more
(0.5 fewer to 0.8 more)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; OR: odds rat io; RCT: randomised controlled trial; RR: risk rat io; SELECT: Selenium and Vitamin E Cancer Prevent ion Trial
GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded one level for moderate heterogeneity (tau² = 0.69, I² = 72%, P = 0.06) not explained.
bDowngraded one level owing to imprecision.
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B A C K G R O U N D
This review is the third update of the Cochrane review titled “Se-
lenium for preventing cancer” (Dennert 2011; Vinceti 2014).
Description of the condition
Cancer is a leading cause of death worldwide (WHO 2017). Ac-
cording to estimates of the International Agency for Cancer Re-
search, 14.1 million people developed and 8.2million died of can-
cer in 2012, and more than half of all new cases occurred in less
developed regions of the world (IARC 2014).
The role of diet and nutrition in carcinogenesis and cancer preven-
tion and the identification of nutritional factors and supplements
with cancer preventive properties have been areas of active research
for decades. Dietary factors that reduce cancer risk would clearly
have major public health implications, but unfortunately, investi-
gations into supplementation of various vitamins, trace elements,
and other dietary constituents have typically yielded disappoint-
ing and even troubling results (Bjelakovic 2014; Fortmann 2013;
Guallar 2013; Rocourt 2013; Schwingshackl 2017). Selenium is
one of these nutritional factors (Vinceti 2013b).
Description of the intervention
The element selenium has received considerable attention as a po-
tential cancer preventive agent, at least in populations with low
intake. Selenium is recognised as nutritionally essential for hu-
mans, but it is toxic at levels slightly higher than those required
for health, with a narrow and still not well-defined safe range of
intake (Jablonska 2015a; Vinceti 2017a). Whether selenium pro-
vides various health benefits (including a cancer preventive effect)
beyond its essential nutritional role continues to be a matter of
debate (Allingstrup 2015; Bodnar 2012; Brigelius-Flohe 2017;
Fortmann 2013; Karp 2013; Lippman 2009, in: SELECT 2009;
Rayman 2012; Stranges 2010; Vinceti 2013a; Vinceti 2013b;
Vinceti 2014a; Vinceti 2017a; Visser 2017;Wichman 2016). Hu-
mans usually ingest this trace element with crop, animal products,
fish, and seafood, and sometimes in supplements (Hurst 2013a;
Vinceti 2017a).
Chemical forms and concentrations of selenium in environmen-
tal matrices, foods, drinking water, and other sources of exposure
vary considerably (Fairweather-Tait 2011). Selenium species can
be classified into organically bound selenium forms (e.g. selenome-
thionine, selenocysteine) and inorganic forms (e.g. selenate, selen-
ite) (Gammelgaard 2011; Weekley 2013). Organically bound se-
lenium is present in the large number of selenoproteins identified
in living organisms including humans, although the exact activity
of some of these proteins remains to be identified (Brigelius-Flohe
2017; Hatfield 2014; Labunskyy 2014). Selenium yeast refers to
a selenium-enriched yeast medium that usually contains selenium
that is almost entirely organically bound, along with a high pro-
portion of selenomethionine (Block 2004; Rayman 2004).
Recommended intake of selenium varies considerably among
different regulatory agencies and scientific authorities (Vinceti
2017a). For example, the USA Institute of Medicine recommends
daily intake of 55 µg/d for adults (Institute of Medicine 2009),
whereas the World Health Organization (WHO) recommends
amounts ranging from 25 to 34 µg/d, depending on age and sex
(WHO 2004). More generally, international bodies have recom-
mended amounts ranging from 25 to 70 µg/d for the adult pop-
ulation (Vinceti 2017a). The main reason for these differences in
recommendations is the differing value and weight given to the
proteomic effects of selenium, in particular whether or not seleno-
proteins sensitive to selenium supply must be up regulated to their
maximal level, and whether any adverse health effects may arise
at lower selenium intakes than those required to maximise seleno-
protein expression (Jablonska 2015a; Vinceti 2017a). In addition,
these standards generally do not take into account the chemical
forms nor the source of selenium (diet, drinking water, air, etc.),
despite established relevance of selenium speciation in addressing
and assessing the health effects of this element (Vinceti 2013a;
Vinceti 2013c; Weekley 2013; Vinceti 2017d).
To prevent adverse effects due to excessive selenium intake, the
USA Institute ofMedicine has set the tolerable upper intake level at
400 µg/d for adults (Office of Dietary Supplements 2009). How-
ever, recent epidemiological studies suggest overt human toxicity
at lower intake levels (Lippman 2009, in: SELECT 2009; Stranges
2007; Vinceti 2017a), and lower upper safe levels have already
been proposed (Tsubota-Utsugi 2012). In addition to the acute
and chronic toxicity of high selenium exposure, possible harmful
effects of long-term overexposure to lower dosages have been a
matter of concern. However, these effects, such as those affecting
the endocrine system, remain inadequately investigated (Vinceti
2001; Vinceti 2017a). Furthermore, evidence shows different bi-
ological activities of the various organic and inorganic forms of
selenium (Hazane-Puch 2013; Mandrioli 2017; Vinceti 2013c;
Vinceti 2017d; Weekley 2013), emphasising the need to better
characterise the specific toxicological and nutritional properties of
each selenium species in humans, in animals, and in the environ-
ment. Recent publications have questioned the adequacy of the
current upper safe limit of intake (Jablonska 2015a; Jerome-Morais
2011;Marschall 2017;Morris 2013;Moyad 2012; Rocourt 2013;
Sacco 2013; Vinceti 2013b; Vinceti 2017a) and have espoused
the need to set different limits for the many different sources of
organic and inorganic selenium. On the other hand, other inves-
tigators have described claims of widespread deficient intake of
selenium (Hughes 2016).
Accurate estimation of selenium exposure in epidemiological stud-
ies presents several challenges. Individual exposure is typically as-
sessed by using peripheral biomarkers of exposure, such as blood
(usually plasma or serum) or nail concentrations, or by estimating
dietary intake (Ashton 2009). Each of these methods has strengths
6Selenium for preventing cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
and limitations and has had its validity questioned (Ashton 2009;
Haldimann 1996; Vinceti 2013b). However, levels of selenium
in peripheral biomarkers such as blood, toenail, and hair have
been found to correlate to a moderate degree with dietary intake
as assessed through self-reported consumption of supplements,
food frequency questionnaires, and dietary records (Hurst 2013a;
Longnecker 1996; Ovaskainen 1993; Pestitschek 2013; van den
Brandt 1993). Stronger correlation has been seen at high intake
levels (Morris 2013), although results of some studies were not
consistent (Hunter 1990; Karita 2003; Satia 2006; Vinceti 2012).
Assessment of selenium levels in specific body tissues is extremely
complex, as these levels are not necessarily homogeneously re-
flected by all biomarkers because overall selenium exposure, as well
as its chemical forms and other factors, influences distribution
of the metalloid into various body compartments (Behne 1996;
Behne 2010; Panter 1996; Vinceti 2000; Vinceti 2013c). For ex-
ample, circulating levels of some selenium species and of total
selenium did not correlate with selenium content in the central
nervous system as assessed by cerebrospinal fluid concentrations
(Solovyev 2013; Vinceti 2013c), indicating both the tissue-spe-
cific significance of biomarkers and the importance of selenium
speciation when the distribution of selenium in different body
compartments, representing target organs for different diseases, is
assessed.
Selenium levels found in human specimens and characterising in-
take of selenium show high global variability due to variation in
factors such as dietary habits, food and soil selenium content,
ethnicity, sex, age, individual metabolism, occupational exposure,
exposure to coal and other sources of combustion, and smok-
ing (Fairweather-Tait 2011; Haldimann 1996; Jablonska 2013;
Rayman 2008). It is interesting to note that smoking tends to
lower selenium biomarker concentrations, even though smoking
is a source of selenium exposure - a phenomenon that might be
related to increased excretion of the metalloid due to interaction
with cadmium or other heavy metals (Jossa 1991; Kafai 2003).
Globally, inconsistencies have been noted as to how these fac-
tors are associated with selenium levels (Haldimann 1996; Vinceti
2000). For example, selenium levels increased with age in women,
but not in men, in the French SU.VI.M.AX cohort study (Arnaud
2007), but decreased with age in a female population in Ohio
(Smith 2000); however, two studies in Switzerland and Austria
could not find an association between age and selenium status
among individuals of either sex (Burri 2008; Gundacker 2006).
Sex-specific nutritional and health behaviours, as well as sex-spe-
cific differences in selenium metabolism and distribution across
various body compartments, may contribute to observed discrep-
ancies in selenium levels between men and women (Combs 2012;
Rodriguez 1995).
How the intervention might work
The ability of selenium to counteract cancer cell growth as ob-
served in a large number of laboratory studies may be due to its
effects on DNA stability, cell proliferation, necrotic and apoptotic
cell death in healthy and malignant cells, and/or regulation of ox-
idative stress and the immune system (for reviews, see: Fernandes
2015; Misra 2015). These abilities have suggested the possible
utility of selenium compounds not only for cancer prevention but
also for cancer therapy - a hypothesis that has been under active
investigation (Bhattacharjee 2017; Shigemi 2017; Vinceti 2017b).
Selenium may be involved in cancer prevention through the an-
tioxidant properties of selenoproteins (Hatfield 2014; Labunskyy
2014), as well as through several other mechanisms (Fernandes
2015; Misra 2015; Weekley 2013). However, laboratory studies
have shown that selenium can promote malignant cell transforma-
tion and progression (Chen 2000; Kandas 2009; Kasaikina 2013;
National Toxicology Program 2011; Novoselov 2005; Rose 2014;
Su 2005; Tsuji 2015), thus confirming the complex ‘dual person-
ality’ of both this Janus-faced element and selenoproteins in pre-
venting and promoting cancer (Hatfield 2014).
In addition, numerous epidemiological studies of observational
design, which have reported an inverse association between sele-
nium exposure and cancer risk (Vinceti 2017b), have provided
support for the potential of selenium in cancer prevention. The
first of these studies used an ecological study design (Schrauzer
1977; Shamberger 1969). These were followed by case-control and
cohort observational studies, then by randomised trials, some of
which received substantial attention from both the general public
and the scientific community (Brinkman 2006; Fortmann 2013;
Steinbrenner 2013; Vinceti 2013b). Some observational and ex-
perimental human studies have suggested that sex-related differ-
ences regarding effects of selenium on cancer risk, as well as differ-
ences in selenium tissue distribution, tumour biology, and other
factors, may explain the possibly greater beneficial effect of sele-
nium formen than for women in the earliest studies (NPCT2002;
Waters 2004).
Why it is important to do this review
Findings of laboratory studies and early epidemiological studies
have led to the suggestion that seleniummay be involved in central
anticarcinogenic processes. This has resulted in widespread mar-
keting of selenium supplements with associated health claims, par-
ticularly claims for prevention of cancer (Dennert 2011; Vinceti
2013b), aswell as preventionof cardiovascular disease (Rees 2013).
However, accumulating evidence suggests that this early optimism
may have been unwarranted (Kryscio 2017; Lance 2017; Lu 2016;
Ramamoorthy 2015; Vinceti 2017a; Vinceti 2017b). In partic-
ular, additional evidence on selenium and cancer risk gathered
by high-quality randomised controlled trials (RCTs) has become
available in recent years, and a few observational studies have been
published, thus justifying an update on epidemiological evidence
regarding selenium exposure and cancer risk. We undertook this
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updated review to perform a comprehensive synthesis of current
epidemiological evidence.
O B J E C T I V E S
To gather and present evidence needed to address two research
questions:.
1. What is the aetiological relationship between selenium
exposure and cancer risk in humans?
2. Which is the efficacy of selenium supplementation for
cancer prevention in humans?
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included published randomised controlled trials (RCTs) and
observational studies of longitudinal design (i.e. cohort studies
and nested case-control studies), irrespective of publication status
or language, provided they were published in extenso. We also
included conference abstracts in this review when we were able to
retrieve them through citation chasing (Vinceti 2017c).
Types of participants
Adult participants (18 years of age and older).
Types of interventions
We considered RCTs for inclusion if they used selenium supple-
mentation at any dose or route of administration for a minimum
of four weeks versus placebo or no intervention. We excluded tri-
als using selenium supplementation as part of a multi-component
preparation if they did not include a study arm using selenium
monotherapy supplementation.
We considered prospective observational studies (cohort studies
and cohort-nested and nested case-control studies) for inclusion if
they assessed baseline exposure to selenium in apparently cancer-
free individuals as a biomarker of selenium status or as dietary
assessment of selenium intake at study entry, provided that such
assessment was based on exposure categories - not just on contin-
uous values.
Types of outcome measures
We systematically analysed all (primary and secondary) outcomes.
Primary outcomes
1. Incidence of any cancer and of site-specific cancers, assessed
as proportions of participants developing cancers during the
study period.
2. Mortality from any cancer and from site-specific cancer,
assessed as proportions of participants dying from cancers during
the study period.
Secondary outcomes
1. Incidence of selected adverse effects, assessed as proportions
of participants developing adverse health conditions (RCTs
only).
Search methods for identification of studies
Using the search strategies described previously, we conducted
updated electronic searches of the Cochrane Central Register of
Controlled Trials (CENTRAL; 2017, Issue 2), MEDLINE (Ovid,
2013 to January 2017, week 4), Embase (2013 to 2017, week 6),
CancerLit (cancer literature database; February 2004), and Clin-
ical Contents in Medicine (CCMed; February 2011). We con-
ducted the initial search in 2004 andupdated searches in July 2007,
January 2009, October 2009, February 2011, February 2013, and
February 2017. AsMEDLINE now includes the journals indexed
in CancerLit no further searches of this database were made after
2004.
We also searched the following online clinical trials databases as
in the previous review Vinceti 2014.
1. Clinical Trials of the American Cancer Society (http://
www.cancer.gov; February 2011).
2. metaRegister of Controlled Trials (http://www.controlled-
trials.com; February 2011).
3. German Cancer Study Register (http://www.studien.de;
February 2011).
4. System for Information on Grey Literature in Europe
(SIGLE) (February 2004, discontinued in 2005).
5. International Standard Registered Clinical/Social Study
Number (ISRCTN) registry (http://www.isrctn.com; February
2017).
6. ClinicalTrials.gov registry (https://clinicaltrials.gov;
February 2017).
We have provided the search strategies in Appendix 1.
Data collection and analysis
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Selection of studies
Two review authors independently checked all electronic search
results for eligibility. When search results could not be rejected
with certainty on the basis of title, abstract, or both, we obtained
full-text material.
We scanned bibliographies of papers retrieved using the described
search strategy to identify additional studies. When additional
information was needed, we contacted the correspondent authors
of included studies; we also asked investigators for information
about unpublished RCTs.
Two review authors (MV and TF) independently applied the in-
clusion and exclusion criteria, if necessary with the assistance of
a translator. We resolved disagreements by discussion and with
involvement of a third review author (CDG).
Data extraction and management
We used piloted extraction forms for epidemiological studies and
RCTs to document data from the original material and to assess
the quality of studies. One review author (TF) extracted data,
and two review authors (MV and CDG) checked extracted data
for discrepancies, which the three review authors (TF, MV, and
CDG) then discussed. If several reports from the same study were
available, we considered as primary publications studies reporting
the entire period of follow-up with active selenium supplementa-
tion, when available, but we also extracted study details and results
available from other publications, if they were not reported in the
primary study reference.
For comparison of selenium exposure measured in serum and
plasma specimens, we converted all data into the unit µg/L. We
converted results provided as ppm (parts per million) or µg/g by
using the factor 1.026 g/mL (density of blood plasma), and we
converted data provided as µmol/L using the factor 78.96 (atomic
weight of selenium).
For inclusion, prospective observational studies had to report es-
timates of risk ratio (RR), such as hazard ratio (HR) or odds ratio
(OR), for various selenium category exposure levels. We did not
include in the analysis studies reporting only the RR for a one-
unit increase in selenium exposure on a continuous scale.
Assessment of risk of bias in included studies
Randomised controlled trials
We categorised generation of allocation sequence, allocation con-
cealment, blinding, and completeness of outcome data as adequate
(low risk of bias), inadequate (high risk of bias), or unclear, accord-
ing to the criteria specified in theCochraneHandbook for Systematic
Reviews of Interventions and Higgins et al (Higgins 2011a; Higgins
2011b). We considered these four items to be key domains for risk
of bias assessment. We considered studies that were categorised as
’adequate’ in all four domains to have low risk of bias; and studies
with ’inadequate’ procedures in one or more key domains to have
high risk of bias. We considered studies with ’unclear’ procedures
in one or more key domains to have unclear risk of bias.
We assessed fulfilment of ethical standards as follows.
1. Was informed consent obtained from participants? (yes/no/
unclear).
2. Was approval obtained from an ethics board? (yes/no/
unclear).
Observational studies
Weassessed risk of bias in observational studies by using assessment
forms adapted from the Newcastle-Ottawa Quality Assessment
Scale (NOS) for cohort and case-control studies (Wells 2004).We
used the NOS form for cohort studies for all included observa-
tional studies, and the NOS case-control form for nested case-
control studies. Both forms must be adapted a priori for use in
a systematic review according to the research questions examined
and the review topic explored. The NOS uses a star system by
which studies are judged on key domains pertaining to selection
and comparability of study groups, ascertainment of exposure and
outcomes, and duration of follow-up. For each domain, we as-
signed either a ’star’ or ’no star’, with a star indicating that study
design element was considered adequate and was less likely to in-
troduce bias. A study could receive a maximum of nine stars dur-
ing the cohort assessment (Appendix 2) and nine stars during as-
sessment of the case-control portion (Appendix 3).
The risk of bias assessment was based on data provided in the
included publications. When relevant data for such assessment
were missing, we tried to contact the trial authors to ask that they
provide them.
Measures of treatment effect
This review includes only the binary outcome of cancer diagnosis
(i.e. cancer incidence) or death from cancer (i.e. cancer mortality),
or a combination of both. We used the term ’cancer risk’ in this
paper as a generic term that refers generally to cancer incidence,
cancer mortality, and combined incidence/mortality data.
For RCTs, we used risk ratios (RRs) and their 95% confidence
intervals (95% CIs). When hazard ratios (HRs) rather than RRs
were reported in the original study, we reported individual study
results as HRs along with their 95% CIs.
For observational studies, we used odds ratios (ORs), risk ratios
(RRs), or hazard ratios (HRs) and their corresponding 95% CIs
as measures of association between cancer risk and selenium expo-
sure. When adjusted estimates were reported, we used those with
the most extensive covariate adjustment reported in the publica-
tion.
Dealing with missing data
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When data were missing or when discrepancies in study publica-
tions were found, we tried to contact the study investigators to re-
quest further information. In most cases, review authors resolved
the issues through collaboration; when no reply came from the
trial authors, we did not use the corresponding data.
When a study combined subgroups, only some of which fulfilled
our eligibility criteria (e.g. including individuals not affected by
cancer), or did not report enough information to be included in
this update, we systematically contacted trial authors to ask that
they provide the additional information. We are grateful to the
several trial authors who agreed to provide these additional data.
Assessment of heterogeneity
Weused theChi² test for heterogeneity and I² statistics to quantify
heterogeneity of study results (Higgins 2003).
Assessment of reporting biases
We evaluated the possibility of reporting bias by using funnel plots.
Data synthesis
We performed data synthesis and analysis separately for RCTs and
observational studies.
For RCTs, we performed meta-analyses for all cancers or site-spe-
cific cancers when at least two trials could provide data, given
their fundamental importance in epidemiological research. When
more than one publication from the same trial was available and
reported different periods of follow-up for the same cancer site, we
included in themeta-analysis only the longest period of follow-up,
provided that the experimental protocol was ongoing at the time
of follow-up (i.e. that selenium supplementation was still actively
supplied).We assessed the stability of effect estimates through their
95% or 99% confidence intervals. We included lack of precision
of effect estimates among the factors used to downgrade the cer-
tainty (quality) of evidence generated by studies via the GRADE
approach (www.gradeworkinggroup.org). For RCTs, we consid-
ered pooled data from studies with low risk of bias as the primary
analysis.
For observational studies, the minimum number of studies for
inclusion in the meta-analysis was five, as in the previous version
of the review. We applied this latter restriction not only to limit
the number of analyses performed, but also because results were
largely expected to be heterogeneous, and heterogeneity cannot be
described and quantified adequately if too few studies are available
(Higgins 2009).
We calculated RRs and 95% CIs using numbers of participants
and cases when these were provided in the publication and the
meta-analysis tool provided by Review Manager 2014; otherwise,
we used RRs reported in the original publication, and, in partic-
ular, we selected RRs with the least adjustment for potential con-
founders. We used the same approach in calculating the RRs of
adverse outcomes. We conducted random-effects meta-analyses of
summary statistics for both observational studies and RCTs. For
observational studies, we used the OR or RR comparing highest
and lowest selenium exposure categories. We entered effect esti-
mates as the natural logarithm of the OR or RR, and we used the
squared standard error of the natural logarithm of theOR or RR as
a weight. We calculated the latter from reported upper and lower
boundaries of the 95% CI of the OR or RR. If a 95% CI was not
reported, we used the total number of cases and the total number
of controls, as well as the number of categories of selenium expo-
sure, to estimate numbers of cases and controls per exposure cat-
egory. We then used the standard normal approximation formula
to calculate the standard error of the OR, comparing the highest
versus the lowest exposure category (lnOR = (1/a + 1/b + 1/c +
1/d), where a, b, c, and d are the four counts needed to calculate
the OR via (a*d)/(b*c)). For experimental studies, we computed
the RR of cancer in the intervention group compared with that in
the placebo group. For one study, which included more than one
treatment (Algotar 2013), we used only results for the lowest dose
(200 µg/d) for consistency with other studies. We conducted all
meta-analyses by using Review Manager 5.3.5 and Stata-15 statis-
tical tools. To do this, we copied logarithmic data for the OR and
the standard error from Stata into Review Manager, then double-
checked results for errors.
Subgroup analysis and investigation of heterogeneity
We carried out a subgroup meta-analysis for high-quality RCTs
while excluding from analysis all trials showing high or uncertain
risk of bias.
For observational studies, we used sex-disaggregated data from
mixed-sex studies, together with data from single-sex cohorts, to
conduct subgroup analyses by sex. We also carried out subgroup
analyses specific for baseline selenium status. For these analyses,
we assessed the evidence for an exposure-response relation by ex-
amining studies in ascending order from the bottom category of
selenium exposure and by examining differences between highest
and lowest exposure categories.
Sensitivity analysis
For RCTs, we considered risk estimates derived by pooling data
from all studies, regardless of risk of bias, as part of a sensitivity
analysis.
For observational studies, we conducted sensitivity analyses to as-
sess the effects of different methods used to assess selenium sta-
tus (i.e. assessment of intake via dietary assessment methods or
measurement of exposure biomarkers such as blood and toenail
selenium content).
’Summary of findings’ table
We presented the overall certainty (quality) of evidence for the
risk of any cancer, colorectal cancer, lung cancer, non-melanoma
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skin cancer, breast cancer, bladder cancer, and prostate cancer from
RCTs with low risk of bias. We also presented the overall certainty
of evidence for these outcomes from observational studies, with
the exception of non-melanoma skin cancer.
We evaluated the overall certainty of evidence according to the
Grading of Recommendations Assessment, Development and
Evaluation (GRADE) approach (GRADEWorking Group 2004),
which takes into account issues related not only to internal validity
(risk of bias, inconsistency, imprecision, publication bias) but also
to external validity, such as directness of results (Langendam 2013).
We created two ’Summary of findings’ tables (Summary of findings
for the main comparison; Summary of findings 2) while adhering
to the methods described in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011a) and using GRADEpro
GDT We used the GRADE checklist and GRADE Working
Group certainty (quality) of evidence definitions (Meader 2014),
as follows.
• High quality:We are very confident that the true effect lies
close to that of the estimate of the effect.
• Moderate quality: We are moderately confident in the
effect estimate: The true effect is likely to be close to the estimate
of the effect, but there is a possibility that it is substantially
different.
• Low quality: Our confidence in the effect estimate is
limited: The true effect may be substantially different from the
estimate of the effect.
• Very low quality:We have very little confidence in the
effect estimate: The true effect is likely to be substantially
different from the estimate of effect.
When possible, for each outcome in RCTs, we based the assumed
risk in the control group on the proportion of events in the in-
cluded studies. In accordance with GRADEmethodological crite-
ria, we based our assessment of the certainty (quality) of evidence
on RCTs with low risk of bias (Guyatt 2011). We downgraded
the evidence from ’high’ quality by one level for serious (or by
two levels for very serious) concerns regarding each of the validity
issues.
R E S U L T S
Description of studies
Citation style: Please note that we reference the sources of relevant
information in a certain way to enhance traceability of our results
for interested readers. When the source of information is not the
primary publication of an included study, we also reference the
specific publication of interest. For example “Hakama 1990, in:
Knekt 1990” indicates that the cited paper is “Hakama 1990” as
part of the mentioned study.
We could not access three full-text theses published in the United
States (Coates 1987, in: Coates 1988; Menkes 1986a, in: Menkes
1986; Schober 1986, in: Menkes 1986). However, later journal
publications were available, and we included them in this review as
main study publications (Coates 1988, in: Coates 1988; Menkes
1986b, in: Menkes 1986; Schober 1987, in: Menkes 1986). Thus
we considered retrieval of the full-text theses to be unnecessary.
Results of the search
In the previous Cochrane review, of 4082 hits of potential rele-
vance, we retrieved 268 publications in full text. Of these, we con-
sidered 137 papers as relevant (see the flow chart of the literature
search in Dennert 2011).
In our first updated search, after we excluded internal duplicates
and duplicates against the database of the literature search con-
ducted in January 2011, we retrieved 766 hits. Of these, we ex-
cluded 744 references as clearly irrelevant on the basis of title and
abstract review (see the flow chart of the literature search in Vinceti
2014).
In the second updated search process, conducted in February
2017, including online database searches and searches within grey
literature, study references, and trial databases, we identified 859
newhits after de-duplication.Of these, we excluded 831 references
as clearly irrelevant on the basis of the title and abstract review (see
the flow chart of the literature search in Figure 1). We considered
the remaining 28 publications of possible relevance and re-evalu-
ated and retrieved them in full text from this updated search.Upon
further review, we considered 20 of these publications relevant.
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Figure 1. Flow chart.
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Included studies
In total, from the previous Cochrane review and from our updates,
we identified 168 papers for inclusion in this review: 105 papers
referred to 70 completed observational studies, and 63 papers re-
ferred to one ongoing and 10 completed RCTs (Figure 1). (The
previous version of the review was based on 148 papers; 89 referred
to one ongoing and 55 completed observational studies, and 59
papers referred to four ongoing and eight completed RCTs.)
We have provided a detailed description of the included studies in
the Characteristics of included studies table.
Randomised controlled trials
We included in this review 11 randomised controlled trials (RCTs)
with a total of 44,743 participants (94% men). All used parallel-
group designs with two arms (Dreno 2007; Karp 2013; Li 2000;
Lubinski 2011;Marshall 2011;NPCT2002; Reid 2008; Yu 1991;
Yu 1997), three arms (Algotar 2013), or four arms (SELECT
2009). Three were conducted in China (Li 2000; Yu 1991; Yu
1997), four in the United States (Karp 2013; Marshall 2011;
NPCT 2002; Reid 2008), one in the United States/New Zealand
(Algotar 2013), one in the United States/Canada/Puerto Rico (
SELECT 2009), and one in Europe (Lubinski 2011).
Investigators administered selenium supplements and placebos
daily. As an active intervention, trials used selenium 200 µg/d
(Dreno 2007; Karp 2013; Marshall 2011; NPCT 2002; Yu 1991;
Yu 1997), or 400 µg/d (Reid 2008), in the form of selenised yeast
tablets, composed almost entirely of organic selenium and partic-
ularly of selenomethionine (Block 2004). Algotar 2013 used 200
µg and 400 µg as different arms. Li 2000 used 500 µg sodium
selenite, and SELECT 2009 used 200 µg/d of selenomethionine.
Lubinski 2011 used 250 µg/d of inorganic selenite.
Three Chinese trials investigated the preventive efficacy of sele-
nium supplementation against primary liver cancer for different
high-risk populations. Participants were carriers of the hepatitis B
surface antigen (HBs-Ag) with normal liver function, or they were
first-degree relatives of patients with liver cancer. Two trials used
selenised yeast (Yu 1991; Yu 1997), and one used sodium selenite
(Li 2000).
The Nutritional Prevention of Cancer Trial (NPCT) investigated
the influence of selenium on the development of non-melanoma
skin cancer (basal and squamous cell carcinoma) in a population
considered at high risk of the disease, namely, patients with a his-
tory of non-melanoma skin cancer (NPCT 2002). Participants
consisted of 1312 men and women from the eastern United States
18 to 80 years of age, with a history of two or more basal cell
carcinomas or of one squamous cell carcinoma. Investigators re-
ported RR estimates for basal cell carcinoma, squamous cell car-
cinoma, and overall non-melanoma skin cancer for two periods
of follow-up: an intermediate study period (from 15 September
1983 to 31 December 1993: Clark 1996, in: NPCT 2002), and
the entire blinded intervention period (from 15 September 1983
to 31 January 1996: Duffield-Lillico 2002 for secondary out-
comes; Duffield-Lillico 2003a for the primary outcome, i.e. non-
melanoma skin cancer; andDuffield-Lillico 2003b for an in-depth
analysis of prostate cancer risk; see NPCT 2002). In the present
analysis, we used only final reports concerning the entire period
of blinded follow-up, which was characterised by active adminis-
tration of selenium supplements.
In 1990, NPCT 2002 identified additional secondary endpoints
post hoc (i.e. total cancer mortality; total cancer incidence; inci-
dence of lung, prostate, and colorectal cancers). Trial publications
also reported incidences of female breast cancer, bladder cancer,
oesophageal cancer, melanoma, haematological cancer, and can-
cers of the head and neck (NPCT 2002).
A substudy of the NPCT investigated the efficacy of a higher
selenium dose, supplied as selenised yeast orally, for prevention of
non-melanoma skin cancer at one of the NPCT study sites (Reid
2008). Study design was similar to that of theNPCT study, except
that investigators randomly assigned 423 participants at this site
to placebo or intervention with 400 µg/d of selenium. Reid 2008
also reported the incidence of internal cancers.
Dreno 2007 evaluated the incidence of skin cancer as a secondary
outcome in a group of 184 organ transplant recipients who re-
ceived 200 µg/d of selenium for three years, then were followed
up for an additional two years. In this multi-centre, randomised,
placebo-controlled trial, investigatorsmonitored 91 selenium-sup-
plemented participants and 93 non-supplemented participants for
development of both non-malignant (warts and various keratoses)
and malignant skin lesions.
The Selenium and Vitamin E Cancer Prevention Trial (SELECT
2009) investigated the effect of selenium as L-selenomethionine
and/or vitamin E supplementation in men of diverse ethnic back-
grounds against the development of prostate cancer and other ’sec-
ondary’ outcomes (i.e. risk of all cancers, lung cancer, colorectal
cancer, and bladder cancer). This study was a very large phase 3
randomized, placebo-controlled trial, activated in June 2001 and
originally designed for a 7- to 12-year period of follow-up, carried
out at 427 sites in the United States, Canada, and Puerto Rico.
However, the independent Data and Safety Monitoring Commit-
tee (DSMC) recommended on 15 September 2008, discontinua-
tion of study supplements based on absence of benefit from vita-
min E or selenium and no possibility of benefit to the planned de-
gree with additional follow-up (SELECT 2009). The Committee
also expressed concern about increased prostate cancer risk among
vitamin E-treated participants and increased diabetes risk among
selenium-supplemented participants (SELECT 2009) (RR 1.07,
13Selenium for preventing cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
99% CI 0.94 to 1.22). Therefore, investigators discontinued ad-
ministration of these supplements on 23 October 2008, in spite
of the planned supplementation period of 12 years. Results of SE-
LECT are based on follow-up provided at the end of the blinded
supplementation period, which included 117,660 person-years of
follow-up - not on an extended period of follow-up, which encom-
passed an additional 32 months of surveillance (144,846 person-
years in total) after the end of the supplementation period (Klein
2011, in: SELECT 2009). Endpoints were prostate cancer (the
’primary’ endpoint) and colorectal cancer, lung cancer, all other
cancers, and all cancers overall. A subsequent study from SELECT
also evaluated the risk of bladder cancer, adding to standard fol-
low-up an additional post supplementation period of 32 months
(Lotan 2012, in: SELECT 2009).
Three phase III trials published in 2011 - Marshall 2011 - and
in 2013 - Algotar 2013; Karp 2013 - also evaluated the effect of
selenium supplementation on prostate cancer. In Marshall 2011
(trial code SWOG S9917), investigators randomly assigned 423
menwith high-grade prostatic intraepithelial neoplasia, and there-
fore considered to be at very high risk of prostate cancer, to sele-
nium (200 µg/d as selenomethionine) or placebo. Algotar 2013
evaluated whether supplementation with 200 or 400 µg/d of sele-
nium as selenised yeast reduced the risk of prostate cancer among
men at high risk of the disease, based on a prostate-specific anti-
gen (PSA) level exceeding 4 ng/L, suspicious digital rectal exam-
ination. and PSA velocity greater than 0.75 ng/mL/y. This trial,
called the Negative Biopsy Trial (NBT), followed study partici-
pants in the United States (where both supplementation and fol-
low-up were completed for such period) for five years, and in New
Zealand for no longer than three years, and was discontinued af-
ter an external DSMC issued a recommendation to stop the trial.
Karp 2013 investigated the effect of supplementation of 200 µg/
d selenium as selenised yeast in 1561 individuals with resected
stage I non-small-cell lung cancer (trial code ECOG 5597). The
primary outcome was the incidence of second primary tumours.
Investigators enrolled both men and women in the study and in-
vestigated all cancer types and a few major side effects during fol-
low-up. Follow-up included the period of active supplementation
and some additional follow-up after the trial anticipated discon-
tinuation. This decision was made by the trial DSMC, which, on
October 21, 2009, reviewed the first planned interim analysis of
the primary endpoint and recommended that the study should
be terminated for futility. Based on that DSMC recommenda-
tion, on November 5, 2009, accrual for the Eastern Cooperative
Oncology Group (ECOG) trial was interrupted, and all current
participants were invited to discontinue selenium/placebo tablets
and were monitored only for follow-up of cancer incidence and
survival. In accordance with recommendations by the trial DSMC
concerning possible adverse effects of selenium supplementation,
the incidence of basal and squamous cell skin cancers, as well as
type 2 diabetes, was monitored. The main paper reported follow-
up until June 2011 (Karp 2013), and results for only second pri-
mary lung tumours were updated as of January 2014, including a
longer post supplementation period of follow-up (Pillai 2014, in:
Karp 2013).
Investigators conducted a trial in Poland that included a female
population of carriers of a breast cancer-related mutation, BRCA1
(Lubinski 2011). Trial authors randomised 1135 women carrying
that mutation to 250 µg/d of selenium in its inorganic tetravalent
form (selenite), or to placebo, in a double-blind trial. Median
follow-up lasted 35 months (ranging from 6 to 62 months), and
final analysis was based on 105 incident cases diagnosed during
follow-up - 60 cases in the selenium-supplemented arm and 45
cases in the placebo arm.
Observational studies
We included in this review 70 completed observational studies.
Forty-five studies were nested case-control studies, the others were
subcohort-controlled or cohort studies, and one study used a co-
hort together with a nested case-control design. Subcohort-con-
trolled studies used (random) samples of the cohort as controls.
The original papers were published between 1983 and 2017. Eight
studies were conducted in Asia (China, Iran, Japan, and Taiwan),
one in Australia, 30 in Europe (Belgium, Denmark, Germany,
Greece, Italy, Netherlands, Norway, Spain, Sweden, Channel Is-
lands, Finland, France, and UK), 30 in the United States, and one
in Canada. Overall, studies included more than 2,300,000 par-
ticipants. Study populations in Europe made up 42.9%, North
America 44.3%, Asia 11.4%, and Australia 1.4% of all study par-
ticipants. Themedian size of study populationswas 11,457. Forty-
one studies included men and women, one did not report sex, 22
included only men, and six included only women. Eleven studies
withmixed-sex populations reported results stratified by sex. Study
populations were derived from 55 different cohorts. Twenty-four
cohorts were non-randomly recruited (e.g. included volunteers),
and 31 cohorts consisted of a random sample of the population
of interest. Fifty-two studies reported mean or median age, 12
studies reported only age range, and six studies did not report this
information on study participants. Most studies included adults
older than 40 years of age.
Sixteen studies investigated nutritional and/or supplemental sele-
nium intake by using food frequency questionnaires or interviews.
Fifty-four studies assessed biochemical selenium status whereby:
1. 9 used toenail specimens;
2. 14 used plasma specimens;
3. 29 used serum specimens;
4. 1 used both serum and plasma specimens; and
5. 1 measured both serum selenium levels and intake.
The mean follow-up period lasted up to three years in five studies,
and longer than three years in the remaining studies. Generally,
study authors grouped cases according to the version of the In-
ternational Classification of Diseases (ICD) that was up-to-date
at the inception of the cohort observation. The level of disaggre-
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gation of data varied markedly between studies. Although some
studies reported cancer risk according to organ system (e.g. urinary
tract, respiratory tract), others reported cancer risk for one or two
organs (e.g. female breast, urinary bladder). Only in the case of
skin cancer did studies also differentiate according to histological
type (e.g. melanoma, basal cell carcinoma).
For the following outcomes, we included five or more studies in
the review and meta-analysed observational data.
1. Any cancer (16 studies).
2. Female breast cancer (8 studies).
3. Urinary bladder cancer (6 studies).
4. Lung cancer (15 studies).
5. Prostate cancer (21 studies).
6. Stomach cancer (5 studies).
7. Colorectal cancer (6 studies) and colon cancer (5 studies).
Goyal 2013 updated results of Bleys 2008, which reported longer
follow-up for the same population.
Table 1 provides an overview of the studies examining each out-
come. Five studies provided data for the group of ’other’ cancers,
which encompassed any type of cancer not reported separately in
study publications. The definition of ’other’ cancers varied be-
tween studies, including rare cancers but also cancers of unknown
origin. We have mentioned results of studies within the category
’other cancers’ for the sake of completeness; however, because of
the diversity of outcomes, we have not included these results in
further analysis or discussion of this review.
Excluded studies
Of 28 potentially relevant papers retrieved in the updated search,
eight papers did not fulfil the inclusion criteria. We rejected six of
these publications as investigators did not report results accord-
ing to inclusion criteria; one paper because trial authors reported
duplicated data from an already included study; and another pa-
per because the trial was carried out in patients with cancer. The
Characteristics of excluded studies table describes the reasons for
exclusion of trials from the previous Cochrane review and from
this update.
Risk of bias in included studies
Randomised controlled trials
We assessed risk of bias of the included RCTs according to
Cochrane criteria (Higgins 2011a; Higgins 2011b). We presented
judgements about each risk of bias item as percentages across all
included RCTs, and we provided a summary of the risk of bias
assessment in Figure 2. We provided details on the judgement for
each RCT and the reason for that judgement in Characteristics of
included studies.
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Figure 2. Review authors’ judgements about each risk of bias item presented as percentages across all
included RCTs and summary of review authors’ judgements about each risk of bias item for the included RCTs.
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We considered all three trials on liver cancer risk (Li 2000; Yu
1991; Yu 1997), as well as the trial on breast cancer (Lubinski
2011), to have unclear risk of bias. These trials did not report gen-
eration of allocation sequence and allocation concealment. One
study mentioned that the dropout rate was similar in intervention
and control groups; the remaining three studies did not report the
completeness of outcome data. We judged blinding as adequate
in three studies, as investigators reported the use of placebo sup-
plements. We inferred from this procedure that at least the study
participants and the physicians directly involved were blinded to-
wards treatment status.
In addition, it is unclear whether Li 2000 was an individually
randomised controlled trial. Study investigators used the phrase
“randomisation based on the residence area” and did not describe
the randomisation procedure any further. As participants were re-
cruited from 17 villages, these villages - not individual participants
- may have been randomly assigned to intervention and control
groups. However, we could not make contact with study investi-
gators to clarify these questions. Randomisation of villages instead
of individuals could have introduced bias into the study results, as
the incidence of liver cancer is known to differ between geograph-
ical areas as a result of lifestyle and environmental factors.
It has been found that RCTs with inadequate or unclear allocation
concealment, especially those with subjective outcomes, may over-
estimate the benefit of interventions (Pildal 2007; Wood 2008).
All three RCTs on liver cancer did not report follow-up and case
detection procedures, so the influence of subjective factors on
case detection, such as interpretation of bodily symptoms as trig-
gers of further diagnostic tests, is unknown. Although we judged
blinding as ’adequate’ in all three liver cancer trials, we do not
know whether blinding was successful in practice for participants,
healthcare providers, and outcome assessors.
These uncertainties about study methods seriously weaken our
confidence in reported RCT results on liver cancer risk.
We considered Algotar 2013, Karp 2013, Marshall 2011, and
SELECT 2009 to have low risk of bias because they reported ad-
equate generation of allocation sequence, allocation concealment,
blinding, and completeness of outcome data.
We judged Dreno 2007 and Duffield-Lillico 2002 to 2003, in:
NPCT 2002 to have unclear risk of bias. Dreno 2007 provided
unclear generation of allocation sequence, allocation concealment,
and blinding; only completeness of outcome data was adequate.
We considered NPCT to be at unclear risk of bias because of ex-
posure-related detection bias for its primary outcome, as the per-
centage of study participants with an abnormal PSA (> 4 ng/mL)
who underwent biopsy varied according to selenium treatment
group, at 35% in the placebo group and 14% in the selenium-
treated group (Duffield-Lillico 2003b, in: NPCT 2002; Marshall
2011). As reported by the trial authors themselves in analyses strat-
ified by baseline selenium concentration, the difference was great-
est among participants in the lowest tertile, in whom the inverse
association between selenium administration and prostate cancer
risk was strongest. The difference in biopsy rates could not be ac-
counted for by factors such as PSA concentration, age at which
abnormal PSA was detected, or alternative diagnostic procedures.
Although a difference this large could have occurred by chance,
this finding raises concerns about possible disruption of blinding.
Investigators provided no information as to the prostate biopsy
rate among participants with lower PSA levels or biopsy rates for
the primary outcome of non-melanoma skin cancer, which also re-
quires pathological confirmation, nor for the secondary outcomes
examined in this trial.
Observational studies
We presented in Table 2 a summary of study ratings according
to the Newcastle-Ottawa Scale (NOS). The median number of
assigned stars was eight for both (nested) case-control and cohort
study assessments, out of a maximum of nine stars each.
All but one cohort study received five to nine stars on the NOS.
The exception (two stars) was an early investigation that was avail-
able only in abstract form for assessment (Clark 1985). In theNOS
cohort assessment, we considered representativeness of the cohort
for the target population to be adequate in 59% of studies, which
received a star; 79% of studies provided evidence that cancer was
not present at study commencement; we considered completeness
of follow-up (≥ 95%) data to be adequate in 93% of studies. The
representativeness of the cohort for the target population is a mat-
ter of external validity and generalisability of study results, but
a systematic deviation of participants from the target population
might also introduce bias into study results. The target popula-
tion of included studies varied with study objectives and could
have been the general population, as well as special occupational
groups. We did not assign a star for this question to studies that
did not identify their target population or to studies that recruited
volunteers. Differential selection of study participants (e.g. vol-
unteers) from the target population can lead to confounding by
factors associated with selenium status and cancer incidence (e.g.
nutritional behaviour, socioeconomic position). All included stud-
ies chose comparison groups (cases/controls or exposed/non-ex-
posed) from the same study population. This approach enhanced
comparability between groups.
We considered follow-up data as complete or as missing data un-
likely to introduce bias to study results in 47% of included ob-
servational studies. In the other cohorts, losses to follow-up were
greater than 5% and trial authors did not provide a description of
losses to follow-up. A high attrition rate may alter the character-
istics of the population under investigation and may impede the
generalisability of study results to the intended target population
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(external validity). The presence of attrition does not necessarily
mean that study results are biased. However, given the possibility
that selenium status may be linked to sociodemographic variables
and socioeconomic position, which may also influence participa-
tion in follow-up procedures, a differential effect of attrition may
introduce bias towards underestimation or overestimation of the
true exposure effect.
Forty-five included observational studies were nested case-control
studies; therefore we assessed them by using the NOS case-control
form. The number of stars in the NOS assessment of case-con-
trol studies ranged from five to nine, with 87% of studies receiv-
ing eight or nine stars. Although we generally assessed included
prospective case-control studies as having low risk of bias, we had
concerns regarding case definition and the question of the repre-
sentativeness of cases in some studies.
We considered the definition of cases as inadequate in 24% of
nested case-control studies, as cases were identified by self-report-
ing; investigators did not describe linkage to databases with un-
clear validity or procedures. The magnitude and direction of bias
that might have been introduced to the study results remain un-
clear.
In 16% of studies, investigators did not include all identified cases
(or an appropriate sample of them) in the trial analyses, or they
did not report selection procedures for analysed cases. Some stud-
ies lost blood specimens as the result of technical problems (e.g.
cooler breakdown at one study centre); other studies reported that
material available for analysis was insufficient; and others selected
cases for analysis in a non-random manner. This might bias the
estimates of association in either direction.
We noted no obvious asymmetry (as an indicator of publication
bias) in the funnel plots of studies on total cancer risk (Figure 3)
and selected cancer types (Figure 4; Figure 5; Figure 6).
Figure 3. Funnel plot of comparison: 1 Highest versus lowest selenium exposure, outcome: 2.1 Total cancer
incidence and mortality.
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Figure 4. Funnel plot of comparison: 1 Observational studies: highest versus lowest selenium exposure,
outcome: 2.8 Colorectal cancer risk.
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Figure 5. Funnel plot of comparison: 1 Observational studies: highest versus lowest selenium exposure,
outcome: 2.12 Lung cancer risk incidence and mortality
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Figure 6. Funnel plot of comparison: 1 Highest versus lowest selenium exposure, outcome: 2.19 Prostate
cancer risk.
Ethical criteria
All trials fulfilled informed consent and ethics board approval
criteria (Algotar 2013; Dreno 2007; Karp 2013; Marshall 2011;
NPCT 2002; Reid 2008; SELECT 2009), except for Li 2000, Yu
1991, Yu 1997, and Lubinski 2011, which did not mention these
criteria.
Effects of interventions
See: Summary of findings for the main comparison Highest
compared with lowest selenium exposure for preventing cancer in
randomised controlled studies with low risk of bias; Summary of
findings 2 Highest compared with lowest selenium exposure for
preventing cancer in observational studies
1. Randomised controlled trials
We reported results from Duffield-Lillico 2002 for all outcomes
evaluated in theNPCT study (NPCT2002) (prostate cancer, lung
cancer, bladder cancer, colorectal and breast cancer, any cancer,
and death from cancer), except for prostate cancer, for which we
also used Duffield-Lillico 2003a, in: NPCT 2002, and for the
primary outcome, non-melanoma skin cancer, whose results were
reported in Duffield-Lillico 2003b, in: NPCT 2002. For the SE-
LECT study (SELECT2009), we included only results fromLipp-
man 2009, in: SELECT 2009, which reported on the blinded
period of follow-up with continuing selenium supplementation -
not from Klein 2011, in: SELECT 2009, which reported a longer
period of follow-up, including a subsequent period without sele-
nium supplementation, and was discontinued in 2008 in compli-
ance with the recommendation of the trial’s independent DSMC
(Lippman 2009 and Klein 2011, in: SELECT 2009). This second
report by Klein et al included an additional period of 32 months
(23% person-time increase), along with the first follow-up period,
and results were essentially similar to those of Lippman et al 2009.
For bladder cancer risk in SELECT, we used data from Lotan
2012, in: SELECT 2009, which encompassed the same extended
period of follow-up as Klein 2011, in: SELECT 2009, but was the
only report available from the SELECT trial on this cancer type.
For prostate cancer in SELECT, we also evaluated three reports
published in 2014 that addressed specific population subgroups
and cancer subtypes (Albanes 2014; Kristal 2014;Martinez 2014).
For the ECOG trial, we used the 2013 report for all cancer types
(Karp 2013).
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1.1. Preventive efficacy outcomes
1.1.1. Any cancer incidence and mortality
Five studies evaluated the outcome of any cancer incidence
(Algotar 2013; Karp 2013; Lubinski 2011;NPCT2002; SELECT
2009); we assessed three of these trials as having low risk of bias
(Algotar 2013; Karp 2013; SELECT2009). Risk ratios (RRs) were
based on detection of 1043 cases among 10,026 participants re-
ceiving supplemental selenium and 942 cases among 9449 par-
ticipants allocated to placebo. We found no evidence of reduced
incident cancer risk in studies at low risk of bias (RR 1.01, 95%
confidence interval (CI) 0.93 to 1.10), nor in the analysis includ-
ing all studies (RR 0.99, 95% CI 0.86 to 1.14) (Analysis 1.1).
When we evaluated mortality from all cancers as an outcome,
we could include only two studies in the analysis (NPCT 2002;
SELECT 2009), one of which was at low risk of bias (SELECT
2009). When we considered only this latter trial, no difference
in mortality rates between selenium and placebo arms emerged
(RR 1.02, 95% CI 0.80 to 1.30). However, when we considered
all studies, risk in the selenium group was lower than risk in the
placebo group (RR 0.81, 95% CI 0.49 to 1.32) (Analysis 1.2).
1.1.2. Head and neck cancer
Two trials investigated effects of selenium supplementation on risk
of head and neck cancer (Karp 2013; NPCT 2002), but only one
was at low risk of bias (Karp 2013). In analysis restricted to the
study having low risk of bias, no relation emerged for the risk of this
cancer type, with a summary RR of 1.00 (95% CI 0.18 to 5.45),
and analysis pooling both studies yielded statistically unstable risk
estimates (RR 1.22, 95% CI 0.52 to 2.85), based on 13 cases in
the selenium arms and 9 cases in the placebo arms (Analysis 1.3).
1.1.3. Esophageal cancer
Two RCTs investigated the risk of oesophageal cancer associated
with selenium supplementation (Karp 2013; NPCT 2002), but
only one was at low risk of bias (Karp 2013). The number of
cases in these studies was very low (3 in the selenium arms and 5
in the placebo arms), thus yielding very imprecise RR estimates.
The summary RR for oesophageal cancer was 1.50 (95% 0.06 to
36.86) in the only study with low risk of bias, and 0.53 (95% CI
0.12 to 2.28) in overall studies (Analysis 1.4).
1.1.4. Colorectal cancer
Three randomised controlled trials investigated the risk of col-
orectal cancer following selenium supplementation. These studies
reported 76 cases in the selenium arms and 83 cases in the placebo
arms (Karp 2013; NPCT 2002; SELECT 2009); two were at low
risk of bias (Karp 2013; SELECT 2009). The summary RR of
colorectal cancer was 0.99 (95% CI 0.69 to 1.43) in the two stud-
ies with low risk of bias, and 0.74 (95% CI 0.41 to 1.33) in all
studies (Analysis 1.5).
1.1.5. Liver cancer
Four RCTs investigated the efficacy of selenium supplementation
for liver cancer prevention, three of which were conducted in
China with participants of different high-risk groups in Qidong
province, and one in the United States among individuals with re-
sected non-small-cell lung cancer (Karp 2013; Li 2000; Yu 1991;
Yu 1997). Yu 1991 reported on a trial with 2474 male and female
first-degree relatives of patients with liver cancer. During the study
period of two years, investigators observed 10 participants in the
selenium group, who received 200 µg selenium yeast/d, and 13
cases in the placebo group (RR 0.55, 95% CI 0.24 to 1.25). Yu
1997 investigated a four-year supplementation period with 200
µg selenium yeast/d in 226 male and female hepatitis B-surface
antigen (HBs-Ag) carriers. Investigators detected 11 cases (person-
time incidence rate: 1573.03/100,000) in the placebo group and
four cases in the selenium group (RR 0.36, 95% CI 0.12 to 1.11)
during the eight-year follow-up period. The mean blood selenium
level during the intervention period was 152 µg/L in the interven-
tion group and 107 µg/L in the control group. Li 2000 randomly
assigned 2065 male HBs-Ag carriers to receive 0.5 mg sodium
selenite or placebo daily for three years. Thirty-four cases of liver
cancer occurred among 1112 participants receiving selenium, and
57 cases occurred among 953 placebo participants (RR 0.51, 95%
CI 0.34 to 0.77).
Karp 2013 allocated 521 individuals with history of resected non-
small-cell lung cancer to 200 µg/d selenium as selenised yeast or to
placebo. During follow-up, investigators diagnosed six new cases
of liver cancer (actually coded as occurring to the ‘liver, gallbladder
and bile duct’)- all in the selenium arm. We deemed this study to
have low risk of bias.
The three Chinese studies had unclear risk of bias owing to lack
of clear reporting of generation of allocation sequence or alloca-
tion concealment, and/or completeness of outcome data. Limit-
ing analysis to the only study not downgraded owing to risk of
bias yielded an RR of 6.52 (95% CI 0.37 to 115.49) (Analysis
1.6). The overall RR of the four studies was 0.52 (95% CI 0.35
to 0.79).
1.1.6. Melanoma
Three RCTs investigated the risk of melanoma following selenium
supplementation (Algotar 2013; Karp 2013; NPCT 2002), but
we judged only two of them to have low risk of bias (Algotar 2013;
Karp 2013). For eight cases in the selenium arms and four cases
in the placebo arms, the summary RR estimate was 1.35 (95% CI
0.41 to 4.52) in RCTs at low risk of bias. The RR estimate was
slightly lower when all studies were considered (RR 1.28, 95% CI
0.63 to 2.59) (Analysis 1.7).
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1.1.7. Non-melanoma skin cancer
1.1.7.1. Total non-melanoma skin cancer
Risk of non-melanoma skin cancerwas the primary outcome of the
NPCT,which reported higher risk in the selenium-supplemented
group than in the placebo group (unadjusted RR 1.27, 95% CI
1.11 to 1.45) (Duffield-Lillico 2003a, in: NPCT 2002). This in-
crease was confirmed by multi-variable analysis after adjustment
for confounders (hazard ratio (HR) 1.17, 95% CI 1.02 to 1.34)
and was concentrated among participants in the highest two ter-
tiles of baseline plasma selenium (≥ 105.6 µg/L), although in-
creased risk for total non-melanoma skin cancer was seen in all
tertiles of baseline plasma selenium levels (Reid 2008). No varia-
tion in this effect appeared to be induced by age, sex, or smoking
habits, and eliminating cases that occurred during the first period
of selenium supplementation (one to two years) induced a slight
decline in RRs. The mean selenium plasma concentration for par-
ticipants was 114 µg/L at the time of randomisation. In the arm of
theNPCT that was carried out in a single location -Macon, Geor-
gia, USA - and included both 200 and 400 µg/d selenium supple-
mentation (Reid 2008), non-melanoma skin cancer risk increased
in the 200-µg/d arm after adjustment for age, sex, and smoking
(unadjusted RR 1.49, 95% CI 1.10 to 2.03; adjusted HR 1.50,
95% CI 1.13 to 2.04) but not in the 400-µg/d arm (unadjusted
RR 0.88, 95% CI 0.66 to 1.16; adjusted HR 0.91, 95% CI 0.69
to 1.20). At the remaining sites, where only 200 µg/d of supple-
mental selenium was given, the RR was 1.24 (95% CI 1.07 to
1.45) and the HR was 1.18 (95% CI 1.02 to 1.37). Distribution
of baseline plasma selenium levels was similar in this substudy to
that in the NPCT main study, and no evidence of effect modifi-
cation according to baseline selenium exposure emerged. Overall,
the NPCT did not support preventive efficacy of selenium yeast
supplementation against non-melanoma skin cancer in these pop-
ulations; on the contrary, investigators reported a cancer-promot-
ing effect of selenium for this cancer type, which was the primary
trial endpoint, raising concern about potentially harmful effects
of such selenium supplementation (NPCT 2002).
SELECT, which is the largest selenium supplementation trial con-
ducted to date (Lippman 2009 and Klein 2011, in: SELECT
2009), thus far has not investigated the incidence of non-
melanoma skin cancer. A small trial in a French population of 184
organ graft recipients who were considered to be at high risk of
premalignant and malignant epithelial lesions (Dreno 2007) in-
vestigated non-melanoma skin cancer. This trial detected a higher
incidence of skin cancer among 91 selenium-supplemented partic-
ipants (six cases; 6.6%) compared with 93 placebo-supplemented
participants (two cases; 2.2%; P = 0.15) during a five-year follow-
up, which in its first three years comprised daily supplementation
with selenised yeast containing 200 µg selenium.
A small trial among participants at high risk for prostate cancer also
investigated the effects of using selenium supplements of 200 and
400 µg/d on risk of non-melanoma skin cancer, with a median fol-
low-up of three years (Algotar 2013). Results for non-melanoma
skin cancer from this study showed the occurrence of three cases
among 232 placebo-treated participants and 11 cases among 467
selenium-supplemented participants (eight cases among 234 indi-
viduals receiving 200 µg/d of selenium, and three cases among 233
individuals receiving 400 µg/d), with increased risk after overall
selenium supplementation (incidence rate ratio from our calcula-
tion 1.8, 95% CI 0.5 to 10.2) but no evidence of a dose-response
relation.
The ECOG trial investigated non-melanoma skin cancer and
found six cases during follow-up of 521 placebo-treated partici-
pants and 11 cases among 1040 selenium-allocated participants
(Karp 2013). The RR of non-melanoma skin cancer in this study
was computed as 0.80 (95% CI 0.44 to 1.45).
Overall, the summary RR for non-melanoma skin cancer in se-
lenium-supplemented participants could be computed by pool-
ing RRs from the above trials, rather than by using numbers of
participants and cases, because the number of skin cancer cases
diagnosed in the NPCT was not reported in the relevant publi-
cation (Duffield-Lillico 2003a, in: NPCT 2002). The estimated
RR limited to the only two trials with low risk of bias indicated a
statistically unstable increased risk of non-melanoma skin cancer
associated with selenium supplementation of 200 µg/d (RR 1.16,
95% CI 0.30 to 4.42), with similar risk results when analysis was
performed on the four trials overall (RR 1.23, 95% CI 0.73 to
2.08) (Analysis 1.8) (Algotar 2013; Karp 2013).
1.1.7.2. Basal cell carcinoma (BCC)
Algotar 2013 found in the 200- and 400-µg/d selenium groups
an RR of 0.86 (95% CI 0.42 to 1.77) and 0.80 (95% CI 0.38 to
1.66), respectively; and anRR in both treatment groups combined
of 0.83 (95%CI 0.45 to 1.54). ECOG 5597 found an RR of 0.54
(95% CI 0.26 to 1.14) (Karp 2013).
At the end of the blinded treatment period in NPCT 2002, the
unadjusted RR for basal cell carcinoma in the 200-µg/d selenium
group was 1.17 (95% CI 1.02 to 1.35), and the adjusted HR
was 1.09 (95% CI 0.94 to 1.26). Eliminating cases that occurred
within the first two years of supplementation had no effect on
the RR. Reid 2008 found a crude RR of 0.90 (95% CI 0.65 to
1.24) and an adjusted HR of 0.95 (95% CI 0.69 to 1.29) for this
cancer type in the 400-µg/d selenium substudy. In a small trial
with no RR estimates (Dreno 2007), three cases of BCC occurred
among 91 selenium-supplemented participants, along with one
case among 93 placebo-receiving participants.
1.1.7.3. Squamous cell carcinoma (SCC)
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Algotar 2013 found anRRof 0.58 (95%CI 0.27 to 1.25) and 0.12
(95%CI 0.03 to 0.50) in the 200- and 400-µg/d trial populations,
respectively, and for all participants, the RR was 0.35 (95% CI
0.17 to 0.72). ECOG 5597 found an RR of 0.92 (95% CI 0.34
to 2.47) (Karp 2013).
In NPCT 2002, selenium supplementation increased the risk of
SCC (unadjusted RR 1.32, 95% CI 1.09 to 1.60; adjusted HR
1.25, 95% CI 1.03 to 1.51). Adverse effects of selenium sup-
plementation on SCC risk appeared to increase with increasing
plasma selenium levels at baseline, in that higher risk was seen
only in participants at the highest two tertiles of baseline levels (≥
105.6 µg/L), suggesting an interaction between supplementation
and baseline exposure. In the 400-µg/d selenium substudy (Reid
2008), investigators reported no change in SCC risk by selenium
supplementation (crude RR 1.20, 95% CI 0.85 to 1.68; adjusted
HR 1.05, 95% CI 0.71 to 1.56). Dreno 2007, the smaller trial,
reported that two among 91 selenium-supplemented individuals
were given a diagnosis of SCC, whereas no cases were observed
among placebo participants.
1.1.8. Lung cancer
Three RCTs have investigated lung cancer risk associatedwith sele-
nium administration (Karp 2013; NPCT 2002; SELECT 2009),
with two assessed as having low risk of bias (Karp 2013; SELECT
2009). Summary RR estimates were 1.16 (95% CI 0.89 to 1.50)
when we limited the analysis to studies at low risk of bias, and
1.03 (95%CI 0.78 to 1.37) whenwe included all studies (Analysis
1.9).
1.1.9. Female breast cancer
Three studies evaluated breast cancer risk associated with selenium
supplementation (Karp 2013; Lubinski 2011; NPCT 2002), one
of which we judged as having low risk of bias (Karp 2013). The
RR from the study with low risk of bias was 2.04 (95% CI 0.44 to
9.55), with statistical imprecision due to the small number of cases
(eight in the selenium arm, two in the placebo arm). The pooled
RR from all studies was 1.44 (95% CI 0.96 to 2.17) (Analysis
1.10).
1.1.10. Bladder cancer
Three studies evaluated bladder cancer outcomes (Karp 2013;
NPCT 2002; SELECT 2009), two of which we judged as having
low risk of bias (Karp 2013; SELECT 2009), The summary RR
from the only studies at low risk of bias was 1.07 (95% CI 0.76
to 1.52). The corresponding RR for all studies, encompassing a
total of 146 cases - 79 in the selenium arms and 67 in the placebo
arms - was 1.10 (95% CI 0.79 to 1.52) (Analysis 1.11).
1.1.11. Prostate cancer
Five trials evaluated prostate cancer (Algotar 2013; Karp 2013;
Marshall 2011; NPCT 2002; SELECT 2009), all of which we
judged as having low risk of bias, except for NPCT 2002. Meta-
analysis for prostate cancer-based trials at low risk of bias yielded
an RR of 1.01 (95% CI 0.90 to 1.14) for the 9630 participants
supplemented with selenium (520 cases) compared with the 9312
participants allocated to placebo (500 cases), indicating no effect
of intervention (supplementation of organic selenium at 200 µg/
d) on prostate cancer risk, with very consistent results and no
heterogeneity across these studies (I² = 0.0%). The overall RR was
0.91 (95% CI 0.75 to 1.12) when all studies were considered;
moderate heterogeneity (I² = 36%) emerged owing to the addition
of the NPCT (Analysis 1.12) (NPCT 2002).
The trial that first investigated the relation between selenium expo-
sure and prostate cancer risk (Duffield-Lillico 2002 and Duffield-
Lillico 2003b, in: NPCT 2002) reported a reduction in prostate
cancer incidence in the selenium-treated group, which was partic-
ularly strong during the first period of follow-up (1983 to 1993;
adjusted HR 0.35, 95% CI 0.16 to 0.65) and was slightly higher
but still much lower than unity during the entire period of fol-
low-up (1983 to 1996; HR 0.48, 95% CI 0.28 to 0.80). Analy-
ses stratified by baseline plasma selenium category showed greatly
reduced risk associated with active treatment among participants
with baseline plasma selenium ≤ 106.4 µg/L (HR 0.14, 95% CI
0.03 to 0.61) in the intermediate category (106.8 to 123.2 µg/L;
HR 0.33, 95% CI 0.13 to 0.82), while in the upper category (>
123.2 µg/L), the HR was 1.14 (95% CI 0.51 to 2.59). Selenium
supplementation in participants with baseline PSA ≤ 4 ng/mL
was associated with considerably reduced risk (HR 0.33, 95% CI
0.14 to 0.79) compared with risk in individuals with PSA > 4 ng/
mL (HR 0.95, 95% CI 0.42 to 2.14). However, interpretation
of these NPCT findings is complicated by a potentially serious
source of bias. As reported in 2003 by the study authors, a con-
siderably higher percentage of participants with elevated PSA lev-
els in the placebo group underwent prostatic biopsy as compared
with participants in the selenium group (35% vs 14%; P < 0.05;
Duffield-Lillico 2003b, in: NPCT 2002). Differences in biopsy
rates were greatest among participants with the lowest baseline se-
lenium concentrations - the subgroup that appeared to derive the
greatest beneficial effects of selenium administration. This may
have contributed to substantial overestimation of the effects of se-
lenium supplementation in the NPCT.
The SELECT trial found no evidence of benefit derived from se-
lenium supplementation (compared with placebo) over a median
of 5.5 years in terms of prostate cancer incidence (HR 1.03, 95%
CI 0.90 to 1.18, 99% CI 0.87 to 1.24) (SELECT 2009). The ad-
justedHR for prostate cancer in the seleniumplus vitaminE group
compared with the placebo group was 1.05 (95% CI 0.91 to 1.20,
99% CI 0.88 to 1.25). The original report of the trial provided no
specific RR estimate according to disease severity, but during an
extended follow-up of this cohort after selenium supplementation
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had ceased (Klein 2011, in: SELECT 2009), investigators found
increased risk of Gleason 7 or greater disease (HR 1.21, 99% CI
0.90 to 1.63). It is interesting to note that the SELECT trial in-
cluded only participants with PSA ≤ 4 ng/mL - the group in the
NPCT that showed greatest apparent benefit. During this further
follow-up of the SELECT cohort, risk of prostate cancer in the
selenium arm also slightly increased compared with that described
in the first report, which had included only the active supplemen-
tation period (Lippman 2009, in: SELECT 2009). In this longer
follow-up based on 575 prostate cancer cases in the selenium arm
and 529 in the placebo arm, the RR of prostate cancer was 1.09
(99% CI 0.93 to 1.27).
Three further reports from SELECT on the relation between sele-
nium administration and prostate cancer risk have been published
(Albanes 2014; Kristal 2014; Martinez 2014); where investigators
looked at more specific associations than were addressed in the two
main publications from this trial (Lippman 2009 and Klein 2011,
in: SELECT 2009). Kristal 2014 performed a case-cohort study
within the SELECT study by including 1739 total prostate cancer
cases (of which 489 showed high-grade (Gleason 7 to 10) disease)
and 3117 randomly selected men composing the control subco-
hort (Kristal 2014). Administration of selenium (both selenium
only and selenium combined with vitamin E) had no effect on
prostate cancer risk among men with low baseline selenium status
(< 60th percentile of toenail selenium), but among participants
in the two upper quintiles of baseline selenium exposure, risk of
prostate cancer was increased (HR 1.20, 95% CI 0.85 to 1.81),
particularly high-grade prostate cancer (HR 1.62, 95% CI 0.95
to 2.77). HRs were even higher when any selenium supplementa-
tion (alone or with vitamin E) was considered because such sup-
plementation increased the risk of any prostate cancer (RR 1.27,
95% CI 0.92 to 1.74) and high-grade disease (RR 1.91, 95% CI
1.20 to 3.05).
Martinez 2014 investigated the effect of selenium supplementa-
tion on prostate cancer risk among participants in SELECT who
had genotypes associated with altered mRNA expression of the
androgen-regulated prostate tumour suppressor protein NKX3.1.
The design was still of the case-cohort type, encompassing 1866
prostate cancer cases and 3135 non-prostate cancer cases. Trial
authors found that selenium administration combined with the
CC genotype at rs11781886 increased overall prostate cancer risk
(HR 1.68, 95% CI 1.01 to 2.78) and low-grade prostate cancer
risk (HR 1.81, 95% CI 1.02 to 3.23), but they noted no such
interaction for the other genotypes.
Finally, in a SELECT subpopulation composed of 1746 prostate
cancer cases and a subcohort of 3211 men, Albanes 2014 investi-
gated a possible association between baseline plasma α-tocopherol
and γ -tocopherol and active supplementation with selenium (and
vitamin E as α-tocopherol) in terms of prostate cancer risk. Trial
authors found a strong excess of risk among participants in the
highest baseline α-tocopherol category (fifth quintile) receiving
selenium supplementation (HR 2.04, 95% CI, 1.29 to 3.22, P
trend 0.005), which was higher with high-grade (Gleason grade 7
to 10) disease among men receiving selenium (HR 2.12, 95% CI,
1.32 to 3.40, P-trend 0.0002). These findings suggest a possible
biological interaction between α-tocopherol status and selenium
supplementation in increasing high-grade prostate cancer risk.
In Marshall 2011, prostate cancer incidence was 35.6% versus
36.6% in selenium-supplemented compared with placebo-treated
participants after three years of follow-up, respectively. The overall
RR was 0.91, with a 95% CI of 0.55 to 1.52 (courtesy of James
Marshall, unpublished data). Analysis of RRs according to baseline
plasma selenium levels showed no dose-response effect, with point
estimates of 0.82 (95% CI 0.40 to 1.69), 1.38 (95% CI 0.68
to 2.78), 0.98 (95% CI 0.58 to 1.68), and 0.91 (95% CI 0.45
to 1.84), when the quartile of selenium status was increased at
baseline.
The NBT reported an HR of prostate cancer of 0.94 (95% CI
0.52 to 1.70) for participants receiving 200 µg/d and 0.90 (95%
CI 0.48 to 1.66) for those receiving 400 µg/d, compared with
placebo (Algotar 2013). Although average baseline selenium sta-
tus, as assessed through plasma selenium, was higher than in the
NPCT (median value 126.1 vs 115.0 µg/L), the lowest tertile of
plasma selenium levels had amedian value (101.1 µg/L) well below
the apparent threshold of around 120 µg/L, at which a beneficial
effect of selenium seemed to occur in the NPCT. Furthermore,
as noted by study authors, 45% of participants enrolled in this
study had baseline plasma selenium levels < 123 µg/L, which is
the upper threshold for a protective effect of selenium supplemen-
tation according to results of the NPCT. Trial authors also stated:
“None of the baseline variables modified the effect of selenium
on the primary endpoint”, and plasma selenium concentration at
baseline was among these variables (Algotar 2013).
Karp 2013, the ECOG trial, carried out in subjects with resected
non-small-cell lung cancer, reported nine and 16 cases of newly
diagnosed prostate cancer among 250 and 509 male participants
in the placebo and selenium groups, respectively. This allowed us
to compute an RR of 0.87 (95% CI 0.39 to 1.45) for prostate
cancer in the selenium-supplemented arm.
Following the NPCT, none of the subsequent, high-quality RCTs
provided evidence suggesting that baseline selenium status could
modify the effect of selenium supplementation on subsequent
prostate cancer occurrence. In the NBT, the bottom category (ter-
tile) of baseline plasma selenium levels in this trial population was
101.1 µg/L, i.e. lower than the upper bound of the bottom cate-
gory (106.4 µg/L) and the middle category (106.8 to 123.2 µg/L)
in the NPCT, both of which had shown a strongly decreased sub-
sequent prostate cancer occurrence (Algotar 2013). In the SWOG
S9917 study, results of selenium supplementation were also made
available for four categories (quartiles) of baseline plasma selenium
and showed no effect of treatment in any categories (Marshall
2011). These categories were < 106, 106-132, 132-162, and > 162
µg/L, and corresponding RRs of prostate cancer in the selenium-
supplemented group were 0.82 (95%CI 0.40 to 1.69), 1.38 (95%
25Selenium for preventing cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
CI 0.68 to 2.78), 0.98 (95% CI 0.58 to 1.68), and 0.91 (95%
CI 0.45 to 1.84), respectively, versus an overall study RR of 0.97
(95% CI 0.68 to 1.39). Therefore, also in this high-quality trial,
the bottom category of baseline selenium exposure was entirely
similar to the corresponding one in the NPCT, but in contrast to
NPCT, no effect of selenium supplementation emerged and no
evidence showed risk of bias. Finally, a case-cohort study carried
out within SELECT and published in 2014 provided data show-
ing the relation between baseline selenium exposure and effects
of selenium supplementation (Kristal 2014). In that study, whose
average selenium exposure was higher than that characterising the
NPCT and the NBT, investigators reported no effect of selenium
supplementation on both overall prostate cancer and low-grade
and high-grade prostate cancer in the three quintiles of baseline
toenail selenium levels, but enhanced risk of high-grade prostate
cancer emerged for the two upper quintiles (alone and combined).
Quintile cutpoints for these categories of the trial population were
0.758, 0.832, 0.901, and 1.003 µg/g. Overall, these results clearly
indicate that even in subgroups with the lowest baseline selenium
status in these Western populations, selenium provided no pro-
tective effect for prevention of prostate cancer, although this is the
cancer type that once was thought to be most strongly associated
with a beneficial effect of selenium supplementation.
1.1.12. Haematological cancers
Two trials evaluated the risk of haematological malignancies as-
sociated with selenium administration (Karp 2013; NPCT 2002)
using 23 cases only - 14 in the selenium arms and 9 in the placebo
arms - but we judged only one trial to be at low risk of bias (Karp
2013). The summary RR was 1.00 (95% CI 0.25 to 3.99) in the
study at low risk of bias and 1.21 (95% CI 0.52 to 2.80) when all
studies were considered (Analysis 1.13).
1.2. Adverse effects outcomes
The RCTs on selenium have provided unexpected information
about the incidence of adverse effects of selenium supplementa-
tion and have unexpectedly become a key source of data for risk
assessment of the upper safe level of selenium exposure in humans
(Vinceti 2017a; Vinceti 2017b). Thirty-five participants withdrew
from the NPCT because of adverse effects, mainly gastrointestinal
upset. The RR for adverse events in the selenium group was 1.51
(95% CI 0.74 to 3.11) (our calculation, based on the number of
randomly assigned participants). Reports of increased risk of glau-
coma in Marshall 2011 and NPCT 2002 prompted additional
studies on this issue (Bruhn 2009), and likely led to inclusion of
cataract and glaucoma among the several potential adverse events
monitored during subsequent trials in which investigators admin-
istered selenium (Algotar 2013).
In the NPCT, a secondary analysis of participants who did not
have diabetes at the start of the study unexpectedly revealed an
excess risk of type 2 diabetes mellitus in the selenium group (ad-
justed HR 1.55, 95% CI 1.03 to 2.33) (Stranges 2007). That
study found increased risk of developing type 2 diabetes associ-
ated with selenium supplementation across all tertiles of baseline
plasma selenium levels, although the excess was much greater for
the upper category of > 121.6 µg/L (RR 2.70, 95% CI 1.30 to
5.61) than for the lower (RR 1.13, 95% CI 0.58 to 2.18) and in-
termediate (RR 1.36, 95% CI 0.60 to 3.09) categories. Increased
risk of diabetes associated with selenium supplementation was in-
dependent of baseline age, sex, smoking status, and body mass in-
dex (BMI), with the exception of participants in the top tertile of
BMI. SELECT reported a slight increase in the incidence of type
2 diabetes in the selenium-alone group (RR 1.07, 99% CI 0.94
to 1.22). Any such excess risk decreased over time after selenium
supplementation ceased, as is shown by results of the Klein study
(Klein 2011, in: SELECT 2009). In this study, the RR of diabetes
was 1.04 (99% CI 0.93 to 1.17), thus supporting a short-term
effect of selenium supplementation on diabetes risk.
Although the three trials on liver cancer and Reid 2008 did not
mention the occurrence of adverse effects, and Dreno 2007 and
Marshall 2011 (the SWOG 2011 trial) apparently performed no
assessment of diabetes incidence, three recent phase 3 RCTs have
investigated the occurrence of diabetes after selenium supplemen-
tation for prevention of malignant and non-malignant cancer. In
the NBT, during five years of follow-up of 699 participants at
high risk for prostate cancer supplemented with 200 or 400 µg/d
of selenium or placebo, Algotar 2013 reported the occurrence of
diabetes in 12, 12, and 7 participants, respectively. This allowed
us to compute an incidence rate ratio of 1.70 (95% CI 0.62 to
5.10) and 1.71 (95% CI 0.62 to 5.12) among 200- and 400-µg/d
selenium-supplemented participants, respectively, compared with
those given placebo. The ECOG trial, which was carried out in
1561 participants with resected stage I non-small-cell lung cancer,
trial authors did not explicitly report the RR of diabetes during
follow-up (Karp 2013). However, occurrence during four years
of follow-up (2007 to 2011) was stated as 26 new diagnoses of
diabetes in the selenium arm (1040 participants at baseline, of
whom 865 underwent toxicity assessment) and 12 new diagnoses
among placebo-treated participants (521/477). On the basis of
these numbers, we could compute an RR of 1.09 (95% CI 0.55
to 2.13) or, for participants with toxicity assessment, 1.19 (95%
CI 0.61 to 2.35) - values comparable with those observed in the
other trials, except for NPCT. Most recently, in an intervention
study investigating the effect of selenium supplementation for pre-
vention of colorectal adenoma recurrence compared with placebo
(the SELCEL trial), 31 cases of diabetes occurred in the selenium-
treated group and 25 in the placebo group during follow-up, with
an RR of 1.25 (95% CI 0.74 to 2.11) (Thompson 2016). There-
fore, an excess incidence of type 2 diabetes systematically emerged
in all trials that investigated this adverse effect (Vinceti 2017b).
The SELECT study also looked at other side effects known to
be associated with selenium overexposure (Vinceti 2001), finding
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an association for some of them. Selenium treatment increased
the occurrence of alopecia (RR 1.28, 95% CI 1.07 to 1.53, based
on 265/206 cases in selenium and placebo arms), dermatitis (RR
1.16, 95% CI 1.03 to 1.29, 619/524), nail changes (RR 1.04,
95% CI 0.96 to 1.13, 1087/1035), and halitosis (RR 1.17, 95%
CI 0.99 to 1.38, 503/427).
2. Observational studies
When risks of cancer for higher and lower levels of selenium ex-
posure are compared, a summary risk estimate of one suggests no
association between selenium exposure and cancer, and summary
risk estimates below and above one suggest a beneficial or harmful
effect of higher selenium exposure, respectively. We evaluated the
statistical precision of the point estimates by assessing the width
of their 95% or 99% confidence intervals.
2.1. Aetiological association: results from meta-analyses
2.1.1. Any cancer
We meta-analysed results of 16 prospective observational studies
on total cancer risk, including data on more than 276,000 par-
ticipants. The cohorts of Salonen 1984 and Salonen 1985 over-
lapped. Hence, we included only data from Salonen 1985 in the
meta-analysis. We had to omit Fex 1987, as the CI value was not
reported and could not be calculated from available data.
For participants in the highest category of pre diagnostic selenium
exposure, the summary risk estimate was odds ratio (OR) 0.72
(95% CI 0.55 to 0.93) for cancer incidence and OR 0.76 (95%
CI 0.59 to 0.97) for cancer mortality for both sexes combined
(Analysis 2.1), when compared with participants in the lowest ex-
posure category. We observed moderate to substantial heterogene-
ity for both incidence (I² = 45%) and mortality (I² = 67%).
Analyses by sex revealed lower point estimates for men (incidence:
OR 0.72, 95% CI 0.46 to 1.14; mortality: OR 0.65, 95% CI
0.45 to 0.94) (Analysis 2.2) than for women (incidence: OR 0.90,
95% CI 0.45 to 1.77; mortality: OR 0.91, 95% CI 0.80 to 1.03)
(Analysis 2.3).
All studies but one (Sun 2016) used a circulating biomarker (serum
and plasma selenium levels) for assessment of selenium status.
Analysis 2.4 shows the results in ascending order of baseline expo-
sure for those studies that reported category borders. The graph
does not reveal any systematic pattern of changes in the relation
between selenium status and cancer risk according to increasing
baseline selenium levels. Analysis 2.5 shows the results in ascend-
ing order for differences in selenium levels.
2.1.2. Stomach cancer
No additional cohort studies on stomach cancer and selenium ex-
posure have been published since the last update of this review;
therefore meta-analysis for this cancer type was still based on five
studies. The summary risk estimate for both sexes combined was
OR 0.66 (95% CI 0.43 to 1.01) in the highest exposure category
when compared with the lowest (I² = 51%) (Analysis 2.6). In this
meta-analysis, we included one cohort twice because trial authors
reported results stratified according to cardia and non-cardia gas-
tric cancer (Mark 2000, in: Wei 2004).
Use of available sex-stratified results for meta-analysis yielded a
risk estimate for men of OR 0.43 (95% CI 0.14 to 1.32) (I² =
56%), and for women of OR 0.73 (95% CI 0.12 to 4.35) (I² =
62%) (Analysis 2.7).
2.1.3. Colorectal/Colon cancer
Six observational studies reported data on the incidence of col-
orectal cancer. The summary risk estimate was OR 0.82 (95% CI
0.72 to 0.94) for both sexes combined (I² = 0.0%) (Analysis 2.8),
with OR 0.86 (95% CI 0.65 to 1.16) for men and OR 0.96 (95%
CI 0.61 to 1.50) for women (Analysis 2.9). Five studies reported
data stratified or restricted to colon cancer. The summary estimate
was OR 0.81 (95% CI 0.69 to 0.96) for both sexes combined (I²
= 0.0%) (Analysis 2.10), with OR 0.84 (95% CI 0.56 to 1.25) for
men and OR 0.68 (95% CI 0.44 to 1.04) for women (Analysis
2.11).
2.1.4. Lung cancer
We included 13 studies in this meta-analysis. We did not meta-
analyse data from Menkes 1986 and Knekt 1990, as the study
population of the former overlapped with that of Comstock 1997
(another meta-analysed study) - and results of the latter were pre-
sented in insufficient detail.
The summary risk estimate for lung cancer incidence for both sexes
combined was 0.82 (95% CI 0.59 to 1.14) (Analysis 2.12). We
noted substantial heterogeneity among study results (I² = 66%).
We found little difference in summary estimates when results were
disaggregated by sex (Analysis 2.13), by indicator of selenium ex-
posure (intake, blood or toenail content) (Analysis 2.14), by base-
line serum/plasma bottom exposure category (Analysis 2.15), and
by ascending differences in selenium levels (Analysis 2.16). In the
latter analyses, we noted no dose-response relation between base-
line selenium and risk.
2.1.5. Female breast cancer
We included eight studies in this meta-analysis. Data show little
association between baseline selenium levels and breast cancer risk,
with a slightly but imprecisely higher risk for higher exposure (OR
1.09, 95% CI 0.87 to 1.37) (Analysis 2.17). The heterogeneity of
results was low (I² = 14%).
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2.1.6. Bladder cancer
Meta-analysis of bladder cancer incidence in five observational
studies revealed an inverse association, with an overall risk esti-
mate of 0.67 (95% CI 0.46 to 0.97) (Analysis 2.18) (heterogene-
ity: I² = 30%). Sex-disaggregated data were available only from
Michaud 2005 and showed an inverse association between sele-
nium exposure and risk in women, but not in men. Two studies
included only male participants (Michaud 2002; Nomura 1987);
both found a reduced but imprecisely estimated bladder cancer
risk for higher selenium exposure (Analysis 2.18). Heterogeneity
was not reduced by sex stratification (I² = 40% in study results for
men). No further studies had been published since the last update
of this review (Vinceti 2014).
2.1.7. Prostate cancer
We included 21 epidemiological studies on prostate cancer inci-
dence in the meta-analysis. The summary risk estimate for higher
selenium exposure was OR 0.84 (95% CI 0.75 to 0.95) (hetero-
geneity: I² = 27%) (Analysis 2.19). Stratification of the analysis
by method of selenium assessment revealed an inverse association
between baseline selenium and risk when exposure was assessed
through blood selenium levels (OR 0.86, 95% CI 0.75 to 0.99)
or toenails (OR 0.60, 95% CI 0.44 to 0.82), but not when dietary
assessment methods were used (OR 0.99, 95% CI 0.85 to 1.15)
(Analysis 2.20). When we stratified analysis according to baseline
(blood) selenium exposure or differences in selenium (blood) lev-
els, no specific relation or pattern emerged between selenium and
prostate cancer risk across the entire exposure spectrum (Analysis
2.21; Analysis 2.22).
2.2. Aetiological association: other results
For all other types of cancer, data were available from fewer than
five epidemiological studies; thus we did not meta-analyse the re-
sults. We have reported in Table 3 results of observational studies
not included inmeta-analyses. None of these study results support
an association between selenium exposure and gynaecological can-
cer risk, and results for cancers of the gastrointestinal, respiratory,
or urological tract are inconsistent. For respiratory and urological
cancers, studies reported either no association or increased risk for
participants with higher selenium exposure. For gastrointestinal
cancers including cancer of the liver and other sites not mentioned
above, studies found either no association or reduced risk with
higher selenium exposure.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Highest compared with lowest selenium exposure for preventing cancer in observational studies
Patient or population: Part icipants in non experimental cohort studies on selenium and cancer
Setting: out-pat ient
Intervention: highest selenium exposure
Comparison: lowest selenium exposure
Outcomes Relative effect
(95% CI)
Certainty of the evidence
(GRADE)
Any cancer risk
No. of part icipants: 76,239
(7 observat ional studies)
OR 0.72
(0.55 to 0.93)
⊕©©©
VERY LOWa
Colorectal cancer risk
No. of part icipants: 712,746
(6 observat ional studies)
OR 0.82
(0.72 to 0.94)
⊕©©©
VERY LOWa
Lung cancer risk
No. of part icipants: 371,067
(11 observat ional studies)
OR 0.82
(0.59 to 1.14)
⊕©©©
VERY LOWa,b,c
Breast cancer risk (women)
No. of part icipants: 169,028
(8 observat ional studies)
OR 1.09
(0.87 to 1.37)
⊕©©©
VERY LOWa,c
Bladder cancer risk
No. of part icipants: 279,100
(5 observat ional studies)
OR 0.67
(0.46 to 0.97)
⊕©©©
VERY LOWa,c
Prostate cancer risk
No. of part icipants: 576,667
(21 observat ional studies)
OR 0.84
(0.75 to 0.95)
⊕©©©
VERY LOWa,d
CI: conf idence interval; OR: odds rat io.
GRADE Working Group grades of evidence.
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate
of the ef fect, but there is a possibility that it is substant ially dif f erent.
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the
est imate of the ef fect.
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent
f rom the est imate of ef fect
aDowngraded one level owing to risk of bias, which we deemed as serious because of inability to rule out unmeasured
confounding, part icularly f rom lifestyle or nutrit ional factors that m ight covary with selenium exposure beyond those
factors taken into account in the mult i-variable analyses.
bDowngraded one level for moderate heterogeneity (tau² = 0.19, I² = 66%, P = 0.0008) not explained.
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cDowngraded one level owing to imprecision.
dDowngraded one level owing to potent ial presence of publicat ion bias suggested by the funnel plot.
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D I S C U S S I O N
Summary of main results
The aims of this review were to examine the efficacy of selenium
supplementation inpreventing cancer and,more generally, to anal-
yse the association between selenium exposure and risk of cancer
in men and women.
Randomised controlled trials (RCTs) and preventive
efficacy
We aimed to identify all RCTs so far carried out, extending the
standard search by using unconventional methods such as cita-
tion chasing and scanning of conference proceedings - methods
that have proved effective in yielding additional high-quality ev-
idence for systematic reviews and meta-analyses for other topics
(Greenhalgh 2005; Vinceti 2017c). Using this approach, we iden-
tified a total of 10 RCTs that investigated monoselenium supple-
ments for prevention of non-melanoma skin cancer, prostate can-
cer, any cancer, and other site-specific cancers. Overall, clear and
consistent evidence indicates that selenium supplementation did
not reduce subsequent cancer incidence, whether this endpoint
was considered a primary or secondary outcome.Most of these tri-
als raised concerns about possible harmful effects of selenium sup-
plements, including increased incidence of non-melanoma skin
cancer in theNutritional Prevention of Cancer Trial (NPCT), der-
matological effects in the Selenium and Vitamin E Cancer Preven-
tion Trial (SELECT), and type 2 diabetes in all RCTs, although
with generally limited and statistically imprecise risk ratios (RRs).
Of the three liver cancer prevention trials, one reported a strongly
reduced risk of liver cancer for male carriers of the hepatitis B
surface antigen (HBs-Ag) taking inorganic selenium supplements
(sodium selenite) for three years, and the other two studies reported
little effect of organic selenium supplements (selenium yeast) for
the same cancer site (Li 2000; Yu 1991; Yu 1997). Owing to sev-
eral methodological concerns related to randomisation and com-
pleteness of outcome data, we judged the risk of bias as unclear
for all three of these RCTs. Therefore, we could not conclude that
we found strong support for selenium supplements as agents for
prevention of liver cancer. Unfortunately, the other trials did not
include liver cancer among their secondary outcomes, with the
exception of ECOG 5597 (Karp 2013). In this RCT, investigators
reported new cases of liver, gallbladder, and bile duct cancer only
among selenium-treated participants; however, trial authors ob-
served a total of only six cases, making risk estimates highly statis-
tically unstable. In addition, the population included in this trial,
which comprised patients with a history of resected non-small-cell
lung cancer, was rather different from the general population.
The NPCT (NPCT 2002) reported strongly decreased risk for all
cancers (-22%), and for oesophageal (-59%), colorectal (-52%),
lung (-28%), andprostate (-46%) cancers, showing lesser decreases
compared with the ad interim report (Clark 1996, in: NPCT
2002), but still indicative of a strong cancer preventive effect. In
addition, when participants were categorised into tertiles accord-
ing to baseline serum selenium, evidence suggested an inverse rela-
tionship between selenium status and effects of supplementation
for all cancers and for prostate cancer in the lower two tertiles,
and no effect in the upper tertile. However, interpretation of these
results is difficult because in 2003, the trial authors acknowledged
the occurrence of a detection bias, namely, a considerably higher
rate of prostate biopsy in the placebo group, whose cause was not
specified. It is unclear whether this detection bias applied only to
prostate cancer or applied more generally to other outcomes (as
would be the case if the bias was due to unblinding, for exam-
ple). This major detection bias forced us to downgrade the reli-
ability of this study. Data show an increase in the incidence of
its primary outcome - non-melanoma skin cancer - in selenium-
supplemented participants, as well as in the incidence of five other
cancer types, including melanoma, bladder cancer, breast cancer,
head and neck cancer, and lymphoma and leukaemia. Trial au-
thors stated: “These results, although non-significant and based
on small case numbers, may indicate potential increased risk with
selenium supplementation”; these authors also relied on previous
observational studies to provide some support for these positive
associations (Duffield-Lillico 2002, in: NPCT 2002).
The turning point of research on selenium and cancer was the
SELECT trial (SELECT 2009), a large, well-conducted prostate
cancer prevention trial carried out in the male general population
of North America not at high risk of prostate cancer (≤ 4 ng/
mL in serum prostate-specific antigen (PSA) and digital rectal ex-
amination not suspicious for cancer). This trial, widely consid-
ered a milestone in cancer prevention and research, found no dif-
ference in prostate cancer incidence for selenium-supplemented
participants as compared with placebo participants after a median
follow-up of 5.5 years (hazard ratio (HR) 1.04, 95% confidence
interval (CI) 0.90 to 1.18), and no effect of selenium on risk of
overall cancer or on risk of other cancers (as well as cardiovascular
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disease). Median selenium at baseline (135 µg/L in serum in the
selenium arm vs 137.6 µg/L in the placebo arm) was higher than
in the NPCT (average plasma selenium 114 µg/L). The interven-
tion used in this trial was different from that used in the NPCT
(selenomethionine in SELECT, and selenised yeast in the former),
although this is unlikely to have been responsible for observed dif-
ferences (Waters 2013); in both cases, the intervention comprised
organic selenium species (Block 2004).
In a small study of organ transplant recipients (Dreno 2007),
an unexpected increase in non-melanoma skin cancer incidence
emerged; this was a matter of concern in the light of results of the
NPCT. In the Polish trial Lubinski 2011, which included 1135
women with high genetic susceptibility to breast cancer due to
BRCA1 mutations, evidence was more consistent with increased
risk of both all cancers and primary breast cancer than with de-
creased risk, although with statistically unstable HRs (1.4, 95%
CI 0.9 to 2.0; and 1.3, 95% CI 0.7 to 2.5, respectively). In this
trial, the intervention consisted of administration of 250 µg/d of
inorganic tetravalent selenium (selenite).
More recently, results of three well-conducted phase 3 trials in par-
ticipants at higher risk for prostate cancer than the general male
population indicated that 200 µg/d of selenium (as selenomethio-
nine in one study - Marshall 2011 - and as selenised yeast in the
other two - Algotar 2013; Karp 2013) did not decrease subsequent
cancer incidence compared with placebo. The baseline selenium
status of populations included in these RCTs was comparable with
that in SELECT for Southwest Oncology Group (SWOG) S9917
(135 to 138 µg/L in the two arms) (Marshall 2011), slightly lower
in the Negative Biopsy Trial (NBT) (126.1 µg/L) (Algotar 2013),
and unfortunately unspecified for Eastern Cooperative Oncology
Group (ECOG) 5597 (Karp 2013). Results of these high-quality
RCTs, all characterised by low risk of bias and two of which were
discontinued before their planned end for futility, were consistent
and showed no beneficial effect of selenium treatment on cancer
risk.
Although not eligible for our meta-analyses because their outcome
was non-malignant neoplasms rather than cancer, two recently
published RCTs on colorectal adenoma risk in participants receiv-
ing selenium are worth noting. One of these trials was embed-
ded in SELECT (Lance 2017), and the other, the SELCEL trial
(an intervention study investigating the effect of selenium sup-
plementation or celecoxib for prevention of colorectal adenoma
recurrence), allocated 1374 men and women who had undergone
removal of colorectal adenomas to either 200 µg/d selenium as
selenised yeast, or placebo (Thompson 2016). Both RCTs did not
find a beneficial effect of selenium for prevention of colorectal
adenoma.
The RCTs carried out on selenium have generated clear evidence
of adverse effects associated with selenium exposure, showing both
the health effects related to overexposure and the amount at which
these effects become evident, thus providing much more reliable
evidence than that generated by environmental studies such as
Vinceti 2017a for use in risk assessments of the safe upper limit
of selenium exposure in humans. The trial that provided the most
evidence about selenium-associated adverse effects was SELECT.
These effects include an excess risk of dermatitis and alopecia, non-
melanoma skin cancer, high-grade prostate cancer, and type 2 dia-
betes. The excess risk of dermatological effects was anticipated as a
potential side effect based on previous knowledge of health conse-
quences of human overexposure to this element (Vinceti 2001), al-
though such effects had been predicted to occur at higher amounts
of selenium exposure than those experienced by SELECT sup-
plemented participants, thus calling for reassessment of the up-
per limit of selenium exposure. The increased incidence of non-
melanoma skin cancer in NPCT and of advanced prostate cancer
in SELECT was extremely disappointing, as they were the pri-
mary endpoints in these studies, and the expectation was that they
would be reduced. The excess risk of diabetes in selenium-sup-
plemented NPCT participants, which was also an unanticipated
finding, was mostly limited to participants in the two highest ter-
tiles of baseline plasma selenium (> 105.2 µg/L), raising concern
about the safety of selenium amounts that thus far had been con-
sidered entirely safe (i.e. on the order of 200 µg/d) (Stranges 2007).
Therefore, subsequent RCTs added this endpoint to monitored
adverse effects that contributed to interruption of the SELECT
trial, together with the null effect on cancer mortality and adverse
effects of vitamin E on prostate cancer risk (Lippman 2009, in:
SELECT 2009). So far, all RCTs that included diabetes among
trial endpoints, including trials investigating risk of colorectal ade-
noma, have shownan increased incidence of type 2 diabetes among
selenium-allocated participants, with RRs ranging from 1.08 to
1.71, although most estimates were statistically imprecise (Vinceti
2017b). In addition, in SELECT, a slight decrease in excess risk
of diabetes in the intervention arm followed completion of se-
lenium supplementation, further suggesting a causal relation be-
tween selenium administration and the disease (Lippman 2009
and Klein 2011, in: SELECT 2009). Currently, an excess risk of
type 2 diabetes appears to be one of the adverse effects of selenium
of greatest concern, and its plausibility is supported by the results
of observational human studies (cohort, case-control, and cross-
sectional), as well as by some biological plausibility (Galan-Chilet
2017; Su 2016; Thompson 2016; Vinceti 2015; Vinceti 2017b;
Zhou 2013). These side effects, in addition to the null results of
RCTs, particularly of those of the highest quality, make imple-
mentation of new trials very unlikely owing to ethical concerns.
Observational studies and aetiological association
From our meta-analyses of 16 prospective observational studies
on overall cancer risk, we found lower cancer risk associated with
highest selenium exposure compared with lowest exposure. Risk of
cancerwas 28%(95%CI7%to45%) lower in the highest category
of selenium exposure than in the lowest, and risk of death from
cancer was 24% (95%CI 3% to 41%) lower. Subgroup analyses by
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sex yielded increased evidence of this inverse association between
selenium exposure and cancer risk in men compared with women.
The inverse association between overall cancer risk and baseline
selenium levels was mainly attributable to lower risks of gastroin-
testinal, lung, and bladder cancer, and for men also prostate can-
cer. No association was seen between selenium and risk of breast
cancer in women. However, when the amount of baseline expo-
sure was taken into consideration, no clear and consistent trend
between baseline selenium exposure and risk emerged for any of
the major outcomes investigated in observational studies. Lack of
lower risk of cancer in the highest versus the lowest selenium cat-
egory among participants with the lowest baseline exposure levels
compared with those with intermediate or high levels, for overall
cancer, lung cancer, and prostate cancer, argues against a causal
association between selenium exposure and cancer risk. This is
supported by lack of a relation between differences in the highest
and lowest categories of selenium exposure and the corresponding
RR, further suggesting that larger differences in exposure are not
associated with large and consistent decreases in RR. Finally, fur-
ther uncertainty of the evidence generated by observational studies
arises from the inconsistent and sometimes sharply conflicting re-
sults on the same cancer type that emerged from different studies.
We saw little evidence of any effect of modification on the rela-
tion of selenium and cancer by geographical area of residence. It
should however be noted that most of the observational cohort
studies that we examined were conducted in Europe and in the
USA, and none were conducted in Africa or South America. This
regional distribution seems to reflect the under representation of
non-Western and resource-poor countries in epidemiological re-
search (Pearce 2004). Differential regional representation in epi-
demiological studies is of special interest for this review, as sele-
nium levels in humans around the world vary significantly. Even if
selenium levels measured in included cohorts reflect a broad range
of naturally occurring selenium exposure, investigators have re-
ported some of the lowest and highest levels of selenium exposure
in populations from South America (Jaffé 1992), Africa (Hurst
2013b), China (Li 2012), and India (Chawla 2016) - regions not
investigated by any of the reviewed observational studies, with
the exception of three Chinese trials. Concerning sex-related ef-
fects, our meta-analysis of longitudinal studies revealed an inverse
association between RR of cancer and selenium status in some
cases in men but not in women for the same cancer type. Un-
fortunately, although more than half of reviewed studies included
mixed-sex populations, most did not report sex-disaggregated re-
sults. In available sex-specific results, men are over represented -
a fact that may potentially hamper assessment of the relation be-
tween selenium exposure and cancer risk in women. Theoretically,
factors such as variations in body composition between men and
women, including lean body mass versus fat composition, or dif-
ferences in metabolism or in nutritional requirements (e.g. higher
antioxidant requirements, particularly for the urological system)
between the two sexes might be associated with differential effects
of selenium for prevention of cancer.
Concerning the indicator used to assess selenium exposure and its
relation with cancer risk, we observed generally null associations
when evaluating selenium status through assessment of dietary
intake, although some inverse associations at specific cancer sites
emerged when we used biomarkers such as blood or toenail sele-
nium levels.We extensively reviewed in the previous version of this
review the characteristics and limitations of indicators of selenium
exposure, with particular reference to dietary assessment meth-
ods and biomarkers, and inconsistencies across studies assessing
the validity of different indicators (Ashton 2009; Fairweather-Tait
2011; Jablonska 2015a; Vinceti 2014). In particular, a large body
of literature concerns the limitations of dietary assessment meth-
ods, mainly linked to large variations of selenium content in single
food types, and the limitations of biomarkers of exposure. Con-
cerning the latter, amajor source of exposure misclassification con-
sists of the different behaviours of inorganic and organic selenium
species, whose tendency to be retained in the body and to accumu-
late in specific body tissues greatly varies, although this does not
necessarily correlate with their biological activity (Behne 1996;
Behne 2010; Kim 2001; Michalke 2017; Panter 1996; Slavik
2008; Solovyev 2013; Steen 2008; Tiwary 2006; Vinceti 2013c).
Investigators have frequently proposed that selenoprotein activity
may be an indicator of selenium status and may be tested in as-
sociation with cancer risk (Vinceti 2017b), but this relation has
been questioned because different sources of oxidative stress, para-
doxically including pro-oxidant selenium species themselves, may
upregulate selenoprotein activity (Jablonska 2015a). Furthermore,
intake of heavy metals and other dietary factors such as vitamins,
metalloids, and amino acids (e.g. methionine) may modify the
health effects of selenium, or the relations between selenium ex-
posure and biomarkers (Jablonska 2015a; Vinceti 2000), owing to
metabolic interactions or changes in tissue-specific deposition and
retention of selenium (Behne 1996; Zeng 2005; Zwolak 2012).
Overall, available evidence indicates the potential for exposure
misclassification in observational studies on selenium, as well as
the pitfalls associated with an approach based on assessment of to-
tal selenium content in peripheral biomarkers, suggesting that in
some instances, measurements of nutritional intake might provide
better exposure estimates than are provided by biomarkers, par-
ticularly in the light of relative exposure to inorganic and organic
species of the element. In general, observational cohort studies on
selenium and cancer are expected to have been characterised by
random exposure misclassification, thus shifting RRs towards the
unity and reducing the ability to detect real associations. However,
some exposure misclassification may have been non-random, such
as that induced by smoking, which although it is a source of sele-
nium exposure also induces lower body selenium levels, possibly
owing to an effect of cadmium in increasing selenium excretion
(Vinceti 2000). In such cases, exposure misclassification based on
biomarkers (serum/plasma selenium levels)may have substantially
biased risk estimates and may have been associated with some
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degree of confounding due to the well-known effect of smoking
on cancer risk, which could not have been adequately captured
and controlled for. Inadequate control for smoking has been sug-
gested to be a major confounder inducing spurious associations
between low selenium levels and enhanced cancer risk in observa-
tional studies (Beane Freeman 2015).
In addition to exposure misclassification, and probably more im-
portant than this, a major issue affecting observational studies is
unmeasured confounding (Vinceti 2016a). This potential bias is a
matter of greater concern than exposure misclassification because
it may have systematically biased RRs in one direction, partic-
ularly for some cancer types. Moreover, detection (and control)
of this bias is extremely difficult and nearly impossible, given the
hundreds of nutritional and non-nutritional lifestyle variables that
may be associated with both variations in selenium intake and can-
cer risk. Among these factors are smoking (Beane Freeman 2015;
Vinceti 2013b), socioeconomic status - which appears to be pos-
itively associated with socioeconomic position in both men and
women (Gundacker 2006; Niskar 2003) -and most likely hun-
dreds of nutritional and toxicological factors that may vary in the
diet, together with selenium intake. An approach that would re-
duce the risk of unmeasured confounding in observational studies
might include investigation of dietary patterns rather than single
nutrients, but these investigations seem not to have made adjust-
ments for diet quality. Finally, it should be noted that most stud-
ies did not take into account the role of genetic factors (related
to selenoproteins or otherwise) in the relation between selenium
exposure and cancer risk, although some studies have suggested
the importance of such relations (Jablonska 2016; Meplan 2014);
the true relevance of genetic factors has not yet been well defined.
Some studies examining selenoprotein-related single-nucleotide
polymorphisms have suggested a role for genetic variants among
genes coding for selenoproteins in modifying cancer risk, or in de-
termining the relation between selenium exposure and subsequent
cancer risk, although results have not been consistent (Geybels
2013; Meplan 2012; Penney 2010; Penney 2013; Slattery 2012;
Takata 2011).
With awareness of the fundamental limitations of observational
studies, even of those of longitudinal design, which may avoid
selection bias or reverse causality, investigators designed and car-
ried out in the 1990s and the 2000s several experimental stud-
ies as RCTs investigating the effect of selenium supplements on
cancer risk. The evidence base from these intervention studies has
become so large and complete as to allow a comprehensive eval-
uation of cancer risk associated with selenium supplementation
for some specific cancer types. It is interesting to note that major
interest in the cancer preventive activity of selenium originated
not just from observational studies (mainly of ecological and co-
hort design) (Vinceti 2013b), but from a randomised trial - the
ad interim analysis of the NPCT, which was published in 1996
and attracted great interest from both the scientific community
and the general public because of the apparently large beneficial
effect that it reported (Clark 1996, in: NPCT 2002). Null results
of the most recent low-bias RCTs - Algotar 2013; Marshall 2011;
SELECT 2009 - also do not suggest a major or strong role of
genetic factors in modifying selenium and cancer relations, given
their generally null or troubling results. An exception can be seen
in recent data from SELECT, which suggest that a genetic variant
of the NKX3.1 androgen-regulated prostate tumour suppressor
protein may modify, or increase, the risk of prostate cancer asso-
ciated with selenium supplementation (Martinez 2014).
From a methodological perspective, we acknowledge that com-
parison of risks between highest and lowest exposure categories in
observational studies, as performed in the present meta-analysis, is
most suitable for identifying an effect when a consistent decrease
or increase is seen across absolute exposure levels. Other associ-
ations (e.g. threshold effects, U-shaped relations) may have been
missed by this method of meta-analysis, or their true effect might
have been diminished.
Overall completeness and applicability of
evidence
RCTs and preventive efficacy
This review investigated a diverse range of cancers, substantially
extending the analysis compared with that performed in previous
reviews. However, cancer is not a uniform condition, and malig-
nant neoplasms show great differences in tumour biology. Only
non-melanoma skin cancer, liver cancer, and prostate cancer have
been investigated as primary outcomes in the included prevention
trials, and, regarding these main outcomes, specific characteris-
tics of study populations may limit the generalisability of results.
Participants in included RCTs on skin and liver cancer belonged
to populations at high risk for the outcome under investigation,
and participants in high-quality prostate cancer trials were at av-
erage risk (Karp 2013; SELECT 2009), or at high risk (Algotar
2013; Marshall 2011), for this disease. Most participants in the
NPCT were older and white, predominantly male inhabitants of
the United States, and the most recent trials were limited to the
USA male population.
Average baseline seleniumexposure in theNPCTwas less than that
characterising subsequent trials carried out in the United States,
although it was more similar to that seen in some European popu-
lations. Although the NPCT suggested that selenium supplemen-
tation was beneficial only at the lowest range of baseline selenium
exposure, the most recent studies, carried out in populations gen-
erally characterised by higher average selenium exposure, did not
confirm such an interaction. The NPCT also found an indication
of strong effectmodification for sex, as demonstrated, for example,
by the HR for all cancers associated with selenium supplementa-
tion - 0.67 (95% CI 0.50 to 0.89) in men and 1.20 (95% CI 0.66
to 2.20) in women (NPCT 2002).
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Participants in the SELECT study on prostate cancer prevention
were apparently healthy men over 50 years of age from the general
population ofNorth America (SELECT 2009). A large sample size
and inclusion of non-white participants from different socioeco-
nomic backgrounds support the generalisability of study findings
to other adequately nourished populations.
Selenium supplements generally contain organic or inorganic
species of selenium, or a mixture of both (e.g. in the form of se-
lenised yeast). Different species of selenium may exhibit different
effects on human health. High-quality RCTs using selenised yeast
supplements, almost entirely comprising organic selenium forms
(Block 2004; Waters 2013), found no effect of supplementation
on the main study outcome and an indication of a harmful effect
(i.e. an excess diabetes risk) (Vinceti 2017b). The SELECT trial
used supplements of L-selenomethionine, which is themajor com-
ponent of selenised yeast, and also found no preventive efficacy.
The only two RCTs investigating sodium selenite supplements
found a protective effect against liver cancer, and null or adverse
effects on breast cancer risk, but we considered these trials to have
unclear risk of bias. It is unclear how applicable these results are
in other settings and in populations with a different nutritional
status. Interpretation of the results of clinical trials using selenium
supplements should consider the different chemical forms of sele-
nium, as well as their potentially different health effects when used
as supplements (Vinceti 2013c;Weekley 2013).Most studies used
organic selenium as selenised yeast (Algotar 2013; NPCT 2002),
or as selenomethionine (Marshall 2011; SELECT 2009). How-
ever, the chemical form used is unlikely to explain the differences
in results betweenNPCT and the other trials (Waters 2013).With
reference to this issue, of interest are the results of a ’natural experi-
ment’ that occurred in Northern Italy, wherein a small population
unintentionally consumed for several years drinking water with
an unusually high content of selenium in its inorganic hexavalent
form - selenate (Vinceti 2000). Follow-up of that population re-
vealed increased risk of neurodegenerative disease - a not entirely
unexpected finding owing to the potential neurotoxicity of inor-
ganic selenium (Vinceti 2014a), along with a slightly increased
risk of cancer, mainly due to excess risk of oropharyngeal cancer,
melanoma, kidney cancer, and lymphoid malignancies (Vinceti
2016b).
An important issue is the possibility that participants with low
baseline selenium status may experience an inverse association be-
tween selenium exposure and cancer risk, as suggested by some
trial authors (Lu 2016; Rayman 2009). This has been suggested to
explain the different results of SELECT and the NPCT, and could
also hypothetically explain, at least in part, the different relations
found in experimental as compared with observational studies.
NPCT found a strong beneficial effect of selenium supplementa-
tion among participants at the lowest tertiles of baseline selenium
levels; however, the risk of cancer changed abruptly from an appar-
ently protective effect in the two lower tertiles (HR 0.51 and 0.70)
to an excess risk in the highest tertile of plasma selenium (HR
1.20, 95% CI 0.77 to 1.86). This occurred despite a difference of
only 16.4 µg/L between lowest and highest tertiles, corresponding
to a change in dietary selenium intake as low as around 10 µg.
This would imply that such a small a change in selenium dietary
intake would change a strongly protective effect of the element on
cancer risk into a possibly detrimental effect - an implausible sce-
nario given the wide range of selenium intake (from about 20 to
several hundred micrograms) characterising Western populations.
Moreover, the intermediate tertile of baseline plasma selenium in
the NPCT (105.6 to 122.0 µg/L) appeared to be associated not
only with reduced overall cancer risk but also with an excess risk
of squamous cell skin carcinoma (HR 1.49, 95% CI 1.05 to 2.12)
and overall non-melanoma skin cancer (NPCT 2002), as well as
diabetes (RR1.36, 95%CI 0.60 to 3.09), whose risk also consider-
ably increased at the highest tertile of baseline selenium (Stranges
2007). Overall, this occurrence of both adverse and beneficial ef-
fects is unlikely if the selenium supplementation was serving to
remedy a selenium deficiency. In addition, the strongest effect of
selenium on overall cancer risk at lower levels of baseline selenium
status was due to a considerable decrease in prostate cancer, but
this finding was subject to detection bias because of a decreased
biopsy rate in selenium-supplemented participants, particularly in
those with lowest baseline selenium status, as recognised by inves-
tigators of the NPCT (NPCT 2002).
In addition, after NPCT, three of the four high-quality RCTs on
selenium supplementation for cancer prevention investigated the
possible modifying effect of baseline selenium exposure and found
no evidence of a beneficial effect of the intervention even in the
lowest baseline exposure category. For instance, in NBT (Algotar
2013), the average baseline plasma selenium level at the lowest
tertile of the study population was 101.1 µg/L - much lower than
the corresponding level at the middle tertile of NPCT (114.6 µg/
L), in which the HR of prostate cancer had been as low as 0.33
(95% CI 0.13 to 0.82). However, in this ‘low’ NBT subgroup,
investigators found no evidence of a beneficial effect of selenium
supplementation on prostate cancer risk. In the SWOG S9917
trial (Marshall 2011), data show no change in the null effect of se-
lenium in the two lowest categories (quartiles) of selenium intake,
whose boundaries were < 106 and 106 to132 µg/L - similar to
cutpoints of the two bottom NPCT tertiles and of the bottom cat-
egory of NBT. In these two subgroups of the SWOG population
with the lowest baseline selenium status, the RR of prostate cancer
was 0.82 (95% CI 0.40 to 1.69) and 1.38 (95% CI 0.68 to 2.78),
and in the third upper quartile, the RR was 0.98 (95% CI 0.58 to
1.68), suggestingno consistent trendof an inverse relationbetween
antecedent selenium exposure and effects of supplementation (as
was also shown by analysis for trend in this study). Investigators in
SELECT reported no reduction in cancer risk among selenium-
supplemented participants, although they did not provide specific
RRs according to baseline selenium status. Calculation of blood
selenium content distribution in SELECT, as well as in the three
other RCTs (NPCT, NBT, SWOG), showed substantial overlap
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of plasma and serum selenium levels between this large trial pop-
ulation and the other study populations (Figure 7). In addition, a
more recent case-cohort study carried outwithin SELECTassessed
the effect of selenium supplementation on prostate cancer risk,
taking into consideration baseline selenium exposure, as assessed
through toenail selenium levels. The study, which involved 1739
prostate cancer cases and 3117 controls, was unable to find a ben-
eficial effect of selenium supplementation in the lowest categories
(quintiles) of baseline toenail selenium (Kristal 2014). Actually, a
dose-response effect in that SELECT population emerged, but it
favoured an increased risk of (high-grade) prostate cancer induced
by selenium supplementation among participants belonging to the
two upper quintiles of baseline selenium exposure (Kristal 2014).
Therefore, it seems reasonable to agree with this SELECT state-
ment: “The analysis of our data using lower cut points for baseline
toenail Se categories, in an attempt to replicate findings from the
NPCT, also showed no evidence of benefit from supplementation
among men with low baseline Se status (data given in Results).
Given these findings, we believe it reasonable to conclude that Se
supplementation of men at the low range of Se intake common in
USA men will not reduce PCa risk” (Kristal 2014).
Figure 7. Baseline circulating selenium levels in the NPC trial (Duffield-Lillico 2003b in: NPCT 2002), the
NBT (Algotar 2013), SWOG trial (as plasma selenium) (Marshall 2011), and SELECT (as serum selenium)
(Lippman 2009, in: SELECT 2009). When median and interquartile values were reported, we estimated mean
and standard deviation according to Cochrane guidelines provided in Higgins 2011a.
Overall, results of recent high-quality RCTs do not support the
hypothesis that differing baseline selenium statusmay explain con-
flicting results between NPCT and SELECT (Lu 2016; Rayman
2009). Results of the most recent RCTs seem therefore to be ap-
plicable to populations with various degrees of background sele-
nium exposure, with the exception of populations characterised
by extremely low (< 20 µg) or high selenium intake.
Observational studies and aetiological association
We reviewed data from prospective observational studies in which
investigators measured selenium exposure in populations without
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evidence of cancer, who were then followed up for a specified pe-
riod of time.We limited our systematic review to cohort studies to
avoid or decrease two major sources of bias in observational inves-
tigations, particularly in case-control and cross-sectional studies
(i.e. selection bias and risk of reverse causality). Data continue to
show important differences among included studies in terms of
selenium exposure assessment, types of outcomes, and study pop-
ulations, which may affect their interpretation. The small number
of studies that examined most of the meta-analysed types of can-
cers prevented a thorough investigation of sources of heterogeneity
between study results. In particular, we had limited opportunity
to explore the influence of specific sources of bias or the method-
ological quality of epidemiological studies on heterogeneity.
Participants examined in this review update include more than
2,300,000 individuals, predominantly from Europe and North
America, and, to a much lesser extent, fromAsia and Australia.We
were able to identify no prospective observational studies on sele-
nium and cancer risk from Africa or South America. This regional
distribution reflects the under representation of non-Western and
resource-poor countries in epidemiological research (Pearce 2004).
Differential regional representation in epidemiological studies is of
special interest for this review, as selenium levels in humans around
the world vary significantly. Selenium levels measured in the in-
cluded cohorts reflect a broad range of naturally occurring sele-
nium exposure, as documented by several epidemiological studies
worldwide. However, some of the lowest and highest selenium lev-
els in humans have been reported in populations in South Amer-
ica (Jaffé 1992) - a region not investigated by any of the reviewed
observational studies.
More than half of the included studies enrolled mixed-sex popu-
lations, but most did not report sex-disaggregated results. In avail-
able sex-specific results, men are over represented - a fact that could
hamper potential assessment of the relation between selenium ex-
posure and cancer risk in women. Despite this sex imbalance, we
systematically saw stronger (inverse) associations with cancer risk
among men than among women, for whom such associations with
antecedent selenium status was nearly absent. This was true for
stomach, colorectal, and lung cancer, and, when added to the in-
verse association for prostate cancer, led to an impact on overall
cancer risk that was clearly lacking in women that could be due to
potential confounders (such as smoking, occupational exposures,
or other dietary factors) or to a real change in the association be-
tween selenium exposure and cancer risk in the two sexes.
The range of selenium exposure experienced by members of co-
horts investigated in the observational studies was generally lower
than that experienced by participants in RCTs, who added sup-
plemental selenium, generally 200 µg/d and in its organic forms,
to their usual background intake, which ranged from about 70 to
90 µg/d as organic selenium, although some RCTs provided no
estimate (Jablonska 2015a). It is theoretically possible that a pre-
ventive effect of selenium against cancer exists only at low (< 30
to 50 µg/d) intake of the element, and that it disappears at higher
intakes, when ‘saturation’ or ‘maximisation’ of selenoprotein ex-
pression driven by selenium occurs. Investigations have frequently
chosen this proteomic endpoint as a reference point for deriving
dietary reference values for selenium (Jablonska 2015a; Vinceti
2017a). Selenium exposure in the range of around 50 to 200 µg of
daily selenium intake has not been tested by intervention studies,
which have used larger amounts of supplemental selenium, and is
unlikely to be tested in RCTs in the future, given the termination
of past trials for futility or safety concerns. This possibility must be
considered, but within the context of the two fundamental limita-
tions of observational studies - exposure misclassification and un-
measured confounding, which limit the reliability of the evidence
they generate and its applicability in terms of cancer prevention.
A few lines of evidence suggest that even at low levels of selenium
exposure, it is unlikely that such an inverse association with cancer
risk exists. First, inconsistencies in the results found in our meta-
analysis for most cancer sites and lack of a dose-response relation
between cancer risk and selenium at varying levels of background
selenium exposure, or of a difference between highest and lowest
exposure categories, argue against a real relation between selenium
and cancer risk. Limited differences between highest and lowest
categories of selenium intake, often amounting to a difference of
only 20 to 30 µg per day, compared with large variations in sele-
nium intake worldwide (from 10 to 15 µg in low-selenium areas
up to several hundred µg in seleniferous areas), also argue against
a true relation. Finally, as previously described, some recent high-
quality RCTs investigated the effect of baseline selenium status on
cancer risk associated with selenium supplementation and found
no beneficial effect of selenium supplementation, even among par-
ticipants with the lowest amounts of baseline exposure. Overall,
these findings do not support an association between higher se-
lenium status and lower cancer risk independently from factors
such as sex, baseline selenium exposure, and cancer type. One
additional observational cohort study, which could not be meta-
analysed in this review because it was released in PubMed in July
2017, appears to confirm these conclusions (Sandsveden 2017).
Quality of the evidence
RCTs and preventive efficacy
SELECT (SELECT 2009), SWOGS9917 (Marshall 2011), NBT
(Algotar 2013), and ECOG5597 (Karp 2013) were the only trials
considered to have low risk of bias with adequate sequence gen-
eration, allocation concealment, blinding, and reporting of find-
ings, and the consistency of their findings for prostate cancer, as
well as for other cancer types for the two trials investigating them
(SELECT and ECOG 5597), added to the statistical power of
the major trial (SELECT), making their overall results highly reli-
able and suitable for yielding useful evidence to assess the relation
between selenium supplementation and cancer prevention. These
trials are also of major importance because (with one exception)
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they have provided information about baseline selenium exposure
and its possible modifying role and about the effect of selenium
supplementation on subsequent cancer incidence. Another impor-
tant feature of these trials has been their ability to address the issue
of selenium overexposure and related adverse effects owing to a
systematic surveillance system for adverse effects, as well as their
ability to extend the monitoring programme to additional effects,
if suggested by new analyses targeting previously unplanned sec-
ondary endpoints, as was the case for diabetes (Stranges 2007).
This is particularly relevant because all of these trials were planned
under the hypothesis, later found to be erroneous but at that time
endorsed by regulatory agencies, that the supplemental selenium
dose administered to intervention arms (200 µg/d in almost all
RCTs) was entirely safe and was well below the upper safe limit
of the element, even with consideration of background selenium
exposure.
These trials may continue to yield important results. Secondary
analysis of additional endpoints, or based on genetic and non-
genetic biomarkers of exposure to selenium and other factors, is
still possible. For example, major contributions were yielded by
SELECT in 2017, concerning outcomes such as prevention of
colorectal adenoma and of Alzheimer’s disease by selenium sup-
plementation, in both cases with null results (Kryscio 2017; Lance
2017).
We assessed the certainty of evidence from high-quality RCTs us-
ing the GRADE approach (http://gdt.guidelinedevelopment.org/
app/handbook/handbook.html#h.svwngs6pm0f2) and reported
the results of this assessment in the ’Summary of findings’ table
(Summary of findings for the main comparison). From prelimi-
nary assignment to a high level of certainty due to the experimental
study design, we did not identify reasons to downgrade trial qual-
ity according to standard GRADE guidelines for risk of all can-
cers, or for risk of colorectal, lung, bladder, or prostate cancer. In
contrast, meta-analysis for breast cancer risk yielded a statistically
imprecise result mainly reflecting the small number of cases, and
meta-analysis for non-melanoma skin cancer showed high statisti-
cal heterogeneity across studies. When addressing factors possibly
increasing the certainty of evidence assessment, we considered as
non-applicable the GRADE item “All plausible confounding would
reduce the demonstrated effect or increase the effect if no effect was
observed”, neither could we evaluate possible dose-response gradi-
ents because unfortunately theywere not tested in these RCTs. We
therefore rated the certainty of evidence as ‘high’ if it indicates no
effect of selenium supplementation on all cancers overall, nor on
colorectal, lung, bladder, and prostate cancer, and we considered
certainty of the evidence as ‘moderate’ if it indicates no effect on
non-melanoma skin cancer and breast cancer, with downgrades
due to heterogeneity and imprecision, respectively. However, stat-
ing that the evidence supporting no effect of selenium on cancer
prevention at these sites is of moderate rather than high certainty
does not mean that the only alternative hypothesis is necessar-
ily that selenium decreases risk of cancer at these sites. Actually,
the overall results of high-quality RCTs, when available, suggest a
slight to moderate although statistically imprecise increase in the
risk of some of these specific cancers following selenium supple-
mentation.
Concerning the RCTs that we downgraded in our appraisal of risk
of bias, we considered the quality of reporting to be an issue in the
three trials on liver cancer prevention, thus leading to their classifi-
cation as having unknown risk of bias. Several papers reported the
individual trials, in some cases discrepantly, and essential questions
regarding sequence generation, allocation concealment, handling
of dropouts and withdrawals, and detection of outcomes remain
unanswered. This might be due to inadequate reporting but might
also hint at flaws in trial design and implementation. We were un-
certain about whether the only trial that reported positive results
for selenium supplements in liver cancer prevention randomly as-
signed participants individually. Cluster randomisation of partic-
ipants who lived in the same area/village, which may have been
the procedure used in this investigation, might have introduced
additional bias to the study results (e.g. as the result of different
environmental factors contributing to liver cancer development
or detection) and might have led to an overestimation of the pro-
tective efficacy of selenium. Duplication of results of trials based
on a rigorous study design would be necessary to assess the effects
of sodium selenite on liver cancer incidence. With regard to the
NPCT (NPCT 2002) and the trial of Dreno 2007, indications of
serious detection bias for the USA study and of unclear method-
ological details (such as blinding) for the French investigation led
us to consider these experimental studies to be at unclear risk of
bias, as discussed in greater detail elsewhere in this review. As far as
the trial on breast cancer is concerned (Lubinski 2011), our down-
grade of evidence certainty was based on incomplete information
provided in the only report that we could retrieve (an abstract),
although we acknowledge the relevance of that trial - the only trial
specifically targeting breast cancer and a genetically specific pop-
ulation - and the fact that complete reporting of trial procedures
may lead to reassessment of trial quality and its upgrade.
Observational studies and aetiological association
The 70 observational studies were heterogeneous, not only in
methodology, but also in the quality and level of detail of reporting
and in their potential biases. We assessed our confidence in the
evidence from these studies using the GRADE approach and re-
ported our findings in Summary of findings 2; we reported judge-
ments only for those outcomes evaluated in the ’Summary of find-
ings’ table for RCTs with low risk of bias.
Confounding and other biases
Selenium measurement and exposure misclassification
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All studies on total cancer risk identified cases by using registry
links or a combination of several methods, and losses to follow-up
were generally very low. One study on cancer incidence and two
studies on cancer mortality analysed less than 80% of all identified
cases (incidence: Coates 1988: 79%; mortality: Kok 1987a: 71%;
Kornitzer 2004: 57%). The main reason for this loss of sample
was missing selenium measurements. Not all studies that assessed
mortality as a measure of cancer risk excluded people with cancer
at study inception. This might have led to overestimation of a
protective effect if selenium levels were lowered by the presence of
cancer. We therefore consider the results for cancer incidence to
be more valid than the cancer mortality results.
Concerning the outcome most frequently investigated - prostate
cancer - all but two of the included studies identified cases by us-
ing links to cancer registries or a combination of personal follow-
up interviews with PSA screening. Two studies with health pro-
fessionals used self-reporting for case identification, followed by
confirmation through medical records. The number of people lost
to follow-up was low in all included studies. However, two stud-
ies included less than 80% of all identified cases in their analyses
because samples were not available for selenium measurement, or
diagnosis was not confirmed (Brooks 2001: 39%; van den Brandt
2003, in: van den Brandt 1993: 77%). In Brooks 2001, bias might
have been introduced to the results to some extent, as demographic
variables differed between identified and analysed cases.
Residual confounding and effect modification
Most of the included studies used controls for smoking and age by
matching or using multi-variate techniques. However, the control
for self-declared smoking habits may be inadequate, and this may
occur particularly in people with a diagnosis of cancer (Connor
Gorber 2009; Gerritsen 2015; Morales 2013). Control for smok-
ing as a known risk factor for several types of cancer is an impor-
tant issue in epidemiological studies on cancer risk, and inade-
quate control for this cancer risk factor has been recognised as a
major methodological issue affecting observational research on se-
lenium and cancer (Beane Freeman 2015). This possible bias may
be particularly relevant for research on selenium biomarkers and
cancer. Cigarette smokers tend to have lower selenium biomarker
levels, although cigarette smoking in itself is a source of selenium
exposure. In addition to this source of non-random exposure mis-
classification, it is well recognised that smoking is a powerful can-
cer risk factor, thus qualifying it also as a major confounder when
the selenium and cancer relation is investigated. Therefore, an in-
verse association between low baseline selenium status and lung
cancer risk might be the result of residual confounding and effect
modification by smoking, and this may also be true for other can-
cer types (Beane Freeman 2015). Exposure to environmental and
household smoking, which has been shown to be associated with
increased risk of cancer (Gorlova 2006; Nishino 2001), might be
associated with selenium status due to differential nutritional be-
haviours or other mechanisms.
Several other factors may act as effect modifiers or confounders.
Possible confounding factors could consist of another food nutri-
ent or a certain behaviour that exhibits cancer protective effects and
may be associated with higher intake of selenium-rich foods. The
number of candidates for such a role is so large that no observa-
tional study can measure all of these factors nor account for them.
Furthermore, it is well known that intake of heavy metals (such
as arsenic, cadmium, and mercury) and other dietary factors such
as methionine may substantially modify selenium health effects or
relations between selenium exposure and biomarkers (overview,
in: Vinceti 2000; Zeng 2005; Zwolak 2012), and may potentially
confound the association between selenium and cancer.
Some potential confounders cluster in population groups accord-
ing to socioeconomic position (SEP), and this factor has been
shown to vary together with selenium status in both men and
women (Gundacker 2006; Niskar 2003). Only a few studies at-
tempted to control for indicators of adult SEP as potential con-
founders (e.g. education, occupation, income). None used a com-
posite index of indicators or considered childhood SEP. Some stud-
ies restricted their cohorts to certain subgroups of a population,
such as occupational groups, and were likely to include only peo-
ple of a similar adult socioeconomic background.
It has been claimed that associations between vitamins and dis-
eases are the result of confounding by social and behavioural fac-
tors acting over the course of a lifetime (Lawlor 2004). Lawlor
2004 argued that divergent results from epidemiological and ran-
domised controlled studies on prevention of cardiovascular disease
can be explained by unmeasured confounding due to SEP. Risk of
most cancers is known to decrease with higher SEP. Research also
indicates a positive association between higher SEP and selenium
biomarkers (Barany 2002; Niskar 2003). However, other investi-
gations have not confirmed these findings: Kant 2007, for exam-
ple, did not find an association between a measure of household
poverty and selenium status.
The hypothesis of possible confounding due to SEP leading to an
indirect association between selenium and cancer would be con-
sistent with results of observational studies for all types of can-
cers in this review, with the exception of prostate cancer. Dalton
2008 found that prostate cancer has been diagnosed more often
in men of a higher SEP, and we saw a protective association of
higher selenium exposure with this cancer type. It remains unclear
whether the more frequent diagnosis of prostate cancer in men
with a higher SEP actually reflects an excess of prostate cancer
incidence in this population. It might also result from differential
health and screening behaviours leading to detection of otherwise
symptom-free cases, while men with a lower SEP tend to be over
represented in diagnoses of the disease at advanced stages (Rapiti
2009). More information on screening and diagnostic behaviours
of male cohort participants would be necessary to further elucidate
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these issues.
Another consideration is genetic factors, which may both con-
found and modify the role of selenium in cancer prevention and
causation. Recent observational studies examining selenoprotein-
related single-nucleotide polymorphisms have suggested a role for
genetic variants in genes coding for selenoproteins or other pro-
teins in modifying cancer risk, or even the relation itself between
selenium and cancer risk, although results have not been consistent
(Gerstenberger 2015; Geybels 2013; Jablonska 2015b; Meplan
2015). Null results of the most recent low-bias RCTs do not sug-
gest that at least the most frequent genotypes strongly influence
the selenium and cancer relation (Algotar 2013; Marshall 2011;
SELECT2009), although such hypotheses cannot be ruled out for
more rare genetic variants of selenoproteins or other proteins. Hy-
pothetically, different genetic factors could increase and decrease
the risk of cancer associated with selenium exposure, cancelling
each other out and resulting in an overall null effect. Additional
data from SELECT based on genotyping of study participants, if
available, might be extremely useful for assessing hypotheses re-
garding genetic variants of selenoenzymes and their interaction
with selenium status. So far, the only evidence derived from SE-
LECT indicates that single-nucleotide polymorphisms related to
the prostate tumour suppressor protein NKX3.1 gene (CC geno-
type at rs11781886) may increase cancer risk following selenium
supplementation (Martinez 2014). Recent observational evidence
also suggests that polymorphisms of selenoproteins and other an-
tioxidant proteins inmenwith non-metastatic prostate cancermay
be associated with increased risk of high-grade disease and subse-
quent prostate cancer recurrence (Gerstenberger 2015).
Summary
In observational studies, factors thatmay have accounted for inter-
study heterogeneity and that may have biased study results include
type of outcome measure, exposure assessment, sex, incomplete
control for confounding (smoking and socioeconomic position),
and unmeasured confounding, linked to both dietary and non-di-
etary factors. Given the high risk of bias due to these factors, partic-
ularly to the unmeasured confounding inherent in observational
studies, along with conflicting results of several studies and lack of
any modification of the selenium and cancer relation by level of
baseline selenium exposure and by the difference between highest
and lowest selenium categories, we consider the evidence provided
by observational studies to have very low certainty (Summary of
findings 2); therefore these results must be interpreted with great
caution and do not allow firm conclusions about a possible can-
cer-preventive effect of selenium intake. Meta-analyses of spuri-
ous findings in observational studies enhance the precision of a
summary risk estimate, which does not itself get nearer to the true
value and may suggest a non-existent association (Egger 1998).
Potential biases in the review process
RCTs and preventive efficacy and observational
studies and aetiological association
The literature search includedmajor international databases in the
English and German languages, and we applied a broad search
strategy supplemented by handsearching for references.We assume
that we identified all randomised controlled studies and prospec-
tive observational studies relevant to our review questions. As we
did not search databases in other languages (e.g. Chinese, Rus-
sian), we cannot rule out that we might have missed smaller stud-
ies that were not published in international journals. However, we
consider it unlikely that we could have missed major sources of
evidence through our approach. We also might have missed ob-
servational studies whose results on selenium exposure and cancer
were reported in the body of a paper but were not mentioned in
the paper’s title or abstract, even if the paper is indexed in the
searched databases. However, our systematic use of backward and
forward citation chasing and our search for relevant abstracts in
conference proceedings or related material should have substan-
tially decreased the risk of missing literature that could have been
relevant for our assessment.
When needed because of lack of complete or appropriate partic-
ipant data (e.g. when cohorts including cancer and non-cancer
participants were mixed in data analysis), we contacted study in-
vestigators to ask for data missing from their studies. We also did
this when we did not have enough data from published reports
to adequately appraise study risk of bias. Sometimes we were un-
able to obtain answers to questions that we had regarding meth-
ods or outcomes, but frequently investigators kindly gave us the
information we needed. We were sometimes unable to obtain an-
swers, particularly for earlier epidemiological studies from which
primary investigators may have relocated or died, or we found that
data were not available in a current electronic format. Similarly,
we could not make contact with primary investigators of Chinese
RCTs.
We based our risk of bias assessment on information included in
the original publications, unless the trial authors that we contacted
gave us additional details. This means that in some instances, we
may have overestimated the true risk of bias of studies that did not
adequately describe their design in the original publications, such
as Lubinski 2011.
Another concern, especially with epidemiological studies, is pub-
lication bias. Cohort and nested case-control studies often are not
exclusively designed to test for a specific exposure-outcome asso-
ciation but enable investigators to investigate a range of questions.
It is conceivable that unfavourable results were less likely to be
published, although we could not find evidence supporting such a
hypothesis. Our analysis of this issue through use of a funnel plot
gave some support to publication bias for prostate cancer.
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We systematically meta-analysed RCTs even when only two stud-
ies were available (Karp 2013; NPCT 2002). Finally, we carried
out two meta-analyses of intervention studies - one on all studies,
and another on RCTs assessed through a standard appraisal tool as
being at low risk of bias - and we emphasised results of the latter,
as derived from high-quality experimental studies. For observa-
tional studies, we decided a priori to conduct meta-analyses only
when five or more studies were available for a study outcome, thus
excluding from meta-analysis the few endpoints for which up to
four studies were available (Table 1). Our primary intention was
to facilitate the investigation of heterogeneity between studies in-
cluded in meta-analyses, to avoid producing more precise, but still
unexplainably biased, results. However, our emphasis was clearly
given to experimental studies because this trial design is widely
recognised as the only one that may provide convincing evidence
of an association between a factor and disease risk, or more gen-
erally biological endpoints, and this may be particularly true in
nutritional epidemiology (Vinceti 2016a).
Finally, the authors of this review, as already noted in the previous
version of the review, came from different disciplines and have
different areas of focus (e.g. epidemiology, biostatistics, clinical
medicine, nutrition). We continue to consider such variety of ex-
pertise to be a strength of this review, and we made use of it by
applying multiple checking procedures during the entire review
process whenever possible.
Agreements and disagreements with other
studies or reviews
Recent reviews that have investigated the relation between se-
lenium and cancer prevention have generally concluded that
this trace element has no clear beneficial effect(Bjelakovic 2012;
Cortes-Jofre 2012; Cui 2017a; Fortmann 2013; Kushi 2012;
Moyer 2014; Posadzki 2013; Schwingshackl 2017), although up-
dated systematic reviews and meta-analyses on selenium encom-
passing all of the most recent intervention studies are lacking.
These results are true for both all cancers and prostate cancer, and
for other specific cancers, such as lung cancer. The turning point
in the evaluation of the effect of selenium on cancer risk is gen-
erally acknowledged to have been SELECT, and the other trials,
although their findings are consistent with SELECT, have received
less attention, probably mainly because of their smaller size. It is
understandable that most of the selenium trials under way during
the 2000s and the 2010s and originally implementedmainly as the
result of the promising results of the original NPCT, particularly
its ad interim 1996 report, were eventually discontinued owing
to the results of SELECT (which was discontinued too) and the
null results of ad interim futility analyses (Vinceti 2017b). This
seems also to be true for Brodin 2015, Chen 2013, and Vinceti
2017a - planned RCTs on the possible utility of selenium for can-
cer therapy - and is an issue of considerable interest that has been
investigated so far in very few phase 2 and phase 3 trials (Goossens
2016; Karamali 2015; Muecke 2014; Stratton 2010) (although
other trials appear to be under way such as Vinceti 2017b).
Concerning observational studies, very few recent reviews have in-
vestigated the selenium and cancer relation, and they have focused
on only a few cancer sites. These reviews have generally yielded
results consistent with ours. For prostate cancer, a recent review
found no association between baseline serum selenium and risk
in cohort studies (Cui 2017b), as was reported by Allen 2016,
which conducted a pooled analysis using individual data from 15
cohort studies. However, in the latter review, baseline serum sele-
nium status was determined to be inversely associated with high-
grade prostate cancer risk, as was toenail selenium and subsequent
prostate cancer incidence. Gong 2016 also found reduced risk of
gastric cancer among participants in the highest baseline selenium
exposure category. Other reviews and meta-analyses considered
other cancer types such as liver, pancreatic, lung, and breast cancer,
but these reviews generally incorporated case-control and cross-
sectional studies in addition to cohort studies, further increasing
the risk of bias due to heterogeneity of study designs. Most reviews
on observational studies have acknowledged the key methodolog-
ical issues noted in this type of study, namely, risk of unmeasured
confounding and potential biases associated with this limitation.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
A large body of evidence is now available from high-quality ran-
domised controlled trials on effects of selenium supplementation
on cancer risk, with two new studies published since the last ver-
sion of this review (Vinceti 2014). None of the new relevant stud-
ies have provided information to change the conclusions of the
previous version of this review.Overall, results of these studies have
consistently shown no effect of selenium in preventing the type of
cancer most consistently and strongly associated with antecedent
selenium exposure - prostate cancer - or in preventing cancer over-
all, even when assessment focused on participants with the low-
est selenium status at baseline. These intervention studies have
suggested that selenium administration on the order of 200 µg/
d increased risk of non-melanoma skin cancer, advanced prostate
cancer (in individuals with highest baseline exposure), dermato-
logical abnormalities, and type 2 diabetes. No trial involving ad-
ministration of low doses of selenium, on the order of 50 to 100
µg/d, has been performed so far.
An update of the meta-analysis of observational cohort studies
continues to show lower risk of cancer and of some specific cancers
(colorectal, prostate, and breast) in participants with highest ex-
posure levels at baseline, but these studies are at substantial risk of
bias from exposure misclassification and unmeasured confound-
ing. In addition, results of these observational studies are incon-
sistent and sometimes are strongly conflicting, and no evidence
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of any dose-response relation emerged from our analysis when we
considered background selenium status or differences in baseline
selenium exposure.
Overall, findings of our review do not provide evidence supporting
a cancer-preventive effect of selenium in humans.
Implications for research
Some questions regarding selenium, such as whether selenium
might influence cancer risk in individuals with very low or very
high baseline exposure to this element, or in individuals with dif-
ferent genotypes, have not been fully resolved, although currently
available evidence from randomised trials offers little support for
such hypotheses. For ethical reasons, in the light of potential tox-
icity of selenium supplementation and failure of the most recent
and well-conducted experimental cohort studies to find beneficial
effects, new randomised trials on the selenium and cancer rela-
tion are unlikely to be undertaken in the future. Therefore ex-
panding results of the SELECT trial and of other high-quality tri-
als to examine additional outcomes such as liver cancer and non-
melanoma skin cancer, as recently happened for other outcomes
(Kryscio 2017; Lance 2017), and to analyse subgroups with spe-
cific characteristics (baseline selenium exposure and genetic fac-
tors), continues to appear to be the best available option for clari-
fying these issues. Unfortunately, most of these randomised con-
trolled trials (RCTs), including the Selenium and Vitamin E Can-
cer Prevention Trial (SELECT), could not address possible sex dif-
ferences because they enrolled only men.
Finally, when interpreting the results of both intervention and
observational studies, it must be taken into account that various
chemical forms of selenium have very different nutritional and
toxicological properties, and that almost all observational studies
have assessed only total selenium exposure. Future observational
studies would contribute to a better understanding of the selenium
and cancer relation by including selenium speciation among their
exposure assessment methods when evaluating cancer risk.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Agalliu 2011
Methods Nested case-cohort study
Country: Canada
Participants Name of parent cohort: Canadian Study of Diet, Lifestyle and Health (CSDLH)
Participants: 22,975 (alumni associations of the University of Western Ontario, 67% of 34,
291)
Recruitment: between 1995 and 1998
Outcome assessment: December 2003
Number of cases:
• Prostate cancer: 661
Case definition: incidence
Years of follow-up: 4.3 to 7.7 mean
Type of selenium marker: supplementation
Interventions d.n.a.
Outcomes Statistical methods: Cox proportional hazard model
Variables controlled in analysis: age at baseline, race, BMI, exercise activity, education
Risk estimates [95% CI] Reference category: zero
Results:
Prostate cancer
• Highest quartile: HR 0.76 (95% CI 0.43 to 1.33)
Selenium levels in exposure categories Lowest quartile (median value): 15.7 µg
Highest quartile (median value): 105.0 µg
Notes
Akbaraly 2005
Methods Cohort/subcohort controlled cohort study
Country: France
Participants Name of parent cohort: Etude du Vieillissement Antériel Study (EVA study)
Participants: 1389 (41% male, 59% female)
Inclusion criteria: 59 to 71 years of age; residents of Nantes; able to undergo examination at
study centre
Recruitment: 1991 to 1993
Outcome assessment: December 2001
Number of cases:
• Any cancer: 45 (male/female: n.r.)
Case definition:mortality
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Akbaraly 2005 (Continued)
Years of follow-up: 9.0
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Statistical methods: Cox proportional hazard model
Variables controlled in analysis: gender, smoking, alcohol intake, medication use, obesity,
diabetes mellitus, hypertension, CVD, age, education, dyslipidaemia, low cognitive function
Risk estimates [95% CI] Reference category: highest quartile
Results:
Any cancer
• Both genders: lowest quartile: RR 4.06 (95% CI 1.51 to 10.92)
Selenium levels in exposure categories Lowest quartile: 14.2 to 75.0 µg/L
Highest quartile: 96.3 to 155.6 µg/L
Notes
Algotar 2013
Methods Randomised controlled trial
Allocation: random
Sequence generation: unclear
Concealment: Study agent (2 doses) and matched placebo caplets were coated with tita-
nium oxide to ensure identical appearance, weight, taste, and smell
Blinding: described only as double-blinded
Dropouts/withdrawals: Study dropout percentage was 34.1%, 41.9%, and 40.8% for
placebo, 200 mg/d selenium group, and 400 mg/d selenium group, respectively (P = 0.
173)
Intention-to-treat-analysis: yes
Recruitment period: not specified
Treatment duration: not specified
Observation period/dermatological follow-up:
Participants were followed every 6 months for up to 5 years.
Detection of cases: Tissue samples from participants’ qualifying biopsies were requested
by participants’ physicians and were compiled in a biospecimen repository
Informed consent: An external Data and Safety Monitoring Committee (DSMC) was
established before study initiation. This committee was responsible for reviewing pro-
tocol amendments, consent forms, accrual and retention rates, adverse events, and data
analysis reports
Participants 699 male participants with a negative prostate biopsy
Countries: United States, New Zealand
Participants: 699 (randomised to selenium 200 µg/d: 234; to selenium 400 µg/d: 233;
to placebo: 233)
Condition:male patients at high risk for prostate cancer (prostate-specific antigen (PSA)
> 4 ng/mL and/or suspicious digital rectal examination and/or PSA velocity > 0.75 ng/
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Algotar 2013 (Continued)
mL/y), but with a negative prostate biopsy
Demographics:mean age 65.2 ± SD 8 years (selenium 200 µg/d), 65.5 ± 7.7 years (sele-
nium 400 µg/d), 65.5 ± 7.4 years (placebo)
Recruitment and setting: urology offices at 20 sites in the United States and New Zealand
Interventions Intervention:
• 200 µg/d selenium supplied as selenium yeast
• 400 µg/d selenium supplied as selenium yeast
Control: placebo
Recruitment: not reported
End of blinded treatment period: For participants in the United States, participation was
complete at 5 years, whereas those in New Zealand received intervention for no longer
than 3 years
Outcomes Primary outcome measure:
• Incidence of biopsy-proven prostate cancer over the course of the study
Other reported outcomes:
• Secondary endpoint was rate of change of PSA over time (i.e. PSA velocity) based on
biannual PSA measurements
Risk estimates [95% CI] Primary outcomes:
• Hazard ratios for risk of developing prostate cancer in the selenium 200-µg/d or the
selenium 400-µg/d group were 0.94 (95% CI 0.52 to 1.7) and 0.90 (95% CI 0.48 to 1.
70), respectively
Other reported outcomes:
• PSA velocity in the selenium arms was not significantly different from that observed
in the placebo group (P = 0.18 and P = 0.17, respectively)
Selenium levels in exposure categories d.n.a.
Notes The DSMC recommended that the trial be stopped before all participants completed
the full intervention duration
Adverse effects:No significant differences were seen in the incidences of cataract/glaucoma
or in hair/nail changes in the 3 treatment groups
HR: adjusted for age at baseline, baseline PSA, baseline selenium concentrations
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Number-based stratified randomisation
Allocation concealment (selection bias) Low risk Treatments and placebo tablets of identical
appearance and taste
Blinding (performance bias and detection
bias)
All outcomes
Low risk Identical appearance, weight, taste, and
smell of tablets for treatments and placebo
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Algotar 2013 (Continued)
Selective reporting (reporting bias) Low risk No problems found
Allen 2008
Methods Matched, nested case-control study
Countries: Denmark, Germany, Greece, Italy, the Netherlands, Spain, Sweden, the UK
Participants Participants: approximately 130,000 men
Inclusion criteria: male participants from the EPIC study
Name of parent cohort: European Prospective Investigation into Cancer andNutrition (EPIC)
Recruitment: 1992 to 2000
Outcome assessment: at each country’s study closure date (between June 1999 and January
2003)
Number of cases:
• Prostate cancer: 959 (male/female: 959/0)
Case definition: incidence
Years of follow-up: median 2.6 (Greece) to 9.2 (Sweden)
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Statistical methods: conditional logistical regression
Variables controlled in analysis:BMI, smoking, alcohol consumption, physical activity,marital
status, education
Variables controlled by matching: age, study centre, time of day of blood collection, time
between blood collection and last meal, sex
Risk estimates [95% CI] Reference category: lowest quintile
Results:
Prostate cancer
• Highest quintile: OR 0.96 (95% CI 0.70 to 1.31)
Selenium levels in exposure categories Lowest quintile < 62.0 µg/L
Highest quintile ≥ 84.1 µg/L
Notes
Banim 2013
Methods Nested case-cohort study
Country: UK
Participants Participants: 23,658 men and women
Inclusion criteria: aged 40 to 74, resident in Norfolk county, registered at 35 general practices
in rural, suburban, and inner city areas, no history of pancreatic cancer at enrolment or
within 12 months of entering the study
Name of parent cohort: European Prospective Investigation of Cancer-Norfolk Study (EPIC-
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Banim 2013 (Continued)
Norfolk)
Recruitment: 1993 to 1997
Case definition: incidence
Type of selenium marker: intake
Banim 2013:
Outcome assessment: June 2010
Number of cases:
• Pancreatic cancer: 86 (male/female: 38/48)
Years of follow-up: 17
Barrass 2013:
Outcome assessment:December 2010
Number of cases:
• Renal cell carcinoma: 65 (male/female: n.r.)
Years of follow-up: not reported (probably 17)
Interventions d.n.a.
Outcomes Statistical methods: Cox proportional hazard model
Variables controlled in analysis: age, sex, smoking, diabetes, total energy intake, body mass
index category, respective antioxidant supplement (only Banim 2013)
Risk estimates [95% CI] Reference category: lowest quartile, lowest quintile
Results:
Banim 2013:
• Pancreatic cancer: highest quartile: HR 0.72 (95% CI 0.36 to 1.43)
Barrass 2013:
• Renal cell cancer: highest quintile: HR 0.40 (95% CI 0.17 to 0.98)
Selenium levels in exposure categories Banim 2013:
• Lowest quartile < 43.6 µg/d
• Highest quartile ≥ 72.0 µg/d
Barrass 2013:
• Lowest and highest quintiles not reported
Notes
Bleys 2008
Methods Cohort study
Country: United States
Participants Name of parent cohort:ThirdNational Health andNutrition Examination Survey (NHANES
III)
Inclusion criteria:male and female adults, aged 20 to 90 years, participating in the NHANES
III: “stratified, multistage probability cluster to provide data representing the noninstitution-
alized US population” (Bleys 2008, p. 404)
Recruitment: 1988 to 1994
Participants: 13,887 men and women
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Bleys 2008 (Continued)
Outcome assessment: 15 December 2000
Number of cases:
• Cancer deaths: 457 (male/female: n.r.)
Case definition:mortality
Years of follow-up: 6 to 12
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Analysed cases: 457 (male/female: n.r.)
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, sex, race, education, annual family income, post-
menopausal status (women), cigarette smoking, serum cotinine level, alcohol consumption
Risk estimates [95% CI] Reference category: lowest tertile
Results:
Cancer deaths
• Both genders: highest tertile: HR 0.69 (95% CI 0.53 to 0.90)
• Both genders: highest tertile: HR 0.68 (95% CI 0.48 to 0.97); cases at baseline excluded
Selenium levels in exposure categories Lowest tertile < 117.31 µg/L
Highest tertile ≥ 130.39 µg/L
Notes Updated results with longer follow-up for the same population reported in Goyal 2013
Brooks 2001
Methods Matched, nested case-control study
Country: United States
Participants Name of parent cohort: Baltimore Longitudinal Study of Aging
Participants: 1555 men
Inclusion criteria: n.r.
Recruitment: n.r.
Outcome assessment: n.r.
Number of cases:
• Prostate cancer: 52 (male/female: 52/0)
Case definition: incidence
Years of follow-up: n.r.
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Analysed cases: 52 of 133 (reason for non-inclusion: plasma and/or histological confirmation
of diagnosis not available)
Statistical methods: logistical regression
Variables controlled in analysis: years between blood donation and diagnosis/follow-up, age,
age by years before diagnosis interaction, BMI, smoking history, alcohol use
66Selenium for preventing cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Brooks 2001 (Continued)
Variables controlled by matching: age
Risk estimates [95% CI] Reference category: lowest quartile
Results:
Prostate cancer
• Highest quartile: OR 0.24 (95% CI 0.07 to 0.77)
Selenium levels in exposure categories Lowest quartile: 82 to 107 µg/L
Highest quartile: 133 to 182 µg/L
Notes
Clark 1985
Methods Cohort/subcohort controlled cohort study
Country: United States
Participants Participants: 177; no information on gender
Inclusion criteria: persons at high risk of non-melanoma skin cancer
Recruitment: n.r.
Outcome assessment: n.r.
Number of cases:
• Skin (non-melanoma): 19 (male/female: n.r.)
Case definition: incidence
Years of follow-up: mean 3
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Statistical methods: Cox proportional hazard model
Risk estimates [95% CI] Reference category: lower half
Results:
Skin (non-melanoma)
• Sex n.r.: higher half: RR 0.77 (CI not reported)
Selenium levels in exposure categories n.r.
Notes
Coates 1988
Methods Matched, nested case-control study
Country: United States
Participants Participants: 6167; both genders
Inclusion criteria: employees of 2 Seattle companies
Recruitment: 1972 to 1973 and 1976
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Coates 1988 (Continued)
Outcome assessment: not stated
Number of cases:
• Any cancer: 154 (male/female: n.r.)
• Gastrointestinal cancer: 28 (male/female: n.r.)
• Breast cancer: 20 (male/female: 0/20)
• Prostate cancer: 13 (male/female: 13/0)
• Haematological cancers: 12 (male/female: n.r.)
• Cervical cancer: 12 (male/female: 0/12)
• Lung cancer: 11 (male/female: n.r.)
• Other: 58 (male/female: n.r.)
Case definition: incidence
Years of follow-up: n.r.
Type of selenium marker: serum and plasma
Interventions d.n.a.
Outcomes Analysed cases: 154 (133 serum, 21 plasma) of 195 collected (reason for non-inclusion: no
sample available for analysis or no control available)
Statistical methods: conditional logistic regression
Variables controlled by matching: age, gender, race/ethnicity, year/month of sample collection,
employer, plasma or serum sample
Risk estimates [95% CI] Reference category: lowest
Results:
Any cancer
• Both genders: highest quintile: OR 1.0 (95% CI 0.5 to 1.8)
Gastrointestinal cancer
• Both genders: highest tertile: OR 1.0 (CI not reported)
Breast cancer
Highest tertile: OR 3.4 (CI not reported)
Prostate cancer
Highest tertile: OR 0.3 (CI not reported)
Haematological cancers
Both genders: highest tertile: OR 0.6 (CI not reported)
Cervical cancer
Highest tertile: OR 1.1 (CI not reported)
Lung cancer
Both genders: highest tertile: OR 0.8 (CI not reported)
Other cancers
Both genders: highest tertile: OR 0.9 (CI not reported)
Selenium levels in exposure categories Serum:
• Lowest quintile: 98 to 142 µg/L
• Highest quintile: 181 to 240 µg/L
• Lowest tertile: 98 to 148 µg/L
• Highest tertile: 171 to 240 µg/L
Plasma:
• Lowest quintile: 115 to 129 µg/L
• Highest quintile: 157 to 207 µg/L
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Coates 1988 (Continued)
• Lowest tertile: 115 to 137 µg/L
• Highest tertile: 151 to 207 µg/L
Notes Primary publication: Coates 1988
Secondary publication: Coates 1987
Combs 1993
Methods Cohort/subcohort controlled cohort study
Country: United States
Participants Participants: 1239 men and women
Inclusion criteria: participants from the NPCT with valid selenium measurement at baseline
Name of parent cohort: Nutritional Prevention of Cancer Trial (NPCT)
Recruitment: see: Nutritional Prevention of Cancer Trial
Outcome assessment: not stated
Number of cases:
• Squamous cell cancer: 204 (male/female: n.r.)
Case definition: incidence
Years of follow-up: 2
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Statistical methods: Cox proportional hazard model
Variables controlled in analysis: age, gender, current smoking, alcohol drinking
Risk estimates [95% CI] Reference category (unadjusted RR): lower half
Results:
Squamous cell cancer
• Both genders: higher half: unadjusted RR 0.69 (95% CI 0.51 to 0.92)
• Both genders: “interquartile contrast” (high vs low), adjusted RR 0.79 (95% CI 0.67 to 0.
94)
Selenium levels in exposure categories Lower half: ≤ 114.00 µg/L
Higher half: ≥ 114.10 µg/L
Notes
Comstock 1997
Methods Matched, nested case-control study
Country: United States
Participants Participants: 44,960 men and women (20,305 from CLUE I; 24,655 from CLUE II)
Inclusion criteria: residents of Washington County
Name of parent cohort: CLUE I and II Cohort
Recruitment: 1974/75 or 1989
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Comstock 1997 (Continued)
Outcome assessment: n.r.
Number of cases:
• Lung cancer: 258 (male/female: 157/101)
Case definition: incidence
Years of follow-up: n.r.
Type of selenium marker: serum/plasma
Interventions d.n.a.
Outcomes Statistical methods: conditional logistical regression
Variables controlled by matching: age, gender, race/ethnicity, year and month of sample col-
lection, participant of Clue I or Clue II cohort
Risk estimates [95% CI] Reference category: lowest quintile
Results:
Lung cancer
• Both genders: highest quintile: OR 0.65 (CI n.r.)
Selenium levels in exposure categories n.r.
Notes
Dong 2008
Methods Cohort study
Country: United States
Participants Participants: 339 (male/female: 275/64)
Inclusion criteria: participants from a surveillance programme for men and women with
Barrett’s oesophagus, no prior history of oesophageal cancer or diagnosis of cancer within
first 3 months of baseline
Name of parent cohort: Seattle Barrett’s Esophagus Program
Recruitment: 1983 to 2004, baseline assessment for this study: 1 February 1995 to 1 July
2004
Outcome assessment: n.r.
Number of cases: oesophageal adenocarcinoma: 37 (male/female: 32/5)
Case definition: incidence
Years of follow-up: mean: 5
Type of selenium marker: intake of selenium supplements (self-administered food frequency
questionnaire)
Interventions d.n.a.
Outcomes Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, sex, fruit and vegetable consumption, per cent energy
from fat, waist-hip ratio, cigarette smoking, non-steroidal anti-inflammatory drug use
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Dong 2008 (Continued)
Risk estimates [95% CI] Reference category: no supplemental selenium intake (lowest exposure category)
Results:
• Both genders: supplement intake ≥ 50 µg/d: HR 0.27 (95% CI 0.03 to 2.21)
Selenium levels in exposure categories Lowest category: no supplemental selenium intake
Middle category: supplemental selenium intake < 50 µg/d
Highest category: supplemental intake ≥ 50 µg/d
Notes
Dorgan 1998
Methods Matched, nested case-control study
Country: United States
Participants Participants: 6426 women
Inclusion criteria: female volunteers with serum available at the Breast Cancer Serum Bank in
Columbia (Missouri)/United States; no history of cancer at baseline; missing serum sample
for analysis excluded
Recruitment: 1987 to 1997
Outcome assessment: 1982 to 1983, 1989
Number of cases:
• Breast cancer: 105 (male/female: 0/105)
Case definition: incidence
Years of follow-up: median: 2.7
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: conditional logistical regression
Variables controlled in analysis: serum cholesterol, packs of cigarettes/d, BMI
Variables controlled bymatching: age, year andmonth of sample collection, diagnosis of benign
breast disease within 2 years before study enrolment, “sequence number of blood draw” for
women who donate blood more than once
Risk estimates [95% CI] Reference category: lowest quartile
Results:
Breast cancer
• Highest quartile: OR 0.9 (95% CI 0.4 to 1.8)
Selenium levels in exposure categories Lowest quartile: ≤ 112.9 µg/L
Highest quartile: 131.9 to 156.3 µg/L
Notes
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Dreno 2007
Methods Multi-centre, randomised, placebo-controlled, parallel-group trial
Allocation: random
Sequence generation: unclear
Concealment: unclear
Blinding: described only as double-blinded
Dropouts/withdrawals: During treatment phase, 38 in the selenium group and 37 in the
placebo group withdrew from the study. This distribution was similar in both treatment
groups
Intention-to-treat-analysis: unclear
Recruitment period: not specified
Treatment duration: 3 years
Observation period/dermatological follow-up:
Participants were followed for 2 years longer after treatment
Detection of cases: Participants were seen by a dermatologist before grafting; any partici-
pants presenting with a non-malignant or malignant skin keratosis or viral warts that had
been present for less than 3 months were not selected. Within 10 weeks following the
graft, a second visit was performed by a dermatologist to check that no new cutaneous
lesion had appeared
Informed consent: The protocol and the consent form had been approved by a National
Ethics Committee before the start of the study.Written informed consent wasmandatory
Participants Participants: 184 (randomised to selenium 200 µg/d: 91; to placebo: 93)
Condition: organ transplant recipient population
Demographics: mean age 44.3 ± SD 13 years (selenium 200 µg/d), 44.4 ± 10.7 years
(placebo)
Interventions Intervention:
• 200 µg/d selenium supplied as selenium yeast
Control: placebo
Outcomes Primary outcome measure:
• Occurrence rates of warts and various keratoses
Other reported outcomes:
• Skin cancers
Risk estimates [95% CI] Primary outcome:
Events in selenium group = 33 (36.3%), events in placebo group = 31 (33.3%); odds
ratio 1.09, P = 0.72
Secondary outcome:
Events in selenium group = 6 (6.6%), events in placebo group = 2 (2.2%); odds ratio 3.
08, P = 0.15
Selenium levels in exposure categories
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Dreno 2007 (Continued)
Random sequence generation (selection
bias)
Low risk Multi-centre randomised
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Described only as double-blinded
Selective reporting (reporting bias) Low risk No problems found
Epplein 2009
Methods Matched, nested case-control study (Epplein 2009; Gill 2009)
Country: United States
Participants Inclusion criteria: participants from the Multiethnic Cohort, aged 45 to 75 years (native
Hawaiians: aged 42 years and older), blood sample provided before cancer diagnosis between
1997 and 2006
Name of parent cohort: Multiethnic Cohort
Recruitment: 1993 to 1996
Case definition: incidence
Type of selenium marker: serum
Epplein 2009:
Participants: 67,594 (male: 29,009/female: 38,585) men and women
Outcome assessment: 2006
Number of cases:
• Lung cancer: 207 (male/female: 136/71)
Years of follow-up: 0 to 10
Gill 2009:
Participants: 29,009 men
Outcome assessment: n.r.
Number of cases:
• Prostate cancer: 467 (male/female: 467/0)
Years of follow-up: n.r.
Interventions d.n.a.
Outcomes Statistical methods: conditional logistical regression
Epplein 2009:
Variables controlled in analysis: age, fasting hours, pack-years, pack-years squared, years of
schooling, family history of lung cancer
Variables controlled by matching: age, sex, race/ethnicity, date of sample collection, time of
day of sample collection, fasting status, smoking
Gill 2009:
Analysed cases: 450 of 467
Variables controlled in analysis: age, fasting hours, BMI, family history of prostate cancer,
education
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Epplein 2009 (Continued)
Variables controlled by matching: age, race/ethnicity, date of sample collection, geographic
site (California, Hawaii), time of day of sample collection, fasting status
Risk estimates [95% CI] Epplein 2009:
Reference category: lowest tertile
Results:
Lung cancer
Male:
Highest tertile: OR 0.70 (95% CI 0.37 to 1.33)
Female:
Highest tertile: OR 0.98 (95% CI 0.42 to 2.29)
Gill 2009:
Reference category: lowest quartile
Results:
Prostate cancer
Highest quartile: OR 0.82 (95% CI 0.59 to 1.14)
Selenium levels in exposure categories Epplein 2009:
Lowest tertile: median 0.12 µg/g of sodium
Highest tertile: median 0.15 µg/g of sodium
Gill 2009:
Lowest quartile: median 0.12 µg/g
Highest quartile: median 0.16 µg/g
Notes Primary publication: Epplein 2009
Other publications: Gill 2009
Fex 1987
Methods Matched, nested case-control study
Country: Sweden
Participants Participants: 7935 men
Inclusion criteria: 46 to 48 years of age; residents of Malmo/Sweden; no restriction regarding
malignant disease at baseline (11 of 35 with diagnosis of cancer at baseline screening exam-
ination and/or died during first year of follow-up)
Name of parent cohort: Malmo Preventive Programme
Recruitment: 1975 to 1979
Outcome assessment: June 1981
Number of cases:
• Any cancer: 35 (male/female: 35/0)
Case definition:mortality
Years of follow-up: 3.5 to 8.0
Type of selenium marker: plasma
Interventions d.n.a.
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Fex 1987 (Continued)
Outcomes Analysed cases: 35 of 61 (reason for non-inclusion: no plasma sample available)
Statistical methods: logistical regression, Mantel-Haenszel
Variables controlled by matching: age, month of sample collection
Risk estimates [95% CI] Reference category: highest quintile
Results:
Any cancer
Male: lowest quintiles: OR 3.8 (CI not reported)
Selenium levels in exposure categories n.r.
Notes CI and number of cases not reported
Fujishima 2011
Methods Prospective cohort study
Country: northern part of Japan
Participants Participants: 1041 men and women
Inclusion criteria: adult haemodialysis patients
Name of parent cohort: “Kaleidoscopic Approaches to Patients with End-stage RENal Disease
Study” (the KAREN Study)
Recruitment: June 2003 to March 2004
Number of cases:
• Malignant disease-related death: 17
Case definition:mortality
Years of follow-up: 5
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: Cox logistical regression
Variables controlled by matching: age, male gender, BMI, hypertension, dyslipidaemia, dia-
betes mellitus, serum albumin levels, high-sensitivity CRP levels, history of myocardial in-
farction, history of stroke, history of malignant disease, smoking status, regular drinking
habit
Risk estimates [95% CI] Reference category: lowest quartile
Results:
Malignant disease-related death
• Highest quartile: HR 2.98 (95% CI 0.62 to 14.35)
Selenium levels in exposure categories Lowest quartile: 18.4 to 85.3 µg/L
Highest quartile: 114.2 to 226.2 µg/L
Notes
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Garland 1995
Methods Matched, nested case-control study
Country: United States
Participants Participants: 62,641 women
Inclusion criteria: female registered nurses in 11 USA states; aged 30 to 55 years at baseline;
completed questionnaire in 1976 and provided toenail sample in 1982; no history of cancer
at baseline
Name of parent cohort: Nurses’ Health Study (NHS)
Recruitment: 1976 (toenail sample collection in 1982)
Outcome assessment: 1 June 1986
Garland 1995:
Number of cases:
• Any cancer (without breast): 503 (male/female: 0/503)
• Colon and rectal cancer: 89 (male/female: 0/89)
• Melanoma: 63 (male/female: 0/63)
• Ovarian cancer: 58 (male/female: 0/58)
• Lung cancer: 47 (male/female: 0/47)
• Other: 155 (male/female: 0/155)
• Uterine cancer: 91 (male/female: 0/91)
Hunter 1990:
Number of cases:
• Breast cancer: 434 (0/434)
Case definition: incidence
Years of follow-up: 2.0 to 4.4
Type of selenium marker: toenail
Interventions d.n.a.
Outcomes Statistical methods: logistical regression, conditional logistical regression
Variables controlled in analysis: smoking status
Variables controlled by matching: age, year and month of sample collection
Hunter 1990 additionally controlled in analysis for age at first birth, age at menarche, alcohol
use, history of benign breast disease, menopausal status, maternal breast cancer, breast cancer
in sister(s), oral contraceptive use, parity, relative weight
Risk estimates [95% CI] Reference category: lowest quintile, lowest tertile
Results:
Garland 1995:
Any cancer (without breast)
• Female: highest quintile: OR 1.44 (95% CI 0.97 to 2.13)
Colon and rectal cancer
• Female: highest tertile: OR 2.04 (95% CI 0.88 to 4.75)
Melanoma
• Female: highest tertile: OR 1.66 (95% CI 0.71 to 3.85)
Ovarian cancer
• Female: highest tertile: OR 1.22 (95% CI 0.44 to 3.38)
Lung cancer
• Female: highest tertile: OR 4.33 (95% CI 0.54 to 34.60)
Other cancer
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Garland 1995 (Continued)
• Female: highest tertile: OR 0.97 (95% CI 0.55 to 1.71)
Uterine cancer
• Female: highest tertile: OR 1.38 (95% CI 0.62 to 3.08)
Hunter 1990:
Breast cancer
• Female: highest quintile: OR 1.10 (95% CI 0.70 to 1.72)
Selenium levels in exposure categories Garland 1995:
• Lowest quintile: ≤ 0.71 µg/g
• Highest quintile: ≥ 0.95 µg/g
Hunter 1990:
• Lowest quintile: ≤ 0.705 µg/g
• Highest quintile: ≥ 0.906 µg/g
Notes Primary publication: Garland 1995
Other publication: Hunter 1990
Glattre 1989
Methods Matched, nested case-control study
Country: Norway
Participants Participants: 100,000 men and women
Inclusion criteria: serum available at Janus serum bank (Norwegian serum bank, which is
consolidated from several sources and is maintained by the Norwegian Cancer Society for
research purposes)
Recruitment: 1972 to 1985
Outcome assessment: end of 1985
Number of cases:
• Thyroid cancer: 43 (male/female: 12/31)
Case definition: incidence
Years of follow-up: 0.0 to 14.0
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: conditional logistical regression
Variables controlled by matching: age, gender, year of sample collection, county of residence
Risk estimates [95% CI] Reference category: highest tertile
Results:
Thyroid cancer
• Both genders: lowest tertiles: OR 7.7 (95% CI 1.3 to 44.7)
• Men: lowest tertiles: OR 6.5 (95% CI 0.2 to 201.9)
• Women: lowest tertiles: OR 8.3 (95% CI 0.9 to 78.5)
Selenium levels in exposure categories Lowest tertile: ≤ 98.7 µg/L
Highest tertile: ≥ 130.3 µg/L
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Glattre 1989 (Continued)
Notes
Goodman 2001
Methods Matched, nested case-control study
Country: United States
Participants Participants: 18,314 (male/female: 12,025/6289)
Inclusion criteria: 4060 male asbestos workers: 45 to 74 years of age; 14,254 (male/female:
7965/6289) smokers > 20 pack-years: 50 to 69 years of age; cohort of an RCT for lung
cancer prevention in high-risk populations
Name of parent cohort: Caret (Carotene and Retinol Efficacy Trial)
Recruitment: 1988 to 1994
Outcome assessment: April 1999
Number of cases:
• Lung cancer: 235 (male/female: n.r.)
• Prostate cancer: 356 (male/female: 356/0)
Case definition: incidence
Years of follow-up: 6.0 to 12.0
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Analysed cases: 235 of 236 prostate cancer cases analysed (reason for non-inclusion: no sample
available for analysis or no control available); 356 of 385 lung cancer cases analysed (reason
for non-inclusion: missing selenium values for case-control pairs)
Statistical methods: conditional logistical regression
Variables controlled bymatching: age, smoking status at randomisation, year of randomisation,
year of sample collection, treatment arm, exposure population
Risk estimates [95% CI] Reference category: lowest quartile
Results:
Lung cancer
• Both genders: highest quartile: OR 1.20 (95% CI 0.77 to 1.88)
• Male: highest quartile: OR 1.53 (95% CI 0.83 to 2.82)
• Female: highest quartile: OR 0.76 (95% CI 0.29 to 2.01)
Prostate cancer
• Highest quartile: OR 1.02 (95% CI 0.65 to 1.60)
Selenium levels in exposure categories Lung cancer
• Lowest quartile: 63.9 to 105.5 µg/L
• Highest quartile: 129.4 to 172.3 µg/L
Prostate cancer
• Lowest quartile: 50.7 to 101.2 µg/L
• Highest quartile: 126.0 to 219.6 µg/L
Notes
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Goyal 2013
Methods Cohort study
Country: United States
Participants Name of parent cohort:ThirdNational Health andNutrition Examination Survey (NHANES
III)
Inclusion criteria:male and female adults, aged 20 to 90 years, participating in the NHANES
III: “stratified, multistage probability cluster to provide data representing the noninstitution-
alized US population” (Bleys 2008, p. 404)
Recruitment: 1988 to 1994
Participants: 13,887 men and women
Outcome assessment: 31 December 2006
Number of cases:
• Cancer deaths: 891 (male/female: n.r.)
Case definition:mortality
Years of follow-up: 14.2
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Analysed cases: 864 (male/female: n.r.)
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, sex, race-ethnicity, level of education, annual family
income, body mass index, smoking status, serum cotinine level, alcohol consumption, fruit
and vegetable intake, physical activity, serum total cholesterol levels, hypertension status,
diabetes status, history of heart attack, congestive heart failure, stroke or cancer, hormone
use in women, supplement use, serum levels of other micronutrients in the study (analysis
only for both genders)
Risk estimates [95% CI] Reference category: lowest tertile
Results:
Cancer deaths
• Both genders: highest quintile: HR 0.84 (95% CI 0.61 to 1.17)
• Male: highest quintile: HR 0.67 (95% CI 0.54 to 0.83)
• Female: highest quintile: HR 0.91 (95% CI 0.71 to 1.16)
Selenium levels in exposure categories Lowest quintile: ≤ 108.96 µg/L
Highest quintile: ≥ 136.60 µg/L
Notes Second report on the same cohort of Bleys 2008; results updated
Graff 2017
Methods Matched, nested case-control study
Country: United States
Participants Name of the parent cohort: Health Professional Follow-up Study
Participants: 18,259 men
Inclusion criteria: patients free from prostate cancer between 1993 and 1995 who returned
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Graff 2017 (Continued)
EDTA-preserved blood samples from HPFS cohort (35% of total cohort)
Recruitment: 1986
Outcome assessment: 31 January 1998
Number of cases:
• Prostate cancer: 166 (male/female: 166/0)
Case definition: incidence
Years of follow-up: up to 5
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Analysesd cases: 154
Statistical methods: conditional logistical regression model
Variables controlled in analysis: age at blood draw, smoking status at blood draw, every PSA
test before blood draw, timing and season of blood draw, time between blood draw and index
date
Variables controlled by matching: year of birth, PSA test before blood draw, timing, season
and year of blood draw
Risk estimates [95% CI] Reference category: lowest quartile
Results:
• Highest quartile: 1.57 (95% CI 0.92 to 2.69)
Selenium levels in exposure categories Lowest quartile: 0.0894 ppm
Highest quartile: 0.1308 ppm
Notes Exposure category cutpoints provided by trial author
Grundmark 2011
Methods Cohort study
Country: Sweden
Participants Participants: 2322 males
Inclusion criteria: male residents in Uppsala county in January 1970, born from 1920 to
1924
Name of parent cohort: Uppsala Longitudinal Study of Adult Men (ULSAM)
Recruitment: 1991 to 1995
Outcome assessment: 31 December 2003
Number of cases:
• Prostate cancer: 208
Case definition: incidence
Years of follow-up: median: 26.5
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: proportional hazard model
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Grundmark 2011 (Continued)
Risk estimates [95% CI] Reference category: lowest level
Results:
Prostate cancer
• Highest level: RR 0.83 (95% CI 0.60 to 1.16)
Selenium levels in exposure categories Lowest level: ≤ 70 µg/L
Highest level: > 81 µg/L
Notes
Han 2013
Methods Cohort study
Country: United States
Participants Name of parent cohort: Vitamins and Lifestyles (VITAL) study
Participants: 70,332 men and women
Inclusion criteria: aged 50 to 76 years, participants recruited from subscribers to commercial
mailing list, residents of western Washington state, no malignant disease at baseline, no (or
missing) history of pancreatic cancer or neuroendocrine tumours
Recruitment: 1 October 2000 to 31 December 2002
Outcome assessment: 31 December 2008
Number of cases:
• Pancreatic cancer: 195 (male/female: n.r.); 184 adenocarcinoma pancreatic cancer and 11
neuroendocrine tumours
Case definition: incidence
Years of follow-up: median: 7.1
Type of selenium marker: intake and supplement use (questionnaire: use of supplements over
the past 10 years, mean supplemental intake/d calculated)
Interventions d.n.a.
Outcomes Analysed cases: Individuals with neuroendocrine tumours were excluded.
Daily intake: 162 out of 184 cases analysed (reason for exclusion: dietary questionnaire
incomplete or implausible total energy intake)
Diet and 10-year supplement use: 158 out of 184 cases analysed (reason for exclusion: dietary
questionnaire incomplete or implausible total energy intake and missing supplement use)
Statistical methods: Cox proportional hazard model
Variables controlled in analysis: age, sex, ethnicity, education, body mass index, physical
activity, cigarette smoking status, total alcohol consumption, family history of pancreatic
cancer, history of diabetes, total energy intake
Risk estimates [95% CI] Reference category: lowest tertile
Results:
Adenocarcinoma pancreatic cancer
• Daily intake: HR 0.44 (95% CI 0.23 to 0.85)
• Diet and 10-year supplement use: HR 0.69 (95% CI 0.39 to 1.20)
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Han 2013 (Continued)
Selenium levels in exposure categories Daily intake
• Lowest tertile: 6.38 to 85.49 µg/d
• Highest tertile: 127.50 to 641.60 µg/d
Diet and 10-year supplement use
• Lowest tertile: 9.81 to 98.76 µg/d
• Highest tertile: 145.66 to 646.60 µg/d
Notes
Hansen 2013
Methods Cohort study
Country: Denmark
Participants Participants: 54,208 men and women
Inclusion criteria: aged 50 to 64, born in Denmark, no diagnosis of cancer registered in the
Danish Cancer Registry, living in the Copenhagen, Frederiksberg Aarhus municipalities,
Hinnerup orHørningmunicipalities in AarhusCounty, and nearly all inCopenhagen county
Recruitment: 1993 to 1997
Outcome assessment: April 1995 to December 2009
Number of cases: 990 (male/female: n.r)
Case definition: incidence
Years of follow-up: median: 13
Type of selenium marker: supplement use
Interventions d.n.a.
Outcomes Analysed cases:
• Colon-rectal cancer: 990 (male/female: n.r.)
• Colon cancer: 642 (male/female: n.r.)
• Rectal cancer: 348 (male/female: n.r.)
Statistical methods: Cox proportional hazard model
Variables controlled in analysis: alcohol consumption, smoking status (ever/never), physical
activity at work and at leisure, non-steroidal anti-inflammatory drug use, body mass index,
education level, intake of red and processed meat, dietary intake, supplemental intake of
nutrients alternatively
Risk estimates [95% CI] Reference category: high use
Results:
• Colon-rectal cancer: HR 1.25 (95% CI 1.05 to 1.48)
• Colon cancer: HR 1.22 (95% CI 0.99 to 1.51)
• Rectal cancer: HR 1.29 (95% CI 0.96 to 1.74)
Selenium levels in exposure categories Supplement use:
• Never use: 0 µg/d
• High use: > 45.80 µg/d
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Hansen 2013 (Continued)
Notes Data on dietary intake and Total intake + supplement use not reported according to inclusion
criteria: only 2 categories - high vs low use
Hartman 1998
Methods Cohort/subcohort controlled cohort study
Country: Finland
Participants Participants: 29,133 men
Inclusion criteria: 50 to 69 years of age; smokers; no history of cancer (other than non-
melanoma skin cancer) at baseline; no severe physical or psychiatric illness; intake of vitamin
E/A/beta-carotene supplements in excess of defined amounts
Name of parent cohort: Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study
Recruitment: 1985 to 1988
Outcome assessment: 30 April 1993
Number of cases:
• Prostate cancer: 302 (male/female: 302/0)
Case definition: incidence
Years of follow-up: 5.0 to 8.0
Type of selenium marker: intake
Interventions d.n.a.
Outcomes Analysed cases: 302 of 317 (reason for non-inclusion: no dietary information available)
• Analysis stratified by randomisation status according to active interventions or placebo
interventions in the RCT
•Results reported separately for total selenium intake and non-supplemental selenium intake
Statistical methods: Cox regression analysis
Variables controlled in analysis: age, living in urban area, beta-carotene intervention, total
energy, BPH
Risk estimates [95% CI] Reference category: lowest quartile
Results:
Prostate cancer
Total (nutritional and supplemental) selenium intake in participants without active alpha-toco-
pherol intervention
• Highest quartile: RR 1.27 (95% CI 0.70 to 2.20)
Total (nutritional and supplemental) selenium intake in participants with alpha-tocopherol in-
tervention
• Highest quartile: RR 0.84 (95% CI 0.43 to 1.67)
Nutritional selenium intake in participants without active alpha-tocopherol intervention
• Highest quartile: RR 1.32 (95% CI 0.70 to 2.47)
Nutritional selenium intake in participants with alpha-tocopherol intervention
• Highest quartile: RR 0.72 (95% CI 0.33 to 1.55)
Selenium levels in exposure categories Total nutritional and supplemental selenium intake:
• Lowest quartile: ≤ 71.51 µg/d
• Highest quartile: ≥ 111.06 µg/d
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Hartman 1998 (Continued)
Nutritional selenium intake:
• Lowest quartile: ≤ 70.10 µg/d
• Highest quartile: ≥ 105.65 µg/d
Notes
Hashemian 2015
Methods Cohort study
Country: Iran
Participants Name of parent cohort: Golestan Cohort Study
Participants: 47,405 (male/female: 19,969/27,436)
Inclusion criteria: aged 40 to 75, stable residents inGolestan region (Gonbad City and villages
in Gonbad, Kalaleh, and Aq-Qala counties); not having a current or previous diagnosis of
upper gastrointestinal cancer
Recruitment: 2004 to 2008
Outcome assessment: 2014
Number of cases:
• Oesophageal squamous cell carcinoma: 201 (male/female: n.r.)
Case definition: incidence
Years of follow-up: median: 7.2
Type of selenium marker: intake
Interventions d.n.a.
Outcomes Analysed cases: 201 (male/female: n.r.)
Statistical methods: Cox proportional hazard model
Variables controlled in analysis: age, sex, total energy, place of residence (urban or rural),
smoking (never or ever), wealth score (low, medium, or high), ethnicity (non-Turkmen or
Turkmen), opiate use (never or ever), BMI, education (illiterate or formal education), marital
status (single or married), physical activity score (continuous), fruit and vegetable intake
Risk estimates [95% CI] Reference category: lowest quartile
Results:
Oesophageal squamous cell carcinoma
• Highest quartile: HR 0.67 (95% CI 0.53 to 1.30)
Selenium levels in exposure categories Lowest quartile: < 116 µg/d
Highest quartile: > 175 µg/d
Notes
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Helzlsouer 2000
Methods Matched, nested case-control study
Country: United States
Participants Participants: 10,456 men
Inclusion criteria: residents of Washington county; cases with second malignancy or missing
pathological confirmation excluded
Name of parent cohort: CLUE II Cohort
Recruitment: 1989
Outcome assessment: September 1996
Number of cases:
• Prostate cancer: 117 (male/female: 117/0)
Case definition: incidence
Years of follow-up: 6.8 to 7.8
Type of selenium marker: toenail
Interventions d.n.a.
Outcomes Analysed cases: 117 of 145 (reason for non-inclusion: no toenail clipping available)
Statistical methods: conditional logistical regression
Variables controlled in analysis: BMI at age 21, education, hours since last meal
Variables controlled by matching: age, race/ethnicity, year and month of sample collection,
size of toenail clipping
Risk estimates [95% CI] Reference category: lowest quintile
Results:
Prostate cancer
• Highest quintile: OR 0.38 (95% CI 0.17 to 0.85)
Selenium levels in exposure categories Lowest quintile: ≤ 0.69 ppm
Highest quintile: ≥ 0.92 ppm
Notes
Hotaling 2011
Methods Cohort study
Country: United States
Participants Participants: 77,050 men and women,
aged 50 to 76 years, participants recruited from subscribers to commercial mailing list,
residents of westernWashington state, non-whites excluded, no malignant disease at baseline
Name of parent cohort: Vitamins and Lifestyle (VITAL) study
Recruitment: 1 October 2000 to 31 December 2002
Outcome assessment: 31 December 2002
Number of cases:
• Urothelial carcinoma: 330
Case definition: incidence
Years of follow-up: median: 6
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Hotaling 2011 (Continued)
Type of selenium marker: supplemental intake (questionnaire: use of supplements over the
past 10 years, mean supplemental intake/day calculated)
Interventions d.n.a.
Outcomes Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, gender, race (white, black, other), education, family
history of bladder cancer, smoking (never; former, quit more than 10 years before start of
VITAL; former, quit less than 10 years before start of VITAL; current), pack-years (never-
smoker and tertiles), fruit and vegetable intake
Risk estimates [95% CI] Reference category: non-use
Results:
• Highest level: HR 0.97 (95% CI 0.72 to 1.31)
Selenium levels in exposure categories Lowest level: non-use
Highest quartile: 20 µg/d
Notes
Hughes 2015
Methods Matched, nested case-control study
Countries:Denmark, France, Germany,Greece, Italy, theNederlands, Spain, United Kindom
Participants Name of parent cohort: European Prospective Investigation into Cancer andNutrition (EPIC)
Participants: 428,917 (male/female: 129,961/298,956)
Inclusion criteria: aged 25 to 70, participants from the EPIC study
Recruitment: 1992 to 2000
Outcome assessment: at each country’s study closure date (between June 2002 and 2003)
Number of cases:
• Colorectal cancer: 966 (male/female: 466/500)
• Colon cancer: 598 (male/female: 272/326)
• Rectal cancer: 368 (male/female: 194/174)
Case definition: incidence
Years of follow-up: average: approximately 4
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: conditional logistical regression
Variables controlled in analysis: smoking status/duration/intensity, BMI, total physical activity,
education level, total dietary energy consumption, intake of total calcium, fruits, vegetables,
red and processed meats, and alcohol
Variables controlled by matching: study centre of enrolment, sex, age at blood collection, time
of blood collection and fasting status; among women, the following: menopausal status.
Premenopausal women were matched on phase of menstrual cycle, and postmenopausal
women were matched on current hormonal replacement therapy (HRT) use
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Hughes 2015 (Continued)
Risk estimates [95% CI] Reference category: lowest quintile
Results:
Colorectal cancer
• Both genders: highest quintile: IRR 0.88 (95% CI 0.64 to 1.21)
• Male: highest quintile: IRR 1.18 (95% CI 0.73 to 1.90)
• Female: highest quintile: IRR 0.64 (95% CI 0.40 to 1.01)
Colon cancer
• Both genders: highest quintile: IRR 0.81 (95% CI 0.54 to 1.23)
• Male: highest quintile: IRR 1.11 (95% CI 0.58 to 2.12)
• Female: highest quintile: IRR 0.61 (95% CI 0.34 to 1.09)
Rectal cancer
• Both genders: highest quintile: IRR 1.09 (95% CI 0.63 to 1.89)
• Male: highest quintile: IRR 1.32 (95% CI 0.55 to 3.19)
• Female: highest quintile: IRR 0.76 (95% CI 0.32 to 1.80)
Selenium levels in exposure categories Both male and female
• Lowest quintile: < 67.7 µg/L
• Highest quintile: > 100.6 µg/L
Notes Data for study population from Riboli 2002
Hughes 2016
Methods Matched, nested case-control study
Countries: Denmark, France, Germany, Greece, Italy, the Nederlands, Norway, Spain, Swe-
den, UK
Participants Name of parent cohort: European Prospective Investigation into Cancer andNutrition (EPIC)
Participants: 521,448
Inclusion criteria: aged 25 to 70 participants of the EPIC study
Recruitment: 1992 to 2000
Outcome assessment: at each country’s study closure date (between December 2002 and De-
cember 2006)
Number of cases: 261 (male/female: n.r.)
Case definition: incidence
Years of follow-up: average: approximately 6
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Analysed cases:
• Hepatocellular carcinoma (HCC): 106 (male/female: n.r)
• Gallbladder and biliary tract cancer (GBTC): 96 (male/female: n.r)
• Intrahepatic bile duct cancer (IHBC): 36 (male/female: n.r)
Statistical methods: conditional logistical regression
Variables controlled in analysis: BMI, waist circumference, baseline alcohol intake, physical
activity (metabolic equivalent tasks), smoking status, education, alcohol intake pattern, self-
reported diabetes, total energy intake
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Hughes 2016 (Continued)
Variables controlled by matching: age at blood collection, sex, study centre, time of day, fasting
status at blood collection. Additionally, women were matched by menopausal status and
hormone replacement therapy use at the time of blood collection
Risk estimates [95% CI] Reference category: lowest tertile
Results
• HCC: highest tertile: OR 0.41 (95% CI 0.23 to 0.72)
• GBTCs: highest tertile: OR 0.74 (95% CI 0.47 to 1.18)
Selenium levels in exposure categories Lowest tertile: ≤ 80.5 µg/L
Highest tertile: ≥ 64.5 µg/L
20 µg/L increase
Notes Estimates for IHBC reported only for 20 µg/L increase: OR 0.42 (95% CI 0.15 to 1.20)
Kabuto 1994
Methods Matched, nested case-control study
Country: Japan
Participants Participants: 20,000 men and women
Inclusion criteria: survivor of the atomic bomb in Hiroshima or Nagasaki; serum available
for analysis
Name of parent cohort: Adult Health Study Hiroshima and Nagasaki
Recruitment: 1960 (blood samples drawn in 1970 to 1972)
Outcome assessment: 1983
Number of cases:
• Stomach cancer: 201 (male/female: 113/88)
• Lung cancer: 77 (male/female: 43/34)
Case definition: incidence
Years of follow-up: 12.0 to 14.0
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: conditional logistical regression
Variables controlled in analysis: radiation dose, smoking, age, gender
Variables controlled by matching: age, gender, year/month of sample collection, city
Risk estimates [95% CI] Reference category: highest quartile
Results:
Stomach cancer
• Both genders: lowest quartile: OR 1.0 (95% CI 0.5 to 1.9)
Lung cancer
• Both genders: lowest quartile: OR 1.8 (95% CI 0.7 to 5.0)
Selenium levels in exposure categories Lowest quartile ≤ 98.90 µg/L
Highest quartile ≥ 128.10 µg/L
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Kabuto 1994 (Continued)
Notes
Karagas 1997
Methods Matched, nested case-control study
Country: United States
Participants Participants: 1805 men and women
Inclusion criteria: at least 1 basal cell or squamous cell cancer before study entry; participants in
an RCT for non-melanoma skin cancer prevention with oral beta-carotene supplementation
Name of parent cohort: Skin Cancer Prevention Study
Recruitment: February 1983 to February 1986
Outcome assessment: 30 September 1989
Number of cases:
• Squamous cell cancer: 131 (89% male/11% female)
Case definition: incidence
Years of follow-up: 3.0 to 5.0
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Statistical methods: conditional logistical regression
Variables controlled in analysis: cigarette smoking
Variables controlled by matching: age, gender, study centre of RCT, time in study (diagnosis
date)
Risk estimates [95% CI] Reference category: lowest quartile
Results:
Squamous cell cancer
Both genders: highest quartile: OR 0.86 (95% CI 0.47 to 1.58)
Selenium levels in exposure categories Lowest quartile: ≤ 0.12 ppm
Highest quartile: ≥ 0.14 ppm
Notes
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Karp 2013
Methods Randomised controlled trial
Phase III Chemoprevention Trial of Selenium Supplementation In Persons With Re-
sected Stage I Non-Small Cell Lung Cancer: ECOG 5597
Allocation: random, permuted blocks stratified by smoking status (current, former, or
never), sex, and stage (IA vs IB with other therapy vs IB without other therapy)
Sequence generation: permuted blocks within strata with dynamic balancing
Concealment: central assignments at ECOG Coordinating Center
Blinding: participant blinded, doctor blinded, outcome assessor/pathologist unclear, re-
view/coding of medical records unblinded
Dropouts/withdrawals: of 1561 randomised participants, no dropouts
Intention-to-treat-analysis: yes
Recruitment period: 6 October 2000 to 5 November 2009
End of study period: 5 November 2009
Treatment duration:
• Intervention was discontinued on 5 November 2009, following the Data Monitoring
Committee recommendation that the study could eventually show significant evidence
of benefit
Observation period: After end of treatment phase, participants enter the follow-up phase.
Analyses till June 2011 reported (until January 2014 in Pillai 2014 with median follow-
up of 5.6 years)
Detection of cases: visit at 3 months for adverse effects, annual visit for other endpoints
Informed consent: yes
Participants 1561 male and female participants with completely resected stage I non-small-cell lung
cancer
Countries: United States, Canada
Participants: 1561 (randomised to selenium group: 1,040; to placebo group: 521)
Condition: adult participants, 6 to 36 months from complete resection of histologically
proven stage IA or IB non-small-cell lung cancer, with chest X-ray or CT scan≤ 8 weeks
before registration without sign of new recurrent lung cancer, no recurrent cancers or
any other prior cancer history within the past 5 years (except NMSC), normal hepatic
function, ECOGperformance status of 0 or 1, not taking selenium supplement regularly
≥ 70µg/d, any therapy (chemo, radio, or biological therapy) completed at least 6months
before study registration and all related symptoms subsided
Demographics:median age 66 in both intervention groups. Selenium and placebo partic-
ipants were well balanced with respect to sex, age, smoking history, and stage at resection
Recruitment and setting: not reported
Interventions Intervention: 200 µg selenised yeast
Control: placebo
Outcomes Primary outcome: incidence of second primary lung tumours
Secondary outcomes: incidence of any other second primary tumours, mortality, overall
survival
Other outcomes: qualitative and quantitative toxicity of selenium
Risk estimates [95% CI] Karp 2013:
Primary outcome:
• Lung cancer: RR 1.23 (95% CI 0.80 to 1.80)
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Karp 2013 (Continued)
Other outcomes:
• Any cancer: RR 1.02 (95% CI 0.80 to 1.21)
• Prostate cancer: RR 0.89 (95% CI 0.40 to 2.00)
• Colorectal cancer: RR 0.50 (95% CI 0.13 to 1.91)
• Melanoma: RR 1.25 (95% CI 0.24 to 6.43)
• NMSC: RR 0.80 (95% CI 0.44 to 1.45)
• Diabete mellitus: RR 1.19 (95% CI 0.61 to 2.35)
Pillai 2014:
Primary outcome:
• Lung cancer: RR 1.29 (95% CI 0.87 to 1.93)
Selenium levels in exposure categories d.n.a.
Notes Karp 2013
Adverse effects:
• Alopecia grade 1 to 2: RR 0.80 (95% CI 0.48 to 1.34)
• Dermatitis grade 1 to 2: RR 1.59 (95% CI 0.75 to 3.37)
• Nail changes grade 1 to 2: RR 0.72 (95% CI 0.46 to 1.12)
• Fatigue grade 1 to 2: RR 1.02 (95% CI 0.68 to 1.53)
• Nausea grade 1 to 2: RR 2.14 (95% CI 1.04 to 4.42)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random, permuted blocks stratified
Allocation concealment (selection bias) Low risk Central assignments
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants blinded and doctor blinded,
outcome assessor/pathologist unclear, re-
view/coding of medical records unblinded
Selective reporting (reporting bias) Low risk No problems found
Knekt 1990
Methods Matched, nested case-control study (Hakama 1990; Knekt 1988; Knekt 1990;Knekt 1996)
Cohort study (Knekt 1991)
Country: Finland
Participants Inclusion criteria: no history of cancer at baseline
Name of parent cohort: Social Insurance Institution’s Mobile Clinic Health Examination
Survey
Recruitment: 1968 to 1972
Knekt 1990:
Participants: 39,268: 21,172 men and 18,096 women
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Knekt 1990 (Continued)
Outcome assessment: 31 December 1980
Number of cases:
• Any cancer: 1096 (male/female: 597/499)
• Stomach cancer: 95 (male/female: 58/37)
• Colon and rectal cancer: 91 (male/female: 32/59)
• Lung cancer: 198 (male/female: 189/9)
• Prostate cancer: 51 (male/female: 51/0)
• Urinary tract cancer: 47 (male/female: 34/13)
• Pancreatic cancer: 45 (male/female: 22/23)
• Breast cancer: 90 (male/female: 0/90)
• Gynaecological cancer (without breast): 86 (male/female: 0/86)
• Basal cell carcinoma (skin): 126 (male/female: 64/62)
• Other: 267 (male/female: 147/120)
Hakama 1990:
Participants: number of participants n.r.; both genders
Inclusion criteria: aged 15 years and older
Outcome assessment: 1977
Number of cases:
• Any cancer: 766 (male/female: n.r.)
• Lung cancer: 151 (male/female: 151/0)
• Breast cancer: 67 (male/female: 0/67)
• Stomach cancer: 76 (male/female: n.r.)
• Prostate cancer: 37 (male/female: 37/0)
Knekt 1988:
Participants: 36,265: 21,172 men and 15,093 women
Outcome assessment: 31 December 1977
Number of cases:
• Oesophageal and stomach cancer: 86 (male/female: 51/35)
• Colon and rectal cancer: 57 (male/female: 21/36)
Knekt 1991:
Participants: 4538 men
Inclusion criteria: aged 20 to 69 years, with dietary history taken
Outcome assessment: 1986
Number of cases:
• Lung cancer: 117 (male/female: 117/0)
Knekt 1996:
Participants: 1896 women
Outcome assessment: 1980
Number of cases:
• Ovarian cancer: 24 (male/female: 0/24)
Case definition: incidence
Years of follow-up: 9 to 20 years
Type of selenium marker: serum (Hakama 1990; Knekt 1988; Knekt 1990;Knekt 1996),
intake (Knekt 1991: dietary history)
Interventions d.n.a.
Outcomes Knekt 1990
Statistical methods: conditional logistical regression
Variables controlled in analysis: smoking
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Knekt 1990 (Continued)
Variables additionally controlled in analysis of highest 4 quintiles vs lowest quintile: occupation,
BMI, parity, cholesterol, haematocrit
Variables controlled by matching: age, gender, municipality, time of baseline examination,
duration of storage of sample
Hakama 1990
Analysed cases: 766 of 864 (reason for non-inclusion: no serum sample)
Statistical methods: conditional logistical regression
Variables controlled in analysis: smoking
Variables additionally controlled in analysis of highest 4 quintiles vs lowest quintile: retinol level,
alpha-tocopherol level
Variables controlled by matching: age, gender, municipality, time of baseline examination,
duration of storage of sample
Knekt 1988
Statistical methods: n.r.
Variables controlled in analysis: smoking, serum cholesterol
Variables controlled by matching: age, gender, municipality, time of baseline examination,
duration of storage of sample
Knekt 1991
Statistical methods: Cox proportional hazard model
Variables controlled in analysis: age, smoking (data stratified according to smoking status)
Knekt 1996
Statistical methods: conditional logistical regression
Variables controlled by matching: age, gender, municipality, time of baseline examination,
duration of storage of sample
Risk estimates [95% CI] Knekt 1990
Reference category: lowest quintile
Results:
Any cancer
Male
• Highest quintile: OR 0.41 (CI not reported)
• Above 20th percentile: OR 0.67 (CI not reported); cases during first 2 years of follow-up
excluded: 476 cases: OR 0.65 (95% CI 0.48 to 0.89)
Female
• Highest quintile: OR 0.86 (CI not reported)
• Above 20th percentile: OR 0.93 (CI not reported); cases during first 2 years of follow-up
excluded: 423 cases: OR 0.97 (95% CI 0.68 to 1.39)
Stomach cancer
Male
• Highest quintile: OR 0.09 (CI not reported)
• Above 20th percentile: OR 0.26 (CI not reported); cases during first 2 years of follow-up
excluded: 43 cases: OR 0.24 (95% CI 0.09 to 0.69)
Female
• Highest quintile: OR 0.27 (CI not reported)
• Above 20th percentile: OR 0.59 (CI not reported); cases during first 2 years of follow-up
excluded: 30 cases: OR 0.48 (95% CI 0.14 to 1.66)
Colon and rectal cancer
Male
• Highest quintile: OR 0.53 (CI not reported)
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Knekt 1990 (Continued)
• Above 20th percentile: OR 0.69 (CI not reported); cases during first 2 years of follow-up
excluded: 29 cases: OR 1.01 (95% CI 0.18 to 5.65)
Female
• Highest quintile: OR 0.80 (CI not reported)
• Above 20th percentile: OR 1.26 (CI not reported); cases during first 2 years of follow-up
excluded: 48 cases: OR 1.10 (95% CI 0.42 to 2.92)
Lung cancer
Male
• Highest quintile: OR 0.30 (CI not reported)
• Above 20th percentile: OR 0.60 (CI not reported); cases during first 2 years of follow-up
excluded: 153 cases: OR 0.66 (95% CI 0.37 to 1.19)
Female
• Third highest quintile: OR 4.62 (CI not reported) (quintile 4 and 5 did not contain any
cases)
Prostate cancer
• Highest quintile: OR 1.15 (CI not reported)
• Above 20th percentile: OR 1.13 (CI not reported); cases during first 2 years of follow-up
excluded: 46 cases: OR 1.00 (95% CI 0.42 to 2.40)
Urinary tract cancer
Male
• Highest quintile: OR 0.81 (CI not reported)
• Above 20th percentile: OR 0.89 (CI not reported); cases during first 2 years of follow-up
excluded: 26 cases: OR 0.34 (95% CI 0.06 to 2.06)
Female
• Highest quintile: OR 4.12 (CI not reported)
• Above 20th percentile: not reported; cases during first 2 years of follow-up excluded: 9
cases: OR 2.51 (95% CI 0.13 to 47.9)
Pancreatic cancer
Male
• Fourth quintile vs lowest: OR 0.58 (CI not reported) (highest quintile did not contain any
cases)
• Above 20th percentile: OR 0.11 (CI not reported); cases during first 2 years of follow-up
excluded: not reported
Female
• Highest quintile: OR 3.49 (CI not reported)
• Above 20th percentile: not reported; cases during first 2 years of follow-up excluded: 22
cases: OR 0.86 (95% CI 0.21 to 3.52)
Breast cancer
• Highest quintile: OR 0.64 (CI not reported)
• Above 20th percentile: OR 0.52 (CI not reported); cases during first 2 years of follow-up
excluded: 74 cases: OR 0.57 (95% CI 0.18 to 1.81)
Gynaecological cancer (without breast)
• Highest quintile: OR 0.96 (CI not reported)
• Above 20th percentile: OR 0.91 (CI not reported); cases during first 2 years of follow-up
excluded: 70 cases: OR 1.03 (95% CI 0.43 to 2.50)
Basal cell carcinoma (skin)
Male
• Highest quintile: OR 0.54 (CI not reported)
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Knekt 1990 (Continued)
• Above 20th percentile: OR 0.65 (CI not reported); cases during first 2 years of follow-up
excluded: 54 cases: OR 0.86 (95% CI 0.35 to 2.12)
Female
• Highest quintile: OR 1.55 (CI not reported)
• Above 20th percentile: OR 1.73 (CI not reported); cases during first 2 years of follow-up
excluded: 52 cases: OR 1.54 (95% CI 0.64 to 3.73)
Other or unspecified cancer:
Male
• Highest quintile: OR 0.42 (CI not reported)
• Above 20th percentile: OR 0.72 (CI not reported); cases during first 2 years of follow-up
excluded: 110 cases: OR 0.70 (95% CI 0.36 to 1.36)
Female
• Highest quintile: OR 0.71 (CI not reported)
• Above 20th percentile: OR 0.87 (CI not reported); cases during first 2 years of follow-up
excluded: 111 cases: OR 0.92 (95% CI 0.44 to 1.92)
Hakama 1990
Reference category: highest quintile
Results:
Any cancer
Male
• Lowest quintile: OR 2.40 (CI not reported)
• Lowest quintile vs 4 highest quintiles: OR 1.60 (CI not reported)
Female
• Lowest quintile: OR 1.20 (CI not reported)
• Lowest quintile vs 4 highest quintiles:0.90 (CI not reported)
Lung cancer
Male:
• Lowest quintile vs 4 highest quintiles: OR 1.80 (CI not reported)
Breast cancer
• Lowest quintile vs 4 highest quintiles: OR 3.10 (CI not reported)
Stomach cancer
Male
• Lowest quintile vs 4 highest quintiles: OR 6.70 (CI not reported)
Female
• Lowest quintile vs 4 highest quintiles: OR 2.00 (CI not reported)
Prostate cancer
• Lowest quintile vs 4 highest quintiles: OR 0.80 (CI not reported)
Knekt 1988
Reference category: highest quintile
Results:
Oesophageal and stomach cancer
Male
• Lowest tertile: OR 2.20 (CI not reported)
• Lowest quintile vs 4 highest quintiles: OR 3.3 (95% CI 1.3 to 9.1)
Female
• Lowest tertile: OR 1.50 (CI not reported)
• Lowest quintile vs 4 highest quintiles: OR 2.4 (95% CI 0.7 to 8.3)
Colon and rectal cancer
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Knekt 1990 (Continued)
Male
• Lowest tertile: OR 0.90 (CI not reported)
• Lowest quintile vs 4 highest quintiles: OR 1.7 (95% CI 0.4 to 7.7)
Female
• Lowest tertile: OR 0.60 (CI not reported)
• Lowest quintile vs 4 highest quintiles: OR 0.8 (95% CI 0.2 to 2.4)
Knekt 1991
Reference category: highest tertile
Results:
Lung cancer
Male non-smokers
• Lowest tertile: OR 1.03 (CI not reported)
Male smokers
• Lowest tertile: OR 0.83 (CI not reported)
Knekt 1996
Reference category: highest tertile
Results:
Ovarian cancer
• Lowest tertile: OR 1.15 (95% CI 0.19 to 4.06)
Selenium levels in exposure categories Knekt 1990
• Lowest quintile: ≤ 48.90 µg/L
• Highest quintile ≥ 78.00 µg/L
Hakama 1990
• Quintiles: not specified
Knekt 1988
Both genders
• Lowest tertile: ≤ 56.90 µg/L
• Highest tertile ≥ 70.10 µg/L
• Lowest quintile: ≤ 50 µg/L
• Highest 4 quintiles > 50 µg/L
Knekt 1991
• Tertiles: n.r.
Knekt 1996
• Lowest tertile: ≤ 56.90 µg/L
• Highest tertile: ≥ 68.10 µg/L
Notes Primary publication: Knekt 1990
Other publications: Hakama 1990, Knekt 1988, Knekt 1991, Knekt 1996
Knekt 1998
Methods Matched, nested case-control study
Country: Finland
Participants Participants: 9101 men and women
Inclusion criteria: 19 years or older; no history of cancer at baseline; serum sample available
for analysis
Name of parent cohort: Social Insurance Institution’s Mobile Clinic Health Examination
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Knekt 1998 (Continued)
Survey
Recruitment: 1973 to 1976
Outcome assessment: end of 1991
Number of cases:
• Lung cancer: 91 (male/female: approximately 95%/5%)
Case definition: incidence
Years of follow-up: 16.0 to 19.0
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Analysed cases: 91 of 95 (male/female: 90/5)
Statistical methods: conditional logistical regression
Variables controlled in analysis: smoking, alpha-tocopherol, serum cholesterol, copper, oro-
somucoid, BMI
Variables controlled bymatching: age, gender, municipality, season of sample collection, length
of storage of sample
Risk estimates [95% CI] Reference category: lowest tertile
Results:
Lung cancer
• Analysis adjusted for smoking only: both genders: highest tertiles: OR 0.44 (95% CI 0.21
to 0.89)
• Analysis adjusted for all variables (number of cases: 77): highest tertiles: OR 0.41 (95%
CI 0.17 to 0.94)
Selenium levels in exposure categories Lowest tertile: ≤ 45.49 µg/L
Highest tertile: ≥ 60.60 µg/L
Notes
Kok 1987a
Methods Matched, nested case-control study
Country: the Netherlands
Participants Participants: 10,532 men and women
Inclusion criteria: inhabitant of Zoetermeer; 5 years or older
Name of parent cohort: EPOZ Cohort (Epidemiologisch onderzoek naar risico-indicatoren
voor hart- en vaatziekten)
Recruitment: 1975 to 1978
Outcome assessment: 31 December 1983
Number of cases:
• Any cancer: 69 (male/female: 40/29)
Case definition:mortality
Years of follow-up: 6.0 to 9.0
Type of selenium marker: serum
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Kok 1987a (Continued)
Interventions d.n.a.
Outcomes Analysed cases: 69 of 114 (reason for non-inclusion: serum or baseline data not available,
deaths in first year of follow-up excluded)
Statistical methods: not specified
Variables controlled in analysis: age, smoking, serum cholesterol, serum vitamins A and E,
systolic and diastolic blood pressure, BMI, week of blood collection, years of education,
gender (in group of both genders)
Variables controlled by matching: age, gender, smoking status
Risk estimates [95% CI] Reference category: highest 4 quintiles
Results:
Any cancer
• Both genders: lowest quintile: OR 1.9 (90% CI 1.0 to 3.5)
• Male: lowest quintile: OR 2.7 (90% CI 1.2 to 6.2)
• Female: lowest quintile: OR 1.5 (90% CI 0.5 to 4.5)
Selenium levels in exposure categories Both genders
• Lowest quintile: ≤ 102.79 µg/L
• Highest 4 quintiles: ≥ 102.80 µg/L
Males
• Lowest quintile: ≤ 100.79 µg/L
• Highest 4 quintiles: ≥ 100.80 µg/L
Females
• Lowest quintile: ≤ 107.29 µg/L
• Highest 4 quintiles: ≥ 107.30 µg/L
Notes Primary publication: Kok 1987b
Other publication: Kok 1987a
Kornitzer 2004
Methods Matched, nested case-control study
Country: Belgium
Participants Participants: 10,902 (male/female: 5,549/5,353)
Inclusion criteria: 25 to 74 years of age
Name of parent cohort: Belgian Interuniversity Study on Nutrition and Health
Recruitment: 1980 to 1984
Outcome assessment: n.r.
Number of cases:
• Any cancer: 193 (male/female: 143/50)
Case definition:mortality
Years of follow-up: 10
Type of selenium marker: serum
Interventions d.n.a.
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Kornitzer 2004 (Continued)
Outcomes Analysed cases: 143 male/50 female cases analysed from 252 male/91 female cases (reason for
non-inclusion: no selenium measurement available)
Statistical methods: not specified
Variables controlled in analysis: BMI, total energy, total fat, saturated fat, alcohol intake, fibre,
retinol, vitamin C, smoking, beta-carotene
Variables controlled by matching: age, gender
Risk estimates [95% CI] Reference category: highest tertile
Results:
Any cancer
• Male: lowest tertile: OR 2.2 (95% CI 1.3 to 3.7)
• Female: lowest tertile: OR 0.7 (95% CI 0.3 to 1.6)
Selenium levels in exposure categories Lowest tertile ≤ 72.00 µg/L
Highest tertile ≥ 85.00 µg/L
Notes
Kristal 2014
Methods Matched, nested case-control study
Countries: United States, Canada, Puerto Rico
Participants Name of parent cohort: SELECT (Selenium and Vitamin E Cancer Prevention Trial), placebo
arm
Participants: 777 men from placebo arm of SELECT study
Inclusion criteria: black men aged ≥ 50 years and all other men aged ≥ 55 years, without
history of prostate cancer, serum PSA level ≤ 4 ng/L and non-suspicious digital rectal
examination
Recruitment: July 2001 to May 2004
Outcome assessment: 31 July 2009
Number of cases:
• Prostate cancer: 404 (male/female:404/0)
Case definition: incidence
Years of follow-up: n.r.
Type of selenium marker: toenail
Interventions d.n.a.
Outcomes Analysed cases: 404 (male/female: 404/0)
Statistical methods: Cox proportional hazard model
Variables controlled in analysis: age and race by matching, family history of prostate cancer,
diabetes, body mass index, prostate-specific antigen
Variables controlled by matching: age and race
Risk estimates [95% CI] Reference category: lowest quintile
Results:
• Prostate cancer: highest quintile: HR 0.76 (95% CI 0.44 to 1.31)
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Kristal 2014 (Continued)
Selenium levels in exposure categories Lowest quintile: < 0.758 µg/g
Highest quintile > 1.003 µg/g
Notes
Kromhout 1987
Methods Cohort/subcohort controlled cohort study
Country: the Netherlands
Participants Participants: 878 men
Inclusion criteria: 40 to 59 years of age; random sample of general male population at specific
age in Zutphen
Name of parent cohort: Zutphen Study
Recruitment: 1960
Outcome assessment: 1985
Number of cases:
• Lung cancer: 63 (male/female: 63/0)
Case definition:mortality
Years of follow-up: 25
Type of selenium marker: intake (interview)
Interventions d.n.a.
Outcomes Statistical methods: Cox proportional hazard model
Variables controlled in analysis: age, pack-years of smoking
Risk estimates [95% CI] Reference category: lowest quartile
Results:
Lung cancer
• Male: highest quartile: RR 0.98 (95% CI 0.41 to 2.36)
Selenium levels in exposure categories Lowest quartile: ≤ 55.00 µg/d
Highest quartile: ≥ 72.10 µg/d
Notes
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Li 2000
Methods Randomised controlled trial
Allocation: randomised, “based on their residence area”
Sequence generation: unclear, not described
Concealment: unclear, not described
Blinding: of participants: adequate (placebo); of investigators and doctors: unclear, not
described
Dropouts/withdrawals: no significant difference between percentages of dropouts in in-
tervention and control group (absolute numbers not reported)
Intention-to-treat-analysis: unclear
Recruitment period: unclear, not described
Observation period: 3 years, started in 1996
Study period: unclear, not described
Detection of cases: unclear; the study followed the diagnostic menu published by the
National Cancer Control and Prevention Center, follow-up procedures not described
Informed consent: unclear, not described
Participants Country: China
Number of participants: 2065 (selenium group: 1112; placebo group: 953)
Condition:HBs-Ag carriers with negative AFP and normal ALT living inQidong, Jiangsu
province
Demographics:men only; aged 20 to 65 years (screening group)
Recruitment and setting: recruitment of 2065 HBs-Ag carriers from 17 villages out of a
screening group of 18,000 men
Interventions Intervention: 0.5 mg sodium selenite p.o. daily for 3 years
Control: placebo
Outcomes Primary outcome measure: incidence of primary liver cancer
Other: blood selenium levels, activity of glutathione peroxidase
Results: person-year incidence rate (number of cases/total number of persons) in inter-
vention and control groups:
• 1st year of follow-up: selenium group 899.25/100,000 (10/1112); placebo group:
1888.77/100,000 (18/953)
• 2nd year of follow-up: selenium group 1708.60/100,000 (19/1112); placebo group:
4302.20/100,000 (41/953)
• 3rd year of follow-up: selenium group 3057.55/100,000 (34/1112); placebo group:
5981.11/100,000 (57/953)
Risk estimates [95% CI] n.r.
Selenium levels in exposure categories d.n.a.
Notes Adverse effects were not mentioned.
Risk of bias
Bias Authors’ judgement Support for judgement
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Li 2000 (Continued)
Random sequence generation (selection
bias)
Unclear risk Randomisation based only on residential
area
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Blinding of participants and doctors
Selective reporting (reporting bias) Low risk No problems found
Li 2004a
Methods Matched, nested case-control study
Country: United States
Participants Participants: 14,916 men
Inclusion criteria: participants of Physicians’ Health Study who provided blood sample
(healthy male physicians); no history of cancer at baseline; several physical conditions ex-
cluded at baseline: chronic renal failure, unstable angina pectoris, liver disease, peptic ulcer,
history of TIA/stroke/myocardial infarction/gout; no use of vitamin A or beta-carotene sup-
plements
Name of parent cohort: Physicians’ Health Study
Recruitment: 1982
Outcome assessment: 1995
Number of cases:
• Prostate cancer: 586 (male/female: 586/0)
Case definition: incidence
Years of follow-up: 13
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Statistical methods: logistical regression
Variables controlled in analysis: age at baseline, smoking status, duration of follow-up
Variables controlled by matching: age, smoking status
Risk estimates [95% CI] Reference category: lowest quintile
Results:
Prostate cancer
• Highest quintile: OR 0.78 (95% CI 0.54 to 1.13)
Selenium levels in exposure categories Lowest quintile: 0.060 to 0.090 ppm
Highest quintile: 0.121 to 0.190 ppm
Notes
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Lubinski 2011
Methods Randomised controlled trial
Allocation: random
Sequence generation: unclear
Concealment: unclear
Blinding: described only as double-blinded
Dropouts/withdrawals: no description
Intention-to-treat-analysis: unclear
Recruitment period: not specified
Treatment duration: unclear
Observation period/dermatological follow-up:
• Median: 35 months (range 6 to 62 months)
Detection of cases: not described
Informed consent: not described
Participants Country: Poland
Number of participants: 1135 (randomised to selenium group: 563, to placebo group:
572)
Condition: adult women, BRCA1+ mutation carriers
Demographics: not reported
Recruitment and setting: not reported
Interventions Intervention:
• 250 µg/d selenium supplied as sodium selenite
Control:
• Placebo
Outcomes Case definition: incidence
• All cancer
• Primary breast cancer
• Ovarian cancer
Risk estimates [95% CI] All cancer: HR 1.4 (95% CI 0.9 to 2.0), cases: selenium 60, placebo 45
Primary breast cancer: HR 1.3 (95% CI 0.7 to 2.5), cases: selenium 38, placebo 29
Ovarian cancer: HR 1.3 (95% CI 0.6 to 2.7), cases: selenium 17, placebo 10
Selenium levels in exposure categories d.n.a
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described only as randomised trial
Allocation concealment (selection bias) Unclear risk Not stated
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Lubinski 2011 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Described only as double-blinded
Selective reporting (reporting bias) Low risk No problems found
Ma 2017
Methods Cohort study
Country: China
Participants Name of parent cohorts: Shangai Men’s Health Study (SMHS) and Shangai Women’s Health
Study (SWHS)
Participants: 133,957 (male/female: 61,470/74,941)
SMHS: 61,480 men
SWHS: 74,941 women
Inclusion criteria:
SMHS: men aged 40 to 74; residents in Shangai with no history of cancer
SWHS: women aged 40 to 70, residents in Shangai with no history of cancer
Recruitment:
SMHS: April 2002 to June 2006
SWHS: March 1997 to May 2000
Outcome assessment: 31 December 2012
Number of cases: 536 (male/female: 344/192)
Case definition: incidence
Years of follow-up:
SMHS: median: 9.3
SWHS: median: 15.2
Type of selenium marker: intake
Interventions d.n.a.
Outcomes Analysed cases:
• Hepatocellular carcinoma: 536 (male/female: 344/192)
Statistical methods: Cox proportional hazard model
Variables controlled in analysis:
• Both genders: sex, age at recruitment, body mass index, total physical activity, total intake
of energy, vegetable, fruit, red meat, egg, fish, and soy, vitamin E intake, income, educa-
tion, smoking history, alcohol consumption, family history of liver cancer, history of viral
hepatitis/chronic liver disease, history of diabetes, history of cholelithiasis and history of
cholecystectomy
• Men: age at recruitment, body mass index, total physical activity, total intake of energy,
vegetable, fruit, red meat, egg, fish, and soy, vitamin E intake, income, education, smoking
history, alcohol consumption, family history of liver cancer, history of viral hepatitis/chronic
liver disease, history of diabetes, history of cholelithiasis and history of cholecystectomy
•Women: age at recruitment, body mass index, total physical activity, total intake of energy,
vegetable, fruit, red meat, egg, fish, and soy, vitamin E intake, income, education, smok-
ing history, alcohol consumption, family history of liver cancer, history of viral hepatitis/
104Selenium for preventing cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ma 2017 (Continued)
chronic liver disease, history of diabetes, history of cholelithiasis, history of cholecystectomy,
menopausal status, ever had oral contraceptive
Risk estimates [95% CI] Reference category: lowest quintile
Results:
Hepatocellular carcinoma
• Both cohorts: highest quintile: HR 0.86 (95% CI 0.52 to 1.43)
SMHS: highest quintile: HR 0.95 (95% CI 0.51 to 1.76)
SWHS: highest quintile: HR 0.70 (95% CI 0.26 to 1.90)
Selenium levels in exposure categories SMHS:
• Lowest quintile: < 31.77 µg/d
• Highest quintile: ≥ 54.52 µg/d
SWHS:
• Lowest quintile: < 36.24 µg/d
• Highest quintile: ≥ 61.14 µg/d
Notes
Marshall 2011
Methods Randomised controlled trial
Allocation: random
Sequence generation: unclear
Concealment: unclear
Blinding: described only as double-blinded. The central pathologist was also blinded to
study assignment
Dropouts/withdrawals: 13/227 in the selenium arm and 12/225 in the placebo arm were
lost to follow-up
Intention-to-treat-analysis: yes
Recruitment period: not specified
Treatment duration: not specified
Observation period/dermatological follow-up:
• Participants were followed for 3 years. They were seen in clinic at baseline and every 6
months thereafter
Detection of cases: Tissue blocks and corresponding pathology reports for all prostate
procedures were to be submitted to the central study pathologist for review
Informed consent: All participants gave oral and written informed consent in accordance
with institutional and federal guidelines. The protocol was approved by the Institutional
Review Boards at participating institutions, and was monitored by the Data and Safety
Monitoring Committee of SWOG
Participants Country: United States
Participants: 452 (randomised to selenium 200 µg/d: 227; to placebo group: 225)
Condition: 40years of age or older; digital rectal examination; biopsy-confirmeddiagnosis
of HGPIN with no evidence of cancer; upper limit of prostate-specific antigen (PSA)
of 10 ng/mL (as measured locally); American Urological Association (AUA) symptom
score < 20 (41), signifying no debilitating urinary problems; ambulatory and able to
carry out work of a light or sedentary nature
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Marshall 2011 (Continued)
Demographics: Selenium and placebo participants were well balanced with respect to age,
race, ethnicity, pre-study PSA category, vitamin E supplements, and number of cores
in the initial biopsy. They also were well balanced in body mass index, baseline blood
selenium, performance status, and number of cores revealing HGPIN
Interventions Participants were randomised in fashion to placebo or 200 µg/d of selenium, with daily
treatment scheduled for 3 years or until a prostate cancer diagnosis
Recruitment: not reported
End of blinded treatment period: at 3 years
Outcomes Primary outcome measure:
• progression of HGPIN to prostate cancer over a 3-year period
Risk estimates [95% CI] Primary outcomes:
• Adjusted OR 0.913 (95% CI 0.55 to 1.52, P = 0.727) for risk of prostate cancer as a
function of treatment group (with placebo as referent group)
Selenium levels in exposure categories d.n.a.
Notes OR estimate was given by the trial author.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Described as randomised
Allocation concealment (selection bias) Low risk Central randomisation with pathology re-
view
Blinding (performance bias and detection
bias)
All outcomes
Low risk Blinding of participants and personnel
Selective reporting (reporting bias) Low risk No problems found
McNaughton 2005
Methods Matched, nested case-control study (McNaughton 2005b)
Cohort study (Heinen 2007; van der Pols 2009)
Country: Australia
Participants Name of parent cohort: Nambour Skin Cancer Study
Recruitment: 1992 to 1996
Case definition: incidence
McNaughton 2005b
Participants: approximately 1000 men and women
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McNaughton 2005 (Continued)
Inclusion criteria: randomly selected adults, aged 20 to 69 years; recruited for participation in
a randomised controlled trial for skin cancer prevention with beta-carotene supplements and
sunscreen application in 1992; living in the Nambour community; free of SCC at baseline;
blood sample and FFQ provided in 1996; participants with extreme energy intakes in FFQ
excluded
Outcome assessment:December 2001
Number of cases:
• Basal cell carcinoma of the skin: 90 (male/female: 39/51)
Years of follow-up: 5.5
Type of selenium marker: serum and intake (FFQ)
Heinen 2007
Participants: 1001 men and women
Inclusion criteria: randomly selected adults, aged 20 to 69 years; recruited for participation in
randomised controlled trial for skin cancer prevention with beta-carotene supplements and
sunscreen application in 1992; living in the Nambour community; blood sample and FFQ
provided in 1996; participants with extreme energy intakes in FFQ andmissing consumption
frequencies for more than 10% of food items excluded
Outcome assessment: 31 December 2004
Number of cases:
• Basal cell carcinoma of the skin: 149 (male/female: 87/62) participants with 321 BCC
tumours
• Squamous cell carcinoma of the skin: 116 (male/female: 70/46) participants with 221 SCC
tumours
Case definition: incidence (tumour-based incidence and person-based incidence)
Years of follow-up: 8
Type of selenium marker: intake (FFQ)
van der Pols 2009:
Participants: 485 (male/female: 223/262) men and women
Inclusion criteria: randomly selected adults, aged 20 to 69 years; recruited for participation
in randomised controlled trial for skin cancer prevention with beta-carotene supplements
and sunscreen application in 1992; randomised to placebo in the intervention trial; living
in the Nambour community; free of SCC at baseline; blood sample and FFQ provided in
1996; participants with extreme energy intakes in FFQ excluded
Outcome assessment: 31 December 2004
Number of cases:
• Basal cell carcinoma of the skin: 77 (male/female: 46/31) participants with 173 BCC
tumours
• Squamous cell carcinoma of the skin: 59 (male/female: 38/21) participants with 124 SCC
tumours
Years of follow-up: 8
Type of selenium marker: serum
Interventions d.n.a.
Outcomes McNaughton 2005b:
Statistical methods: conditional logistical regression
Variables controlled in analysis: age, gender
Variables controlled by matching: age, gender
Heinen 2007
Statistical methods: generalised linear models
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McNaughton 2005 (Continued)
Variables controlled in analysis: age, sex, intervention arm in RCT, energy intake, skin colour,
elastosis of the neck, smoking, use of dietary supplements, history of skin cancer
van der Pols 2009
Statistical methods: generalised linear models
Variables controlled in analysis: age, sex, pack-years of smoking, alcohol intake, time spent
outdoors on weekdays, history of skin cancer before 1996
Risk estimates [95% CI] McNaughton 2005b
Reference category: lowest quartile
Results:
Basal cell carcinoma (skin)
• Both genders: highest quartile: OR 0.86 (95% CI 0.38 to 1.96) biochemical selenium level
• Both genders: highest quartile: OR 1.13 (95% CI 0.47 to 2.74) selenium intake
Heinen 2007
Reference category: lowest tertile
Results:
Basal cell carcinoma (skin)
• Both genders: highest tertile: RR 0.95 (95% CI 0.59 to 1.50)
Squamous cell carcinoma (skin)
• Both genders: highest tertile: RR 1.3 (95% CI 0.77 to 2.3)
van der Pols 2009
Reference category: lowest exposure category
Results:
Basal cell carcinoma (skin)
• Both genders: highest exposure category: RR 0.58 (95% CI 0.32 to 1.07)
Squamous cell carcinoma (skin)
• Both genders: highest exposure category: RR 0.49 (95% CI 0.24 to 0.99)
Selenium levels in exposure categories McNaughton 2005b
n.r.
Heinen 2007
• Lowest tertile ≤ 76.20 µg/d
• Highest tertile ≥ 89.31 µg/d
van der Pols 2009
• Lowest exposure category ≤ 78.96 µg/L
• Highest exposure category ≥ 102.65 µg/L
Notes Primary publication: McNaughton 2005b
Other publications: Heinen 2007, van der Pols 2009
Tumour-based incidence: number of newly developed histologically confirmed BCCs or
SCCs divided by person-years of follow-up accumulated over follow-up period
Person-based incidence: number of persons newly affected by BCC or SCC during the same
person-years of follow-up time as calculated for the tumour-based analysis
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Menkes 1986
Methods Matched, nested case-control study
Country: United States
Participants Participants: 20,305 men and women
Inclusion criteria: female and male inhabitants of Washington county/Maryland; history of
cancer at baseline excluded
Name of parent cohort: CLUE I Cohort
Recruitment: September to November 1974
Menkes 1986b
Outcome assessment: 1983
Number of cases:
• Lung cancer: 99 (69% male/31% female)
Helzlsour 1996
Inclusion criteria: women only; women who used hormones at baseline excluded
Outcome assessment: 1989
Number of cases:
• Ovarian cancer: 35 (male/female: 0/35)
Breslow 1995
Outcome assessment: 1994
Number of cases:
• Melanoma: 23 (male/female: n.r.)
• Basal cell carcinoma (skin): 17 (male/female: n.r.)
• Squamous cell cancer: 37 (male/female: n.r.)
Zheng 1993
Outcome assessment: 1990
Number of cases:
• Oral and pharyngeal: 28 (male/female: n.r.)
Batieha 1993
Inclusion criteria: 15,161 women
Outcome assessment: 31 May 1990
Number of cases:
• Cervical cancer: 50 (male/female: 0/50)
Helzlsour 1989
Inclusion criteria: 20,305 men and women
Outcome assessment: 1986
Number of cases:
• Bladder cancer: 35 (male/female: n.r.)
Burney 1989
Outcome assessment: 1986
Number of cases:
• Pancreatic cancer: 22 (male/female: 9/13)
Ko 1994
Outcome assessment: 25 September 1991
Number of cases:
• Colon cancer: 121 (male/female: 50/71)
Case definition: incidence
Years of follow-up: 8.0 to 16.8
Type of selenium marker: serum
Interventions d.n.a.
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Menkes 1986 (Continued)
Outcomes Menkes 1986b
Statistical methods: conditional logistical regression
Variables controlled by matching: age, gender, race/ethnicity, smoking status, year and month
of sample collection
Helzlsour 1986
Statistical methods: conditional logistical regression
Variables controlled by matching: age, race/ethnicity, day and time of blood sample collec-
tion, hours since last meal, time since last menstrual period (postmenopausal: years, pre-
menopausal: days)
Breslow 1995
Statistical methods: conditional logistical regression
Analysed cases: 17 of 98 basal cell carcinoma cases and 23 of 30 melanoma cases (and all
squamous cell carcinoma cases) included in analysis
Variables controlled by matching: age, gender, race/ethnicity
Zheng 1993
Statistical methods: n.r.
Variables controlled in analysis: smoking
Variables controlled by matching: age, gender, race/ethnicity, year and month of sample col-
lection, hours between previous meal and blood collection
Batieha 1993
Statistical methods: conditional logistical regression
Analysed cases: 50 of 60 (CIS and invasive cervical cancer) (reason for non-inclusion: no
matched control available)
Variables controlled by matching: age, race/ethnicity, year and month of blood collection,
hours since last meal, time since last menstrual period
Helzlsour 1989
Statistical methods: n.r.
Variables controlled in analysis: cigarette smoking, use of vitamin supplements
Variables controlled by matching: age, gender, race/ethnicity, hours since last meal (all samples
collected in same year)
Burney 1989
Statistical methods: n.r.
Variables controlled by matching: age, gender, race/ethnicity, hours since last meal
Ko 1994
Analysed cases: 121 of 154 (reason for non-inclusion: no serum sample available, tumour
pathology or localisation unclear)
Statistical methods: conditional logistical regression
Variables controlled by matching: age, gender, race/ethnicity, year and month of sample col-
lection, hours since last meal, women: time since last menstrual period, women: use of hor-
mones/hormonal contraceptives
Risk estimates [95% CI] Menkes 1986b
Reference category: highest quintile
Results:
Lung cancer
• Both genders: lowest quintile: OR 0.68 (CI not reported)
Helzlsouer 1986
Reference category: lowest tertile
Results:
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Menkes 1986 (Continued)
Ovarian cancer
• Highest tertiles: OR 0.58 (95% CI 0.20 to 1.70)
Breslow 1995
Reference category: lowest tertile
Results:
Melanoma
• Both genders: highest tertile: OR 0.9 (95% CI 0.3 to 2.5)
Basal cell carcinoma (skin)
• Both genders: highest tertile: OR 0.8 (95% CI 0.1 to 4.5)
Squamous cell cancer
• Both genders: highest tertile: OR 0.6 (95% CI 0.2 to 1.5)
Zheng 1993
Reference category: lowest tertile
Results:
Oral and pharyngeal cancer
• Both genders: highest tertile: OR 5.43 (CI not reported)
Batieha 1993
Reference category: highest tertile
Results:
Cervical cancer
• Lowest tertile: OR 1.12 (95% CI 0.50 to 2.53)
Helzlsour 1989
Reference category: highest tertile
Results:
Bladder cancer
• Both genders: lowest tertile: OR 2.06 (95% CI 0.67 to 6.35)
Burney 1989
Reference category: highest tertile
Results:
Pancreatic cancer
• Both genders: lowest tertile: OR 4.5 (CI not reported) (unmatched analysis)
• Both genders: lowest tertile vs higher 2 tertiles: OR 3.90 (95% CI 1.13 to 13.2) (matched
analysis)
• Male: 12.5 (95% CI 1.8 to 84.0) (unmatched analysis)
• Female: 1.2 (95% CI 0.6 to 2.5) (unmatched analysis)
Ko 1994
Reference category: highest quartile
Results:
Colon cancer
• Both genders: lowest quartile: OR 0.82 (95% CI 0.35 to 1.92)
Selenium levels in exposure categories Menkes 1986b
• Quintiles: n.r.
Helzlsouer 1986
Women
• Lowest tertile: ≤ 105.0 µg/L
• Highest tertile: ≥ 116.1 µg/L
Breslow 1995
• Tertiles: n.r.
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Menkes 1986 (Continued)
Zheng 1993
• Tertiles: n.r.
Batieha 1993
Women
• Lowest tertile: ≤ 0.109 ppm
• Highest tertile: ≥ 0.124 ppm
Helzlsour 1989
Both genders
• Lowest tertile: ≤ 109.0 µg/L
• Highest tertile: ≥ 119.1 µg/L
Burney 1989
• Lowest: 0.99 to 1.26 µmol/L; highest: 1.44 to 1.81 µmol/L
Ko 1994
• Lowest quartile: ≤ 99.0 µg/L
• Highest quartile: ≥ 118.1 µg/L
Notes Primary publication: Menkes 1986b
Other publications: Helzlsour 1996, Breslow 1995, Zheng 1993, Batieha 1993, Helzlsour
1989, Burney 1989, Ko 1994, Schober 1987 (cases included in Ko 1994), Menkes 1986a
(case included in Menkes 1986b)
Michaud 2002
Methods Matched, nested case-control study
Country: Finland
Participants Participants: 29,133 men
Inclusion criteria: 50 to 69 years of age; smokers; no history of cancer (other than non-
melanoma skin cancer) at baseline; no severe physical or psychiatric illness; intake of vitamin
E/A/beta-carotene supplements in excess of defined amounts
Name of parent cohort: Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study
Recruitment: 1985 to 1988
Outcome assessment: 30 April 1993
Number of cases:
• Bladder cancer: 133 (male/female: 133/0)
Case definition: incidence
Years of follow-up: 5 to 8
Type of selenium marker: toenail
Interventions d.n.a.
Outcomes Statistical methods: conditional logistical regression
Variables controlled in analysis: smoking dose and duration
Variables controlled by matching: age, year/month of sample collection, intervention group
status in RCT (only male smokers included in cohort)
Risk estimates [95% CI] Reference category: lowest tertile/quartile
Results:
Bladder cancer
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Michaud 2002 (Continued)
• Male: highest tertile: OR 0.90 (95% CI 0.45 to 1.78)
• Male: highest quartile: OR 0.87 (95% CI 0.30 to 2.52)
Selenium levels in exposure categories n.r.
Notes
Michaud 2005
Methods Matched, nested case-control study
Country: United States
Participants Participants: 101,950 (male/female: 33,737/68,213)
Inclusion criteria: cohort of HPFS (men) and NHS (women); no history of cancer at baseline
Name of parent cohort: Health Professional Follow-Up Study (HPFS) and Nurses’ Health
Study (NHS)
Recruitment: 1987 (HPFS), 1983 (NHS)
Outcome assessment: 2000
Number of cases:
• Bladder cancer: 337 (male/female: 221/116)
Case definition: incidence
Years of follow-up: 13 to 17
Type of selenium marker: toenail
Interventions d.n.a.
Outcomes Statistical methods: conditional logistical regression
Variables controlled in analysis: pack-years of smoking, heavy smoking at baseline
Variables controlled by matching: age, gender, smoking status, month of sample collection
Risk estimates [95% CI] Reference category: lowest quartile
Results:
Bladder cancer
• Male: highest quartile: OR 1.17 (95% CI 0.66 to 2.07)
• Female: highest quartile: OR 0.36 (95% CI 0.14 to 0.91)
Selenium levels in exposure categories Men
• Lowest quartile: ≤ 0.722 µg/g
• Highest quartile: ≥ 0.912 µg/g
Women
• Lowest quartile: ≤ 0.686 µg/g
• Highest quartile: ≥ 0.840 µg/g
Notes
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Muka 2017
Methods Cohort study
Country: the Netherlands
Participants Name of parent cohort: The Rotterdam Study
Participants: 5435 (male/female: n.r.)
Inclusion criteria: aged ≥ 55 and living in the Ommoord district
Recruitment: 1989 to 1993
Outcome assessment:December 2011
Number of cases: 211 (male/female: 128/83)
Case definition: incidence
Years of follow-up: mean: 15.2
Type of selenium marker: intake
Interventions d.n.a.
Outcomes Analysed cases: 211 (male/female: 128/83)
Statistical methods: Cox proportional hazard model
Variables controlled in analysis: age, sex, alcohol intake, body mass index, smoking status,
physical activity, Dutch healthy diet index, dietary processed meat intake, dietary unpro-
cessed red meat intake, total energy intake, hormone replacement therapy, diabetes mellitus,
education status, income status, total energy, adjusted sum of other minerals (excluding se-
lenium), and family history of cancer
Risk estimates [95% CI] Reference category: lowest tertile
Results:
Lung cancer
• Highest tertile: HR 1.39 (95% CI 0.97 to 1.99)
Selenium levels in exposure categories n.r.
Notes Lung cancer: highest tertile: HR 1.44 (95% CI 0.98 to 2.11) after exclusion of lung cancer
within the first 2 years of follow-up
Nomura 1987
Methods Unmatched, nested case-control study
Country: United States
Participants Participants: 6860 men
Inclusion criteria: born 1900 to 1919; Japanese ancestry; inhabitants of Oahu/Hawaii; par-
ticipants in the Honolulu Heart Program (1965 to 1968)
Name of parent cohort: Honolulu Heart Program
Recruitment: 1971 to 1975
Outcome assessment: n.r.
Number of cases:
• Any cancer: 280 (male/female: 280/0)
• Stomach cancer: 66 (male/female: 66/0)
• Rectal cancer: 32 (male/female: 32/0)
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• Lung cancer: 71 (male/female: 71/0)
• Colon cancer: 82 (male/female: 82/0)
• Bladder cancer: 29 (male/female: 29/0)
Case definition: incidence
Years of follow-up: 11
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: proportional hazard regression/Cox regression
Variables controlled in analysis:
• Age at examination, cigarettes/d (any cancer, lung cancer, bladder cancer)
• Age at examination (stomach, rectum, colon)
Risk estimates [95% CI] Reference category: highest quintile
Results:
Stomach cancer
• Male: lowest quintile: OR 0.9 (CI not reported)
Rectal cancer
• Male: lowest quintile: OR 1.6 (CI not reported)
Lung cancer
• Male: lowest quintile: OR 1.1 (CI not reported)
Colon cancer
• Male: lowest quintile: OR 1.8 (CI not reported)
Bladder cancer
• Male: lowest quintile: OR 3.1 (CI not reported)
All five types of cancer
• Male: lowest quintile: OR 1.3 (CI not reported)
Selenium levels in exposure categories Lowest quintile: ≤ 103.0 µg/L
Highest quintile: ≥ 133.1 µg/L
Notes N.B.: “Any cancer” in this study comprises all cancer cases for stomach, rectal, lung, colon,
and bladder cancer
Nomura 2000
Methods Matched, nested case-control study
Country: United States
Participants Participants: 9345 men
Inclusion criteria: no cancer diagnosis at baseline, blood sample available for analysis, men
from 2 cohorts: subcohort 1: participants of Nomura 1987; subcohort 2: brothers of partic-
ipants in Nomura 1987
Recruitment: 1971 to 1977
Outcome assessment: 1995
Number of cases:
• Prostate cancer: 249 (male/female: 249/0)
Case definition: incidence
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Years of follow-up: 19 to 25
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Analysed cases: random sample of 249 (out of 360) because of limited resources
Statistical methods: generalised linear model
Variables controlled in analysis: cigarette smoking history, age
Variables controlled by matching: age, year/month of sample collection, recruitment in sub-
cohort 1 or 2
Risk estimates [95% CI] Reference category: lowest quartile
Results:
Prostate cancer
• Highest quartile: OR 0.5 (95% CI 0.3 to 0.9)
Selenium levels in exposure categories Lowest quartile: ≤ 119.29 µg/L
Highest quartile: ≥ 147.20 µg/L
Notes
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NPCT 2002
Methods Randomised controlled trial
Nutritional Prevention of Cancer Trial (NPCT)
Allocation: random, block/stratified by clinic
Sequence generation: computer-generated random numbers
Concealment: central assignment (sealed pill bottles)
Blinding: participant blinded, doctor blinded, outcome assessor/pathologist unclear, re-
view/coding of medical records blinded
Dropouts/withdrawals: “9 patients (5 in the selenium group and 4 in the placebo group)
declined to provide additional illness information” (Clark 1996, p. 1959) - 0 participants
lost to vital follow-up
Intention-to-treat-analysis: yes
Recruitment period: 1983 to 1991
End of predefined study period: 31 December 1993
Blinded intervention continued until end of blinded period: 31 January 1996
Intervention duration:
• 31 December 1993 (end of study period): mean = 4.5 years
• 31 January 1996 (end of blinded period): mean = 7.9 years
Observation period/dermatological follow-up:
• 31 December 1993 (end of study period): mean = 6.4 years
• 31 January 1996 (end of blinded period): mean = 7.4 years
Detection of cases: dermatological examination and interview every 6 months during
follow-up; incident BCC and SCC diagnosed by biopsy and confirmed by another
dermatopathologist
Informed consent:written informed consent forms, approval by institutional review board
of participating institutions
Participants Country: United States
Participants: 1312 (randomised to selenium group: 653; to placebo group: 659)
Condition:male and female participants with history of 2 or more squamous cell or basal
cell skin cancers
Demographics: mean age 63.4 years (selenium)/63.0 years (placebo); 73.8% men (sele-
nium), 75.6% men (placebo)
Recruitment and setting: 7 dermatological clinics (3 academic units, 4 private practices)
in the United States
Interventions Intervention: 200 µg selenium supplied as 500 mg selenium yeast tablets p.o. daily
Control: placebo
Outcomes Primary outcome measure: incidence of basal and squamous cell carcinoma of the skin:
• All analyses were based on 1250 participants with initial blood collection within 4 days
after randomisation (621 in the selenium group and 629 in the placebo group)
Other reported outcomes and secondary outcome measures:
• Reported in Clark 1996: incidence of lung cancer, prostate cancer, colorectal cancer,
any cancer, head and neck cancer, bladder cancer, oesophageal cancer, breast cancer,
melanoma, haematological cancer
• Reported in Duffield-Lillico 2002: overall cancer mortality
Risk estimates [95% CI] Primary outcomes:
At end of study period (31 December 1993) (Clark 1996)
• BCC: RR 1.10 (95% CI 0.95 to 1.28); cases: selenium group: 377, placebo group:
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NPCT 2002 (Continued)
350; incidence per person-year under follow-up: selenium group 0.16, placebo group 0.
15
• SCC: RR 1.14 (95% CI 0.93 to 1.39); cases: selenium group 218, placebo group: 190;
incidence per person-year under follow-up: selenium group 0.07, placebo group 0.06
At end of blinded period (31 January 1996) (Duffield-Lillico 2003)
• BCC: RR 1.17 (95% CI 1.02 to 1.35), HR 1.09 (95% CI 0.94 to 1.26); number of
cases not reported; incidence per person-year under follow-up: selenium group: 0.16,
placebo group 0.13
• SCC: RR 1.32 (95% CI 1.09 to 1.60), HR 1.25 (95% CI 1.03 to 1.51); number of
cases not reported; incidence per person-year under follow-up: selenium group: 0.05,
placebo group 0.07
• NMSC: RR 1.27 (95% CI 1.11 to 1.45), HR 1.17 (95% CI 1.02 to 1.34); number
of cases not reported; incidence per person-year under follow-up: selenium group: 0.20,
placebo group 0.16
Other reported outcomes and secondary outcomes:
At end of study period (31 December 1993) (Clark 1996)
• Lung cancer: RR 0.54 (95% CI 0.30 to 0.98), adjusted HR 0.56 (95% CI 0.31 to 1.
01) cases selenium: 17, placebo: 31
• Prostate cancer: RR 0.37 (95% CI 0.18 to 0.71), adjusted HR 0.35 (95% CI 0.18 to
0.65) cases selenium: 13, placebo: 35
• Colorectal cancer: RR 0.42 (95% CI 0.18 to 0.95), adjusted HR 0.39 (95% CI 0.17
to 0.90) cases selenium: 8, placebo: 19
• Any cancer: RR 0.63 (95% CI 0.47 to 0.85), adjusted HR 0.61 (95% CI 0.46 to 0.
82) cases selenium: 77, placebo: 119
• Head and neck cancer: RR 0.74 (95% CI 0.21 to 2.43), adjusted HR 0.77 (95% CI
0.27 to 2.24) cases selenium: 6, placebo: 8
• Bladder cancer: RR 1.32 (95% CI 0.40 to 4.61), adjusted HR 1.27 (95% CI 0.44 to
3.67) cases selenium: 8, placebo: 6
• Oesophageal cancer: RR 0.33 (95% CI 0.03 to 1.84), adjusted HR 0.30 (95% CI 0.
06 to 1.49) cases selenium: 2, placebo: 6
• Breast cancer: RR 2.88 (95% CI 0.72 to 16.5), adjusted HR 2.95 (95% CI 0.80 to
10.9) cases selenium: 9, placebo:3
• Melanoma: RR 0.97 (95% CI 0.32 to 2.96), adjusted HR 0.92 (95% CI 0.34 to 2.
45) cases selenium: 8, placebo: 8
• Haematological cancer: RR 1.58 (95% CI 0.46 to 6.14), adjusted HR 1.50 (95% CI
0.49 to 4.60) cases selenium: 8, placebo: 5
• Other specific carcinomas: RR 0.55 (95% CI 0.14 to 1.82), adjusted HR 0.54 (95%
CI 0.18 to 1.62), cases selenium: 5, placebo: 9
• Total carcinoma: RR 0.55 (95% CI 0.40 to 0.77), adjusted HR 0.54 (95% CI 0.39 to
0.75), cases selenium: 59; placebo: 104
• Leukaemia/lymphoma: RR 1.58 (95% CI 0.46 to 6.14), adjusted HR 1.50 (95% CI
0.49 to 4.60), cases selenium: 8, placebo 5
• Other specific non-carcinomas: RR 0.99 (95% CI 0.13 to 7.37), HR 0.99 (95% CI
0.20 to 4.94), cases selenium: 3, placebo: 3
• Total non-carcinomas: RR 1.17 (95% CI 0.57 to 2.44), adjusted HR 1.16 (95% CI
0.60 to 2.27), cases selenium: 19; placebo: 16
At end of blinded period (31 January 1996) (Duffield-Lillico 2002)
• Lung cancer: RR 0.70 (95% CI 0.40 to 1.21), adjusted HR 0.74 (95% CI 0.44 to 1.
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NPCT 2002 (Continued)
24), cases selenium: 25, placebo: 35
• Prostate cancer: RR 0.51 (95% CI 0.29 to 0.87), adjusted HR 0.48 (95% CI 0.28 to
0.80), cases selenium: 22, placebo: 42
• Colorectal cancer: RR 0.46 (95% CI 0.19 to 1.08), adjusted HR 0.46 (95% CI 0.21
to 1.02), cases selenium: 9, placebo: 19
• Any cancer: RR 0.75 (95% CI 0.58 to 0.98), adjusted HR 0.75 (95% CI 0.58 to 0.
97), cases selenium: 105, placebo: 137
• Head and neck cancer: RR 1.27 (95% CI 0.42 to 4.01), adjusted HR 1.27 (95% CI
0.47 to 3.42), cases selenium: 9, placebo: 7
• Bladder cancer: RR 1.24 (95% CI 0.44 to 3.61), adjusted HR 1.28 (95% CI 0.50 to
3.25), cases selenium: 10, placebo: 8
• Oesophageal cancer: RR 0.39 (95% CI 0.04 to 2.41), adjusted HR 0.40 (95% CI 0.
08 to 2.07), cases selenium: 2, placebo: 5
• Breast cancer: RR 1.82 (95% CI 0.62 to 6.01), adjusted HR 1.89 (95% CI 0.69 to 5.
14), cases selenium: 11, placebo: 6
• Melanoma: RR 1.21 (95% CI 0.46 to 3.30), adjusted HR 1.18 (95% CI 0.49 to 2.
85), cases selenium: 11, placebo: 9
• Haematological cancer (lymphoma and leukaemia): RR 1.32 (95% CI 0.40 to 4.61),
adjusted HR 1.25 (95% CI 0.43 to 3.61), cases selenium: 8, placebo: 6
• Cancer mortality, all sites: RR 0.59 (95% CI 0.39 to 0.89), adjusted HR 0.59 (95%
CI 0.39 to 0.87), cases selenium: 40, placebo: 66
• Other carcinomas: RR 0.66 (95% CI 0.19 to 2.07), adjusted HR 0.67 (95% CI 0.24
to 1.88), cases selenium: 6, placebo:9
• Other non-carcinomas: RR 0.59 (95% CI 0.09 to 3.04), adjusted HR 0.59 (95% CI
0.14 to 2.47), cases selenium: 3, placebo: 5
Selenium levels in exposure categories d.n.a.
Notes Adverse effects: Clark 1996: 35 participants (21 in selenium and 14 in control group)
complained of adverse effects, mostly involving gastrointestinal upset, and withdrew
treatment
Post hoc introduced secondary outcomes: all-cause mortality, total cancer mortality, total
cancer incidence, and incidence of lung/prostate/colorectal cancers
HR: adjusted for sex, age, smoking status, clinic site, plasma selenium concentration,
clinical sun damage, sunscreen use at baseline, and number of BCCs/SCCs/NMSCs in
the 12 months before randomisation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random, block/stratified by clinic, com-
puter-generated random numbers
Allocation concealment (selection bias) Low risk Central assignment (sealed pill bottles)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Occurrence of a detection bias, namely, a
considerably higher rate of prostate biopsy
in the placebo group
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Selective reporting (reporting bias) Low risk No problems found
O’Grady 2014
Methods Cohort study
Country: United States
Participants Name of parent cohort:National Institute of Health-American Association of Retired Persons
(NIH-AARP) Diet and Health Study
Participants: 482,807 (male/female: 287,944/194,863)
Inclusion criteria: 50 to 71 years of age, AARP members, no previous diagnosis of cancer
other than NMSC
Recruitment: 1995 to 1996
Outcome assessment:December 2006
Number of cases: 592 (male/female: 257/335)
Case definition: incidence
Years of follow-up: mean: 9.1
Type of selenium marker: intake
Interventions d.n.a.
Outcomes Analysed cases:
• Total thyroid cancer: 592 (male/female: 257/335)
• Papillary thyroid cancer subtype: 406 (male/female: 164/242)
• Follicular thyroid cancer subtype: 113 (male/female: 57/56)
Statistical methods: Cox proportional hazard model
Variables controlled in analysis: entry age, sex, calories, smoking status, race, education, BMI,
physical activity, vitamin C, vitamin E, beta-carotene, and folate
Risk estimates [95% CI] Reference category: lowest quintile
Results:
Total thyroid cancer
• Both genders: highest quintile: HR 1.35 (95% CI 0.99 to 1.84)
• Male: highest quintile: HR 1.23 (95% CI 0.71 to 2.12)
• Female: highest quintile: HR 1.14 (95% CI 0.65 to 2.02)
Papillar subtype
• Both genders: highest quintile: HR 1.35 (95% CI 0.92 to 1.98)
• Male: highest quintile: HR 1.32 (95% CI 0.65 to 2.69)
• Female: highest quintile: HR 1.29 (95% CI 0.68 to 2.46)
Follicular subtype
• Both genders: highest quintile: HR 1.41 (95% CI 0.71 to 2.79)
• Male: highest quintile: HR 1.32 (95% CI 0.43 to 4.03)
• Female: highest quintile: HR 0.88 (95% CI 0.20 to 3.87)
Selenium levels in exposure categories Lowest quintile: median 47 µg/d
Highest quintile: median 150.1 µg/d
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Notes
Outzen 2016
Methods Matched, nested case-control study
Country: Denmark
Participants Name of parent cohort: Danish Prospective Diet, Cancer and Health Study
Participants: 27,179 men
Inclusion criteria: aged 50 to 64, born in Denmark, residents in the Copenhagen and Aarhus
areas, no previous history of cancer
Recruitment: December 1993 to May 1997
Outcome assessment: 31 December 2007
Number of cases: 911 (male/female: 911/0)
Case definition: incidence
Years of follow-up: 8
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Analysed cases:
Prostate cancer
• 784 (male/female: 784/0)
Statistical methods: conditional logistical regression
Variables controlled in analysis: body mass index, education, smoking status, duration and
frequency, and participation in sport
Variables controlled by matching: age at blood collection, time of day of blood collection, and
fasting status
Risk estimates [95% CI] Reference category: lowest quartile
Results:
Prostate cancer
• Highest quartile: OR 0.95 (95% CI 0.70 to 1.29)
Selenium levels in exposure categories Lowest quartile: ≤ 71.4 µg/d
Highest quartile: > 88.9 µg/d
Notes
Overvad 1991
Methods Cohort/subcohort controlled cohort study
Country: Channel Islands (UK)
Participants Participants: 5162 women
Inclusion criteria: ≥ 35 years of age; ostensibly healthy inhabitants of Guernsey
Name of parent cohort: Channel Island Cohort
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Recruitment: 1967 to 1976
Outcome assessment: end of 1985
Number of cases:
• Breast cancer: 46 (male/female: 0/46)
Case definition: incidence
Years of follow-up: mean: 11 years for cases
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Analysed cases: 46 of 88 (reason for non-inclusion: no plasma available)
Statistical methods: logistical regression
Variables controlled in analysis: age, age at menarche, age at first baby, parity, BMI
Risk estimates [95% CI] Reference category: highest quartile
Results:
Breast cancer
• Lowest quartile: RR 0.80 (95% CI 0.29 to 2.19)
Selenium levels in exposure categories Lowest quartile: ≤ 84.90 µg/L
Highest quartile: ≥ 116.00 µg/L
Notes
Pantavos 2015
Methods Cohort study
Country: the Netherlands
Participants Name of parent cohort: The Rotterdam Study
Participants: 4877 women
Inclusion criteria: aged ≥ 55 and living in the Ommoord district. no history of previous
breast cancer
Recruitment: July 1989 to September 1993
Outcome assessment:December 2010
Number of cases: 199 (male/female: 0/199)
Case definition: incidence
Years of follow-up: median: 17 years
Type of selenium marker: intake
Interventions d.n.a.
Outcomes Analysed cases: 199 (male/female: 0/199)
Statistical methods: Cox proportional hazard model
Variables controlled in analysis: age, body mass index, education level, family history of breast
cancer, smoking status, alcohol consumption, use of multi-vitamin supplement
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Risk estimates [95% CI] Reference category: lowest tertile
Results:
Breast cancer
• Highest tertile: HR 1.34 (95% CI 0.94 to 1.91)
Selenium levels in exposure categories Lowest tertile: median 23.58 µg/d
Highest tertile: median 37.46 µg/d
Notes
Park 2015
Methods Cohort study
Country: United States (Hawaii and California)
Participants Name of parent cohort: The Multiethnic Cohort
Participants: 75,216 men
Inclusion criteria: aged 45 to 75, African Americans, Native Hawaiians, Japanese American,
Latinos, and white men, without a previous diagnosis of prostate cancer
Recruitment: 1993 to 1996
Outcome assessment: 31 December 2010
Number of cases:
• Prostate cancer: 7115
Case definition: incidence
Years of follow-up: mean: 13.9
Type of selenium marker: intake
Interventions d.n.a.
Outcomes Analysed cases:
• Prostate cancer: 7115
Statistical methods: Cox proportional hazard model
Variables controlled in analysis: age at entry, race/ethnicity, family history of prostate cancer,
bodymass index, height, smoking status, education level, history of diabetes, physical activity,
daily intakes of alcohol, calcium, legume, and lycopene
Risk estimates [95% CI] Reference category: lowest quintile
Results:
Prostate cancer
• Highest quintile: RR 1.01 (95% CI 0.84 to 1.20)
Selenium levels in exposure categories Lowest quintile: < 44.0 µg/1000 kcal/d
Highest quintile ≥ 60.1 µg/1000 kcal/d
Notes
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Peleg 1985
Methods Matched, nested case-control study
Country: United States
Participants Participants: 2530 men and women
Inclusion criteria: 15 years of age and older; residents of Evans County; cases within first 2
years of follow-up excluded
Name of parent cohort: Evans County Study
Recruitment: 1967 to 1969
Outcome assessment: January 1981
Number of cases:
• Any cancer: 130 (male/female: 78/52)
Case definition: incidence
Years of follow-up: 11 to 14
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: n.r.
Variables controlled by matching: age, gender, race/ethnicity, year/month of sample collection
Risk estimates [95% CI] Reference category: highest quartile
Results:
Any cancer
• Both genders: lowest quartile: OR 1.0 (CI not reported)
Selenium levels in exposure categories Lowest quartile: ≤ 103 µg/L
Highest quartile: ≥ 127 µg/L
Notes
Peters 2007
Methods Matched, nested case-control study
Country: United States
Participants Participants: 26,975 white non-Hispanic men
Inclusion criteria: 55 to 74 years of age; excluded: no baseline questionnaire/informed con-
sent/blood sample, no further contact after screening
Name of parent cohort: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
Recruitment: September 1993 to June 2001
Outcome assessment: 1 October 2001
Number of cases:
• Prostate cancer: 724 (male/female: 724/0)
Case definition: incidence
Years of follow-up: 0.3 to 8.0
Type of selenium marker: serum
Interventions d.n.a.
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Outcomes Analysed cases: 724 of 803 (reason for non-inclusion: no selenium measurement available)
Statistical methods: n.r.
Variables controlled in analysis: age, time since initial screening, year of blood collection, study
centre
Variables controlled by matching: age, month of sample collection, time since initial screening
Risk estimates [95% CI] Reference category: lowest quartile
Results:
Prostate cancer
• Highest quartile: OR 0.84 (95% CI 0.62 to 1.14)
Selenium levels in exposure categories Lowest quartile: 50.5 to 126.7 µg/L
Highest quartile: 158.0 to 253.0 µg/L
Notes
Peters 2008
Methods Cohort study
Country: United States
Participants Inclusion criteria: aged 50 to 76 years, participants recruited from subscribers to commercial
mailing list, residents of western Washington state, non-whites excluded, no malignant dis-
ease at baseline
Name of parent cohort: Vitamins and Lifestyle (VITAL) study
Recruitment: 1 October 2000 to 31 December 2002
Type of selenium marker: supplemental intake (questionnaire: use of supplements over past
10 years, mean supplemental intake/day calculated)
Case definition: incidence
Peters 2008
Participants: 35,242 men
Outcome assessment: 31 December 2004
Number of cases:
• Prostate cancer: 818 (male/female: 818/0)
Years of follow-up: 2 to 4
Asgari 2009
Participants: 69,671 men and women
Outcome assessment: 31 December 2006
Number of cases:
• Melanoma: 461 (male/female: n.r.)
Years of follow-up: 4 to 5 years
Interventions d.n.a.
Outcomes Peters 2008
Analysed cases: 818 of 830 (reason for non-inclusion: not reported)
Statistical methods: Cox proportional hazard regression analysis
Variables controlled in analysis: age, family history of prostate cancer, BPH, income, multi-
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vitamin use
Asgari 2009
Analysed cases: 1 case not analysed (reason for non-inclusion: not reported)
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, sex, education, family history of melanoma, personal
history of non-melanoma skin cancer, mole removal, freckles, sunburns, hair colour, reaction
to sunlight exposure
Risk estimates [95% CI] Reference category: no supplemental selenium intake (lowest exposure category)
Peters 2008
Results:
Prostate cancer
• Highest exposure category: RR 0.90 (95% CI 0.62 to 1.30)
Asgari 2009
Results:
Melanoma
• Highest exposure category HR 0.98 (95% CI 0.69 to 1.41)
Selenium levels in exposure categories Stratification according to supplemental selenium intake
Peters 2008
• Lowest category: no supplemental intake
• Highest category ≥ 51 µg/d
Asgari 2009
• Lowest exposure category: no supplemental intake
• Highest exposure category ≥ 50 µg/d
Notes
Ratnasinghe 2000
Methods Matched, nested case-control study
Country: China
Participants Participants: 9143 men
Inclusion criteria: 35 years or older; tin miners employed by the Yunnan Tin Corporation;
10 or more years of underground mining/smelting; no history of cancer at baseline
Recruitment: 1992 to 1997
Outcome assessment: 1997
Number of cases:
• Lung cancer: 108 (male/female: 108/0)
Case definition: incidence
Years of follow-up: 3
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Analysed cases: plasma available for 108 of a total of 339 identified cases
Statistical methods: logistical regression, conditional logistical regression, Wilcoxon rank sum
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test
Variables controlled in analysis: radon exposure, smoking
Variables controlled by matching: age, year and month of sample collection
Risk estimates [95% CI] Reference category: lowest tertile
Results:
Lung cancer
• Highest tertile: OR 1.2 (95% CI 0.6 to 2.4)
Selenium levels in exposure categories Lowest tertile: 20 to 39 µg/L
Highest tertile: 55 to 121 µg/L
Notes
Reid 2008
Methods Randomised controlled trial
Substudy of the Nutritional Prevention of Cancer Trial (NPCT 2002)
Allocation: random
Sequence generation: computer-generated random numbers
Concealment: central assignment (sealed pill bottles)
Blinding: participant blinded, doctor blinded, outcome assessor/pathologist unclear, review/
coding of medical records blinded
Dropouts/withdrawals: 2 participants declined to provide additional illness information, no
participant lost to vital follow -up
Intention-to-treat-analysis: yes
Recruitment period: 1989-1992
Treatment duration:
• Blinded intervention continued until the end of the blinded period; 1 February 1996
Observation period/dermatological follow-up:
1 February 1996
Detection of cases: dermatological examination and interview every 6 months during follow-
up; incident BCC and SCC diagnosed by biopsy and confirmed by another dermatopathol-
ogist
Informed consent: written informed consent forms, approval by institutional review boards
of participating institutions
Participants 423 male and female participants with prior non-melanoma skin cancer
Country: United States
Participants: 423 (randomised to selenium group: 210, to placebo group: 213)
Condition:male and female with history of 2 or more squamous cell or basal cell skin cancers
Demographics:mean age 63.8 years (selenium)/63.8 years (placebo); 66.2% men (selenium)
. 68.2% men (placebo)
Recruitment and setting: dermatological clinic in Macon, Georgia
Interventions Intervention:
• 400 µg selenium supplied as selenium yeast tablets p.o. daily
Control:
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• Placebo
• 400 µg/d of selenium yeast or identical-appearing low selenium yeast placebo
Recruitment: 12 September 1989 to 3 April 1992
End of blinded treatment period: 2 February 1996
Outcomes Primary outcome measure: incidence of basal and squamous cell carcinoma of the skin
• All analyses were based on n = 423 participants with initial blood collection within 4 days
after randomisation
Other reported outcomes:
• Total internal cancer incidence
Risk estimates [95% CI] Primary outcomes:
• BCC: RR 0.90 (95% CI 0.65 to 1.24); cases: selenium group: 76, placebo group: 83;
adjusted HR: 0.95 (95% CI 0.69 to 1.29)
• SCC: RR 1.05 (95% CI 0.71 to 1.56); cases: selenium group: 56, placebo group: 53;
adjusted HR: 1.05 (95% CI 0.72 to 1.53)
• NMSC: RR 0.88 (95% CI 0.66 to 1.16); cases: selenium group: 98, placebo group: 108;
adjusted HR: 0.91 (95% CI 0.69 to 1.20)
• NMSC in women: RR 0.40 (95% CI 0.20 to 0.80)
Other reported outcomes:
• Total internal cancer incidence:
RR 1.10 (95% CI 0.57 to 2.17); cases: selenium group: 21, placebo group: 19
Selenium levels in exposure categories d.n.a.
Notes Information on study design, which was not reported in Reid 2008, was taken from infor-
mation available on the Nutritional Prevention of Cancer Trial
Adverse effects: not reported
HR: adjusted for: age (continuous), smoking status (never, former, current), gender
Ringstad 1988
Methods Matched, nested case-control study
Country: Norway
Participants Participants: 9364 men and women
Inclusion criteria: 20 to 54 years of age (men), 20 to 49 years of age (women); inhabitants of
Tromso; blood sample provided in 1979; no history of cancer at baseline
Name of parent cohort: Tromso Heart Study II
Recruitment: 1979 to 1980
Outcome assessment: 1985
Number of cases:
• Any cancer: 60 (male/female: 26/34)
Case definition: incidence
Years of follow-up: 5 to 7
Type of selenium marker: serum
Interventions d.n.a.
128Selenium for preventing cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ringstad 1988 (Continued)
Outcomes Analysed cases: 60 of 72 (reason for non-inclusion: no sample available)
Statistical methods: n.r.
Variables controlled by matching: age, gender, smoking status, month of sample collection,
place of residence (district of Tromso)
Risk estimates [95% CI] Reference category: highest 3 quartiles
Results:
Any cancer
• Both genders: lowest quartile: OR 1.4 (95% CI 0.6 to 3.5)
Selenium levels in exposure categories Lowest quartile: ≤ 114.49 µg/L
Highest 3 quartiles: 114.50 to 114.51 µg/L
Notes
Sakoda 2005
Methods Matched, nested case-control study
Country: China
Participants Participants: 41,563 men and women
Inclusion criteria: inhabitants of Haiman city of Chinese origin; written consent; toenail
clipping available
Recruitment: January 1993 to December 1993
Outcome assessment: 30 September 2000
Number of cases:
• Primary liver cancer: 166 (male/female: 154/12)
Case definition:mortality
Years of follow-up: 6.8 to 7.8
Type of selenium marker: toenail
Interventions d.n.a.
Outcomes Analysed cases: 166 of 455 observed cases (only cases with questionnaire, blood sample, and
toenail specimen analysed after 2000 owing to different methods of selenium analysis)
Statistical methods: not specified
Variables controlled in analysis:
• Both genders: age, gender, HBsAg status, alcohol intake, history of acute hepatitis, occu-
pation
•Men: age, HBs-Ag status, alcohol intake, history of acute hepatitis, family history of HCC,
occupation
• Women: HBs-Ag status, age, history of acute hepatitis
Variables controlled by matching: age, gender, township of residence
Risk estimates [95% CI] Reference category: lowest quartile
Results:
Primary liver cancer
• Both genders: highest quartile: OR 0.50 (95% CI 0.28 to 0.90)
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Sakoda 2005 (Continued)
• Male: highest quartile: OR 0.57 (95% CI 0.31 to 1.05)
• Female: highest 3 quartiles: OR 0.18 (95% CI 0.03 to 1.13)
Selenium levels in exposure categories Both genders and men
• Lowest quartile: 0 to 1.70 ppm
• Highest quartile: ≥ 4.43 ppm
Women
• Lowest quartile: 0.00 to 1.70 ppm
• Highest 3 quartiles: ≥ 1.71 ppm
Notes
Salonen 1984
Methods Matched, nested case-control study
Country: Finland
Participants Participants: 8113 men and women
Inclusion criteria: 31 to 59 years of age; random sample of inhabitants of 2 Finnish provinces;
initially free of cancer
Name of parent cohort: North Karelia Project
Recruitment: February to April 1972
Outcome assessment: 31 December 1978
Number of cases:
• Any cancer: 128 (male/female: n.r.)
Case definition: incidence
Years of follow-up: 8.5
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: logistical regression/paired-sample OR
Variables controlled in analysis: tobacco consumption, serum cholesterol, beer consumption,
dietary saturated fats, years of education, study area
Variables controlled bymatching: age, gender, smoking (tobacco use/d), total serum cholesterol
Risk estimates [95% CI] Reference category: above 30th percentile
Results:
Any cancer
• Both genders: ≤ 30th percentile: OR 3.1 (95% CI 1.5 to 7.7)
• Both genders: ≤ 0 percentile: OR 3.0 (95% CI 1.2 to 21.9)
Selenium levels in exposure categories 1st to 10th percentile ≤ 34.00 µg/L
Above 30th percentile ≥ 45.00 µg/L
Notes
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Salonen 1985
Methods Matched, nested case-control study
Country: Finland
Participants Participants: 12,155 men and women
Inclusion criteria: 30 to 64 years of age; random sample of residents of 2 Finnish provinces;
initially free of cancer
Name of parent cohort: North Karelia Project
Recruitment: January to March 1977
Outcome assessment: 31 December 1980
Number of cases:
• Any cancer: 51 (male/female: 30/21)
Case definition:mortality
Years of follow-up: 3.7
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Analysed cases: 51 out of 56 (reason for non-inclusion: no serum sample available)
Statistical methods: logistical regression
Variables controlled by matching: age, gender, smoking (tobacco use/d)
Risk estimates [95% CI] Reference category: highest 2 tertiles
Results:
Any cancer
• Both genders: lowest tertile: OR 5.8 (95% CI 1.2 to 29.0)
Selenium levels in exposure categories Lowest tertile: ≤ 47.00 µg/L
Highest 2 tertiles ≥ 47.10 µg/L
Notes
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SELECT 2009
Methods Randomised controlled trial
SELECT (Selenium and Vitamin E Cancer Prevention Trial)
Allocation: random, block/stratified by clinic
Sequence generation: computer-generated random numbers
Concealment: central assignment (pill bottles)
Blinding: participant blinded, doctor blinded, outcome assessor/pathologist blinded,
review/coding of medical records blinded
Dropouts/withdrawals: of 35,533 randomised participants, 645 were excluded from anal-
ysis because they had prior prostate cancer, did not give informed consent, or participated
at 2 study sites that were excluded owing to management and regulatory issues
Intention-to-treat-analysis: yes
Recruitment period: 22 August 2001 to 24 June 2004
End of study period: 1 August 2009
Blinded intervention was discontinued on 23 October 2008 following the recommen-
dation of the Data Safety and Monitoring Committee after the second formal interim
analysis in September 2008
Detection of cases: Participants had clinic visits once every 6months and reported prostate
cancers to the study staff. Study staff obtained medical records to verify the diagnosis.
Tissue and the corresponding pathology report were sent to the central pathology labo-
ratory for confirmation
Informed consent: yes
Participants Countries: United States, Canada, Puerto Rico
Number of participants: 34,888 men, randomised to 4 groups: placebo (8696), vitamin
E (8737), selenium (8752), selenium + vitamin E (8703)
Condition: healthy men, aged 50 years or older (African American) or 55 years or older
(all other), no prior diagnosis of prostate cancer, 4 ng/mLor less of PSA in serum, a digital
rectal examination not suspicious for cancer, no current use of anticoagulant therapy
other than 175mg/d or less of acetylsalicylic acid, or 81mg/d or less of acetylsalicylic acid
with clopidogrel bisulphate, no history of haemorrhagic stroke, normal blood pressure
Demographics: median age: 62.3 to 62.6 years in all 4 intervention groups, 79% white
in all 4 intervention groups
Recruitment and setting: 427 participating sites
Interventions Group 1: placebo + placebo
Group 2: 400 IU/d all rac-alpha-tocopheryl acetate + placebo
Group 3: 200 µg/d L-selenomethionine + placebo
Group 4: 400 IU/d all rac-alpha-tocopheryl acetate + 200 µg/d L-selenomethionine
Outcomes Primary outcome: incidence of prostate cancer as determined by routine clinical manage-
ment
Secondary outcomes: incidence of any cancer/lung cancer/colorectal cancer, diabetes mel-
litus, cardiovascular events, death from any cause
Risk estimates [95% CI] Results are presented for the comparison of selenium alone (group 3) vs placebo (group
1)
Primary outcome:
• Prostate cancer: HR 1.04 (95%CI 0.90 to 1.18) (99%CI 0.87 to 1.24), cases: selenium
432 (5-year rate: 4.56%), placebo 416 (5-year rate 4.43%)
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SELECT 2009 (Continued)
Secondary outcomes:
• Any cancer: HR 1.01 (95% CI 0.89 to 1.15)
• Lung cancer: HR 1.12 (99% CI 0.73 to 1.72)
• Colorectal cancer: HR 1.05 (99% CI 0.66 to 1.67)
• Other primary cancer (excluding prostate cancer, basal cell and squamous cell skin
cancer): HR 0.95 (99% CI 0.77 to 1.17)
• Diabetes mellitus: HR 1.07 (99% CI 0.94 to 1.22)
• Cardiovascular events: HR 1.02 (99% CI 0.92 to 1.13)
• Deaths: HR 0.99 (99% CI 0.82 to 1.19)
• Deaths from cancer: HR 1.02 (99% CI 0.74 to 1.41)
Selenium levels in exposure categories d.n.a.
Notes Adverse effects:
• Alopecia: RR 1.28 (99% CI 1.01 to 1.62)
• Dermatitis grade 1 to 2: RR 1.17 (99% CI 1.00 to 1.35)
• Dermatitis grade 3 to 4: RR 1.74 (99% CI 0.56 to 5.44)
• Halitosis: RR 1.17 (99% CI 0.99 to 1.38)
• Nail changes: RR 1.04 (99% CI 0.94 to 1.16)
• Fatigue grade 1 to 2: RR 1.09 (99% CI 0.95 to 1.26)
• Fatigue grade 3 to 4: RR 0.87 (99% CI 0.40 to 1.88)
• Nausea grade 1 to 2: RR 1.19 (99% CI 0.94 to 1.52)
• Nausea grade 3: RR 0.99 (99% CI 0.30 to 3.34)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random, block/stratified by clinic, com-
puter-generated random numbers
Allocation concealment (selection bias) Low risk Central assignment
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants, doctors, outcomes
Selective reporting (reporting bias) Low risk No problems found
Steevens 2010
Methods Cohort/subcohort controlled cohort study
Country: the Netherlands
Participants Name of parent cohort: Netherlands Cohort Study (NLCS)
Recruitment: 1986
van den Brandt 1993b
Participants: 120,852 (male/female: 58,279/ 62,573); aged 55 to 69 years; returned baseline
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Steevens 2010 (Continued)
questionnaire; no history of cancer at baseline
Outcome assessment: 31 December 2002
Number of cases:
• Oesophageal squamous cell carcinoma (ESCC): 64 (male/female: 40/24)
• Oesophageal adenocarcinoma (EAC): 112 (male/female: 93/19)
• Gastric cardia adenocarcinoma (GCA): 114 (male/female: 97/17)
Case definition: incidence
Years of follow-up: 16.3
Type of selenium marker: toenail
Interventions d.n.a.
Outcomes Analysed cases:
• Oesophageal squamous cell carcinoma (ESCC): 64 of 71
• Oesophageal adenocarcinoma (EAC): 112 of 129
• Gastric cardia adenocarcinoma (GCA): 114 of 127
Statistical methods: Cox proportional hazard model
Variables controlled in analysis: age, sex, cigarette smoking (current yes/no, number of
cigarettes smoked daily, and number of smoking years), alcohol consumption (g/d), and
BMI (kg/m²)
Risk estimates [95% CI] Reference category: lowest quartile
Results:
Esophageal squamous cell carcinoma (ESCC)
• Both genders: highest quartile: RR 0.37 (95% CI 0.16 to 0.86)
• Men: highest quartile: RR 0.81 (95% CI 0.64 to 1.4)
• Women: highest quartile: RR 0.79 (95% CI 0.63 to 0.99)
Oesophageal adenocarcinoma (EAC)
• Both genders: highest quartile: RR 0.76 (95% CI 0.41 to 1.40)
• Men: highest quartile: RR 1.07 (95% CI 0.99 to 1.15)
• Women: highest quartile: RR 0.72 (95% CI 0.61 to 0.84)
Gastric cardia adenocarcinoma (GCA)
• Both genders: highest quartile: RR 0.52 (95% CI 0.27 to 1.02)
• Men: highest quartile: RR 0.94 (95% CI 0.84 to 1.06)
• Women: highest quartile: RR 0.73 (95% CI 0.56 to 0.95)
Selenium levels in exposure categories Lowest quartile: ≤ 0.498 µg/g
Highest quartile: ≥ 0.613 µg/g
Notes
Steinbrecher 2010
Methods Nested case-control study
Country: Germany
Participants Participants: 11,928 men (from the total cohort of 25,540 men and women)
Name of parent cohort: EPIC-Heidelberg cohort
Recruitment: 1994 to 1998
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Steinbrecher 2010 (Continued)
Outcome assessment: 2/2007
Number of cases:
• Prostate cancer: 248
Case definition: incidence
Years of follow-up: mean: 3
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: conditional logistical regression
Variables controlled in analysis: family history of prostate cancer, participation in PSA testing,
smoking status, and vigorous physical activity
Variables controlled in matching: age group and time of recruitment
Risk estimates [95% CI] Reference category: lowest quartile
Results:
Prostate cancer
• Highest quartile: OR 1.10 (95% CI 0.58 to 2.09)
Selenium levels in exposure categories Lowest quartile: ≤ 78.9 µg/L
Highest quartile: ≥ 95.0 µg/L
Notes
Suadicani 2012
Methods Cohort study
Country: Denmark
Participants Participants: 3333 males;male participants were derived from 14 workplaces in Copenhagen:
the Air Force, Army,Navy, EmergencyManagement Agency, Postal Service, Customs Service,
a railroad company, a national bank, a telephone company, 3 municipal service centres (for
electricity and engineering and a fire brigade), a pharmaceutical company, and a building
contractor company
Name of parent cohort: Copenhagen male study
Recruitment: from 1970 to 1971/1985 to 1986
Outcome assessment: 1985 to 1986/2001
Number of cases:
• Deaths for lung cancer: 167
Case definition: death for lung cancer
Years of follow-up: 16
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: Cox logistical regression
Variables controlled in analysis: age, pack-years of smoking, spirits intake, and dietary markers
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Suadicani 2012 (Continued)
Risk estimates [95% CI] Reference category: lowest exposure category: 0.4 to 1.0 µmol/L
Results:
Deaths from lung cancer
• Highest exposure category: HR 1.43 (95% CI 0.96 to 2.14)
Selenium levels in exposure categories Lowest category: 31.58 to 78.96 µg/L
Highest category: 120.65 to 236.88 µg/L
Notes
Sun 2016
Methods Cohort study
Country: China
Participants Name of parent cohorts: Shangai Men’s Health Study (SMHS) and Shangai Women’s Health
Study (SWHS)
Participants: 133,957 (male/female: 61,470/74,941)
• SMHS: 61,480 men
• SWHS: 74,941 women
Inclusion criteria:
• SMHS: men aged 40 to 74, residents in Shangai with no history of cancer
• SWHS: women aged 40 to 70, residents in Shangai with no history of cancer
Recruitment:
• SMHS: April 2002 to June 2006
• SWHS: March 1997 to May 2000
Outcome assessment: 31 December 2012
Number of cases: 2603 (male/female: 1798/805)
Case definition:mortality
Years of follow-up:
• SMHS: median: 8.37
• SWHS: median: 13.90
Type of selenium marker: intake
Interventions d.n.a
Outcomes Analysed cases:
Cancer mortality: 2603 (male/female: 1798/805)
Statistical methods: Cox proportional hazard model
Variables controlled in analysis: age, birth cohort, education, income, marital status, occupa-
tion, body mass index, physical activity, total energy intake, dietary fat intake, supplement
use, smoking status, drinking status, status with regard to history of hypertension, diabetes,
coronary hearth disease, or stroke, family history of cancer and menopausal status (women
only)
Risk estimates [95% CI] Reference category: lowest quintile
Results:
Cancer mortality
136Selenium for preventing cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sun 2016 (Continued)
• SMHS: highest quintile: HR 0.97 (95% CI 0.81 to 1.13)
• SWHS: highest quintile: HR 0.90 (95% CI 0.77 to 1.05)
Selenium levels in exposure categories SMHS:
• Lowest quintile: < 19.36 µg/1000 kcal/d
• Highest quintile: ≥ 31.92 µg/1000 kcal/d
SWHS:
• Lowest quintile: < 19.05 µg/1000 kcal/d
• Highest quintile: ≥ 33.36 µg/1000 kcal/d
Notes
Thomson 2008
Methods Cohort study
Country: United States
Participants Participants: 133,614 women
Inclusion criteria: postmenopausal participants (aged 50 to 79 years) of theWHI clinical trial
and observational study
Name of parent cohort: Women’s Health Initiative (WHI)
Recruitment: n.r.
Outcome assessment: December 2004
Number of cases:
• Ovarian cancer: 451
Case definition: incidence
Years of follow-up: mean: 7
Type of selenium marker: supplemental selenium intake
Interventions d.n.a.
Outcomes Statistical methods: Cox logistical regression
Variables controlled in analysis: participation in observational or intervention study, age, log
calories, number of relatives with breast/ovarian cancer, dietary modification randomisation
arm, hysterectomy, minority race, pack-years of smoking, physical activity, NSAID use,
parity, infertility, duration of oral contraceptive use, number of lifetime ovulatory cycles,
partial oophorectomy, age at menopause, hormone therapy at study entry
Risk estimates [95% CI] Reference category: no intake of supplemental selenium (lowest exposure category)
Results:
Ovarian cancer
• Highest exposure category: HR 1.00 (95% CI 0.73 to 1.37)
Selenium levels in exposure categories Lowest exposure category: no supplemental selenium intake
Highest exposure category: > 20 µg/d supplemental selenium intake
Notes
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van den Brandt 1993
Methods Cohort/subcohort controlled cohort study
Country: the Netherlands
Participants Name of parent cohort: Netherlands Cohort Study (NLCS)
Recruitment: 1986
Case definition: incidence
van den Brandt 1993b
Participants: 120,852: 58,279men and 62,573women; aged 55 to 69 years; returned baseline
questionnaire; no history of cancer at baseline
Outcome assessment: n.r.
Number of cases:
• Stomach cancer: 104 (male/female: 84/20)
• Colon cancer: 234 (male/female: 121/113)
• Rectal cancer: 113 (male/female: 77/36)
van den Brandt 1993a
Participants: 120,852: 58,279 men and 62,573 women; age 55 to 69 years; returned baseline
questionnaire; no history of cancer at baseline
Outcome assessment: n.r.
Number of cases:
• Lung cancer: 370 (male/female: 335/35)
van den Brandt 1994
Participants: 62,573 postmenopausal women
Outcome assessment: 1989
Number of cases:
• Breast cancer (postmenopausal): 355 (male/female: 0/355)
• Breast cancer (postmenopausal), multi-variate analysis: 270 (male/female: 0/270)
Zeegers 2002
Participants: 120,852: 58,279 men and 62,573 women
Outcome assessment: December 1992
Number of cases:
• Bladder cancer: 431 (male/female: 372/59)
van den Brandt 2003
Participants: 58,279 men
Outcome assessment: n.r. (probably December 1992)
Number of cases:
• Prostate cancer: 540 (male/female: 540/0)
Years of follow-up:
• 3.3 (Brandt 1993a; Brandt 1993b; Brandt 1994)
• 6.3 (Zeegers 2002; Brandt 2003)
Type of selenium marker: toenail
Interventions d.n.a.
Outcomes van den Brandt 1993b
Analysed cases: 234 of 351 colon cancer cases/104 of 176 stomach cancer cases/113 of 185
rectal cancer cases analysed (reasons for non-inclusion: history of cancer at baseline not
available, no pathological confirmation or CIS, no toenail clipping available)
Statistical methods:Mantel-Haenszel
Variables controlled in analysis: age, gender
van den Brandt 1993a
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van den Brandt 1993 (Continued)
Analysed cases: 370 of 617 (reasons for non-inclusion: history of cancer at baseline not avail-
able, no toenail clipping, no pathological confirmation, problems with selenium measure-
ment)
Statistical methods:Mantel-Haenszel
Variables controlled in analysis: age, gender
van den Brandt 1994
Analysed cases: 355 of 553 (reasons for non-inclusion: history of cancer at baseline not
available, CIS, no toenail sample or problems with selenium detection)
Statistical methods:multi-variate case-cohort analysis
Variables controlled in analysis: age, history of benign breast disease, maternal breast cancer,
breast cancer in sister(s), age at menarche, age at menopause, oral contraceptive use, parity,
age at first birth, body mass index, education, current cigarette smoking, alcohol intake,
energy intake
Zeegers 2002
Analysed cases: 431 of 619 (reason for non-inclusion: no toenails available)
Statistical methods: exponentially distributed failure time regression models
Variables controlled in analysis: age, gender, number of cigarettes/d, years of cigarette smoking
van den Brandt 2003
Analysed cases: 540 of 704 (reason for non-inclusion: no toenail samples or seleniumdetection
not possible)
Statistical methods: exponentially distributed failure time regression models
Variables controlled in analysis: age, family history of prostate cancer, number of cigarettes/
d, years of cigarette smoking, level of education
Risk estimates [95% CI] Reference category: lowest quartile/quintile
Results:
van den Brandt 1993b
Stomach cancer
• Both genders: highest quintile: RR 0.61 (95% CI 0.33 to 1.11); highest quintile: RR 0.64
(95% CI 0.33 to 1.27) (max. adj.)
• Men: highest quintile: RR 0.40 (95% CI 0.17 to 0.96) (max. adj.)
• Women: highest quartile: RR 1.68 (95% CI 0.43 to 6.54) (max. adj.)
Colon cancer
• Both genders: highest quintile: RR 0.77 (95% CI 0.49 to 1.19); highest quintile: RR 0.80
(95% CI 0.50 to 1.29) (max. adj.)
• Men: highest quintile: RR 0.82 (95% CI 0.43 to 1.58) (max. adj.)
• Women: highest quintile: RR 0.77 (95% CI 0.41 to 1.45) (max. adj.)
Rectal cancer
• Both genders: highest quintile: RR 1.01 (95% CI 0.55 to 1.84); highest quintile: RR 1.05
(95% CI 0.54 to 2.03) (max. adj.)
• Men: highest quintile: RR 0.91 (95% CI 0.41 to 2.00) (max. adj.)
• Women: highest quartile: RR 1.58 (95% CI 0.59 to 4.22) (max. adj.)
van den Brandt 1993a
Lung cancer
• Both genders: highest quintile: RR 0.40 (95% CI 0.27 to 0.59)
• Men: highest quintile: RR 0.50 (95% CI 0.30 to 0.82)
• Women: highest quartile: RR 0.40 (95% CI 0.13 to 1.24)
van den Brandt 1994
Breast cancer
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van den Brandt 1993 (Continued)
• Multi-variate analysis: highest quintile: RR 0.84 (95% CI 0.55 to 1.27)
• Age-stratified analysis: highest quintile: RR 0.93 (95% CI 0.65 to 1.33)
Zeegers 2002
Bladder cancer
• Both genders: highest quintile: RR 0.67 (95% CI 0.46 to 0.97)
van den Brandt 2003
Prostate cancer
• Highest quintile: RR 0.69 (95% CI 0.48 to 0.99)
Selenium levels in exposure categories van den Brandt 1993b
• Lowest quintile: ≤ 0.483 µg/g
• Highest quintile: ≥ 0.631 µg/g
• Lowest quartile: ≤ 0.497 µg/g
• Highest quartile: ≥ 0.613 µg/g
van den Brandt 1993a
Both genders and men
• Lowest quintile: ≤ 0.483 µg/g
• Highest quintile: ≥ 0.631 µg/g
Women
• Lowest quartile ≤ 0.497 µg/g
• Highest quartile ≥ 0.613 µg/g
van den Brandt 1994
Women
• Lowest quintile: ≤ 0.499 µg/g
• Highest quintile: ≥ 0.646 µg/g
Zeegers 2002
• Lowest quintile: ≤ 0.483 µg/g
• Highest quintile: ≥ 0.631 µg/g
van den Brandt 2003
Men
• Lowest quintile: ≤ 0.467 µg/g
• Highest quintile: ≥ 0.617 µg/g
Notes Primary publication: van den Brandt 1993b
Other publications: Zeegers 2002, van den Brandt 1993a, van den Brandt 1994, van den
Brandt 2003
van Noord 1987
Methods Matched, nested case-control study
Country: the Netherlands
Participants Participants: 8760 women
Inclusion criteria: 42 to 52 years of age; premenopausal; inhabitants of Utrecht
Name of parent cohort: DOM (Diagnostic onderzoek mammacarcinoom) Study
Recruitment: n.r.
Outcome assessment: 1 February 1986
Number of cases:
• Breast cancer (premenopausal): 27 (male/female: 0/27)
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van Noord 1987 (Continued)
Case definition: incidence
Years of follow-up: 0.6 to 3.5, mean: 2.1
Type of selenium marker: toenail
Interventions d.n.a.
Outcomes Analysed cases: 7 detected during initial mammography screening in this study and not
included in the analysis of incident cases
Statistical methods: n.r.
Variables controlled by matching: age, date of birth, premenopausal status
Risk estimates [95% CI] Reference category: lowest quartile
Results:
Breast cancer (premenopausal)
• Highest quartile: OR 1.1 (95% CI 0.5 to 2.9)
Selenium levels in exposure categories n.r.
Notes
Virtamo 1987
Methods Cohort/subcohort controlled cohort study
Country: Finland
Participants Participants: 1110 men
Inclusion criteria: 55 to 74 years of age; inhabitants of Finnish rural areas; participants of
prior study on CHD; serum sample available: cases within first year of follow-up excluded
Name of parent cohort: Men in rural East and West Finland
Recruitment: 1974
Outcome assessment: 31 December 1983
Number of cases:
• Any cancer: 109 (male/female: 109/0)
Case definition: incidence
Years of follow-up: 10
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: conditional logistical regression
Variables controlled in analysis: age, area of residence, smoking, serum cholesterol, alcohol
intake
Risk estimates [95% CI] Reference category: highest tertile
Results:
Any cancer
• Lowest tertile OR 1.14 (95% CI 0.66 to 1.98)
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Virtamo 1987 (Continued)
Selenium levels in exposure categories Lowest tertile: 15 to 46 µg/L
Highest tertile: 60 to 136 µg/L
Notes
Walter 2011
Methods Cohort study
Country: United States
Participants Inclusion criteria: aged 50 to 76 years, recruited from subscribers to commercial mailing list,
residents of westernWashington state, non-whites excluded, no malignant disease at baseline
Name of parent cohort: Vitamins and Lifestyle (VITAL) study
Number of participants: 66,227 men and women (male/female: n.r.)
Recruitment: 1 October 2000 to 31 December 2002
Outcome assessment: 31/12/2008
Number of cases:
• Haematological malignancies: 588
Case definition: incidence
Years of follow-up: mean: 6.5 years
Type of selenium marker: supplemental intake (questionnaire: use of supplements over past
10 years, mean supplemental intake/d calculated)
Interventions d.n.a.
Outcomes Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: sex, race/ethnicity (white, Hispanic, other), education (high
school graduate or less, some college, college or advanced degree), smoking (pack-years), self-
rated health (excellent, very good, good, fair, poor), vegetable servings per day (excluding
potato servings); fruit servings per day; history of coronary artery disease (defined as history
of heart attack, coronary bypass surgery, angioplasty, and/or angina; yes, no), history of
rheumatoid arthritis (yes, no), history of fatigue or lack of energy over the year before baseline
(yes, no), and number of first-degree relatives with a history of leukaemia or lymphoma
(none, 1, 2)
Risk estimates [95% CI] Reference category: none
Results:
Highest level: RR 0.95 (95% CI 0.75 to 1.20)
Selenium levels in exposure categories Lowest level: none
Highest level: 20.1 to 400.0 µg/d
Notes
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Wei 2004
Methods Frequency-matched cohort-controlled study
Country: China
Participants Participants:Mark 2000: 29,584 men and women; Wei 2004: 1103 people who were origi-
nally selected as disease-free controls in Mark 2000
Inclusion criteria: 40 to 69 years of age; healthy inhabitants of 4 Linxian communities;
participants of a randomised controlled trial
Name of parent cohort: General Population Trial Linxian
Recruitment: 1985
Outcome assessment:May 1991 (Mark 2000); n.r. (Wei 2004)
Number of cases:
Wei 2004
• Oesophageal cancer: 75 (male/female: 49/26) mortality
• Stomach, cardia cancer: 36 (male/female: 22/14) mortality
• Stomach, non-cardia cancer: 24 (male/female: 20/4) mortality
• Other: 32 (male/female: 22/10) mortality
Mark 2000
• Oesophageal cancer: 590 (male/female: 286/304) incidence
• Oesophageal cancer: 332 (male/female: n.r.) mortality
• Stomach, cardia cancer: 402 (male/female: 239/163) incidence
• Stomach, cardia cancer: 232 (male/female: n.r.) mortality
• Stomach, non-cardia cancer: 87 (male/female: 66/21) incidence
• Stomach, non-cardia cancer: 68 (male/female: n.r.) mortality
Case definition:mortality, incidence
Years of follow-up: unclear/approximately 9 (Wei 2004), 6 (Mark 2000)
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: Cox-proportional hazard model
Variables controlled in analysis: Wei 2004: age, cholesterol, smoking, alcohol intake, BMI;
Mark 2000: age
Variables controlled by matching: age category, gender
Risk estimates [95% CI] Wei 2004
Reference category: lowest quartile
Results:
Oesophageal cancer
• Both genders: highest quartile: RR 0.35 (95% CI 0.16 to 0.81)
Stomach, cardia cancer
• Both genders: highest quartile: RR 0.31 (95% CI 0.11 to 0.87)
Stomach, non-cardia cancer
• Both genders: highest quartile: RR 1.64 (95% CI 0.49 to 5.48)
Other cancers
• Both genders: highest quartile: RR 1.95 (95% CI 0.66 to 5.81)
Mark 2000
Reference category: lowest quartile
Results:
Oesophageal cancer
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Wei 2004 (Continued)
• Both genders/incidence: highest quartile: RR 0.56 (95% CI 0.44 to 0.71)
• Both genders/mortality: highest quartile: RR 0.62 (95% CI 0.44 to 0.89)
Stomach, cardia cancer
• Both genders/incidence: highest quartile: RR 0.47 (95% CI 0.33 to 0.65)
• Both genders/mortality: highest quartile: RR 0.59 (95% CI 0.39 to 0.90)
Stomach, non-cardia cancer
• Both genders/incidence: highest quartile: OR 1.07 (95% CI 0.55 to 2.08)
• Both genders/mortality: highest quartile: OR 1.03 (95% CI 0.85 to 2.02)
Selenium levels in exposure categories Wei 2004
• Lowest quartile: 0.0 to 60.0 µg/L
• Highest quartile ≥ 84.5 µg/L
Mark 2000
• Lowest quartile: 0.00 to 59.70 µg/L
• Highest quartile ≥ 82.20 µg/L
Notes Primary publication: Wei 2004
Other publication: Mark 2000
Remark:
Wei 2004 measured serum selenium in a subcohort derived from 29,584 male and female
participants of the Linxian Population Trial. The earlier publication of this study,Mark 2000,
reported 332 fatal cases and 590 incident cases. The later publication, Wei 2004, reported
deaths from oesophageal cancer among disease-free controls in Mark 2000 and analysed 75
fatal cases
Willett 1983
Methods Matched, nested case-control study
Country: United States
Participants Participants: 10,940 men and women
Inclusion criteria: 30 to 69 years of age; serum sample available (only 4480 samples of cohort
were available because of freezer breakdown); participants of an RCT on hypertension;
institutionalised and bedfast people excluded
Name of parent cohort: Hypertension Detection Follow-Up Programme (HDFP)
Recruitment: 1973 to 1974
Outcome assessment: n.r.
Number of cases:
• Any cancer: 111 (male/female: 60/51)
Case definition: incidence
Years of follow-up: 5
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: logistical regression of unmatched data
Variables controlled by matching: age, gender, race/ethnicity, smoking status, year/month of
sample collection, initial blood pressure, use of antihypertensive medication, randomisation
group
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Willett 1983 (Continued)
• In women: parity, menopausal status
Risk estimates [95% CI] Reference category: highest quintile, highest 3 quintiles
Results:
Any cancer
• Both genders: lowest quintile vs highest quintile: OR 2.0 (CI not reported)
• Both genders: lowest quintile vs highest 3 quintiles: OR 1.9 (95% CI 1.1 to 3.3)
Selenium levels in exposure categories Lowest quintile: ≤ 114 µg/L
Highest quintile: ≥ 154 µg/L
Notes
Yoshizawa 1998
Methods Matched, nested case-control study
Country: United States
Participants Participants: 33,737 men
Inclusion criteria: 40 to 75 years of age; physicians from all 50 US states; provision of toenails
in 1987 and completed baseline questionnaire in 1986; exclusion of histologically confirmed
prostate cancer at baseline, and cases within first 2 years of follow-up
Name of parent cohort: Health Professionals Follow-Up Study (HPFS)
Recruitment: 1986 to 1987
Outcome assessment: 1994
Number of cases:
• Prostate cancer: 181 (male/female: 181/0)
Case definition: incidence
Years of follow-up: 8 to 9
Type of selenium marker: toenail
Interventions d.n.a.
Outcomes Statistical methods: logistical regression, conditional logistical regression
Variables controlled in analysis: quintiles of lycopene, saturated fat, calcium, family history of
prostate cancer, BMI, vasectomy
Variables controlled by matching: age, smoking status, year/month of sample collection
Risk estimates [95% CI] Reference category: lowest quintile
Results:
Prostate cancer (advanced)
• Highest quintile: OR 0.39 (95% CI 0.18 to 0.84)
Selenium levels in exposure categories Lowest quintile: 0.530 to 0.730 µg/g
Highest quintile: 0.941 to 7.090 µg/g
Notes
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Yu 1991
Methods Randomised controlled trial
Allocation: random
Sequence generation: unclear, not described
Concealment: unclear, not described
Blinding: described as double-blind; blinding of participants: adequate, placebo tablets;
blinding of investigators and doctors: unclear
Dropouts/withdrawals: unclear, not described
Intention-to-treat-analysis: unclear, not described
Recruitment period: unclear, not described
Observation period: 2 years
Study period: 2 years
Detection of cases: unclear, use of “national standards” for the diagnosis of liver cancer
Informed consent: unclear, not described
Participants Country: China
Number of participants: 2474
Condition: first-degree relatives within 3 generations of families with 2 or more cases of
liver cancer during the period 1972 to 1985
Demographics: gender distribution not reported; age: 15 to 75 years
Recruitment and setting: Participants were residents in Qidong province.
Interventions Intervention: 200 µg selenium as selenised yeast p.o. daily, intervention period unclear
Control: placebo
Outcomes Primary outcome measure: incidence of primary liver cancer within 2 years after start of
intervention
Results:
• 13 cases in 1030 placebo participants
• 10 cases in 1444 selenium participants
Risk estimates [95% CI] n.r.
Selenium levels in exposure categories d.n.a.
Notes Data were extracted from Yu 1991.
We identified 2 later publications (Li 1992, Yu 1993), which we assumed to report on
the same trial as Yu 1991. However, the total number of participants differed from the
initial report (N = 3849 in the later publications, with 1485 receiving placebo and 2364
receiving selenium). The total number of cases was not reported in either Li 1992 or Yu
1993
Reported results were as follows:
Li 1992
Person-year incidence rate in intervention and control groups:
• Within 1 year of follow-up: selenium group 175.36/100,000; placebo group: 414.65/
100,000
•Within 2 years of follow-up: selenium group 219.37/100,000; placebo group: 553.15/
100,000
Yu 1993
Cumulated incidence
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Yu 1991 (Continued)
• After 1 year: selenium group 1.75/1000; placebo group: 4.15/1000
• After 2 years: selenium group 2.19/1000; placebo group: 5.53/1000
• We could not make contact with study investigators to clarify these discrepancies. As
we could not clarify the actual number of liver cancer cases in the later publications, we
decided to use the data of Yu 1991 for this review.
• Adverse effects were not mentioned in Yu 1991 or Li 1992. Yu 1993 stated that no
cases of selenosis were observed in the trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants blinded, doctors stated only as
double-blind
Selective reporting (reporting bias) Unclear risk Recruitment period unclear; dropout un-
clear
Yu 1997
Methods Randomised controlled trial
Allocation: random
Sequence generation: unclear, not described
Concealment: unclear, not described
Blinding: of participants: adequate (placebo); of investigators and doctors: unclear, not
described
Dropouts/withdrawals: unclear, not described
Recruitment period: unclear, not described
Intention-to-treat-analysis: unclear, not described
Observation period: 1987 to 1994
Intervention period: 1987 to 1990
Detection of cases: unclear, monthly blood sample during follow-up for liver enzymes
(SGPT, ZnTT), use of “national standards” for the diagnosis of liver cancer
Informed consent: unclear, not described
Participants Country: China
Number of participants: 226 (selenium group: 113; placebo group 113)
Condition: HBs-antigen carriers with normal liver function
Demographics: 95 men, 131 women; age: 21 to 63 years
Recruitment and setting: recruitment “through screening in a village in the city Qidong”
(Li 1992)
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Yu 1997 (Continued)
Interventions Intervention: 200 µg selenium as selenised yeast p.o. daily for 4 years
Control: placebo
Outcomes Primary outcome measure: incidence of primary liver cancer (defined as increase in SGPT
and ZnTT)
Results:
At end of intervention period
• 0 cases in the selenium group
• 7 cases in the placebo group for a total of 445 person-years of observation (person-time
incidence rate: 1573.03/100,000)
Risk estimates [95% CI] n.r.
Selenium levels in exposure categories d.n.a.
Notes Adverse effects: “No side effects have been found in these trials” (Yu 1997, p. 124)
Further data reported in: Li 1992 (Chinese, translated); Yu 1991
In Yu 1991, a different incidence was reported for the selenium group (5 cases). We
could not clarify this discrepancy with later papers Li 1992 and Yu 1997.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants blinded, doctors stated only as
double-blind
Selective reporting (reporting bias) Unclear risk Recruitment period unclear; dropout un-
clear
Yu 1999
Methods Matched, nested case-control study
Country: China (Taiwan)
Participants Participants: 4841 men
Inclusion criteria: 30 to 65 years of age; HBs-Ag-positive or/and HCV-positive; recruited at
2 centres: Government Employee Central Clinics and Liver Unit of Chang-Gung Memorial
Hospital
Recruitment: August 1988 to June 1992
Outcome assessment: 31 December 1996
Number of cases:
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Yu 1999 (Continued)
• Primary liver cancer: 69 (male/female: 69/0)
Case definition: incidence
Years of follow-up: 4.5 to 8.3
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Analysed cases: 69 of 73 (reason for non-inclusion: no sample available)
Statistical methods: conditional logistical regression
Variables controlled in analysis: age, cigarette smoking, alcohol intake, plasma levels of retinol/
alpha-tocopherol/alpha-carotene/beta-carotene/lycopene
Variables controlled by matching: age, year and season of sample collection, recruitment clinic
Risk estimates [95% CI] Reference category: lowest quintile
Results:
Primary liver cancer
• Highest quintile: OR 0.62 (95% CI 0.21 to 1.86)
Selenium levels in exposure categories Lowest quintile ≤ 124.90 µg/L
Highest quintile ≥ 162.40 µg/L
Notes
µ: micro.
AFP: alpha-fetoprotein.
ALT: alanine aminotransferase.
ATBC: alpha-tocopherol, beta-carotene cancer prevention study.
AU: arbitrary unit.
AUA: American Urological Association.
BCC: basal cell carcinoma.
BMI: body mass index.
BPH: benign prostate hyperplasia.
CARET: Carotene and Retinol Efficacy Trial.
CHD: coronary heart disease.
CI: confidence interval.
CIS: carcinoma in situ.
CSDLH: Canadian Study of Diet, Lifestyle and Health.
CT: computed tomography.
CVD: cardiovascular disease.
dL: deciliter.
d.n.a.: does not apply.
DOM: Diagnostic onderzoek mammacarcinoom.
DSMC: Data and Safety Monitoring Committee.
ECOG: EasternCooperativeOncologyGroup.EPIC: European Prospective Investigation of Cancer.EVA: Etude duVieillissement
Antériel.
EPOZ: Epidemiologisch onderzoek naar risico-indicatoren voor hart- en vaatziekten.
FFQ: food-frequency questionnaire.
g: gram.
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GBTC: gallbladder and biliary tract cancer.
HBs-Ag: hepatitis B surface antigen.
HCC: hepatocellular carcinoma.
HCV: hepatitis C virus.
HGPIN: high-grade prostatic intraepithelial neoplasia.
HPFP: Hypertension Detection Follow-up Programme.
HPFS: Health Professionals Follow-up Study.
HR: hazard ratio.
HRT: hormone replacement therapy.
IHBC: intrahepatic bile duct cancer.
IRR: incident rate ratio.
IU: international unit.
L: litre.
m: milli.
max. adj.: maximally adjusted.
MHC: Mobile Health Clinic.
n: nano.
NHS: Nurses‘ Health Study.
NLCS: Netherlands Cohort Study.
NMSC: non-melanoma skin cancer.
NPCT: Nutritional Prevention of Cancer Trial.
n.r.: not reported.
NSAID: non-steroidal anti-inflammatory drug.
OR: odds ratio.
p.: page.
p.o.: per os.
ppm: parts per million.
PSA: prostate-specific antigen.
RCT: randomised controlled trial.
RR: risk ratio.
SCC: squamous cell carcinoma.
SD: standard deviation.
SGPT: alanine aminotransferase.
TIA: transient ischaemic attack.
UK: United Kingdom.
USA: United States of America.
VITAL: Vitamins and Lifestyle study.
WHI: Women’s Health Initiative.
ZnTT: zinc turbidity test.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Albanes 2014 Same results of SELECT 2009, stratified according to tocopherol status
Bates 2011 Results not reported according to inclusion criteria: HR estimated per SD increase of selenium level reported
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(Continued)
Bostick 1993 Cohort study: Iowa Women’s Health Study cohort
Selenium exposure not assessed according to eligibility: only intake of selenium supplements yes/no in ques-
tionnaire assessed
Brock 1991 Case-control study with precancerous condition (carcinoma in situ of the cervix)
Chen 1988 Case-control study
Chen 2003 Case-control study
Connelly-Frost 2009 Case-control study
Costello 2001 APPOSE (Australian Prostate Cancer Prevention Trial Using Selenium): Publication describes study design;
trial was not started
Criqui 1991 Population-based, prospective case-control study: Lipid Research Clinic Prevalence and Follow-Up study
Results not reported according to inclusion criteria: differences in mean selenium levels reported
Cui 2007 Nested case-control study
Selenium exposure not assessed according to eligibility: selenium measurement conducted in tissue of benign
breast disease
Davies 2002 Nested case-control study: EPIC Norfolk study cohort
Results not reported according to inclusion criteria: RR estimate per unit increase in selenium level reported
Epplein 2014 Results not reported according to inclusion criteria: selenium not reported as independent variable - only
selenoprotein P
Fleshner 2003 Randomised Study of Vitamin E, Selenium, and Soy Protein Isolate in Patients with High-Grade Prostatic
Intraepithelial Neoplasia:
Multi-component Intervention
Geybels 2013 Same population as van den Brandt 1993, restricted only to advanced prostate cancer cases
Geybels 2014 Same population as Geybels 2013, stratified according to genetic variation in SePP1 and GPX1
Hagmar 1992 Historical cohort study
Harris 2012 Cancer was not a study endpoint.
Hartman 2002 Nested case-control study: ATBC cohort
Results not reported according to inclusion criteria: differences inmean selenium levels reported;OR reported
as graph and could not be calculated from reported data
Huzarski 2006 Interventional studywithout control groupwith 1489 female participants withBRCA1mutationwho received
a selenium-containing nutritional supplement
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(Continued)
Joniau 2007 Intervention study without control group with male participants with high-grade intraepithelial neoplasia of
the prostate who received a selenium-containing nutritional supplement
Karunasinghe 2012 Results not reported according to inclusion criteria: differences in mean selenium levels reported
Kellen 2008 Case-control study
Kilander 2001 Cohort study in Uppsala/Sweden
Results not reported according to inclusion criteria: RR estimate per unit increase in selenium level reported
Knekt 1988a Nested case-control study: Mobile Health Clinic cohort
Results not reported according to inclusion criteria: differences in mean selenium levels reported
Knekt 1988b Nested case-control study: Mobile Health Clinic cohort
Results not reported according to inclusion criteria: differences in mean selenium levels reported
Knekt 1991 Nested case-control study: Mobile Health Clinic cohort
Results not reported according to inclusion criteria: differences in mean selenium levels reported
Kok 1987b Nested case-control study: Zoetermeer cohort
Results not reported according to inclusion criteria: differences in mean selenium levels reported
Kune 2006 Case-control study
Kuroda 1988 Case-control study
Lane 2017 Some study participants had cancer at baseline.
Lawson 2007 Cohort study on multi-vitamin use and risk of prostate cancer
Le Marchand 2006 Case-control study
Li 2004b RCT for gastric cancer prevention with multi-component intervention (200 mg synthetic allitridum and 100
µg selenium per day)
Limburg 2005 Randomised controlled trial: Primary endpoint in this 2-by-2 factorial design trial with selenomethionine 200
µg daily and/or celecoxib 200 mg twice daily was the per-participant change (regression, stable, progression)
in pre-existing oesophageal dysplasia - cancer incidence and mortality were not endpoints in this study
Linxian Pilot 2000 Randomised controlled trial of selenium supplements and celecoxib in participants with oesophageal squa-
mous dysplasia in Linxian, China
Endpoint was “regression of disease”; cancer was not an endpoint in this investigation
Loeb 2015 Selenium exposure not assessed according to eligibility: only intake of selenium supplements yes/no on
questionnaire assessed
Martinez 2014 Same participants as SELECT 2009, stratified according to NKX3.1 genetic variant
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(Continued)
Neuhouser 2009 Cohort study (Women’s Health Initiative) on multi-vitamin use and risks of cancer and cardiovascular disease
No data reported for selenium and cancer risk
Persson 2000 Selenium exposure not assessed according to eligibility
Ray 2006 Cohort study (Women’s Health and Aging Studies I and II) on selenium and carotenoid serum levels and
mortality
No data reported for selenium and cancer mortality
Rayman 2001 PRECISE trial (Prevention of Cancer by Intervention with Selenium): Trial has been stopped
Rendon Randomised controlled trial: Vitamin E, Selenium, and Soy Protein in Preventing Cancer in Patients With
High-Grade Prostate Neoplasia: Multi-component Intervention
Steevens 2010b Cancer was not a study endpoint.
Thompson 2009 Cohort study: Iowa Women’s Health Study cohort
Selenium exposure was not assessed according to eligibility; only intake of selenium supplements yes/no on
questionnaire was assessed
Tsugane 1996 Case-control and cross-sectional studies
Ujiie 2002 Part of this study is a prospective cohort study in Miyagi/Japan
Results were not reported according to inclusion criteria; differences in mean selenium levels were reported
van Noord 1992 Nested case-control study: DOM cohort
Results were not reported according to inclusion criteria; differences in mean selenium levels were reported
van Noord 1993 Nested case-control study: DOM II cohort
Results were not reported according to inclusion criteria; RR estimate per unit increase in selenium levels
were reported
van’t Veer 1996 Case-control study
Wallace 2009 Case-control study
Watters 2009 Cohort study on smoking and prostate cancer risk. Selenium was not reported as an independent variable
Wright 2004 Cohort study: ATBC cohort
Exposure to antioxidants was assessed via a self-developed index
You 2005 Randomised controlled trial to test retardation of progression of precancerous gastric lesions among 3400
adults in Shandong, China. Intervention: vitamin C, vitamin E, selenium, garlic preparation
Multi-component intervention
Yuan 2006 Nested case-control study: Shanghai cohort study
No data reported on selenium and cancer risk
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(Continued)
Zeegers 2009 Cohort study on factors influencing recurrence or progression of bladder cancer: West Midlands Bladder
Cancer Prognosis Programme
µ: micro.
APPOSE: Australian Prostate Cancer Prevention Trial Using Selenium.
ATBC: alpha-tocopherol, beta-carotene cancer prevention study.
BRCA: breast cancer.
DOM: Diagnostic Onderzoek Mammacarcinoom.
EPIC: European Prospective Investigation of Cancer.
m: milli.
g: gram.
OR: odds ratio.
PRECISE: Prevention of Cancer by Intervention with Selenium.
RCT: randomised controlled trial.
SELECT: Selenium and Vitamin E Cancer Prevention Trial.
Characteristics of ongoing studies [ordered by study ID]
Argos 2013
Trial name or title Bangladesh Vitamin E and Selenium Trial (BEST)
Methods Double-blind, placebo-controlled, 2-by-2 factorial, randomised controlled trial
Participants 7000 adults having manifest arsenical skin lesions in Bangladesh
Inclusion
• Manifest arsenical skin lesions
• Aged 25 to 65 years
• Signed informed consent
Exclusion
• Currently pregnant
• Not a permanent resident of study area
• Unwillingness to discontinue current vitamin use
• History of cancer
• Too ill to participate
• Unwillingness to provide biological samples (blood and urine)
Interventions 6-year supplementation, divided into 4 study arms:
• Vitamin E (alpha-tocopherol, 100 mg daily)
• Selenium (L-selenomethionine, 200 µg daily)
• Vitamin E and selenium
• Placebo
Outcomes Primary endpoints
• Prevention of non-melanoma skin cancer
Secondary endpoints:
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Argos 2013 (Continued)
• All-cause and cancer mortality
• Diabetes mellitus
• Oxidative stress biomarkers
Starting date April 2006
Contact information Dr. Habibul Ahsan
Center for Cancer Epidemiology and Prevention, The University of Chicago
5841 South Maryland Avenue, MC 2007
Chicago, IL 60637
Notes
BEST: Bangladesh Vitamin E and Selenium Trial.
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D A T A A N D A N A L Y S E S
Comparison 1. Randomised controlled trials: highest versus lowest selenium exposure
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Any cancer risk 5 Risk Ratio (IV, Random, 95% CI) Subtotals only
1.1 Studies with low RoB 3 19475 Risk Ratio (IV, Random, 95% CI) 1.01 [0.93, 1.10]
1.2 All studies 5 21860 Risk Ratio (IV, Random, 95% CI) 0.99 [0.86, 1.14]
2 Cancer mortality 2 Risk Ratio (IV, Random, 95% CI) Subtotals only
2.1 Studies with low RoB 1 17448 Risk Ratio (IV, Random, 95% CI) 1.02 [0.80, 1.30]
2.2 All studies 2 18698 Risk Ratio (IV, Random, 95% CI) 0.81 [0.49, 1.32]
3 Head and neck cancer risk 2 Risk Ratio (IV, Random, 95% CI) Subtotals only
3.1 Studies with low RoB 1 1561 Risk Ratio (IV, Random, 95% CI) 1.00 [0.18, 5.45]
3.2 All studies 2 2811 Risk Ratio (IV, Random, 95% CI) 1.22 [0.52, 2.85]
4 Oesophageal cancer risk 2 Risk Ratio (IV, Random, 95% CI) Subtotals only
4.1 Studies with low RoB 1 1561 Risk Ratio (IV, Random, 95% CI) 1.50 [0.06, 36.86]
4.2 All studies 2 2811 Risk Ratio (IV, Random, 95% CI) 0.53 [0.12, 2.28]
5 Colorectal cancer risk 3 Risk Ratio (IV, Random, 95% CI) Subtotals only
5.1 Studies with low RoB 2 19009 Risk Ratio (IV, Random, 95% CI) 0.99 [0.69, 1.43]
5.2 All studies 3 20259 Risk Ratio (IV, Random, 95% CI) 0.74 [0.41, 1.33]
6 Liver cancer risk 4 Risk Ratio (IV, Random, 95% CI) Subtotals only
6.1 Studies with low RoB 1 1561 Risk Ratio (IV, Random, 95% CI) 6.52 [0.37, 115.49]
6.2 All studies 4 6326 Risk Ratio (IV, Random, 95% CI) 0.52 [0.35, 0.79]
7 Melanoma risk 3 Risk Ratio (IV, Random, 95% CI) Subtotals only
7.1 Studies with low RoB 2 2027 Risk Ratio (IV, Random, 95% CI) 1.35 [0.41, 4.52]
7.2 All studies 3 3277 Risk Ratio (IV, Random, 95% CI) 1.28 [0.63, 2.59]
8 Non-melanoma skin cancer risk 4 Risk Ratio (Random, 95% CI) Subtotals only
8.1 Studies with low RoB 2 2027 Risk Ratio (Random, 95% CI) 1.16 [0.30, 4.42]
8.2 All studies 4 3461 Risk Ratio (Random, 95% CI) 1.23 [0.73, 2.08]
9 Lung cancer risk 3 Risk Ratio (IV, Random, 95% CI) Subtotals only
9.1 Studies with low RoB 2 19009 Risk Ratio (IV, Random, 95% CI) 1.16 [0.89, 1.50]
9.2 All studies 3 20259 Risk Ratio (IV, Random, 95% CI) 1.03 [0.78, 1.37]
10 Breast cancer risk 3 Risk Ratio (IV, Random, 95% CI) Subtotals only
10.1 Studies with low RoB 1 802 Risk Ratio (IV, Random, 95% CI) 2.04 [0.44, 9.55]
10.2 All studies 3 2260 Risk Ratio (IV, Random, 95% CI) 1.44 [0.96, 2.17]
11 Bladder cancer risk 3 Risk Ratio (IV, Random, 95% CI) Subtotals only
11.1 Studies with low RoB 2 19009 Risk Ratio (IV, Random, 95% CI) 1.07 [0.76, 1.52]
11.2 All studies 3 20259 Risk Ratio (IV, Random, 95% CI) 1.10 [0.79, 1.52]
12 Prostate cancer risk 5 Risk Ratio (IV, Random, 95% CI) Subtotals only
12.1 Studies with low RoB 4 18942 Risk Ratio (IV, Random, 95% CI) 1.01 [0.90, 1.14]
12.2 All studies 5 19869 Risk Ratio (IV, Random, 95% CI) 0.91 [0.75, 1.12]
13 Leukaemia and lymphoma risk 2 Risk Ratio (IV, Random, 95% CI) Subtotals only
13.1 Studies with low RoB 1 1561 Risk Ratio (IV, Random, 95% CI) 1.00 [0.25, 3.99]
13.2 All studies 2 2811 Risk Ratio (IV, Random, 95% CI) 1.21 [0.52, 2.80]
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Comparison 2. Observational studies: highest versus lowest selenium exposure
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total cancer incidence and
mortality
14 Odds Ratio (Random, 95% CI) Subtotals only
1.1 Incidence 7 Odds Ratio (Random, 95% CI) 0.72 [0.55, 0.93]
1.2 Mortality 7 Odds Ratio (Random, 95% CI) 0.76 [0.59, 0.97]
2 Total cancer incidence and
mortality (men)
8 Odds Ratio (Random, 95% CI) Subtotals only
2.1 Incidence 4 Odds Ratio (Random, 95% CI) 0.72 [0.46, 1.14]
2.2 Mortality 4 Odds Ratio (Random, 95% CI) 0.65 [0.45, 0.94]
3 Total cancer incidence and
mortality (women)
6 Odds Ratio (Random, 95% CI) Subtotals only
3.1 Incidence 2 Odds Ratio (Random, 95% CI) 0.90 [0.45, 1.77]
3.2 Mortality 4 Odds Ratio (Random, 95% CI) 0.91 [0.80, 1.03]
4 Total cancer incidence and
mortality (ascending order of
selenium levels)
13 Odds Ratio (Random, 95% CI) Subtotals only
4.1 Incidence 7 1642 Odds Ratio (Random, 95% CI) 0.72 [0.55, 0.93]
4.2 Mortality 6 1230 Odds Ratio (Random, 95% CI) 0.63 [0.39, 1.01]
5 Total cancer incidence and
mortality (ascending order of
differences in selenium levels)
13 Odds Ratio (Random, 95% CI) Subtotals only
5.1 Incidence 7 190 Odds Ratio (Random, 95% CI) 0.72 [0.55, 0.93]
5.2 Mortality 6 106 Odds Ratio (Random, 95% CI) 0.63 [0.39, 1.01]
6 Stomach cancer risk 5 Odds Ratio (Random, 95% CI) 0.66 [0.43, 1.01]
7 Stomach cancer risk (by sex) 5 Odds Ratio (Random, 95% CI) 0.66 [0.42, 1.04]
7.1 All (male + female) 2 Odds Ratio (Random, 95% CI) 0.75 [0.41, 1.36]
7.2 Male 3 Odds Ratio (Random, 95% CI) 0.43 [0.14, 1.32]
7.3 Female 2 Odds Ratio (Random, 95% CI) 0.73 [0.12, 4.35]
8 Colorectal cancer risk 6 Odds Ratio (Random, 95% CI) 0.82 [0.72, 0.94]
9 Colorectal cancer risk (by sex) 6 Odds Ratio (Random, 95% CI) 0.83 [0.72, 0.95]
9.1 All (male + female) 1 Odds Ratio (Random, 95% CI) 0.80 [0.68, 0.94]
9.2 Male 4 Odds Ratio (Random, 95% CI) 0.86 [0.65, 1.16]
9.3 Female 4 Odds Ratio (Random, 95% CI) 0.96 [0.61, 1.50]
10 Colon cancer risk 5 Odds Ratio (Random, 95% CI) 0.81 [0.69, 0.96]
11 Colon cancer risk (by sex) 5 Odds Ratio (Random, 95% CI) 0.81 [0.69, 0.96]
11.1 All (male + female) 2 Odds Ratio (Random, 95% CI) 0.84 [0.68, 1.03]
11.2 Male 3 Odds Ratio (Random, 95% CI) 0.84 [0.56, 1.25]
11.3 Female 2 Odds Ratio (Random, 95% CI) 0.68 [0.44, 1.04]
12 Lung cancer incidence and
mortality
13 Odds Ratio (Random, 95% CI) Subtotals only
12.1 Incidence 11 Odds Ratio (Random, 95% CI) 0.82 [0.59, 1.14]
12.2 Mortality 2 Odds Ratio (Random, 95% CI) 1.34 [0.93, 1.93]
13 Lung cancer risk
(sex-disaggregated data)
13 Odds Ratio (Random, 95% CI) 0.89 [0.69, 1.14]
13.1 All (male + female) 5 Odds Ratio (Random, 95% CI) 0.74 [0.43, 1.28]
13.2 Male 7 Odds Ratio (Random, 95% CI) 0.98 [0.68, 1.39]
13.3 Female 4 Odds Ratio (Random, 95% CI) 0.83 [0.43, 1.61]
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14 Lung cancer risk (by exposure
assessment)
13 Odds Ratio (Random, 95% CI) 0.88 [0.65, 1.18]
14.1 Intake 2 Odds Ratio (Random, 95% CI) 1.32 [0.95, 1.84]
14.2 Serum or plasma 9 Odds Ratio (Random, 95% CI) 0.91 [0.70, 1.18]
14.3 Toenail 2 Odds Ratio (Random, 95% CI) 1.05 [0.11, 10.36]
15 Lung cancer risk (ascending
order of selenium levels)
8 1938 Odds Ratio (Random, 95% CI) 0.97 [0.74, 1.27]
16 Lung cancer risk (ascending
order of differences in selenium
levels)
8 188 Odds Ratio (Random, 95% CI) 0.97 [0.74, 1.27]
17 Breast cancer risk (women) 8 Odds Ratio (Random, 95% CI) 1.09 [0.87, 1.37]
18 Bladder cancer risk 5 Odds Ratio (Random, 95% CI) 0.67 [0.46, 0.97]
18.1 All (male + female) 2 Odds Ratio (Random, 95% CI) 0.65 [0.46, 0.92]
18.2 Male 3 Odds Ratio (Random, 95% CI) 0.82 [0.41, 1.62]
18.3 Female 1 Odds Ratio (Random, 95% CI) 0.36 [0.14, 0.92]
19 Prostate cancer risk 21 Odds Ratio (Random, 95% CI) 0.84 [0.75, 0.95]
20 Prostate cancer risk (by
exposure assessment)
21 Odds Ratio (Random, 95% CI) 0.84 [0.75, 0.95]
20.1 Intake and supplement 4 Odds Ratio (Random, 95% CI) 0.99 [0.85, 1.15]
20.2 Serum or plasma 13 Odds Ratio (Random, 95% CI) 0.86 [0.75, 0.99]
20.3 Toenail 4 Odds Ratio (Random, 95% CI) 0.60 [0.44, 0.82]
21 Prostate cancer risk (ascending
order of selenium levels)
13 2816 Odds Ratio (Random, 95% CI) 0.86 [0.75, 0.99]
22 Prostate cancer risk (ascending
order of differences in selenium
levels)
13 345 Odds Ratio (Random, 95% CI) 0.86 [0.75, 0.99]
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Analysis 1.1. Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure,
Outcome 1 Any cancer risk.
Review: Selenium for preventing cancer
Comparison: 1 Randomised controlled trials: highest versus lowest selenium exposure
Outcome: 1 Any cancer risk
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Studies with low RoB
SELECT 2009 837/8752 824/8696 84.0 % 1.01 [ 0.92, 1.11 ]
Algotar 2013 37/234 35/232 3.9 % 1.05 [ 0.69, 1.60 ]
Karp 2013 169/1040 83/521 12.1 % 1.02 [ 0.80, 1.30 ]
Subtotal (95% CI) 10026 9449 100.0 % 1.01 [ 0.93, 1.10 ]
Total events: 1043 (Experimental), 942 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
2 All studies
NPCT 2002 105/621 137/629 21.0 % 0.78 [ 0.62, 0.98 ]
SELECT 2009 837/8752 824/8696 39.1 % 1.01 [ 0.92, 1.11 ]
Lubinski 2011 60/563 45/572 11.2 % 1.35 [ 0.94, 1.96 ]
Algotar 2013 37/234 35/232 8.9 % 1.05 [ 0.69, 1.60 ]
Karp 2013 169/1040 83/521 19.8 % 1.02 [ 0.80, 1.30 ]
Subtotal (95% CI) 11210 10650 100.0 % 0.99 [ 0.86, 1.14 ]
Total events: 1208 (Experimental), 1124 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 7.41, df = 4 (P = 0.12); I2 =46%
Test for overall effect: Z = 0.10 (P = 0.92)
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Analysis 1.2. Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure,
Outcome 2 Cancer mortality.
Review: Selenium for preventing cancer
Comparison: 1 Randomised controlled trials: highest versus lowest selenium exposure
Outcome: 2 Cancer mortality
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Studies with low RoB
SELECT 2009 128/8752 125/8696 100.0 % 1.02 [ 0.80, 1.30 ]
Subtotal (95% CI) 8752 8696 100.0 % 1.02 [ 0.80, 1.30 ]
Total events: 128 (Experimental), 125 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
2 All studies
NPCT 2002 40/621 66/629 45.8 % 0.61 [ 0.42, 0.89 ]
SELECT 2009 128/8752 125/8696 54.2 % 1.02 [ 0.80, 1.30 ]
Subtotal (95% CI) 9373 9325 100.0 % 0.81 [ 0.49, 1.32 ]
Total events: 168 (Experimental), 191 (Control)
Heterogeneity: Tau2 = 0.10; Chi2 = 4.86, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.85 (P = 0.39)
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Analysis 1.3. Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure,
Outcome 3 Head and neck cancer risk.
Review: Selenium for preventing cancer
Comparison: 1 Randomised controlled trials: highest versus lowest selenium exposure
Outcome: 3 Head and neck cancer risk
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Studies with low RoB
Karp 2013 4/1040 2/521 100.0 % 1.00 [ 0.18, 5.45 ]
Subtotal (95% CI) 1040 521 100.0 % 1.00 [ 0.18, 5.45 ]
Total events: 4 (Experimental), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.0)
2 All studies
NPCT 2002 9/621 7/629 74.9 % 1.30 [ 0.49, 3.48 ]
Karp 2013 4/1040 2/521 25.1 % 1.00 [ 0.18, 5.45 ]
Subtotal (95% CI) 1661 1150 100.0 % 1.22 [ 0.52, 2.85 ]
Total events: 13 (Experimental), 9 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.65)
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Analysis 1.4. Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure,
Outcome 4 Oesophageal cancer risk.
Review: Selenium for preventing cancer
Comparison: 1 Randomised controlled trials: highest versus lowest selenium exposure
Outcome: 4 Oesophageal cancer risk
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Studies with low RoB
Karp 2013 1/1040 0/521 100.0 % 1.50 [ 0.06, 36.86 ]
Subtotal (95% CI) 1040 521 100.0 % 1.50 [ 0.06, 36.86 ]
Total events: 1 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
2 All studies
NPCT 2002 2/621 5/629 79.3 % 0.41 [ 0.08, 2.08 ]
Karp 2013 1/1040 0/521 20.7 % 1.50 [ 0.06, 36.86 ]
Subtotal (95% CI) 1661 1150 100.0 % 0.53 [ 0.12, 2.28 ]
Total events: 3 (Experimental), 5 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.40)
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Analysis 1.5. Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure,
Outcome 5 Colorectal cancer risk.
Review: Selenium for preventing cancer
Comparison: 1 Randomised controlled trials: highest versus lowest selenium exposure
Outcome: 5 Colorectal cancer risk
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Studies with low RoB
SELECT 2009 63/8752 60/8696 93.2 % 1.04 [ 0.73, 1.48 ]
Karp 2013 4/1040 4/521 6.8 % 0.50 [ 0.13, 2.00 ]
Subtotal (95% CI) 9792 9217 100.0 % 0.99 [ 0.69, 1.43 ]
Total events: 67 (Experimental), 64 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.02, df = 1 (P = 0.31); I2 =2%
Test for overall effect: Z = 0.04 (P = 0.97)
2 All studies
NPCT 2002 9/621 19/629 30.9 % 0.48 [ 0.22, 1.05 ]
SELECT 2009 63/8752 60/8696 54.7 % 1.04 [ 0.73, 1.48 ]
Karp 2013 4/1040 4/521 14.4 % 0.50 [ 0.13, 2.00 ]
Subtotal (95% CI) 10413 9846 100.0 % 0.74 [ 0.41, 1.33 ]
Total events: 76 (Experimental), 83 (Control)
Heterogeneity: Tau2 = 0.13; Chi2 = 3.82, df = 2 (P = 0.15); I2 =48%
Test for overall effect: Z = 1.01 (P = 0.31)
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Analysis 1.6. Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure,
Outcome 6 Liver cancer risk.
Review: Selenium for preventing cancer
Comparison: 1 Randomised controlled trials: highest versus lowest selenium exposure
Outcome: 6 Liver cancer risk
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Studies with low RoB
Karp 2013 6/1040 0/521 100.0 % 6.52 [ 0.37, 115.49 ]
Subtotal (95% CI) 1040 521 100.0 % 6.52 [ 0.37, 115.49 ]
Total events: 6 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
2 All studies
Yu 1991 10/1444 13/1030 22.3 % 0.55 [ 0.24, 1.25 ]
Yu 1997 4/113 11/113 12.9 % 0.36 [ 0.12, 1.11 ]
Li 2000 34/1112 57/953 62.7 % 0.51 [ 0.34, 0.77 ]
Karp 2013 6/1040 0/521 2.1 % 6.52 [ 0.37, 115.49 ]
Subtotal (95% CI) 3709 2617 100.0 % 0.52 [ 0.35, 0.79 ]
Total events: 54 (Experimental), 81 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 3.39, df = 3 (P = 0.34); I2 =12%
Test for overall effect: Z = 3.04 (P = 0.0024)
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Analysis 1.7. Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure,
Outcome 7 Melanoma risk.
Review: Selenium for preventing cancer
Comparison: 1 Randomised controlled trials: highest versus lowest selenium exposure
Outcome: 7 Melanoma risk
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Studies with low RoB
Algotar 2013 3/234 2/232 45.8 % 1.49 [ 0.25, 8.82 ]
Karp 2013 5/1040 2/521 54.2 % 1.25 [ 0.24, 6.43 ]
Subtotal (95% CI) 1274 753 100.0 % 1.35 [ 0.41, 4.52 ]
Total events: 8 (Experimental), 4 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.62)
2 All studies
NPCT 2002 11/621 9/629 65.5 % 1.24 [ 0.52, 2.97 ]
Algotar 2013 3/234 2/232 15.8 % 1.49 [ 0.25, 8.82 ]
Karp 2013 5/1040 2/521 18.7 % 1.25 [ 0.24, 6.43 ]
Subtotal (95% CI) 1895 1382 100.0 % 1.28 [ 0.63, 2.59 ]
Total events: 19 (Experimental), 13 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.50)
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Analysis 1.8. Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure,
Outcome 8 Non-melanoma skin cancer risk.
Review: Selenium for preventing cancer
Comparison: 1 Randomised controlled trials: highest versus lowest selenium exposure
Outcome: 8 Non-melanoma skin cancer risk
Study or subgroup Experimental Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Studies with low RoB
Karp 2013 1040 521 -0.4168 (0.2996) 59.3 % 0.66 [ 0.37, 1.19 ]
Algotar 2013 234 232 0.9722 (0.6706) 40.7 % 2.64 [ 0.71, 9.84 ]
Subtotal (95% CI) 1274 753 100.0 % 1.16 [ 0.30, 4.42 ]
Heterogeneity: Tau2 = 0.69; Chi2 = 3.58, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 0.22 (P = 0.83)
2 All studies
NPCT 2002 621 629 0.239 (0.0687) 48.1 % 1.27 [ 1.11, 1.45 ]
Dreno 2007 91 93 1.1204 (0.8031) 9.1 % 3.07 [ 0.64, 14.80 ]
Karp 2013 1040 521 -0.4168 (0.2996) 30.7 % 0.66 [ 0.37, 1.19 ]
Algotar 2013 234 232 0.9722 (0.6706) 12.1 % 2.64 [ 0.71, 9.84 ]
Subtotal (95% CI) 1986 1475 100.0 % 1.23 [ 0.73, 2.08 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 7.11, df = 3 (P = 0.07); I2 =58%
Test for overall effect: Z = 0.77 (P = 0.44)
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Analysis 1.9. Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure,
Outcome 9 Lung cancer risk.
Review: Selenium for preventing cancer
Comparison: 1 Randomised controlled trials: highest versus lowest selenium exposure
Outcome: 9 Lung cancer risk
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Studies with low RoB
SELECT 2009 75/8752 67/8696 62.8 % 1.11 [ 0.80, 1.54 ]
Karp 2013 69/1040 28/521 37.2 % 1.23 [ 0.81, 1.89 ]
Subtotal (95% CI) 9792 9217 100.0 % 1.16 [ 0.89, 1.50 ]
Total events: 144 (Experimental), 95 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.27)
2 All studies
NPCT 2002 25/621 35/629 24.4 % 0.72 [ 0.44, 1.19 ]
SELECT 2009 75/8752 67/8696 44.4 % 1.11 [ 0.80, 1.54 ]
Karp 2013 69/1040 28/521 31.2 % 1.23 [ 0.81, 1.89 ]
Subtotal (95% CI) 10413 9846 100.0 % 1.03 [ 0.78, 1.37 ]
Total events: 169 (Experimental), 130 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 2.79, df = 2 (P = 0.25); I2 =28%
Test for overall effect: Z = 0.24 (P = 0.81)
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Analysis 1.10. Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure,
Outcome 10 Breast cancer risk.
Review: Selenium for preventing cancer
Comparison: 1 Randomised controlled trials: highest versus lowest selenium exposure
Outcome: 10 Breast cancer risk
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Studies with low RoB
Karp 2013 8/531 2/271 100.0 % 2.04 [ 0.44, 9.55 ]
Subtotal (95% CI) 531 271 100.0 % 2.04 [ 0.44, 9.55 ]
Total events: 8 (Experimental), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
2 All studies
NPCT 2002 11/164 6/159 17.6 % 1.78 [ 0.67, 4.69 ]
Lubinski 2011 38/563 29/572 75.4 % 1.33 [ 0.83, 2.13 ]
Karp 2013 8/531 2/271 7.0 % 2.04 [ 0.44, 9.55 ]
Subtotal (95% CI) 1258 1002 100.0 % 1.44 [ 0.96, 2.17 ]
Total events: 57 (Experimental), 37 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.48, df = 2 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.77 (P = 0.078)
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Analysis 1.11. Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure,
Outcome 11 Bladder cancer risk.
Review: Selenium for preventing cancer
Comparison: 1 Randomised controlled trials: highest versus lowest selenium exposure
Outcome: 11 Bladder cancer risk
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Studies with low RoB
SELECT 2009 60/8752 53/8696 88.6 % 1.12 [ 0.78, 1.63 ]
Karp 2013 9/1040 6/521 11.4 % 0.75 [ 0.27, 2.10 ]
Subtotal (95% CI) 9792 9217 100.0 % 1.07 [ 0.76, 1.52 ]
Total events: 69 (Experimental), 59 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.52, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.69)
2 All studies
NPCT 2002 10/621 8/629 12.4 % 1.27 [ 0.50, 3.19 ]
SELECT 2009 60/8752 53/8696 77.7 % 1.12 [ 0.78, 1.63 ]
Karp 2013 9/1040 6/521 10.0 % 0.75 [ 0.27, 2.10 ]
Subtotal (95% CI) 10413 9846 100.0 % 1.10 [ 0.79, 1.52 ]
Total events: 79 (Experimental), 67 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.63, df = 2 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
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Analysis 1.12. Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure,
Outcome 12 Prostate cancer risk.
Review: Selenium for preventing cancer
Comparison: 1 Randomised controlled trials: highest versus lowest selenium exposure
Outcome: 12 Prostate cancer risk
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Studies with low RoB
SELECT 2009 432/8752 416/8696 79.4 % 1.03 [ 0.90, 1.18 ]
Marshall 2011 48/135 49/134 13.5 % 0.97 [ 0.71, 1.34 ]
Karp 2013 16/509 9/250 2.1 % 0.87 [ 0.39, 1.95 ]
Algotar 2013 24/234 26/232 5.0 % 0.92 [ 0.54, 1.55 ]
Subtotal (95% CI) 9630 9312 100.0 % 1.01 [ 0.90, 1.14 ]
Total events: 520 (Experimental), 500 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.41, df = 3 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
2 All studies
NPCT 2002 22/457 42/470 12.7 % 0.54 [ 0.33, 0.89 ]
SELECT 2009 432/8752 416/8696 46.2 % 1.03 [ 0.90, 1.18 ]
Marshall 2011 48/135 49/134 23.6 % 0.97 [ 0.71, 1.34 ]
Karp 2013 16/509 9/250 5.7 % 0.87 [ 0.39, 1.95 ]
Algotar 2013 24/234 26/232 11.8 % 0.92 [ 0.54, 1.55 ]
Subtotal (95% CI) 10087 9782 100.0 % 0.91 [ 0.75, 1.12 ]
Total events: 542 (Experimental), 542 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 6.25, df = 4 (P = 0.18); I2 =36%
Test for overall effect: Z = 0.86 (P = 0.39)
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Analysis 1.13. Comparison 1 Randomised controlled trials: highest versus lowest selenium exposure,
Outcome 13 Leukaemia and lymphoma risk.
Review: Selenium for preventing cancer
Comparison: 1 Randomised controlled trials: highest versus lowest selenium exposure
Outcome: 13 Leukaemia and lymphoma risk
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Studies with low RoB
Karp 2013 6/1040 3/521 100.0 % 1.00 [ 0.25, 3.99 ]
Subtotal (95% CI) 1040 521 100.0 % 1.00 [ 0.25, 3.99 ]
Total events: 6 (Experimental), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.0)
2 All studies
NPCT 2002 8/621 6/629 63.3 % 1.35 [ 0.47, 3.87 ]
Karp 2013 6/1040 3/521 36.7 % 1.00 [ 0.25, 3.99 ]
Subtotal (95% CI) 1661 1150 100.0 % 1.21 [ 0.52, 2.80 ]
Total events: 14 (Experimental), 9 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.66)
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Analysis 2.1. Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 1
Total cancer incidence and mortality.
Review: Selenium for preventing cancer
Comparison: 2 Observational studies: highest versus lowest selenium exposure
Outcome: 1 Total cancer incidence and mortality
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Incidence
Willett 1983 -0.64185387 (0.28025823) 12.5 % 0.53 [ 0.30, 0.91 ]
Peleg 1985 0 (0.32691842) 10.3 % 1.00 [ 0.53, 1.90 ]
Virtamo 1987 -0.13102825 (0.28025823) 12.5 % 0.88 [ 0.51, 1.52 ]
Nomura 1987 -0.26236423 (0.29924162) 11.6 % 0.77 [ 0.43, 1.38 ]
Ringstad 1988 -0.33647222 (0.44989504) 6.6 % 0.71 [ 0.30, 1.73 ]
Coates 1988 0 (0.32676883) 10.4 % 1.00 [ 0.53, 1.90 ]
Knekt 1990 -0.89159813 (0.19836824) 17.4 % 0.41 [ 0.28, 0.60 ]
Knekt 1990 -0.15082287 (0.17949557) 18.8 % 0.86 [ 0.60, 1.22 ]
Subtotal (95% CI) 100.0 % 0.72 [ 0.55, 0.93 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 12.75, df = 7 (P = 0.08); I2 =45%
Test for overall effect: Z = 2.54 (P = 0.011)
2 Mortality
Salonen 1985 -1.757858 (0.81249343) 2.2 % 0.17 [ 0.04, 0.85 ]
Kok 1987a -0.64185387 (0.33397056) 9.2 % 0.53 [ 0.27, 1.01 ]
Kornitzer 2004 0.35667496 (0.4270348) 6.6 % 1.43 [ 0.62, 3.30 ]
Kornitzer 2004 -0.78845738 (0.26682873) 11.9 % 0.45 [ 0.27, 0.77 ]
Akbaraly 2005 -1.401183 (0.5047159) 5.1 % 0.25 [ 0.09, 0.66 ]
Fujishima 2011 1.0919 (0.801) 2.3 % 2.98 [ 0.62, 14.32 ]
Goyal 2013 -0.1744 (0.1632) 17.7 % 0.84 [ 0.61, 1.16 ]
Sun 2016 -0.1054 (0.0796) 22.7 % 0.90 [ 0.77, 1.05 ]
Sun 2016 -0.0305 (0.0868) 22.3 % 0.97 [ 0.82, 1.15 ]
Subtotal (95% CI) 100.0 % 0.76 [ 0.59, 0.97 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 23.90, df = 8 (P = 0.002); I2 =67%
Test for overall effect: Z = 2.17 (P = 0.030)
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Analysis 2.2. Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 2
Total cancer incidence and mortality (men).
Review: Selenium for preventing cancer
Comparison: 2 Observational studies: highest versus lowest selenium exposure
Outcome: 2 Total cancer incidence and mortality (men)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Incidence
Peleg 1985 0.10536054 (0.49602147) 14.1 % 1.11 [ 0.42, 2.94 ]
Peleg 1985 0.51082558 (0.85634884) 6.2 % 1.67 [ 0.31, 8.93 ]
Nomura 1987 -0.26236423 (0.29924162) 23.9 % 0.77 [ 0.43, 1.38 ]
Virtamo 1987 -0.13102825 (0.28025823) 25.1 % 0.88 [ 0.51, 1.52 ]
Knekt 1990 -0.89159813 (0.19836824) 30.7 % 0.41 [ 0.28, 0.60 ]
Subtotal (95% CI) 100.0 % 0.72 [ 0.46, 1.14 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 9.12, df = 4 (P = 0.06); I2 =56%
Test for overall effect: Z = 1.39 (P = 0.17)
2 Mortality
Kok 1987a -0.99325179 (0.43360709) 12.3 % 0.37 [ 0.16, 0.87 ]
Kornitzer 2004 -0.78845738 (0.26682873) 21.0 % 0.45 [ 0.27, 0.77 ]
Goyal 2013 -0.4005 (0.1101) 32.6 % 0.67 [ 0.54, 0.83 ]
Sun 2016 -0.0305 (0.0868) 34.1 % 0.97 [ 0.82, 1.15 ]
Subtotal (95% CI) 100.0 % 0.65 [ 0.45, 0.94 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 15.16, df = 3 (P = 0.002); I2 =80%
Test for overall effect: Z = 2.30 (P = 0.021)
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Analysis 2.3. Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 3
Total cancer incidence and mortality (women).
Review: Selenium for preventing cancer
Comparison: 2 Observational studies: highest versus lowest selenium exposure
Outcome: 3 Total cancer incidence and mortality (women)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Incidence
Peleg 1985 -1.757858 (1.2286268) 7.3 % 0.17 [ 0.02, 1.92 ]
Peleg 1985 0.51082558 (0.6016002) 23.9 % 1.67 [ 0.51, 5.42 ]
Knekt 1990 -0.15082287 (0.17949557) 68.7 % 0.86 [ 0.60, 1.22 ]
Subtotal (95% CI) 100.0 % 0.90 [ 0.45, 1.77 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 2.90, df = 2 (P = 0.23); I2 =31%
Test for overall effect: Z = 0.32 (P = 0.75)
2 Mortality
Kok 1987a -0.40546511 (0.52696443) 1.6 % 0.67 [ 0.24, 1.87 ]
Kornitzer 2004 0.35667496 (0.4270348) 2.4 % 1.43 [ 0.62, 3.30 ]
Goyal 2013 -0.0943 (0.1238) 28.1 % 0.91 [ 0.71, 1.16 ]
Sun 2016 -0.1054 (0.0796) 68.0 % 0.90 [ 0.77, 1.05 ]
Subtotal (95% CI) 100.0 % 0.91 [ 0.80, 1.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.48, df = 3 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.14)
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Analysis 2.4. Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 4
Total cancer incidence and mortality (ascending order of selenium levels).
Review: Selenium for preventing cancer
Comparison: 2 Observational studies: highest versus lowest selenium exposure
Outcome: 4 Total cancer incidence and mortality (ascending order of selenium levels)
Study or subgroup Lowest category Highest category log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Incidence
Virtamo 1987 (1) 46 60 -0.131028 (0.280258) 12.5 % 0.88 [ 0.51, 1.52 ]
Knekt 1990 49 78 -0.891598 (0.198368) 17.4 % 0.41 [ 0.28, 0.60 ]
Knekt 1990 49 78 -0.150823 (0.179496) 18.8 % 0.86 [ 0.60, 1.22 ]
Peleg 1985 103 127 0 (0.326918) 10.3 % 1.00 [ 0.53, 1.90 ]
Nomura 1987 103 133 -0.262364 (0.299242) 11.6 % 0.77 [ 0.43, 1.38 ]
Ringstad 1988 114 115 -0.336472 (0.449895) 6.6 % 0.71 [ 0.30, 1.73 ]
Willett 1983 114 154 -0.641854 (0.280258) 12.5 % 0.53 [ 0.30, 0.91 ]
Coates 1988 148 171 0 (0.326769) 10.4 % 1.00 [ 0.53, 1.90 ]
Subtotal (95% CI) 726 916 100.0 % 0.72 [ 0.55, 0.93 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 12.75, df = 7 (P = 0.08); I2 =45%
Test for overall effect: Z = 2.54 (P = 0.011)
2 Mortality
Salonen 1985 47 47 -1.757858 (0.812493) 6.8 % 0.17 [ 0.04, 0.85 ]
Kornitzer 2004 72 85 0.356675 (0.427035) 14.4 % 1.43 [ 0.62, 3.30 ]
Kornitzer 2004 72 85 -0.788457 (0.266829) 19.5 % 0.45 [ 0.27, 0.77 ]
Akbaraly 2005 75 96 -1.401183 (0.50472) 12.3 % 0.25 [ 0.09, 0.66 ]
Fujishima 2011 85 114 1.0919 (0.801) 6.9 % 2.98 [ 0.62, 14.32 ]
Kok 1987a 103 103 -0.641854 (0.333971) 17.3 % 0.53 [ 0.27, 1.01 ]
Goyal 2013 109 137 -0.1744 (0.1632) 22.8 % 0.84 [ 0.61, 1.16 ]
Subtotal (95% CI) 563 667 100.0 % 0.63 [ 0.39, 1.01 ]
Heterogeneity: Tau2 = 0.24; Chi2 = 17.87, df = 6 (P = 0.01); I2 =66%
Test for overall effect: Z = 1.90 (P = 0.057)
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Analysis 2.5. Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 5
Total cancer incidence and mortality (ascending order of differences in selenium levels).
Review: Selenium for preventing cancer
Comparison: 2 Observational studies: highest versus lowest selenium exposure
Outcome: 5 Total cancer incidence and mortality (ascending order of differences in selenium levels)
Study or subgroup Difference log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Incidence
Ringstad 1988 (1) 1 0 -0.33647 (0.4499) 6.6 % 0.71 [ 0.30, 1.73 ]
Virtamo 1987 14 0 -0.13103 (0.28026) 12.5 % 0.88 [ 0.51, 1.52 ]
Coates 1988 23 0 0 (0.32677) 10.4 % 1.00 [ 0.53, 1.90 ]
Peleg 1985 24 0 0 (0.32692) 10.3 % 1.00 [ 0.53, 1.90 ]
Knekt 1990 29 0 -0.15082 (0.1795) 18.8 % 0.86 [ 0.60, 1.22 ]
Knekt 1990 29 0 -0.8916 (0.19837) 17.4 % 0.41 [ 0.28, 0.60 ]
Nomura 1987 30 0 -0.26236 (0.29924) 11.6 % 0.77 [ 0.43, 1.38 ]
Willett 1983 40 0 -0.64185 (0.28026) 12.5 % 0.53 [ 0.30, 0.91 ]
Subtotal (95% CI) 190 0 100.0 % 0.72 [ 0.55, 0.93 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 12.75, df = 7 (P = 0.08); I2 =45%
Test for overall effect: Z = 2.54 (P = 0.011)
2 Mortality
Salonen 1985 1 0 -1.75786 (0.81249) 6.8 % 0.17 [ 0.04, 0.85 ]
Kok 1987a 1 0 -0.64185 (0.33397) 17.3 % 0.53 [ 0.27, 1.01 ]
Kornitzer 2004 13 0 0.35668 (0.42704) 14.4 % 1.43 [ 0.62, 3.30 ]
Kornitzer 2004 13 0 -0.78846 (0.26683) 19.5 % 0.45 [ 0.27, 0.77 ]
Akbaraly 2005 21 0 -1.40118 (0.50472) 12.3 % 0.25 [ 0.09, 0.66 ]
Goyal 2013 28 0 -0.1744 (0.1632) 22.8 % 0.84 [ 0.61, 1.16 ]
Fujishima 2011 29 0 1.0919 (0.801) 6.9 % 2.98 [ 0.62, 14.32 ]
Subtotal (95% CI) 106 0 100.0 % 0.63 [ 0.39, 1.01 ]
Heterogeneity: Tau2 = 0.24; Chi2 = 17.87, df = 6 (P = 0.01); I2 =66%
Test for overall effect: Z = 1.90 (P = 0.057)
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Analysis 2.6. Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 6
Stomach cancer risk.
Review: Selenium for preventing cancer
Comparison: 2 Observational studies: highest versus lowest selenium exposure
Outcome: 6 Stomach cancer risk
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Nomura 1987 0.10536052 (0.60607205) 9.3 % 1.11 [ 0.34, 3.64 ]
Knekt 1990 -2.4079456 (1.0652725) 3.7 % 0.09 [ 0.01, 0.73 ]
Knekt 1990 -1.3093333 (0.88197684) 5.1 % 0.27 [ 0.05, 1.52 ]
van den Brandt 1993 -0.4462871 (0.3437958) 18.1 % 0.64 [ 0.33, 1.26 ]
Kabuto 1994 0 (0.3405615) 18.2 % 1.00 [ 0.51, 1.95 ]
Wei 2004 0.06765865 (0.33933798) 18.3 % 1.07 [ 0.55, 2.08 ]
Wei 2004 -0.75502258 (0.1729285) 27.3 % 0.47 [ 0.33, 0.66 ]
Total (95% CI) 100.0 % 0.66 [ 0.43, 1.01 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 12.20, df = 6 (P = 0.06); I2 =51%
Test for overall effect: Z = 1.93 (P = 0.053)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 7
Stomach cancer risk (by sex).
Review: Selenium for preventing cancer
Comparison: 2 Observational studies: highest versus lowest selenium exposure
Outcome: 7 Stomach cancer risk (by sex)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 All (male + female)
Kabuto 1994 0 (0.3405615) 17.4 % 1.00 [ 0.51, 1.95 ]
Wei 2004 0.06765865 (0.33933798) 17.4 % 1.07 [ 0.55, 2.08 ]
Wei 2004 -0.75502258 (0.1729285) 24.0 % 0.47 [ 0.33, 0.66 ]
Subtotal (95% CI) 58.9 % 0.75 [ 0.41, 1.36 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 7.12, df = 2 (P = 0.03); I2 =72%
Test for overall effect: Z = 0.94 (P = 0.35)
2 Male
Nomura 1987 0.10536052 (0.60607205) 9.6 % 1.11 [ 0.34, 3.64 ]
Knekt 1990 -2.4079456 (1.0652725) 4.1 % 0.09 [ 0.01, 0.73 ]
van den Brandt 1993 -0.91629073 (0.44161603) 13.9 % 0.40 [ 0.17, 0.95 ]
Subtotal (95% CI) 27.6 % 0.43 [ 0.14, 1.32 ]
Heterogeneity: Tau2 = 0.53; Chi2 = 4.56, df = 2 (P = 0.10); I2 =56%
Test for overall effect: Z = 1.47 (P = 0.14)
3 Female
Knekt 1990 -1.3093333 (0.88197684) 5.6 % 0.27 [ 0.05, 1.52 ]
van den Brandt 1993 0.51879379 (0.69436409) 8.0 % 1.68 [ 0.43, 6.55 ]
Subtotal (95% CI) 13.6 % 0.73 [ 0.12, 4.35 ]
Heterogeneity: Tau2 = 1.04; Chi2 = 2.65, df = 1 (P = 0.10); I2 =62%
Test for overall effect: Z = 0.35 (P = 0.73)
Total (95% CI) 100.0 % 0.66 [ 0.42, 1.04 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 15.22, df = 7 (P = 0.03); I2 =54%
Test for overall effect: Z = 1.79 (P = 0.074)
Test for subgroup differences: Chi2 = 0.74, df = 2 (P = 0.69), I2 =0.0%
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Analysis 2.8. Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 8
Colorectal cancer risk.
Review: Selenium for preventing cancer
Comparison: 2 Observational studies: highest versus lowest selenium exposure
Outcome: 8 Colorectal cancer risk
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Nomura 1987 -0.47 (0.4214) 2.4 % 0.63 [ 0.27, 1.43 ]
Nomura 1987 -0.5877 (0.4214) 2.4 % 0.56 [ 0.24, 1.27 ]
Knekt 1990 -0.63487833 (0.7845604) 0.7 % 0.53 [ 0.11, 2.47 ]
Knekt 1990 -0.22314354 (0.52904067) 1.5 % 0.80 [ 0.28, 2.26 ]
van den Brandt 1993 -0.2231 (0.2438) 7.2 % 0.80 [ 0.50, 1.29 ]
van den Brandt 1993 0.0488 (0.3364) 3.8 % 1.05 [ 0.54, 2.03 ]
Garland 1995 0.71294979 (0.43009643) 2.3 % 2.04 [ 0.88, 4.74 ]
Hansen 2013 -0.2231 (0.0823) 63.4 % 0.80 [ 0.68, 0.94 ]
Hughes 2015 -0.1278 (0.1625) 16.3 % 0.88 [ 0.64, 1.21 ]
Total (95% CI) 100.0 % 0.82 [ 0.72, 0.94 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 6.89, df = 8 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 2.95 (P = 0.0032)
Test for subgroup differences: Not applicable
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Analysis 2.9. Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 9
Colorectal cancer risk (by sex).
Review: Selenium for preventing cancer
Comparison: 2 Observational studies: highest versus lowest selenium exposure
Outcome: 9 Colorectal cancer risk (by sex)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 All (male + female)
Hansen 2013 -0.2231 (0.0823) 56.2 % 0.80 [ 0.68, 0.94 ]
Subtotal (95% CI) 56.2 % 0.80 [ 0.68, 0.94 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.71 (P = 0.0067)
2 Male
Nomura 1987 -0.5877 (0.4214) 2.9 % 0.56 [ 0.24, 1.27 ]
Nomura 1987 -0.47 (0.4214) 2.9 % 0.63 [ 0.27, 1.43 ]
Knekt 1990 -0.63487833 (0.7845604) 0.8 % 0.53 [ 0.11, 2.47 ]
van den Brandt 1993 -0.0943 (0.4018) 3.2 % 0.91 [ 0.41, 2.00 ]
van den Brandt 1993 -0.1985 (0.3346) 4.6 % 0.82 [ 0.43, 1.58 ]
Hughes 2015 0.1655 (0.243) 8.5 % 1.18 [ 0.73, 1.90 ]
Subtotal (95% CI) 23.0 % 0.86 [ 0.65, 1.16 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.76, df = 5 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
3 Female
Knekt 1990 -0.22314354 (0.52904067) 1.9 % 0.80 [ 0.28, 2.26 ]
van den Brandt 1993 -0.2614 (0.3229) 4.9 % 0.77 [ 0.41, 1.45 ]
van den Brandt 1993 0.4574 (0.5012) 2.1 % 1.58 [ 0.59, 4.22 ]
Garland 1995 0.71294979 (0.43009643) 2.8 % 2.04 [ 0.88, 4.74 ]
Hughes 2015 -0.4463 (0.2328) 9.2 % 0.64 [ 0.41, 1.01 ]
Subtotal (95% CI) 20.9 % 0.96 [ 0.61, 1.50 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 7.25, df = 4 (P = 0.12); I2 =45%
Test for overall effect: Z = 0.18 (P = 0.85)
Total (95% CI) 100.0 % 0.83 [ 0.72, 0.95 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 11.35, df = 11 (P = 0.41); I2 =3%
Test for overall effect: Z = 2.60 (P = 0.0093)
Test for subgroup differences: Chi2 = 0.68, df = 2 (P = 0.71), I2 =0.0%
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Analysis 2.10. Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 10
Colon cancer risk.
Review: Selenium for preventing cancer
Comparison: 2 Observational studies: highest versus lowest selenium exposure
Outcome: 10 Colon cancer risk
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Menkes 1986 0.19845095 (0.43422125) 3.8 % 1.22 [ 0.52, 2.86 ]
Nomura 1987 -0.58778664 (0.42140211) 4.1 % 0.56 [ 0.24, 1.27 ]
van den Brandt 1993 -0.26136479 (0.32223513) 7.0 % 0.77 [ 0.41, 1.45 ]
van den Brandt 1993 -0.19845095 (0.3319885) 6.6 % 0.82 [ 0.43, 1.57 ]
Hansen 2013 -0.1989 (0.1077) 62.5 % 0.82 [ 0.66, 1.01 ]
Hughes 2015 -0.2107 (0.2131) 16.0 % 0.81 [ 0.53, 1.23 ]
Total (95% CI) 100.0 % 0.81 [ 0.69, 0.96 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.72, df = 5 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 2.42 (P = 0.016)
Test for subgroup differences: Not applicable
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Analysis 2.11. Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 11
Colon cancer risk (by sex).
Review: Selenium for preventing cancer
Comparison: 2 Observational studies: highest versus lowest selenium exposure
Outcome: 11 Colon cancer risk (by sex)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 All (male + female)
Menkes 1986 0.19845095 (0.43422125) 3.9 % 1.22 [ 0.52, 2.86 ]
Hansen 2013 -0.1989 (0.1077) 63.3 % 0.82 [ 0.66, 1.01 ]
Subtotal (95% CI) 67.2 % 0.84 [ 0.68, 1.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.79, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 1.68 (P = 0.092)
2 Male
Nomura 1987 -0.58778664 (0.42140211) 4.1 % 0.56 [ 0.24, 1.27 ]
van den Brandt 1993 -0.19845095 (0.3319885) 6.7 % 0.82 [ 0.43, 1.57 ]
Hughes 2015 0.1044 (0.3312) 6.7 % 1.11 [ 0.58, 2.12 ]
Subtotal (95% CI) 17.5 % 0.84 [ 0.56, 1.25 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.68, df = 2 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.39)
3 Female
van den Brandt 1993 -0.26136479 (0.32223513) 7.1 % 0.77 [ 0.41, 1.45 ]
Hughes 2015 -0.4943 (0.2982) 8.3 % 0.61 [ 0.34, 1.09 ]
Subtotal (95% CI) 15.3 % 0.68 [ 0.44, 1.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.77 (P = 0.077)
Total (95% CI) 100.0 % 0.81 [ 0.69, 0.96 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.54, df = 6 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 2.43 (P = 0.015)
Test for subgroup differences: Chi2 = 0.79, df = 2 (P = 0.67), I2 =0.0%
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Analysis 2.12. Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 12
Lung cancer incidence and mortality.
Review: Selenium for preventing cancer
Comparison: 2 Observational studies: highest versus lowest selenium exposure
Outcome: 12 Lung cancer incidence and mortality
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Incidence
Nomura 1987 -0.0953102 (0.42360895) 7.7 % 0.91 [ 0.40, 2.09 ]
Coates 1988 -0.22314354 (0.948341) 2.6 % 0.80 [ 0.12, 5.13 ]
van den Brandt 1993 -0.91629072 (0.19941339) 12.3 % 0.40 [ 0.27, 0.59 ]
Kabuto 1994 -0.58778664 (0.50155941) 6.4 % 0.56 [ 0.21, 1.48 ]
Garland 1995 1.4655675 (1.0612346) 2.2 % 4.33 [ 0.54, 34.66 ]
Comstock 1997 -0.43078295 (0.26193982) 10.9 % 0.65 [ 0.39, 1.09 ]
Knekt 1998 -0.89159813 (0.43624526) 7.5 % 0.41 [ 0.17, 0.96 ]
Ratnasinghe 2000 0.1823216 (0.35364652) 9.0 % 1.20 [ 0.60, 2.40 ]
Goodman 2001 0.1823216 (0.22771341) 11.7 % 1.20 [ 0.77, 1.88 ]
Epplein 2009 -0.35667496 (0.32638552) 9.6 % 0.70 [ 0.37, 1.33 ]
Epplein 2009 -0.02020269 (0.43266643) 7.5 % 0.98 [ 0.42, 2.29 ]
Muka 2017 0.3293 (0.1836) 12.6 % 1.39 [ 0.97, 1.99 ]
Subtotal (95% CI) 100.0 % 0.82 [ 0.59, 1.14 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 32.01, df = 11 (P = 0.00076); I2 =66%
Test for overall effect: Z = 1.20 (P = 0.23)
2 Mortality
Kromhout 1987 -0.02020269 (0.44649482) 17.2 % 0.98 [ 0.41, 2.35 ]
Suadicani 2012 0.3577 (0.2033) 82.8 % 1.43 [ 0.96, 2.13 ]
Subtotal (95% CI) 100.0 % 1.34 [ 0.93, 1.93 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.58 (P = 0.11)
Test for subgroup differences: Chi2 = 3.91, df = 1 (P = 0.05), I2 =74%
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Analysis 2.13. Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 13
Lung cancer risk (sex-disaggregated data).
Review: Selenium for preventing cancer
Comparison: 2 Observational studies: highest versus lowest selenium exposure
Outcome: 13 Lung cancer risk (sex-disaggregated data)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 All (male + female)
Coates 1988 -0.22314354 (0.948341) 1.6 % 0.80 [ 0.12, 5.13 ]
Kabuto 1994 -0.58778664 (0.50155941) 4.5 % 0.56 [ 0.21, 1.48 ]
Comstock 1997 -0.43078295 (0.26193982) 9.1 % 0.65 [ 0.39, 1.09 ]
Knekt 1998 -0.89159813 (0.43624526) 5.4 % 0.41 [ 0.17, 0.96 ]
Muka 2017 0.3293 (0.1836) 11.2 % 1.39 [ 0.97, 1.99 ]
Subtotal (95% CI) 31.8 % 0.74 [ 0.43, 1.28 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 11.27, df = 4 (P = 0.02); I2 =64%
Test for overall effect: Z = 1.07 (P = 0.29)
2 Male
Nomura 1987 -0.0953102 (0.42360895) 5.6 % 0.91 [ 0.40, 2.09 ]
Kromhout 1987 -0.02020269 (0.44649482) 5.3 % 0.98 [ 0.41, 2.35 ]
van den Brandt 1993 -0.69314718 (0.25651067) 9.2 % 0.50 [ 0.30, 0.83 ]
Ratnasinghe 2000 0.1823216 (0.35364652) 6.9 % 1.20 [ 0.60, 2.40 ]
Goodman 2001 0.42526772 (0.31200675) 7.8 % 1.53 [ 0.83, 2.82 ]
Epplein 2009 -0.35667496 (0.32638552) 7.5 % 0.70 [ 0.37, 1.33 ]
Suadicani 2012 0.3577 (0.2033) 10.6 % 1.43 [ 0.96, 2.13 ]
Subtotal (95% CI) 53.0 % 0.98 [ 0.68, 1.39 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 13.77, df = 6 (P = 0.03); I2 =56%
Test for overall effect: Z = 0.14 (P = 0.89)
3 Female
van den Brandt 1993 -0.91629072 (0.57533986) 3.7 % 0.40 [ 0.13, 1.24 ]
Garland 1995 1.4655675 (1.0612346) 1.3 % 4.33 [ 0.54, 34.66 ]
Goodman 2001 -0.27443686 (0.49387987) 4.6 % 0.76 [ 0.29, 2.00 ]
Epplein 2009 -0.02020269 (0.43266643) 5.5 % 0.98 [ 0.42, 2.29 ]
Subtotal (95% CI) 15.2 % 0.83 [ 0.43, 1.61 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 4.21, df = 3 (P = 0.24); I2 =29%
Test for overall effect: Z = 0.54 (P = 0.59)
Total (95% CI) 100.0 % 0.89 [ 0.69, 1.14 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 29.76, df = 15 (P = 0.01); I2 =50%
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Chi2 = 0.71, df = 2 (P = 0.70), I2 =0.0%
0.01 0.1 1 10 100
184Selenium for preventing cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.14. Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 14
Lung cancer risk (by exposure assessment).
Review: Selenium for preventing cancer
Comparison: 2 Observational studies: highest versus lowest selenium exposure
Outcome: 14 Lung cancer risk (by exposure assessment)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Intake
Kromhout 1987 -0.02020269 (0.44649482) 6.0 % 0.98 [ 0.41, 2.35 ]
Muka 2017 0.3293 (0.1836) 10.7 % 1.39 [ 0.97, 1.99 ]
Subtotal (95% CI) 16.7 % 1.32 [ 0.95, 1.84 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.52, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.64 (P = 0.10)
2 Serum or plasma
Nomura 1987 -0.0953102 (0.42360895) 6.4 % 0.91 [ 0.40, 2.09 ]
Coates 1988 -0.22314354 (0.948341) 2.1 % 0.80 [ 0.12, 5.13 ]
Kabuto 1994 -0.58778664 (0.50155941) 5.3 % 0.56 [ 0.21, 1.48 ]
Comstock 1997 -0.43078295 (0.26193982) 9.2 % 0.65 [ 0.39, 1.09 ]
Knekt 1998 -0.89159813 (0.43624526) 6.2 % 0.41 [ 0.17, 0.96 ]
Ratnasinghe 2000 0.1823216 (0.35364652) 7.5 % 1.20 [ 0.60, 2.40 ]
Goodman 2001 0.1823216 (0.22771341) 9.9 % 1.20 [ 0.77, 1.88 ]
Epplein 2009 -0.02020269 (0.43266643) 6.2 % 0.98 [ 0.42, 2.29 ]
Epplein 2009 -0.35667496 (0.32638552) 8.0 % 0.70 [ 0.37, 1.33 ]
Suadicani 2012 0.3577 (0.2033) 10.3 % 1.43 [ 0.96, 2.13 ]
Subtotal (95% CI) 71.1 % 0.91 [ 0.70, 1.18 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 13.40, df = 9 (P = 0.15); I2 =33%
Test for overall effect: Z = 0.74 (P = 0.46)
3 Toenail
van den Brandt 1993 -0.91629072 (0.19941339) 10.4 % 0.40 [ 0.27, 0.59 ]
Garland 1995 1.4655675 (1.0612346) 1.8 % 4.33 [ 0.54, 34.66 ]
Subtotal (95% CI) 12.2 % 1.05 [ 0.11, 10.36 ]
Heterogeneity: Tau2 = 2.25; Chi2 = 4.87, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.04 (P = 0.97)
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(. . . Continued)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Total (95% CI) 100.0 % 0.88 [ 0.65, 1.18 ]
Heterogeneity: Tau2 = 0.18; Chi2 = 38.18, df = 13 (P = 0.00027); I2 =66%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Chi2 = 3.05, df = 2 (P = 0.22), I2 =34%
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Analysis 2.15. Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 15
Lung cancer risk (ascending order of selenium levels).
Review: Selenium for preventing cancer
Comparison: 2 Observational studies: highest versus lowest selenium exposure
Outcome: 15 Lung cancer risk (ascending order of selenium levels)
Study or subgroup Lowest category Highest category log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Ratnasinghe 2000 (1) 39 55 0.182322 (0.353647) 11.3 % 1.20 [ 0.60, 2.40 ]
Knekt 1998 45 61 -0.891598 (0.436245) 8.1 % 0.41 [ 0.17, 0.96 ]
Suadicani 2012 79 103 0.3577 (0.2033) 22.7 % 1.43 [ 0.96, 2.13 ]
Kabuto 1994 99 128 -0.587787 (0.501559) 6.4 % 0.56 [ 0.21, 1.48 ]
Goodman 2001 106 129 0.182322 (0.227713) 20.1 % 1.20 [ 0.77, 1.88 ]
Nomura 1987 103 133 -0.09531 (0.423609) 8.5 % 0.91 [ 0.40, 2.09 ]
Epplein 2009 128 139 -0.020203 (0.432666) 8.2 % 0.98 [ 0.42, 2.29 ]
Epplein 2009 128 144 -0.356675 (0.326386) 12.7 % 0.70 [ 0.37, 1.33 ]
Coates 1988 148 171 -0.223144 (0.948341) 2.0 % 0.80 [ 0.12, 5.13 ]
Total (95% CI) 875 1063 100.0 % 0.97 [ 0.74, 1.27 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 10.79, df = 8 (P = 0.21); I2 =26%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
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Analysis 2.16. Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 16
Lung cancer risk (ascending order of differences in selenium levels).
Review: Selenium for preventing cancer
Comparison: 2 Observational studies: highest versus lowest selenium exposure
Outcome: 16 Lung cancer risk (ascending order of differences in selenium levels)
Study or subgroup Difference log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Epplein 2009 (1) 11 0 -0.0202 (0.43267) 8.2 % 0.98 [ 0.42, 2.29 ]
Ratnasinghe 2000 16 0 0.18232 (0.35365) 11.3 % 1.20 [ 0.60, 2.40 ]
Knekt 1998 16 0 -0.8916 (0.43625) 8.1 % 0.41 [ 0.17, 0.96 ]
Epplein 2009 16 0 -0.35668 (0.32639) 12.7 % 0.70 [ 0.37, 1.33 ]
Coates 1988 23 0 -0.22314 (0.94834) 2.0 % 0.80 [ 0.12, 5.13 ]
Goodman 2001 23 0 0.18232 (0.22771) 20.1 % 1.20 [ 0.77, 1.88 ]
Suadicani 2012 24 0 0.3577 (0.2033) 22.7 % 1.43 [ 0.96, 2.13 ]
Kabuto 1994 29 0 -0.58779 (0.50156) 6.4 % 0.56 [ 0.21, 1.48 ]
Nomura 1987 30 0 -0.09531 (0.42361) 8.5 % 0.91 [ 0.40, 2.09 ]
Total (95% CI) 188 0 100.0 % 0.97 [ 0.74, 1.27 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 10.79, df = 8 (P = 0.21); I2 =26%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
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Analysis 2.17. Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 17
Breast cancer risk (women).
Review: Selenium for preventing cancer
Comparison: 2 Observational studies: highest versus lowest selenium exposure
Outcome: 17 Breast cancer risk (women)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
van Noord 1987 0.0953102 (0.44843315) 6.3 % 1.10 [ 0.46, 2.65 ]
Coates 1988 1.2237755 (0.59689179) 3.7 % 3.40 [ 1.06, 10.95 ]
Knekt 1990 -0.44628712 (0.44815248) 6.3 % 0.64 [ 0.27, 1.54 ]
Overvad 1991 0.22314354 (0.51575917) 4.8 % 1.25 [ 0.45, 3.43 ]
van den Brandt 1993 -0.17435342 (0.21348313) 22.3 % 0.84 [ 0.55, 1.28 ]
Garland 1995 0.0953102 (0.22933655) 20.0 % 1.10 [ 0.70, 1.72 ]
Dorgan 1998 -0.10536054 (0.3836932) 8.4 % 0.90 [ 0.42, 1.91 ]
Pantavos 2015 0.2927 (0.1809) 28.3 % 1.34 [ 0.94, 1.91 ]
Total (95% CI) 100.0 % 1.09 [ 0.87, 1.37 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 8.15, df = 7 (P = 0.32); I2 =14%
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 2.18. Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 18
Bladder cancer risk.
Review: Selenium for preventing cancer
Comparison: 2 Observational studies: highest versus lowest selenium exposure
Outcome: 18 Bladder cancer risk
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 All (male + female)
Menkes 1986 -0.72270596 (0.57370723) 9.1 % 0.49 [ 0.16, 1.49 ]
van den Brandt 1993 -0.40047754 (0.19032388) 36.7 % 0.67 [ 0.46, 0.97 ]
Subtotal (95% CI) 45.8 % 0.65 [ 0.46, 0.92 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 2.39 (P = 0.017)
2 Male
Nomura 1987 -1.1314021 (0.64600567) 7.4 % 0.32 [ 0.09, 1.14 ]
Michaud 2005 0.15700371 (0.29159795) 24.4 % 1.17 [ 0.66, 2.07 ]
Michaud 2002 -0.13926206 (0.54291624) 10.0 % 0.87 [ 0.30, 2.52 ]
Subtotal (95% CI) 41.9 % 0.82 [ 0.41, 1.62 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 3.32, df = 2 (P = 0.19); I2 =40%
Test for overall effect: Z = 0.57 (P = 0.57)
3 Female
Michaud 2005 -1.0216512 (0.47750056) 12.3 % 0.36 [ 0.14, 0.92 ]
Subtotal (95% CI) 12.3 % 0.36 [ 0.14, 0.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.14 (P = 0.032)
Total (95% CI) 100.0 % 0.67 [ 0.46, 0.97 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 7.10, df = 5 (P = 0.21); I2 =30%
Test for overall effect: Z = 2.11 (P = 0.035)
Test for subgroup differences: Chi2 = 1.96, df = 2 (P = 0.38), I2 =0.0%
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Analysis 2.19. Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 19
Prostate cancer risk.
Review: Selenium for preventing cancer
Comparison: 2 Observational studies: highest versus lowest selenium exposure
Outcome: 19 Prostate cancer risk
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Coates 1988 -1.2039728 (1.118034) 0.3 % 0.30 [ 0.03, 2.68 ]
Knekt 1990 0.13976192 (0.5352475) 1.2 % 1.15 [ 0.40, 3.28 ]
van den Brandt 1993 -0.37106368 (0.18467318) 6.3 % 0.69 [ 0.48, 0.99 ]
Hartman 1998 0.23901689 (0.2921256) 3.3 % 1.27 [ 0.72, 2.25 ]
Yoshizawa 1998 -0.94160858 (0.39297066) 2.0 % 0.39 [ 0.18, 0.84 ]
Helzlsouer 2000 -0.96758404 (0.4105709) 1.9 % 0.38 [ 0.17, 0.85 ]
Nomura 2000 -0.69314718 (0.28025822) 3.6 % 0.50 [ 0.29, 0.87 ]
Goodman 2001 0.01980261 (0.2297925) 4.8 % 1.02 [ 0.65, 1.60 ]
Brooks 2001 -1.4271164 (0.61170797) 0.9 % 0.24 [ 0.07, 0.80 ]
Li 2004a -0.2484614 (0.1883683) 6.2 % 0.78 [ 0.54, 1.13 ]
Peters 2007 -0.17435342 (0.15537348) 7.7 % 0.84 [ 0.62, 1.14 ]
Peters 2008 -0.10536054 (0.18887756) 6.2 % 0.90 [ 0.62, 1.30 ]
Allen 2008 -0.04082202 (0.15987297) 7.4 % 0.96 [ 0.70, 1.31 ]
Epplein 2009 -0.19845095 (0.16802577) 7.0 % 0.82 [ 0.59, 1.14 ]
Steinbrecher 2010 -0.2485 (0.2372) 4.6 % 0.78 [ 0.49, 1.24 ]
Agalliu 2011 -0.2744 (0.2906) 3.4 % 0.76 [ 0.43, 1.34 ]
Grundmark 2011 -0.1863 (0.1656) 7.2 % 0.83 [ 0.60, 1.15 ]
Kristal 2014 -0.2744 (0.2778) 3.6 % 0.76 [ 0.44, 1.31 ]
Park 2015 0.01 (0.094) 11.3 % 1.01 [ 0.84, 1.21 ]
Outzen 2016 -0.0513 (0.1558) 7.6 % 0.95 [ 0.70, 1.29 ]
Graff 2017 0.4511 (0.2747) 3.7 % 1.57 [ 0.92, 2.69 ]
Total (95% CI) 100.0 % 0.84 [ 0.75, 0.95 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 30.61, df = 20 (P = 0.06); I2 =35%
Test for overall effect: Z = 2.89 (P = 0.0039)
Test for subgroup differences: Not applicable
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Analysis 2.20. Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 20
Prostate cancer risk (by exposure assessment).
Review: Selenium for preventing cancer
Comparison: 2 Observational studies: highest versus lowest selenium exposure
Outcome: 20 Prostate cancer risk (by exposure assessment)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Intake and supplement
Hartman 1998 0.23901689 (0.2921256) 3.3 % 1.27 [ 0.72, 2.25 ]
Peters 2008 -0.10536054 (0.18887756) 6.2 % 0.90 [ 0.62, 1.30 ]
Agalliu 2011 -0.2744 (0.2906) 3.4 % 0.76 [ 0.43, 1.34 ]
Park 2015 0.01 (0.094) 11.3 % 1.01 [ 0.84, 1.21 ]
Subtotal (95% CI) 24.2 % 0.99 [ 0.85, 1.15 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.85, df = 3 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
2 Serum or plasma
Coates 1988 -1.2039728 (1.118034) 0.3 % 0.30 [ 0.03, 2.68 ]
Knekt 1990 0.13976192 (0.5352475) 1.2 % 1.15 [ 0.40, 3.28 ]
Nomura 2000 -0.69314718 (0.28025822) 3.6 % 0.50 [ 0.29, 0.87 ]
Brooks 2001 -1.4271164 (0.61170797) 0.9 % 0.24 [ 0.07, 0.80 ]
Goodman 2001 0.01980261 (0.2297925) 4.8 % 1.02 [ 0.65, 1.60 ]
Li 2004a -0.2484614 (0.1883683) 6.2 % 0.78 [ 0.54, 1.13 ]
Peters 2007 -0.17435342 (0.15537348) 7.7 % 0.84 [ 0.62, 1.14 ]
Allen 2008 -0.04082202 (0.15987297) 7.4 % 0.96 [ 0.70, 1.31 ]
Epplein 2009 -0.19845095 (0.16802577) 7.0 % 0.82 [ 0.59, 1.14 ]
Steinbrecher 2010 -0.2485 (0.2372) 4.6 % 0.78 [ 0.49, 1.24 ]
Grundmark 2011 -0.1863 (0.1656) 7.2 % 0.83 [ 0.60, 1.15 ]
Outzen 2016 -0.0513 (0.1558) 7.6 % 0.95 [ 0.70, 1.29 ]
Graff 2017 0.4511 (0.2747) 3.7 % 1.57 [ 0.92, 2.69 ]
Subtotal (95% CI) 62.0 % 0.86 [ 0.75, 0.99 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 16.10, df = 12 (P = 0.19); I2 =25%
Test for overall effect: Z = 2.14 (P = 0.032)
3 Toenail
van den Brandt 1993 -0.37106368 (0.18467318) 6.3 % 0.69 [ 0.48, 0.99 ]
Yoshizawa 1998 -0.94160858 (0.39297066) 2.0 % 0.39 [ 0.18, 0.84 ]
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(. . . Continued)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Helzlsouer 2000 -0.96758404 (0.4105709) 1.9 % 0.38 [ 0.17, 0.85 ]
Kristal 2014 -0.2744 (0.2778) 3.6 % 0.76 [ 0.44, 1.31 ]
Subtotal (95% CI) 13.8 % 0.60 [ 0.44, 0.82 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 3.69, df = 3 (P = 0.30); I2 =19%
Test for overall effect: Z = 3.20 (P = 0.0014)
Total (95% CI) 100.0 % 0.84 [ 0.75, 0.95 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 30.61, df = 20 (P = 0.06); I2 =35%
Test for overall effect: Z = 2.89 (P = 0.0039)
Test for subgroup differences: Chi2 = 8.01, df = 2 (P = 0.02), I2 =75%
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Analysis 2.21. Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 21
Prostate cancer risk (ascending order of selenium levels).
Review: Selenium for preventing cancer
Comparison: 2 Observational studies: highest versus lowest selenium exposure
Outcome: 21 Prostate cancer risk (ascending order of selenium levels)
Study or subgroup Lowest category Highest category log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Knekt 1990 (1) 49 78 0.13976 (0.53525) 1.7 % 1.15 [ 0.40, 3.28 ]
Allen 2008 62 84 -0.04082 (0.15987) 12.3 % 0.96 [ 0.70, 1.31 ]
Grundmark 2011 70 81 -0.1863 (0.1656) 11.8 % 0.83 [ 0.60, 1.15 ]
Outzen 2016 71 89 -0.0513 (0.1558) 12.7 % 0.95 [ 0.70, 1.29 ]
Steinbrecher 2010 79 95 -0.2485 (0.2372) 7.1 % 0.78 [ 0.49, 1.24 ]
Graff 2017 89 130 0.4511 (0.2747) 5.6 % 1.57 [ 0.92, 2.69 ]
Li 2004a 92 124 -0.24846 (0.18837) 9.9 % 0.78 [ 0.54, 1.13 ]
Goodman 2001 101 126 0.0198 (0.22979) 7.4 % 1.02 [ 0.65, 1.60 ]
Brooks 2001 107 133 -1.42712 (0.61171) 1.3 % 0.24 [ 0.07, 0.80 ]
Nomura 2000 119 147 -0.69315 (0.28026) 5.4 % 0.50 [ 0.29, 0.87 ]
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(. . . Continued)
Study or subgroup Lowest category Highest category log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Peters 2007 127 158 -0.17435 (0.15537) 12.8 % 0.84 [ 0.62, 1.14 ]
Epplein 2009 127 159 -0.19845 (0.16803) 11.6 % 0.82 [ 0.59, 1.14 ]
Coates 1988 148 171 -1.20397 (1.11803) 0.4 % 0.30 [ 0.03, 2.68 ]
Total (95% CI) 1241 1575 100.0 % 0.86 [ 0.75, 0.99 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 16.10, df = 12 (P = 0.19); I2 =25%
Test for overall effect: Z = 2.14 (P = 0.032)
Test for subgroup differences: Not applicable
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Analysis 2.22. Comparison 2 Observational studies: highest versus lowest selenium exposure, Outcome 22
Prostate cancer risk (ascending order of differences in selenium levels).
Review: Selenium for preventing cancer
Comparison: 2 Observational studies: highest versus lowest selenium exposure
Outcome: 22 Prostate cancer risk (ascending order of differences in selenium levels)
Study or subgroup Difference log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Grundmark 2011 (1) 11 0 -0.1863 (0.1656) 11.8 % 0.83 [ 0.60, 1.15 ]
Steinbrecher 2010 16 0 -0.2485 (0.2372) 7.1 % 0.78 [ 0.49, 1.24 ]
Allen 2008 22 0 -0.04082 (0.15987) 12.3 % 0.96 [ 0.70, 1.31 ]
Coates 1988 23 0 -1.20397 (1.11803) 0.4 % 0.30 [ 0.03, 2.68 ]
Goodman 2001 25 0 0.0198 (0.22979) 7.4 % 1.02 [ 0.65, 1.60 ]
Brooks 2001 26 0 -1.42712 (0.61171) 1.3 % 0.24 [ 0.07, 0.80 ]
Nomura 2000 28 0 -0.69315 (0.28026) 5.4 % 0.50 [ 0.29, 0.87 ]
Knekt 1990 29 0 0.13976 (0.53525) 1.7 % 1.15 [ 0.40, 3.28 ]
Outzen 2016 29 0 -0.0513 (0.1558) 12.7 % 0.95 [ 0.70, 1.29 ]
Peters 2007 31 0 -0.17435 (0.15537) 12.8 % 0.84 [ 0.62, 1.14 ]
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(. . . Continued)
Study or subgroup Difference log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Epplein 2009 32 0 -0.19845 (0.16803) 11.6 % 0.82 [ 0.59, 1.14 ]
Li 2004a 32 0 -0.24846 (0.18837) 9.9 % 0.78 [ 0.54, 1.13 ]
Graff 2017 41 0 0.4511 (0.2747) 5.6 % 1.57 [ 0.92, 2.69 ]
Total (95% CI) 345 0 100.0 % 0.86 [ 0.75, 0.99 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 16.10, df = 12 (P = 0.19); I2 =25%
Test for overall effect: Z = 2.14 (P = 0.032)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Included observational studies by outcome
Organ sys-
tem
Outcome Num-
ber of stud-
ies/case def-
initions
Meta-
analysis
Countries Num-
ber of par-
ticipants
Number of
cases
Selenium
assessment
Reporting
study
Any cancer Any cancer total: 16
incidence: 7
mortality: 7
incidence
and mortal-
ity
combined: 1
√
yes USA
Finland
Netherlands
Sweden
Norway
Belgium
France
China
Japan
total: ~ 276,
000
total: 6488
male: 3196
female:
1541
serum: 12
plasma: 2
serum +
plasma: 1
dietary
intake: 1
Willett
1983
Salonen
1984
Peleg 1985
Salonen
1985
Nomura
1987
Virtamo
1987
Coates 1988
Fex 1987
Kok 1987a
Ringstad
1988
Knekt 1990
Kornitzer
2004
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Table 1. Included observational studies by outcome (Continued)
Akbaraly
2005
Bleys 2008
Fujishima
2011
Sun 2016
Gynaeco-
logical can-
cer
Fe-
male breast
cancer
total: 8
incidence: 8
mortality: 0
incidence
and mortal-
ity
combined: 0
√
yes USA
Finland
Netherlands
Channel Is-
lands
total/
female: 169,
028
total/fe-
male: 1277
serum: 2
plasma: 1
serum +
plasma: 1
toenail: 3
intake: 1
van Noord
1987
Coates 1988
Knekt 1990
Overvad
1991
van den
Brandt 1993
Garland
1995
Dorgan
1998
Pantavos
2015
Cervical
cancer
total: 2
incidence: 2
mortality: 0
incidence
and mortal-
ity
combined: 0
× no USA to-
tal/female: >
15,161
(1 study did
not re-
port cohort
size by sex)
total/
female: 62
serum: 2 Menkes
1986
Coates 1988
Uterine can-
cer
total: 1
incidence: 1
mortality: 0
incidence
and mortal-
ity
combined: 0
× no USA total/
female: 62,
641
total/
female: 91
toenail: 1 Garland
1995
Ovarian
cancer
total: 4
incidence: 4
mortality: 0
incidence
and mortal-
ity
combined: 0
× no USA
Finland
total/fe-
male: ~ 214,
000
total/
female: 568
serum: 2
toenail: 1
supplemen-
tal intake: 1
Menkes
1986
Knekt 1990
Garland
1995
Thomson
2008
Gynaeco-
logical can-
cer (without
breast can-
total: 1
incidence: 1
mortality: 0
incidence
× no Finland total/
female: 18,
096
total/
female: 86
serum: 1 Knekt 1990
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Table 1. Included observational studies by outcome (Continued)
cer) and mortal-
ity
combined: 0
Urological
cancers
Renal cancer total: 1
incidence: 1
mortality: 0
incidence
and mortal-
ity
combined: 0
× no United Kin-
dom
total: 23,
658
total: 65 dietary
intake: 1
Banim 2013
Uri-
nary bladder
cancer
total: 6
incidence: 6
mortality: 0
incidence &
mortality
combined: 0
√
yes USA/
Hawaii
Finland
Netherlands
total: 279,
100
female: 130,
786
male: 128,
009
total: 1295
female: 175
male 755
serum: 3
toenail: 3
Menkes
1986
Nomura
1987
van den
Brandt 1993
Michaud
2002
Michaud
2005
Hotaling
2011
Urinary
tract cancer
total: 1
incidence: 1
mortality: 0
incidence &
mortality
combined: 0
× no Netherlands total: 38,
500
total: 47
male: 34
female: 13
serum: 1 Knekt 1990
Respi-
ratory tract
cancers
Lung cancer total: 15
incidence:
13
mortality: 2
incidence
and mortal-
ity
combined: 0
√
yes China
Japan
USA
Finland
Netherlands
Denmark
total: 371,
067
male: 125,
341
female: 181,
895
total: 2223
male: 1384
female: 416
serum: 9
serum +
plasma: 2
toenail: 2
dietary
intake: 2
(1 study re-
ported both
serum levels
and food in-
take)
Menkes
1986
Kromhout
1987
Nomura
1987
Coates 1988
Knekt 1990
van den
Brandt 1993
Kabuto
1994
Garland
1995
Comstock
1997
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Table 1. Included observational studies by outcome (Continued)
Knekt 1998
Ratnasinghe
2000
Goodman
2001
Epplein
2009
Suadicani
2012
Muka 2017
Oral/pha-
ryngeal can-
cer
total: 1
incidence: 1
mortality: 0
incidence
and mortal-
ity
combined: 0
× no USA total: 20,
305
total: 28 serum: 1 Menkes
1986
Andrologi-
cal cancers
Prostate
cancer
total: 21
incidence:
21
mortality: 0
incidence
and mortal-
ity
combined: 0
√
yes USA
Canada
Puerto Rico
Europe
total/male:
576,667
total/male:
14,950
serum: 8
plasma: 5
toenail: 4
dietary
intake: 4
Coates 1988
van den
Brandt 1993
Hartman
1998
Yoshizawa
1998
Helzlsouer
2000
Nomura
2000
Brooks 2001
Goodman
2001
Li 2004a
Peters 2007
Allen 2008
Peters 2008
Epplein
2009
Kristal 2014
Park 2015
Outzen
2016
Graff 2017
Gastroin-
testinal
cancers
Oe-
sophageal
cancer
total: 2
incidence: 2
mortality: 1
incidence
× no China
USA
total: 29,
923
total: > 959 serum: 1
supplemen-
tal intake: 1
Wei 2004
Dong 2008
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Table 1. Included observational studies by outcome (Continued)
and mortal-
ity
combined: 0
Oe-
sophageal
squamous
cell
carcinoma
total:2
incidence: 2
mortality: 0
incidence
and mortal-
ity
combined: 0
× no Netherlands
Iran
total: 168,
257
total: 265 toenail: 1
intake: 1
Steinbrecher
2010
Hashemian
2015
Oe-
sophageal
adenocarci-
noma
total:1
incidence:1
mortality:0
incidence
and mortal-
ity
combined: 0
× no Netherlands total: 120,
852
total: 112 toenail: 1 Steinbrecher
2010
Oe-
sophageal/
stomach
cancer
total: 1
incidence: 1
mortality: 0
incidence
and mortal-
ity
combined: 0
× no Netherlands total: 36,
265
total: 86
male: 51
female: 35
serum: 1 Knekt 1998
Gastric car-
dia adeno-
carcinoma
total:1
incidence:1
mortality:0
incidence
and mortal-
ity
combined: 0
× no Netherlands total: 120,
852
total:114 toenail: 1 Steinbrecher
2010
Stomach
cancer
total: 5
incidence: 5
mortality: 1
incidence
and mortal-
ity
combined: 0
√
yes China
Japan
USA/
Hawaii
Finland
Netherlands
total: ~ 197,
000
male: 86,
311
female: 80,
669
total: 955
male: 626
female: 329
serum: 4
toenail: 1
Nomura
1987
Knekt 1990
van den
Brandt 1993
Kabuto
1994
Wei 2004
Primary
liver cancer
total: 4
incidence: 3
mortality: 1
incidence
× no China
Europe
Taiwan
total: 701,
809
male: 61,
470
total: 877
male: 567
female: 204
plasma: 1
serum: 1
toenail: 1
intake: 1
Yu 1999
Sakoda
2005
Hughes
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Table 1. Included observational studies by outcome (Continued)
and mortal-
ity
combined: 0
female: 74,
941
2016
Ma 2017
Pancreatic
cancer
total: 4
incidence: 4
mortality: 0
incidence
and mortal-
ity
combined: 0
× no USA
Finland
UK
total: 159,
062
total: 311
male: 69
female: 84
serum: 2
intake: 1
supplemen-
tal intake: 1
Menkes
1986
Knekt 1990
Banim 2013
Han 2013
Colorectal
cancer
total: 6
incidence: 6
mortality: 0
incidence
and mortal-
ity
combined: 0
√
yes USA/
Hawaii
Europe
total: 712,
746
male: 216,
272
female: 442,
266
total: 2627
male: 810
female: 797
serum: 3
toenail: 2
supplement
use: 1
Nomura
1987
Knekt 1990
van den
Brandt 1993
Garland
1995
Hansen
2013
Hughes
2015
Colon can-
cer
total: 5
incidence: 5
mortality: 0
incidence
and mortal-
ity
combined: 0
√
yes USA/
Hawaii
Europe
total: 636,
641
male: 195,
100
female: 361,
529
total: 1677
male: 525
female: 510
serum: 3
toenail: 1
supplement
use: 1
Menkes
1986
Nomura
1987
van den
Brandt 1993
Hansen
2013
Hughes
2015
Rectal can-
cer
total: 4
incidence: 4
mortality: 0
incidence
and mortal-
ity
combined: 0
× no USA/
Hawaii
Europe
total: 610,
837
male: 195,
100
female: 361,
529
total: 861
male: 303
female: 210
serum: 2
toenail: 1
supplement
use:1
Nomura
1987
van den
Brandt 1993
Hansen
2013
Hughes
2015
All gastroin-
testinal can-
cers
total: 1
incidence: 1
mortality: 0
incidence
and mortal-
ity
× no USA total: 6,167 total: 143 plasma and
serum: 1
Coates 1988
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Table 1. Included observational studies by outcome (Continued)
combined: 0
Skin cancer Melanoma total: 3
incidence: 3
mortality: 0
incidence
and mortal-
ity
combined: 0
× no USA total: ~ 158,
000
total: 547 serum: 1
toenail: 1
supplemen-
tal intake: 1
Menkes
1986
Garland
1995
Peters 2008
Basal cell
carcinoma
total: 3
incidence: 3
mortality: 0
incidence
and mortal-
ity
combined: 0
× no Australia
USA
Finland
total: > 66,
000
total: 292 serum: 3
dietary
intake: 1
Menkes
1986
Knekt 1990
Mc-
Naughton
2005
Squamous
cell
carcinoma
total: 4
incidence: 4
mortality: 0
incidence
and mortal-
ity
combined: 0
× no Australia
USA
total: ~ 30,
000
total: 488 serum: 2
plasma: 1
dietary
intake: 1
Menkes
1986
Combs
1993
Karagas
1997
Mc-
Naughton
2005
Total non-
melanoma
skin cancer
total: 1
incidence: 1
mortality: 0
incidence
and mortal-
ity
combined: 0
× no USA total: 117 total: 19 plasma: 1 Clark 1985
Rare and
other can-
cers
Haemato-
logical can-
cers
total: 1
incidence: 1
mortality: 0
incidence
and mortal-
ity
combined: 0
× no USA total: 6167 total: 12 serum +
plasma: 1
Coates 1988
Thyroid
cancer
total: 2
incidence: 2
mortality: 0
incidence
and mortal-
× no Norway total: 582,
807
male: 287,
944
female: 194,
total: 635
male: 269
female: 366
serum: 1
intake:1
Glattre
1989
O’Grady
2014
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Table 1. Included observational studies by outcome (Continued)
ity
combined: 0
863
Other can-
cers
total: 4
incidence: 3
mortality: 1
incidence
and mortal-
ity
combined: 0
× no China
USA
Finland
total: 109,
179
male: 21,
172
female: 80,
737
total: 512
male: 169
female: 285
serum: 2
serum +
plasma: 1
toenail: 1
Coates 1988
Knekt 1990
Garland
1995
Wei 2004
Some studies did not report the sex of participants or cancer cases; consequently, figures for women and men do not always sum up to
the total number of participants or cancer cases.
Table 2. Risk of bias: observational studies
Study Publica-
tion
Newcastle-Ottawa Scale (cohort) Newcastle-Ottawa Scale (case-control)
Selection Compara-
bility
Outcome Total Selection Compara-
bility
Exposure Total
Agalliu
2011
Agalliu
2011
0-1-0-1 1 1-1-0 5 0-1-0-1 1 1-1-0 5
Akbaraly
2005
Akbaraly
2005
0-1-1-1 2 0-1-0 6 .-.-.-. . .-.-. .
Allen 2008 Allen 2008 1-1-1-1 2 1-1-0 8 1-1-1-1 2 1-1-1 9
Banim
2013
Banim
2013
1-1-1-1 2 1-1-1 9 1-1-1-1 2 1-1-1 9
Barrass
2013
1-1-1-1 2 1-1-1 9 1-1-1-1 2 1-1-1 9
Bleys 2008 Bleys 2008 1-1-1-1 2 1-1-1 9 .-.-.-. . .-.-. .
Goyal
2013
1-1-1-1 2 1-1-1 9 .-.-.-. . .-.-. .
Brooks
2001
Brooks
2001
0-1-1-0 2 1-0-0 5 1-0-1-1 2 1-1-0 7
Clark
1985
Clark
1985
0-1-1-0 0 0-0-0 2 .-.-.-. . .-.-. .
Coates
1988
Coates
1988
0-1-1-0 1 1-1-0 5 1-0-1-0 1 1-1-1 6
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Table 2. Risk of bias: observational studies (Continued)
Coates
1987
.-.-.-. . .-.-. . .-.-.-. . .-.-. .
Combs
1993
Combs
1993
0-1-1-0 2 1-0-0 5 .-.-.-. . .-.-. .
Comstock
1997
Comstock
1997
0-1-1-0 2 1-1-0 6 1-1-1-1 2 1-1-1 9
Dong
2008
Dong
2008
1-1-1-1 2 1-1-1 9 .-.-.-. . .-.-. .
Dorgan
1998
Dorgan
1998
0-1-1-1 2 0-1-0 6 1-1-1-1 2 1-1-1 9
Epplein
2009
Epplein
2009
0-1-1-1 2 1-1-0 7 0-1-1-1 2 1-1-1 8
Gill 2009 0-1-1-1 1 1-1-0 6 0-1-1-1 1 1-1-1 7
Fex 1987 Fex 1987 1-1-1-0 2 1-1-1 8 1-0-1-1 2 1-1-1 8
Fujishima
2011
Fujishima
2011
1-1-1-1 2 1-1-1 9 .-.-.-. . .-.-. .
Garland
1995
Garland
1995
0-1-1-1 2 1-1-1 8 1-1-1-1 2 1-1-1 9
Hunter
1990
0-1-1-1 2 1-1-1 8 1-1-1-1 2 1-1-1 9
Glattre
1989
Glattre
1989
0-1-1-0 1 1-1-1 6 1-1-1-1 1 1-1-1 8
Goodman
2001
Goodman
2001
0-1-1-0 2 1-1-0 6 1-1-1-1 2 1-1-1 9
Graff 2017 Graff 2017 0-1-1-1 2 1-1-0 7 1-1-1-1 2 1-1-1 9
Grund-
mark
2011
Grund-
mark
2011
1-1-1-1 2 1-1-1 9 .-.-.-. . .-.-. .
Han 2013 Han 2013 0-1-0-1 2 1-1-0 7 .-.-.-. . .-.-. .
Hansen
2013
Hansen
2013
0-1-1-1 1 1-1-1 7 .-.-.-. . .-.-. .
Hartman
1998
Hartman
1998
1-1-0-1 2 1-1-0 7 .-.-.-. . .-.-. .
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Table 2. Risk of bias: observational studies (Continued)
Hashemian
2015
Hashemian
2015
1-1-1-1 2 1-1-1 9 .-.-.-. . .-.-. .
Helzlsouer
2000
Helzlsouer
2000
0-1-1-1 1 1-1-0 6 1-1-1-1 1 1-1-1 8
Hughes
2015
Hughes
2015
1-1-1-1 2 0-1-0 7 0-1-1-1 2 1-1-1 8
Hughes
2016
Hughes
2016
1-1-1-1 2 0-1-1 8 0-1-1-1 2 1-1-1 8
Kabuto
1994
Kabuto
1994
0-1-1-1 2 1-1-0 7 0-1-1-1 2 1-1-1 8
Karagas
1997
Karagas
1997
0-1-1-1 2 1-1-1 8 1-1-1-1 2 1-1-1 9
Knekt
1990
Knekt
1990
1-1-1-1 2 1-1-1 9 0-1-1-1 2 1-1-1 8
Hakama
1990
1-1-1-1 2 1-1-1 9 0-1-1-1 2 1-1-1 8
Knekt
1988
1-1-1-1 2 1-1-1 9 0-0-1-1 2 1-1-1 7
Knekt
1996
1-1-1-1 1 1-1-1 8 0-1-1-1 1 1-1-1 7
Knekt
1991
1-1-1-1 2 1-1-1 9 0-1-1-1 2 1-1-1 8
Knekt
1998
Knekt
1998
1-1-1-1 2 1-1-1 9 0-1-1-1 2 1-1-1 8
Kok 1987a Kok1987b 1-1-1-1 2 1-1-1 9 1-0-1-1 2 1-1-1 8
Kok 1987a .-.-.-. . .-.-. . .-.-.-. . .-.-. .
Kornitzer
2004
Kornitzer
2004
1-1-1-0 1 1-1-1 7 1-1-1-1 1 1-1-1 8
Kristal
2014
Kristal
2014
1-1-1-1 1 1-1-1 8 1-1-1-1 1 1-1-1 8
Kromhout
1987
Kromhout
1987
1-1-1-0 2 1-1-1 8 .-.-.-. . .-.-. .
Li 2004a Li 2004a 0-1-1-1 2 0-1-1 7 1-1-1-1 2 1-1-1 9
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Table 2. Risk of bias: observational studies (Continued)
Ma 2017 Ma 2017 1-1-1-1 2 1-1-0 8 .-.-.-. . .-.-. .
Mc-
Naughton
2005
Mc-
Naughton
2005
1-1-1-1 1 1-1-0 7 1-1-1-1 1 1-1-1 8
Heinen
2007
1-1-1-1 2 1-1-1 9 .-.-.-. . .-.-. .
van der
Pols 2009
1-1-1-1 2 1-1-0 8 .-.-.-. . .-.-. .
Menkes
1986
Menkes
1986
0-1-1-1 2 1-1-0 7 1-1-1-1 2 1-1-1 9
Batieha
1993
0-1-1-1 2 1-1-0 7 1-1-1-1 2 1-1-1 9
Breslow
1995
0-1-1-1 2 1-1-0 7 1-0-1-1 2 1-1-1 8
Burney
1989
0-1-1-1 2 1-1-0 7 0-1-1-1 2 1-1-1 8
Helzlsouer
1996
0-1-1-1 2 1-1-0 7 0-1-1-1 2 1-1-1 8
Helzlsouer
1989
0-1-1-1 2 1-1-0 7 1-1-1-1 2 1-1-1 9
Ko 1994 0-1-1-0 2 1-1-0 6 1-1-1-1 2 1-1-1 9
Menkes
1986
.-.-.-. . .-.-. . .-.-.-. . .-.-. .
Schober
1987
0-1-1-1 1 1-1-0 6 0-1-1-1 1 1-1-1 7
Schober
1986
.-.-.-. . .-.-. . .-.-.-. . .-.-. .
Zheng
1993
0-1-1-1 2 1-1-0 7 0-1-1-1 2 1-1-1 8
Michaud
2002
Michaud
2002
1-1-1-1 2 1-1-0 8 0-1-1-1 2 1-1-1 8
Michaud
2005
Michaud
2005
0-1-1-1 2 0-1-0 6 1-1-1-1 2 1-1-1 9
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Table 2. Risk of bias: observational studies (Continued)
Muka
2017
Muka
2017
1-1-1-1 2 1-1-1 9 .-.-.-. . .-.-. .
Nomura
1987
Nomura
1987
1-1-1-1 2 1-1-1 9 1-1-1-1 2 1-1-1 9
Nomura
2000
Nomura
2000
1-1-1-1 2 1-1-1 9 1-1-1-1 2 1-1-1 9
O’Grady
2014
O’Grady
2014
1-1-1-1 2 1-1-1 9 .-.-.-. . .-.-. .
Outzen
2016
Outzen
2016
1-1-1-1 2 1-1-1 9 1-0-1-1 2 1-1-1 8
Overvad
1991
Overvad
1991
1-1-1-0 1 1-1-0 6 .-.-.-. . .-.-. .
Pantavos
2015
Pantavos
2015
1-1-1-1 2 1-1-1 9 .-.-.-. . .-.-. .
Park 2015 Park 2015 1-1-1-1 2 1-1-1 9 .-.-.-. . .-.-. .
Peleg 1985 Peleg 1985 1-1-1-1 1 1-1-0 7 1-1-1-1 1 1-1-1 8
Peters
2007
Peters
2007
0-1-1-1 2 1-1-0 7 1-1-1-1 2 1-1-1 9
Peters
2008
Peters
2008
0-1-1-1 1 1-1-1 7 .-.-.-. . .-.-. .
Asgari
2009
0-1-1-1 1 1-1-0 6 .-.-.-. . .-.-. .
Hotaling
2011
0-1-0-1 0 1-1-1 5 .-.-.-. . .-.-. .
Walter
2011
0-1-0-1 2 1-1-1 7 .-.-.-. . .-.-. .
Ratnas-
inghe
2000
Ratnas-
inghe
2000
1-1-1-1 2 1-0-0 7 0-0-1-1 2 1-1-1 7
Ringstad
1988
Ringstad
1988
1-1-1-1 2 1-1-0 8 1-1-1-1 2 1-1-1 9
Thomson
2008
Thomson
2008
0-1-1-1 2 0-1-0 6 .-.-.-. . .-.-. .
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Table 2. Risk of bias: observational studies (Continued)
Sakoda
2005
Sakoda
2005
0-1-1-0 1 1-1-0 5 1-1-1-1 1 1-1-1 8
Salonen
1984
Salonen
1984
1-1-1-1 2 1-1-1 9 0-1-1-1 2 1-1-1 8
Salonen
1985
Salonen
1985
1-1-1-1 2 1-1-1 9 1-1-1-1 2 1-1-1 9
Stein-
brecher
2010
Stein-
brecher
2010
1-1-1-1 2 0-1-0 7 1-1-1-1 2 0-1-1 8
Suadicani
2012
Suadicani
2012
0-1-1-1 2 1-1-1 8 .-.-.-. . .-.-. .
Sun 2016 Sun 2016 1-1-1-1 2 1-1-0 8 .-.-.-. . .-.-. .
van
den Brandt
1993
van
den Brandt
1993
1-1-1-1 2 1-1-1 9 .-.-.-. . .-.-. .
van
den Brandt
1994
1-1-1-1 2 1-1-1 9 .-.-.-. . .-.-. .
van
den Brandt
1993
1-1-1-1 2 1-1-1 9 .-.-.-. . .-.-. .
van
den Brandt
2003
1-1-1-1 2 1-1-1 9 .-.-.-. . .-.-. .
Zeegers
2002
1-1-1-1 2 1-1-1 9 .-.-.-. . .-.-. .
Steevens
2010
1-1-1-1 2 1-1-1 9 0-1-1-1 2 1-0 6
van Noord
1987
van Noord
1987
1-1-1-0 1 1-0-1 6 1-1-1-0 1 1-1-1 7
Virtamo
1987
Virtamo
1987
0-1-1-1 2 1-1-1 8 .-.-.-. . .-.-. .
Wei 2004 Wei 2004 1-1-1-1 1 1-1-1 8 .-.-.-. . .-.-. .
Mark 2000 1-1-1-1 1 1-1-1 8 .-.-.-. . .-.-. .
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Table 2. Risk of bias: observational studies (Continued)
Willett
1983
Willett
1983
1-1-1-0 2 1-1-0 7 1-1-1-1 2 1-1-1 9
Yoshizawa
1998
Yoshizawa
1998
0-1-1-1 2 1-1-1 8 1-0-1-1 2 1-1-1 8
Yu 1999 Yu 1999 0-1-1-1 2 1-1-0 7 1-1-1-1 2 1-1-1 9
Table 3. Results of observational studies not included in meta-analysis
Organ system Cancer Case
definition
Risk ratio es-
timate (high-
est vs lowest
exposure cat-
egory)
95% CI Selenium
marker
Sex Study
Gynaecologi-
cal
Cervix incidence 0.89 0.40 to 2.00 serum women Menkes 1986
(Batieha 1993)
1.10 n.r. serum Coates 1988
Gynaeco-
logical (with-
out breast)
incidence 0.96 n.r. serum Knekt 1990
Ovary incidence 0.87 0.25 to 5.26 serum Knekt 1990 (Knekt
1996)
1.22 0.44 to 3.38 toenail Garland 1995
0.58 0.2 to 1.7 serum Menkes 1986 (Helzl-
sour 1996)
1.00 0.73 to 1.37 suppl. intake Thomson 2008
Uterus incidence 1.38 0.62 to 3.08 toenail Garland 1995
Gastroin-
testinal
Gastrointesti-
nal tract (all)
incidence 1.00 n.r. serum/plasma both Coates 1988
Oesophageal
squamous cell
carcinoma
incidence 0.37 0.16 to 0.86 toenail both Steevens 2010
0.67 0.53 to 1.30 intake both Hashemian 2015
Oe-
sophageal ade-
nocarcinoma
incidence 0.76 0.41 to 1.40 toenail both Steevens 2010
207Selenium for preventing cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 3. Results of observational studies not included in meta-analysis (Continued)
Oesophagus incidence 0.56 0.44 to 0.71 serum both Wei 2004 (Mark
2000)
mortality 0.62 0.44 to 0.89 serum
mortality 0.35 0.16 to 0.81 serum both Wei 2004 (Wei
2004)
incidence 0.27 0.03 to 2.21 suppl. intake both Dong 2008
Gastric cardio
adenocarci-
noma
incidence 0.52 0.27 to 1.02 toenail both Steevens 2010
Oesophagus
and stomach
incidence 0.45 n.r. serum men Knekt 1990 (Knekt
1988)
incidence 0.67 n.r. serum women
Liver incidence 0.62 0.21 to 1.86 plasma men Yu 1999
0.41 0.23 to 0.72 serum both Hughes 2016
0.86 0.52 to to 1.43 intake both Ma 2017
0.95 0.51 to 1.76 men
0.70 0.26 to 1.90 women
mortality 0.50 0.28 to 0.90 toenail both Sakoda 2005
0.57 0.31 to 1.05 men
0.18 0.03 to 1.13 women
Pancreas incidence 0.08 0.01 to 0.56 serum men Menkes 1986 (Bur-
ney 1989)
0.83 0.40 to 1.67 women
0.58 n.r. serum men Knekt 1990
3.49 n.r. women
0.72 0.36 to 1.43 intake both Banim 2013
0.69 0.39 to 1.20 supplemental
intake
both Han 2013
Rectum incidence 0.625 n.r. serum men Nomura 1987
1.05 0.54 to 2.03 toenail both van den Brandt 1993
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Table 3. Results of observational studies not included in meta-analysis (Continued)
0.91 0.41 to 2.00 men
1.58 0.59 to 4.22 women
0.80 0.68 to 0.95 supplement
use
both Hansen 2013
1.09 0.63 to 1.89 serum both Hughes 2015
1.32 0.55 to 3.19 men
0.76 0.32 to 1.80 women
Urological
cancers
Renal cancer incidence 0.40 0.17 to 0.98 dietary intake both Banim 2013
Urinary tract
(all)
incidence 0.97 0.72 to 1.31 serum both Hotaling 2011
0.81 n.r. serum men Knekt 1990
4.12 n.r. women
Respiratory
tract
Cavum oris/
pharynx
incidence 5.43 n.r. serum both Menkes 1986
(Zheng 1993)
Skin Melanoma incidence 1.66 0.71 to 3.85 toenail women Garland 1995
0.90 0.30 to 2.50 serum both Menkes 1986 (Bres-
low 1995)
0.98 0.69 to 1.41 suppl. intake both Peters 2008 (Asgari
2009)
Any non-
melanoma
cancer
incidence 0.77 n.r. plasma both Clark 1985
Basal cell car-
cinoma
incidence 0.54 n.r. serum men Knekt 1990
1.55 n.r. women
0.80 0.10 to 4.5 serum both Menkes 1986 (Bres-
low 1995)
0.86 0.38 to 1.96 serum both McNaughton 2005
0.95 0.59 to 1.50 intake
Squamous cell
carcinoma
incidence 0.69 0.51 to 0.92 plasma both Combs 1993
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Table 3. Results of observational studies not included in meta-analysis (Continued)
0.60 0.20 to 1.50 serum both Menkes 1986 (Bres-
low 1995)
0.86 0.47 to 1.58 plasma both Karagas 1997
1.30 0.77 to 2.3 intake both McNaughton 2005
0.49 0.24 to 0.99 serum
Other Haematologi-
cal
incidence 0.60 n.r. serum/plasma both Coates 1988
incidence 0.95 0.75 to 1.20 suppl. intake both Walter 2011
Thyroid incidence 0.13 0.02 to 0.77 serum both Glattre 1989
0.15 0.0 to 5.0 men
0.12 0.01 to 1.11 women
1.35 0.99 to 1.84 intake both O’Grady 2014
1.23 0.71 to 2.12 men
1.14 1.65 to 2.02 women
n.r. = not reported.
A P P E N D I C E S
Appendix 1. Electronic search strategies
Database Date of most recent literature
search
Search strategy Comment
www.cancer.gov 4 Feb 2011 medication: selenium
indication: prevention
Cancerlit Oct 2004 1 selen* OR organoselen*
OR natriumselen*
2 random* OR placebo* OR
clinical trial* OR controlled
trial* OR controlled clinical
Now included in MEDLINE
database
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(Continued)
trial* OR double blind* OR
single blind*
3 epidemiologic stud*ORco-
hort OR case-control stud* OR
nested case-control* OR case-
control design* OR prospectiv*
4 2 OR 3
5 1 AND 4
Clinical Contents in Medicine
(CCMed)
4 Feb 2011 selen*ORorganoselen*ORna-
triumselen*
CENTRAL 2017, Issue 2 #1 MeSH descriptor: [Sele-
nium] this term only
#2 MeSH descriptor: [Sele-
nium Compounds] explode all
trees
#3 MeSH descrip-
tor: [Organoselenium Com-
pounds] explode all trees
#4 selen*
#5 #1 or #2 or #3 or #4
#6 MeSH descriptor: [Neo-
plasms] explode all trees
#7 (neoplasm* or cancer* or
tumor* or tumour* or car-
cino* or malignan* or ade-
nocarcinoma* or sarcoma* or
adenoma* or chondrosarcoma*
or fibrosarcoma* or dermatofi-
brosarcoma* or neurofibrosar-
coma* or hemangiosarcoma*
or leiomyosarcoma* or liposar-
coma* ormyosarcoma* or rhab-
domyosarcoma* or myxosar-
coma* or osteosarcoma* or lym-
phoma*)
#8 #6 or #7
#9 #5 and #8
metaRegister of Controlled Tri-
als (mRCT, www.controlled-
trials.com)
4 Feb 2011 selen AND cancer Now included in the ISRCTN
registry
Embase Ovid 2017 week 6 1 selenium/
2 selen*.mp.
3 selenium derivative/
4 methylseleninic acid/
5 methylselenium.mp.
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(Continued)
6 exp organoselenium deriva-
tive/
7 1 or 2 or 3 or 4 or 5 or 6
8 exp neoplasm/
9 (neoplasm* or cancer*
or tumor* or tumour* or car-
cino* or malignan* or ade-
nocarcinoma* or sarcoma* or
adenoma* or chondrosarcoma*
or fibrosarcoma* or dermatofi-
brosarcoma* or neurofibrosar-
coma* or hemangiosarcoma*
or leiomyosarcoma* or liposar-
coma* ormyosarcoma* or rhab-
domyosarcoma* or myxosar-
coma* or osteosarcoma* or lym-
phoma*).mp
10 8 or 9
11 7 and 10
12 exp clinical study/
13 crossover procedure/
14 double-blind procedure/
15 single-blind procedure/
16 cohort analysis/
17 observational study/
18 (random* or factorial* or
crossover* or cross-over* or
cross over* or placebo* or (dou-
ble adj blind*) or (singl* adj
blind*) or assign* or allocat*
or volunteer* or observ* or co-
hort* or prospectiv* or (case*
and control*)).mp
19 12 or 13 or 14 or 15 or 16
or 17 or 18
20 11 and 19
21 (exp animal/ or nonhuman/
or exp animal experiment/) not
human/
22 20 not 21
key:
[mp=
title, abstract, subject headings,
headingword, drug trade name,
original title, device manufac-
turer, drug manufacturer, de-
vice trade name, keyword]
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(Continued)
GermanCancer StudyRegister:
www.studien.de
Feb 2017 selen
MEDLINE (via Ovid) Jan 2017, week 4 1 Selenium/
2 exp Selenium Compounds/
3 exp Organoselenium Com-
pounds/
4 selen*.mp.
5 1 or 2 or 3 or 4
6 exp Neoplasms/
7 (neoplasm* or cancer*
or tumor* or tumour* or car-
cino* or malignan* or ade-
nocarcinoma* or sarcoma* or
adenoma* or chondrosarcoma*
or fibrosarcoma* or dermatofi-
brosarcoma* or neurofibrosar-
coma* or hemangiosarcoma*
or leiomyosarcoma* or liposar-
coma* ormyosarcoma* or rhab-
domyosarcoma* or myxosar-
coma* or osteosarcoma* or lym-
phoma*).mp
8 6 or 7
9 5 and 8
10 randomized controlled trial.
pt.
11 controlled clinical trial.pt.
12 randomized.ab.
13 placebo.ab.
14 drug therapy.fs.
15 randomly.ab.
16 trial.ab.
17 groups.ab.
18 exp case-control studies/
19 exp Cohort Studies/
20 (cohort* or observ* or
prospectiv* or (case* and con-
trol*)).mp
21 10 or 11 or 12 or 13 or 14
or 15 or 16 or 17 or 18 or 19 or
20
22 9 and 21
23 exp animals/ not humans.sh.
24 22 not 23
key:
mp=title, abstract, original ti-
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(Continued)
tle, name of substance word,
subject heading word, keyword
heading word, protocol supple-
mentary concept, rare disease
supplementary concept, unique
identifier
pt=publication type
ab=abstract
fs=floating subheading
SIGLE Oct 2004 ?selen? database discontinued in 2005
ISRCTN Registry
(www.isrctn.com)
Feb 2017 selen AND cancer
ClinicalTrials.gov Registry
(www.clinicaltrials.gov)
Feb 2017 selen AND cancer
Appendix 2. Newcastle-Ottawa Scale for Cohort Studies
((*) means that a ’star’ was assigned to the study for the corresponding item)
1) Selection
1.1) representativeness of the exposed cohort
a) truly representative of the average ˙˙˙˙˙˙˙˙˙˙˙˙˙ (target population) in the community (*)
b) somewhat representative of the average ˙˙˙˙˙˙˙˙˙˙˙˙˙ (target population) in the community (*)
c) selected group of users, e.g., volunteers / nurses
d) no description of the derivation of the cohort
1.2) selection of the non-exposed cohort
a) drawn from the same community as the exposed cohort (*)
b) drawn from a different source
c) no description
1.3) ascertainment of selenium exposure
a) secure record (biochemical records) (*)
b) structured interview (*)
c) written self report or medical record only
d) no description
1.4) demonstration that outcome of interest was not present at start of study
a) no history of disease or exclusion of cases that occurred in the first 12 months (*)
b) not stated
2) Comparability
2.1.) comparability of cohorts on the basis of the design or analysis
a) study controls for AGE (*)
b) study controls for SMOKING (*)
3) Outcome
3.1) assessment of outcome
a) independent blind validation (> 1 person/record/time/process to extract information or reference to primary source such as X-rays/
hospital records) (*)
b) record linkage (e.g., ICD codes in databases) (*)
c) self report
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d) no description
3.2) Was follow-up long enough for outcomes to occur?
a) yes (> 3 years)
b) no
3.3) adequacy of follow up of cohorts
a) complete follow-up of all subjects (*)
OR
b) subjects lost to follow-up unlikely to introduce bias (< 5% lost to follow-up or description provided of lost people) (*)
c) follow-up-rate < 95% and no description of those lost
d) no statement
Appendix 3. Additional Newcastle-Ottawa Scale for Nested Case-Control Studies
((*) means that a ’star’ was assigned to the study for the corresponding item)
1) Selection
1.1) case definition
a) independent validation (> 1 person/record/time/process to extract information or reference to primary source such as X-rays/hospital
records) (*)
b) record linkage (e.g., ICD codes in databases) or self-report with no reference to primary record
c) no description
1.2) representativeness of cases:
a) all eligible cases with outcome of interest over a defined period, cases in a defined catchment area/hospital etc. or an appropriate/
random sample of those cases (*)
b) not satisfying requirements in part (a) or not stated
1.3) selection of controls:
a) community controls (same community and would be cases if had outcome) (*)
b) hospital controls (within the same population e.g., city as cases)
c) no description
1.4) definition of controls
a) cases had no history of outcome controls had no history of outcome OR case had new (not necessarily first) occurrence of outcome
controls with previous occurrence of outcome should not be excluded (*)
b) no mention of history of outcome
2) Comparability
(validated in cohort assessment in question 2 - number of stars was copied)
3) Exposure
3.1) ascertainment of selenium exposure:
(validated in cohort assessment in question 1.3 - number of stars was copied)
3.2) Same method of ascertainment for cases and controls
a) yes (*)
b) no
3.3) non-response rate
a) same rate for both groups (*)
b) non-respondents described
c) rate different and no designation
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F E E D B A C K
2 Selenium for preventing cancer, 30 October 2014
Summary
Comment: Selenium for preventing cancer; The Cochrane Library 2014, Issue 3 Vinceti M, Dennert G, Crespi CM, Zwahlen M,
Brinkman M, Zeegers MPA, Horneber M, D’Amico R, Del Giovane C
We are pleased to see that a revised version of the review has now been published though it has taken longer than we would have wished.
In the updated review, the authors have remedied some of the shortcomings which we pointed out, but not all. I have attached detailed
comments on what we think still needs to be changed and hope that these points can be remedied in the very near future.
Comments by section are given below.
Abstract
1. Selection criteria refer to including RCTs with “healthy adult participants”. However, it is clear that SELECT was the only trial that
included “healthy adult participants”, all other trials included participants with a high risk of cancer (Li, Yu 1991, Yu 1997, Marshall,
Algotar, Dreno) or a previous history of cancer (NPCT 2002, Reid 2008). The word “healthy” should be removed and the statement
should be modified to reflect the high proportion of participants at high risk of cancer.
2. The main results of the pooled analysis of RCTs overwhelmingly reflect the results of by far the largest trial, SELECT. However,
SELECT was carried out in a population of high selenium status. This needs to be mentioned either under “Main results” or under
“Authors’ conclusions”. Not to mention it is to ignore a fact that is likely to be highly relevant to the outcome.
3. The “Authors’ conclusions” assert that there is “little evidence of any influence of baseline selenium status”, but that lack of evidence
all relates to trials in populations of much higher baseline selenium status than the NPCT where such an effect was seen: baseline
plasma Se was 114 µg/L in the NPCT compared to 126.1 µg/L in Algotar and 135.2-138.1 µg/L in Marshall. [No such effect was seen
in SELECT, but baseline selenium status was also high - 136 µg/L (Kristal et al. 2014).]
Plain language summary
The sentence that begins “Recent trials that were judged to be well conducted and reliable… “ should be modified to read “Recent trials
that were judged to be well conducted and reliable, though conducted in high-selenium populations, have found no effects of selenium
supplementation on reducing the overall risk of cancer or on reducing the risk of particular cancers, including prostate cancer”.
Main text
Page 5 column 2: We previously pointed out that having inclusion criteria that allowed RCTs of only four-weeks’ length to be included
is unjustifiable. While no studies as short as that were included, clearly a four-week intervention with Se is insufficient to alter cancer
risk so what is the justification retaining this inclusion criterion?
Page 21 column 1: We previously objected to the description of an increased risk of diabetes mellitus type 2 being found in SELECT
yet such a description is there again: “An increase in diabetes mellitus type 2 was seen in the selenium-alone group (RR 1.07, 99% CI
0.94 to 1.22)”, despite the confidence interval spanning 1. The only trial in which an increased risk of type-2 diabetes was seen was
the NPCT. The authors also refer to a short-term effect of selenium supplementation on type-2 diabetes risk. However, there is no
mention, either here or elsewhere, of our RCT that found no increased risk of type-2 diabetes in 500 people treated with 100, 200
or 300 µg selenium or placebo for a period of six months (Rayman et al. A randomized trial of selenium supplementation and risk of
type-2 diabetes, as assessed by plasma adiponectin. PLoS One. 2012;7:e45269).
Page 20-21: There should have been some mention of baseline selenium status in this section. Clearly SELECT was showing evidence
of toxicity, which is unsurprising given the high baseline status and substantial level of supplementation.
Page 23 column 2: In discussing the change from a protective to a possibly detrimental effect, the authors should be aware of the
possibility of a threshold effect that may relate to a mechanism dependent on selenoprotein concentration/activity. Furthermore,
discussing the relationship between selenium status and the risk of non-melanoma skin cancer and type-2 diabetes in the same breath
ignores the likelihood of totally different mechanisms applying.
Page 23 column 2: The sentence “Little evidence of a beneficial effect of selenium supplementation was noted among participants with
the lowest baseline selenium exposure (plasma selenium < 106 µg/L) in either the prostate cancer trial of Marshall et al. (Marshall
2011) or the prostate cancer trial of Algotar et al. (Algotar 2013), despite the fact that 45% of the participants in that study had
baseline plasma selenium levels < 123 µg/L - the suggested threshold for beneficial effects of selenium supplementation according to
the NPCT (NPCT 2002)”, should be qualified by pointing out that both the Marshall and Algotar trials were in men at high risk for
prostate cancer and in whom prostate cancer was probably already initiated. Thus this is not an appropriate test for evidence of benefit
of selenium supplementation for primary prevention in those with low selenium status.
216Selenium for preventing cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Page 24 column 2: SNPs could be mentioned as a potential explanation of “the … unexplained heterogeneity in the reaction of
participants’ plasma selenium levels to selenium supplementation”.
Page 25 column 1: As explained in our criticisms of the primary review, we and others profoundly disagree with the statement that
“measurements of nutritional intake might provide better exposure estimates than do biomarkers, which may considerably mis-classify
the exposure to inorganic and organic selenium sources”. This is particularly true of exposure to selenium where food concentration
data differ very considerably from one part of the world to another and many countries have no such data.
Page 28 column 1: The paragraph that contains the sentence “These ideas stimulated the largest ever cancer prevention trial, SELECT,
which failed to provide support for this hypothesis, and two additional prostate cancer trials (Algotar 2013; Marshall 2011),whose
results were in line with the SELECT findings in failing to find a beneficial effect of selenium”, needs to point out that SELECT,
Algotar 2013 and Marshall 2011 were all carried out in high-selenium populations and that Algotar 2013 and Marshall 2011 were
both in men at high risk of prostate cancer.
Page 29 column 2: It is not especially accurate or informative to say that the Blot and Hercberg trials produced divergent results.
Although they were both RCTs, they used very different designs in hugely different populations with different baseline selenium levels.
It could equally fairly be said that they produced comparable results in that they both saw beneficial effects (of one sort or another).
Page 30 column 1: Karp was a secondary prevention trial in lung-cancer patients. In relation to that trial, there should be some mention
of the likely difference in mechanisms of primary prevention and those relevant to prevention of secondary tumours in already initiated
patients.
Page 30 column 1: the previous RCT that found no increased risk of type-2 diabetes in 500 people treated with 100, 200 or 300 µg
selenium or placebo for a period of six months should be mentioned (Rayman et al. A randomized trial of selenium supplementation
and risk of type-2 diabetes, as assessed by plasma adiponectin. PLoS One. 2012;7:e45269).
Page 30 column 1: Under the heading, “Implications for practice”, it should be made clear that the “Results from the most recent
randomised controlled trials, which were carried out in men and had a low risk of bias” were all in men of high selenium status.
Page 30 column 2: Under “Implications for research”, there is a statement that needs qualifying, “whether selenium might influence
cancer risk in individuals with very low or very high baseline exposure to this element …….. have not been fully resolved, although
currently available evidence from randomised trials offers little support for such hypotheses”. It needs to be acknowledged that there
are no cancer trials of selenium as a single nutrient in people with low baseline selenium status.
Even if the results of SELECT are expanded to look at other endpoints, they will still not apply to low-selenium populations and cannot
compare truly low to higher levels; this also needs to be specified.
A question that remains ignored by this review, by design, is whether selenium in combination with other agents may be beneficial in
cancer. This deserves some sort of comment under “Implications for research”.
Errors
Page 4, column 2: Though we pointed out in our previous set of comments that SU.VI.M.AX was incorrect, it has not been corrected.
Page 6 column 2: 78.96 is described as the molecular weight of selenium; it should be atomic weight.
Page 28 column 2: we have previously pointed out that selenium supplement are not aggressively marketed to women with regard to
breast cancer prevention and treatment.
Contributors (in alphabetical order):
Professor Regina Brigelius-Flohé, University of Potsdam, German Institute of Human Nutrition Professor GF Combs Jr, Grand Forks
Human Nutrition Research Center, ARS/USDA, USA Dr Cindy D Davis, Office of Dietary Supplements, NIH, USA Dr Fiona R
Green, Reader in Functional Genomics, University of Surrey, UK Professor John Hesketh, Institute for Cell & Molecular Biosciences,
University of Newcastle, UK Professor Josef Köhrle, Charité Universitätsmedizin Berlin, Germany Dr Alan Kristal, Fred Hutchinson
Cancer Research Center, Seattle, USA Professor Margaret Rayman, Faculty of Health and Medical Sciences, University of Surrey,
UK Professor Lutz Schomburg, Charité Universitätsmedizin Berlin, Germany Dr Phil Taylor, Division of Cancer Epidemiology and
Genetics, NCI, USA Piet van den Brandt, Professor of Epidemiology, Maastricht University, The Netherlands Professor David J.
Waters, Purdue University, USA Professor Phil Whanger, Oregon State University, USA
I agree with the conflict of interest statement below:
I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of
my feedback.
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21-1-2015
We wish to thank Dr. Brigelius-Flohé and colleagues for their interest in our Cochrane review on selenium for preventing cancer.
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Before addressing the specific points in their letter, we would like to clarify that our publication Vinceti et al. ‘Selenium for preventing
cancer, Cochrane Database Syst Rev. 2014 Mar 30;3:CD005195’ was not a revised version of the previous Cochrane but rather an
update, taking into account the additional three years of scientific literature on the topic, according to standard procedures of the
Cochrane Collaboration.
With regard to the use of the term ‘healthy’ in RCTs, we used the term ‘healthy’ adult participants to mean that the (adult) individuals
enrolled in the studies were free at the beginning of the trial from the disease representing the primary outcome, an incident cancer, as
required when we deal with primary prevention trials. Being at high, low or intermediate risk of cancer, or affected by any other disease,
or previously affected by another cancer, was not considered to be an exclusion criteria and did not preclude the term ‘healthy’ with
respect to the trial outcome(s), which in all cases consisted of the incidence of a primary cancer. In our review, we specifically listed
in detail the enrolment criteria for the trials, and before performing the meta-analysis we excluded studies retrieved with our literature
search that were not based on healthy adults (397 studies removed - see Figure 1 of our review). Being ‘totally’ healthy- i.e., apparently
free from any disease and at a low risk for cancer or other chronic disease, was not a selection criteria for any of the selenium (Se) trials,
including SELECT itself (for example, we used the term ‘apparently healthy men’ for the SELECT population in page 23).
As noted by Brigelius-Flohé et al., the pooled analysis is obviously influenced by the largest trial, SELECT, and this is even more true
when we limited the analysis, as recommended by the Cochrane review guidelines, to the trials at low risk of bias. SELECT has been
of fundamental importance in selenium (Se) research for its large size, long follow-up, and broad range of outcomes, all of which are
important for defining the so far uncertain relation between Se and primary prevention of cancer and the adverse health effects of
the metalloid. Results from SELECT, which are continuing to emerge in the literature (Kristal et al., JNCI; Martinez et al., Cancer
Prev Res; Albanes et al., Cancer Prev Res 2014), in addition to other recent relevant trials (Karp et al., 2013), have been systematically
confirmed by all the high-quality, low-bias trials so far carried out (some of which could unfortunately not be included in our review,
having been published after our literature search deadline), with the exception of the excess high-grade prostate cancer risk in the
Se-supplemented individuals with the highest baseline selenium status recently reported in SELECT (Kristal et al., JNCI 2014), an
unexpected and concerning finding so far not investigated in the other trials with the partial exception of Marshall et al. (Cancer Prev
Res 2011).
Assuming that the SELECT population was a group with ‘high Se status’ while NPC subjects had a low Se status, and suggesting
that their different results were likely due to this, as claimed by Brigelius-Flohé et al., is not well-founded. Defining a low-Se status
and a high-Se status is very subjective and debatable, but whatever approach is chosen, no such difference between these two trial
populations emerges. We would argue that the more important distinctions between the two trials are that one had low risk of bias
and high statistical power (SELECT), while the other one had high risk of bias and much lower power (NPC). The two trials also
used different Se preparations. In fact, if we estimate Se intake though its relation with serum/plasma level computed with the rule
of thumb proposed by Haldimann et al. (J Trace Elem Med Biol 1996) in the 30-120 µg/l of plasma or serum Se, average baseline
dietary exposure corresponding to their blood Se levels was around 90 µg/day for SELECT participants, and 76 for NPC subjects. If
we compare these values to the Se recommended dietary intake (or comparable indexes defined as ‘recommended intake level’, ‘dietary
reference value’, ‘average nutrient requirement’ etc.), both are well above these reference values for Se, whether using the 26-34 µg/day
recommended intake of the World Health Organization and Food Agriculture Organization (WHO-FAO 2004), the 25-35 µg/day
range of the Japanese Ministry of Health Labour andWelfare (2005), the 55 µg/day of the US Institute of Medicine and Food Nutrition
Board (2000), the 70 µg/day of European Food Safety Authority (EFSA 2014) or the 55 µg/day of the Italian Human Nutrition Society
(SINU,Milan 2014). For a comprehensive review of this issue we refer to among other sources the Eurreca database at www.eurreca.org,
Cavellaars et al., Eur J Clin Nutr 2010, Vinceti et al. 2013 Sci Total Environ, and to the EFSA journal, 2014. Thus, according to
all of these standards, both the SELECT and NPC populations should be defined as having a ‘high Se status’. This would be further
strengthened should we use the 110 µg/L serum Se cutpoint for Se toxicity (increased prevalence of depressive symptoms and higher
levels of urinary 8-oxo-7,8-dihydroguanine) recently suggested by two observational studies (Galan-Chilet et al., Free Rad Biol Med
2014 and Conner et al., J Nutr 2014): according to such threshold values, all the RCTs included in our review including SELECT and
NPC, with the exception of the Chinese ones, should be considered as carried out in populations with ‘very high’ Se status.
In our review, given the uncertainties and complexity of the issue, we consciously avoided labelling the populations in RCTs as low or
high Se status, preferring instead to report baseline exposure levels and to use relative measures for their comparison (such as ‘lower
status’, ‘the lowest exposure category’ instead of ‘low Se status’, and the converse for higher exposures). This was done particularly for
the most influential studies in the review, the RCTs, to facilitate assessment of whether baseline Se exposure may influence the response
to Se supplementation in terms of cancer risk and comparison of distributions of baseline Se exposure. We refer Brigelius-Flohé et al. to
our analysis in the review (pages 22/24), which found the following points, among others: themarginal difference in intake of around 15
µg/day between the SELECT and NPC populations, in contrast with usual differences of Se intake at the population and the individual
level, which span hundreds of micrograms; the occurrence of adverse effects even in the trials with the lowest baseline exposure level,
such as the increased incidence of skin cancer in NPC and of type 2 diabetes in all trials which so far investigated this outcome; and the
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considerable overlap of Se exposure levels between the various RCTs. Finally, in our review we had to state that ‘analyses stratified by
baseline Se status are not available for SELECT: Such analyses would greatly help to elucidate this issue.’ Fortunately, such evaluation
(though so far only for prostate cancer) has been subsequently published (Kristal et al., JNCI 2014, and specifically its table 4). As it
happens, their finding based on quintiles of baseline Se exposure is consistent with our previous assessment. In fact, the abstract of that
paper reported that ‘Se supplementation did not benefit men with low Se status but increased the risk of high-grade PCa among men
with high Se status.’
When programming the update of this Cochrane review, we decided not to further restrict the inclusion criteria for studies compared
with the 2011 review, but rather to relax them somewhat. For example, meta-analysis was carried out for site-specific cancer types when
only 2 randomised trials were available. We even discussed whether to include trials reported only as abstracts and not in extenso, but
decided against this due to lack of consensus, even though this precluded consideration of at least two possible relevant RCTs, the Karp
et al. trial for prevention of second primary tumours in patients with resected lung cancer (Karp et al., J Clin Oncol 2010) and a trial
on the risk of cancer in BRCA1 carriers (Lubinski et al., Hered Cancer Clin Pract 2011). We agree with Dr. Brigelius-Flohé et al. that
a trial with only 4 weeks of supplementation would be very unsatisfactory, even in case of ‘mega-dose’ Se administration, and such a
dosage scheme would not have passed un-remarked upon in our literature review, had we found such a study.
As far as Brigelius-Flohé et al. comments about the excess diabetes incidence in SELECT among subjects allocated to Se administration,
we are surprised to see this objection: reporting and commenting on the adverse effects of RCTs is mandatory according to the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins JPT andGreen S, Chapter 4 ‘Adverse effects’) andmore generally according
to ethical and scientific issues. We also note that Brigelius-Flohé et al. when commenting on the excess diabetes incidence rely entirely
on statistical significance testing (‘..despite the confidence interval spanning 1’), an approach generally considered to be inappropriate
for evaluating findings from epidemiologic studies (Sterne and Davey Smith, BMJ 2001; Rothman, Greenland and Lash, Modern
Epidemiology 2008; Stang, Poole and Kuss, Eur J Epidemiol 2010), especially for adverse effects that the studies were not necessarily
powered to detect. The excess diabetes risk was one of the concerning findings yielded by SELECT (Vinceti et al., Rev Environ Health
2009), mirroring the observation of an increased diabetes incidence detected in the previous NPC trial (Stranges et al., 2007). We also
noted that such excess risk was found in all four RCTs that investigated this outcome, and this was also supported by some biological
plausibility, though we did not carry out an in-depth investigation of the diabetes & Se relation, for which we refer to recent literature
(Steinbrenner 2013; Vinceti et al., J Trace Elem Med Biol 2015). Contrary to the claims of Brigelius-Flohé et al., we did not mention
the 2012 Rayman et al. trial published in PLoS One for the obvious reason that it did not include cancer nor diabetes among the
outcomes under investigation.
The comment by Brigelius-Flohé et al. stating that ‘Clearly SELECT was showing evidence of toxicity, which is unsurprising given the
high baseline Se status and substantial level of supplementation’ is also unfounded. Being ourselves among the few investigators who
have systematically reviewed the human health risks of chronic low-dose Se overexposure, (Vinceti et al., Rev Environ Health 2001
and 2009; Vinceti et al., Sci Total Environ 2013; Vinceti et al., Toxicol Lett 2014), we must point out that the upper limit of ‘safe’ Se
exposure was and is set at a higher level than that of the SELECT study groups allocated to Se administration, i.e. at 400 µg/day (US
Institute of Medicine 2000; World Health Organization Food Agriculture Organization 2004, and the Office of Dietary Supplements
of the National Institute of Health accessed at ods.od.nih.gov/factsheets/Selenium-HealthProfessional/ on January 20, 2015).
Brigelius-Flohè et al. challenge discussing the excess risk of diabetes and of non-melanoma risk cancer ‘in the same breath’ since this
would ‘ignore the likelihood of totally different mechanisms’. This misrepresents the review, which makes no claim that risk of non-
melanoma skin cancer and diabetes operate through the same mechanisms.
Brigelius-Flohè et al. state that the participants in the Marshall et al. and Algotar et al. studies were at high risk for prostate cancer (as we
mentioned in our review) and that prostate cancer was probably already initiated in them. The participants in these trials were biopsy-
negative for prostate cancer, and therefore the latter statement by Brigelius-Flohè et al. is speculation not supported by the available
evidence. Contrary to the claims of Brigelius-Flohè et al., the Marshall et al. 2011 trial and the Algotar et al. 2013 trial were important,
not only since they confirmed key results of SELECT trial, but also since they addressed the issue of influence of baseline Se status
on the effect of Se supplementation on (prostate) cancer risk. We refer Brigelius-Flohè et al. to pages 23 and 24 of our review where
we analyzed this issue in-depth, and specifically to the following text: “Little evidence of a beneficial effect of Se supplementation was
noted among participants with the lowest baseline Se exposure (plasma Se < 106 µg/L) in either the prostate cancer trial of Marshall
et al. (Marshall 2011) or the prostate cancer trial of Algotar et al. (Algotar 2013), despite the fact that 45% of the participants in that
study had baseline plasma Se levels < 123 µg/L-the suggested threshold for beneficial effects of Se supplementation according to the
NPCT (NPCT 2002)”. In addition, as previously mentioned, a 2014 report published after final submission of our review showed
that SELECT subjects in the lowest baseline status categories did not benefit from Se supplementation with regard to (prostate) cancer
risk, though they did not experience the increased risk of high-grade prostate cancer induced by the Se supplementation observed in
the highest exposure groups (Kristal et al. JNCI 2014).
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We did not mention SNPs as a potential explanation of “the ... unexplained heterogeneity in the reaction of participants” since we were
specifically reporting the comments of Ashton et al. Am J Clin Nutr 2009, who did not primarily focus on this possibility. However, as
Brigelius-Flohè et al. may note from several statements within our review, we agree about the potential importance of SNPs, and this
is why we frequently mention the potential role of genetic factors in our review.
Page 25, column 1 (assessment of Se exposure): though we could not review in-depth all studies concerning methods for assessing Se
exposure and related issues, we wanted to mention the human studies finding an association between dietary and biomarker Se, those
unable to find it, and the advantages and limitations of all these approaches.We refer Brigelius-Flohè et al. to specific reviews or research
papers on this important issue, which show that inadequate Se exposure classification made on the basis of dietary intake or of hair,
blood, urine and toenail levels may have had a major role in the inconsistencies among various observational studies and between the
observational and the experimental investigations. We stand behind the brief statement in our review concerning Se exposure assessment
methods in the human body.
Contrary to the claims of Brigelius-Flohé et al., the Blot and Hercberg trials indeed produced divergent results, and the statement
about these two trials that ‘both saw beneficial effects’ is untrue. Though the effects of these trials administering (different) mixtures
of vitamins and minerals and carried out in very different populations cannot be adequately summarized in few words, it can be easily
appreciated that the Chinese trial found beneficial effects on decreased mortality, mainly due to reduced cancer rates (especially for
stomach cancer) (Blot et al., JNCI 1993 and Am J Clin Nutr 1995) while the second trial found beneficial, null and adverse effects
of supplementation overall as well as specifically for cancer (Hercberg et al., Arch Intern Med 2004 and Br J Nutr 2006). Among the
adverse effects following supplementation, Hercberg et al. found an alteration of the lipid profile (Hercberg et al., Lipids 2005) and an
increase in melanoma incidence (Hercberg et al., J Nutr 2007), later shown to decrease during the post-intervention follow-up, further
supporting a causative role of the treatment (Ezzedine et al., Eur J Cancer 2010). However, since these two trials did not include an
intervention arm receiving Se alone, they were excluded from our meta-analysis as were all trials that administered Se together with
other substances. They were included in a different Cochrane review (Bjelakovic et al. Cochrane Database Syst Rev 2012).
Page 30, column 1: contrary to the statements of Brigelius-Flohé et al., the Karp et al. trial, published in extenso in J Clin Oncol 2014,
was not a secondary prevention trial, but a primary prevention trial, as we indicated in our review. As literally abstracted from the Karp
paper, study objectives were “to evaluate the efficacy of Se supplementation in reducing the incidence of lung second primary tumors in patients
who had been treated for stage I non-small-cell lung cancer; to evaluate the qualitative and quantitative toxicity of daily Se supplementation;
and to compare the incidence of specific cancers, mortality from cancer, and overall survival of patients treated with Se supplementation versus
placebo”. The study population was therefore comparable to that of the NPC trial in the sense that both included participants with
a recent history of cancer: the first trial comprised 1561 individuals who had been treated for stage I non-small-cell lung cancer with
complete surgical resection, while the second RCT included 1312 individuals with a history of two or more basal cell carcinomas or
one squamous cell carcinoma of the skin, with one of these occurring within the year prior to randomization. We note that the results
of the low-bias Karp et al. trial, which could not be meta-analyzed in our review having been published in extenso beyond the literature
search deadline, were fully consistent with the conclusions of our review.
Brigelius-Flohé et al. state that ‘A question that remains ignored by this review, by design, is whether Se in combination with other
agents may be beneficial in cancer’. As they correctly recognize, this was not included among the objectives of our review. However,
we agree with Brigelius-Flohé et al. concerning the use of selenium compounds in cancer therapy warranting strong attention and in-
depth investigation, as stated in our section ‘Se as a potential cancer therapeutic agent’ in Vinceti et al., J Environ Sci Health C Environ
Carcinog Ecotoxicol Rev 2013. However, caution must be used when addressing this issue, also due to the concerning results of a recent
study in patients affected by nonmetastatic prostate cancer, where supplementation of ≥140 µg/day Se was found to be associated with
excess mortality from prostate cancer (Kenfield et al., JNCI 2015).
We wish to thank Brigelius-Flohé et al. for their search for typos and mistakes in our 193 page review. They claim that three errors
were found; however, these were not errors. The acronym SU.VI.M.AX was sometimes used by the authors of that trial, and we used
it in our review only when citing a reference titled with that form of the acronym (Arnaud et al., J Trace Elem Med Biol 2007),
while we used the more common ‘SU.VI.MAX’ for the remaining papers. As far as the 78.96 ‘molecular weight’ of Se is concerned,
we recognize that the adjective ‘atomic’ is more commonly used than ‘molecular’, but the latter may also be used in connection with
‘weight’ for Se, as it may be observed at the PubChem Open Chemistry database of the US National Institute of Health (http://
pubchem.ncbi.nlm.nih.gov/compound/Se, accessed January 20, 2015) or the USCenter for Disease Control and Prevention - National
Institute for Occupational Safety and Health website (http://www.cdc.gov/niosh/docs/81-123/pdfs/0550.pdf, accessed January 20,
2015). Finally, aggressive marketing of Se supplements for breast cancer can be detected through a simple Google Internet search.
Admittedly, this is also true for other cancers, including of course prostate cancer, and more generally for chronic disease or conditions
claimed to be due to oxidative stress and alleged to be prevented by Se. However, such marketing approaches differed depending on
the diseases, populations, sources of information, strategies, and periods involved, and were not analyzed because they were outside the
scope of our current review.
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Contributors
Marco Vinceti, Gabriele Dennert, Catherine M Crespi, Marcel Zwahlen, Maree Brinkman, Maurice PA Zeegers, Markus Horneber,
Roberto D’Amico, Cinzia Del Giovane
Selenium for preventing cancer, 23 November 2011
Summary
Re: Dennert et al., Selenium for preventing cancer, The Cochrane Library, 2011, Issue 5. As selenium scientists with considerable
knowledge of the selenium-cancer field, we wish to draw to the attention of The Cochrane Collaboration the shortcomings of the
recent review cited above. We contend that the quality of this review is not up to the expected standard of Cochrane systematic reviews.
We are not criticising the way in which the analyses were performed, but rather the ways they were interpreted and summarised, which
we believe to be overly negative and rather biased. For these reasons, we find the resulting report to be misleading to the reader. Some
of the weaknesses are listed below.
Abstract and Plain Language Summary:
These sections do not fairly represent the findings of the review. Contrary to the impression given in these summaries, the review itself
demonstrates that there is in fact a considerable body of evidence, much of it from prospective observational studies, for a beneficial
effect of selenium on a number of cancers. The stated summary of RCT findings is more conclusive than it should be, given the very
small number of published clinical trials with selenium alone and the limited trial data that the review authors arbitrarily chose to
consider. Furthermore, the NPCT is treated very harshly, and its secondary findings (lung, colorectal and prostate cancers) are more or
less discounted.
Body of the Paper:
1. Lack of appreciation of the importance of baseline selenium status in influencing trial outcomes (i.e. the fact that only people with
a low selenium status profited from supplementation). For example, no acknowledgement was made of the fact that lack of benefit
of a 200 µg/d dose of selenium for cancer risk in SELECT occurred in participants with relatively high baseline serum selenium
concentrations-well above those found to confer benefit from selenium supplementation in the NPC trial (NPCT). This point was
raised by us previously (Rayman et al. JAMA 2010).
2. Lack of discrimination between trials in which supplementation with selenium had the capacity tomaximise selenoprotein expression/
concentration (e.g., NPCT) and those (e.g., SELECT) in which selenoprotein expression/concentration would already have been
maximised at baseline.
3. Lack of appreciation that, despite the high selenium status of SELECT men, the effects of selenium supplementation on type 2
diabetes risk were not significant.
4. Failure to understand that biomarkers of selenium status are considerably more reliable than dietary data, which we know to be
much more error-prone.
5. Frequent failure to distinguish between significant and non-significant findings.
6. Lack of familiarity with the relevant selenium literature.
7. No mention of oesophageal or gastric cardia cancer results (although RCT results for these are not based on selenium alone) and, in
relation to colorectal cancer, no mention of adenoma data.
8. In ’Implications for research’, no mention is made of the need to carry out randomised controlled trials in low-selenium populations,
nor to take into consideration selenoprotein genotype, which has been shown to affect selenium metabolism. The relevance of the
species of selenium administered in various trials is not mentioned.
Reply
The authorswish to thank the colleaguesDoctorsBrigelius-Flohé,Combs,Davis,Green,Hesketh,Köhrle, Kristal, Rayman, Schomburg,
Taylor, van den Brandt, Waters and Whanger for their detailed commentary on the selenium review.
Their comments captured some of the same concerns that we had regarding the methodological challenges associated with conducting
a systematic review in the field of selenium and cancer.
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In response to the commentary, we will first address concerns related to the specific setting of this review as a Cochrane review and will
then respond to concerns regarding the content of the review.
We strongly agree with the concerns that it is difficult to capture all differentiations elaborated on by the review in the abstract and
summary, which are limited to a certain length. Similarly, length limitations were applied to the background section. We also share
the opinion that some headings in the review do not adequately reflect the content of the text that follows. For readers who have
not authored Cochrane reviews themselves, we wish to explain that Cochrane reviews are submitted in an electronic format that does
not allow for all adaptations authors might wish to make. The headings, for example, cannot be changed. This electronic format is
optimised for reviews on intervention studies. Our review included both RCTs and epidemiological studies, and so we encountered
several structural challenges throughout the review process. We hope that both the commentary of our colleagues and our experiences
will contribute to the continuing work of advancing the structural processes of The Cochrane Collaboration, including the electronic
software Review Manager, and to developing a more inclusive format for reviews, which encompasses epidemiological studies.
Has the condensation of information in the abstract and the plain text summary led to a distortion in the presentation of the review
results?
The abstract and the plain text summary present to readers the body of evidence that was reviewed as the main results for both study
questions. Our aim was to report the answers to our research questions, and although space was a limitation for the abstract and
summary results sections, we have endeavoured to provide across the entire review all the best available evidence for the role of selenium
in preventing cancer.
We agree with our colleagues that no studies can be found on the association of selenium with cancer in children or on the preventive
efficacy of selenium supplements in children. Hence, as stated in the abstract, there is currently no convincing evidence that selenium
supplementation may prevent cancer in children. However, we are completely happy not to mention children in the abstract if this
may be considered misleading.
We agree with our colleagues that long-term supplementation is more likely than short-term supplementation to influence cancer risk,
if any effect exists. The minimum of four weeks has been chosen arbitrarily. However, no consistent current agreement has indicated
where to draw the line between short-term and long-term selenium supplementation, so any cutoff would be arbitrary to some extent.
In addition, we wished to avoid making assumptions about supplementation effects in our inclusion criteria and decided rather to
address the question of the effect of shorter supplementation periods in the review discussion, if any trial would have been identified.
To our knowledge, there is currently no universal recommended daily allowance for selenium intake or upper tolerable level; therefore
recommending a selenium dose or level of safe intake would not be appropriate in this instance. This is clearly an area for further
research, taking into account some of the potential influencing factors cited in our review (e.g., baseline levels, gender, population,
source). We would like to thank the commentators for the hint to the RNI (reference nutrient intake) values for selenium in the UK,
which we are happy to include in a future update of the review. Nevertheless, regarding the RNI, we would like to draw attention to the
latest draft of a position paper on selenium by the Scientific Advisory Committee on Nutrition (2011), which notes “that the selenium
dietary reference value was set on very limited data and could be set too high” (p74).
Dr Brigelius-Flohé and colleagues commented that “Quoted recommendations such as 30 and 40 µg/d for men and women (WHO
2004) are no longer credible to anyone with up-to-date knowledge of the endpoints and biomarkers (SePP, GPx activity) that we have
in 2011. There is no justification for quoting the Vinceti 2009a opinion that 20 µg/day organic selenium should be the maximum safe
level.”
The suggestion of an upper safe limit of organic selenium of 20 µg/d was made by Vinceti et al. on the basis of preliminary results of
the ORDET study (Vinceti 2009b), published in 2010 (Stranges 2010), and of other studies (please see for a review Vinceti 2009a).
The recent availability of new data on endocrine (Lippman 2009; Stranges 2007) and dermatological (Lippman 2009) toxicity of low
doses of organic selenium adds new findings supporting the recommendations by the WHO Group. We would like to draw attention
to other recent studies on selenium toxicity (reviewed by Vinceti 2009a and Nogueira/Rocha 2011) and the issue of risk assessment
of selenium (including the use of uncertainty factors (UF) or alternative approaches) (Aggett 2010; Douron 2010; Renwick 2006;
Renwick/Walker 2008).
The diverse recommendations and the controversial discussions clearly underline the need for a systematic review in this field.
To address our research question-What evidence exists on the efficacy of selenium supplementation for cancer prevention?-we restricted
our focus to RCTs with mono-selenium supplementation. Multicomponent interventions, such as those chosen in the SU.VI.MAX,
involve several nutritional/antioxidant supplements (e.g., 120 mg of ascorbic acid, 30 mg of vitamin E, 6 mg of beta carotene, 100
µg of selenium, and 20 mg of zinc in SU.VI.MAX), some of which are reportedly thought to have a potentially synergistic effect
with selenium (Willett 1983); others may act as antagonists (Schrauzer/White/Schneider 1977) or may have an unknown biological
interaction. Although all these factors are important considerations for the overall efficacy of selenium in the long term, we thought
that inclusion of these studies in attempts to elucidate an actual anticarcinogenic role for selenium in its own right could potentially
conceal the true effects (positive or negative) of selenium. By including the four studies that were mentioned in the commentary, which
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used multicomponent interventions, we may have gained numbers but lost out in trying to elucidate the actual effects of selenium.
Therefore, these RCTs, which use selenium in combination with other nutritional factors, were outside the scope of the current review
process but have been addressed in the background and discussions and could be the focus of future valuable investigations.
To avoid any potential preferential and non-systematic selection of studies and hence results, we established a set of a priori inclusion
criteria during the initial stages of the study design. These were outlined in the protocol of the review, which has been available on The
Cochrane Library website and for comment since 2005.
The details of all selenium supplementation have been reported for each RCT, including the form of selenium when available, and
we emphasised the importance of carefully evaluating the different biological activity and toxicity of each selenium compound. Please
refer to the plain language summary: “In general there are two types of selenium supplements: one type uses the salt of selenium as the
main ingredient, the other type uses organic selenium. These two types may act differently in the human body when ingested,” and
in the RCTs and preventive efficacy section: “Interpretation of the results of clinical trials using selenium supplements should consider
the different biological forms as well as their potential differential health effects when supplemented”; and please refer to the table
Characteristics of included studies, for details on each RCT.
References are made throughout the review text to the baseline selenium status of study participants and potential interactions with
study results. Please refer to Section 2.3. Adverse effects, “The RR for developing type II diabetes mellitus was higher in the participants
in the upper two tertiles of plasma selenium levels, indicating a possible interaction with baseline exposure status”, for instance, or
page 38 in our review: “SELECT participants had a higher selenium level at randomisation than men in the NPCT. While the mean
plasma selenium concentration was 113 to 114 µg/L in the NPCT, median serum concentration was 135 to 138 µg/L in the different
study arms in SELECT. Lower prostate cancer incidence in the NPCT trial was confined to men with baseline selenium levels in the
lower two thirds (below 121 µg/L). Subgroup analyses of the SELECT trial are underway to investigate a possible modification by pre-
intervention selenium levels“.
Regarding the findings of NPCT and SELECT for type 2 diabetes, we would like to refer our readers to Section 2.3. Adverse effects, “A
statistically non-significant increase in diabetes mellitus type II in the selenium-alone group (HR 1.07 (99% CI 0.94: 1.22)) was seen.
An increased risk for diabetes mellitus type II was also observed in the NPCT (Stranges 2007, in: NPCT 1996). A secondary analysis
of participants who did not have diabetes at start of the study revealed an excess risk in the selenium group (adjusted HR 1.55 (95% CI
1.03 to 2.33))”. We have previously outlined the section that referred to the fact that selenium baseline levels were higher in this group
and would like to cite the original paper by Stranges et al. (2007), which stated: “Despite the lack of statistically significant interactions
between treatment group and baseline co-variates, the risk for type 2 diabetes was consistently higher in the selenium group within all
subgroups of baseline age, sex, smoking
status, and BMI.” (p220). Regarding the issue of a potential diabetogenic effect of selenium supplements and gender, we would like
to draw attention to a recent observational cohort study by Stranges (2010), which documented an excess risk of diabetes among a
large cohort of women from Varese, Northern Italy. Such a diabetogenic effect of selenium is also supported by suggestive laboratory
evidence, recently reviewed by Steinbrenner al. (2011).
Lippman et al. (2009) stated in their publication about the SELECT trial: “The data and safety monitoring committee had some
concern over the statistically non-significant increase in prostate cancer in the vitamin E-alone group (P=.09 per interim data of August
1, 2008) and over a non-significant increase in diabetes mellitus associated with selenium (P=.08 per interim data of August 1, 2008)”
(p45).
The observation from SELECT (Klein 2011) that the effect diminished over time may suggest exactly the opposite to that hypothesised
by Dr Brigelius-Flohé and colleagues. A decrease in the diabetogenic effect of selenium administration over time after interruption
of such administration may well indicate a decreasing adverse effect over time, as expected, of a causal association. This was what
occurred in the SU.VI.MAX study, in which administration of selenium/vitamins C-E/beta-carotene/zinc led to an excess incidence of
skin cancer, including melanoma (Hercberg 2004), which entirely disappeared after interruption of the intervention (Ezzedine 2010).
The investigators interpreted such decreasing risk as an indication of the causal effect of the treatment of skin cancer and the origin of
melanoma (Ezzedine 2010).
Regarding the interaction of baseline PSA levels with selenium effects in the NPCT, we would like to quote the original publication:
“The protective effect of SS [selenium supplements; GD] appeared to be confined to those with a baseline PSA level of <= 4 ng/
mL (0.35, 0.13-0.87), although the interaction of baseline PSA and treatment was not statistically significant“ (p608, Duffield-Lillico
2003a). To summarise, no statistically significant interaction was noted between baseline PSA levels and prostate cancer incidence, as
reported by the study authors.
Dr Brigelius-Flohé highlighted a sentence on page 4 that might be misunderstood if taken out of its context (“risk ratios (RRs) with
confidence intervals (CIs) were not calculated because of low numbers”). Our colleagues rightly stated that Hercberg et al. (2004)
provided hazard ratios for cancer incidence by gender. However, the sentence our colleagues quoted from our review reads in the context
as follows: “In the more recent French SU.VI.M.AX trial (Hercberg 2004), a supplementation with beta-carotene, vitamin C, vitamin
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E and 100 µg selenium-enriched yeast did not alter the incidence of cancer of the digestive tract after a median period of 7.5 years in
women. In men, the incidence rate was lower in the intervention group than in the placebo group, but risk ratios (RRs) with confidence
intervals (CIs) were not calculated because of low numbers”. The part of the sentence our colleagues cited about the men’s incidence
rate refers to cancer of the digestive tract. Site-specific cancer rates were not calculated or reported by gender: “We were not able to
analyze differences in site-specific cancers between men and women because of low statistical power” (p2340, Hercberg 2004).
Our colleagues highlighted another sentence on page 39: “Results from two randomised controlled trials (NPCT and SELECT) have
failed to provide evidence that non-melanoma skin cancer or prostate cancer can be prevented by selenium supplementation in men”.
This statement refers to the primary study outcomes of both investigations, which were non-melanoma skin cancer in NPCT and
prostate cancer in SELECT, and is correct. Contrary to what was stated by Dr Brigelius-Flohé and colleagues, the outcome measures in
the NPCT were incident basal cell carcinomas and squamous cell carcinomas, and recurrent skin tumors were excluded from analysis,
as summarised in the report of the primary NPCT endpoint by Duffield-Lillico et al. (2003b). We clearly stated in our review that the
NPCT was carried out among non-melanoma skin cancer participants at baseline.
Our conclusions have been based on the available evidence, and we have highlighted the paucity of literature and data available
from RCTs. Please refer to the ’Implications for research’ section: “Potential differential effects of sex/gender and the use of selenium
supplements in populations with a high burden of specific types of cancer diseases and differing selenium exposure levels, e.g., known
low nutritional selenium intake, require further examination”.
Dr Brigelius-Flohé and colleagues have also expressed concerns regarding our inclusion criteria for epidemiological studies and the ways
results of epidemiological studies were included and presented in the systematic review.
In reply to their concern, we might have omitted three relevant studies for gastrointestinal cancers; we would like to refer them to the
detailed references to both studies, Mark 2000 andWei 2004, throughout the review. The Steevens (2010) study has not been included,
as it was not available at the time of our review process and submission to The Cochrane Collaboration Group (please refer to Methods
section, Search strategy). As reported in Section 1.1.6 of the review, the strength of association varied according to what was included
in analyses (e.g., cardia vs non-cardia cancers, gender), thus preventing any clear and concise conclusion to be drawn between selenium
levels and upper gastrointestinal cancers in the observational summary results.
As we understood the publications Wei 2004 and Mark 2000, Wei 2004 reports on a population that was part of the population at risk
in Mark 2000. Participants in Wei 2004 were the disease-free controls for the cases of Mark 2000. Because of this overlap, we decided
to report the papers jointly and put emphasis on the detailed description of both papers and their study populations (please refer to
the Characteristics of included studies).
Dr Brigelius-Flohé and colleagues criticised inclusion in the review of observational studies assessing selenium exposure as intake (e.g.,
with food frequency questionnaires).
Regarding the problems associated with dietary assessment, please refer to the section ’Bias and confounding’: “Assessment of total
selenium intake from food-frequency questionnaires (FFQ) or interviews has proven difficult in other investigations because of the lack
of food composition data which adequately reflects regional and seasonal variations in selenium concentration”. Additionally, “The
FFQ overestimated the mean selenium intake in study participants when compared with laboratory analyses of duplicate meals” and
”Validity problems, possibly leading to misclassification, have also been reported when questionnaires are used to assess supplement
use”.
However, studies using dietary assessment add a valuable perspective to the discussion of the relationship between selenium exposure
and cancer risk. Furthermore, in addition to the literature cited by Dr Brigelius-Flohé, other studies (van den Brandt PA et al, 1993;
Longnecker et al., 1996; Haldimann et al., 1996) have reported a direct correlation between dietary and body selenium (please also see
for a review of this topic Vinceti et al. 2000b and Vinceti et al. in press).
We consider the issue of selenium exposure assessment to be more complex than has been implicated by our colleagues´ comments.
Assessment of selenium intake, despite the difficulties associated with its variability and possible individual variability in absorption, in
some cases might even yield better estimates of actual exposure compared with biomarkers. This adds an important perspective to the
discussion of why several observational studies have suggested a protective effect of higher selenium exposure towards cancer risk and
others have not.
With regard to toxicity, animal studies have demonstrated that the intake of equivalent amounts of selenium, when administered in
different species, might induce a stronger effect even when retained to a lesser extent (Panter et al., 1996), as shown for the inorganic
compounds. The wealth of toxicological data from laboratory studies is clearly and, for obvious ethical reasons, much greater than those
yielded by human studies. The same is true for studies investigating tissue distribution and biological activity of the different selenium
compounds (see: Hatfield/Berry/Gladyshev 2012). We consider references to laboratory and animal studies as a necessary and valuable
contribution to the understanding of selenium effects in humans.
Dr Brigelius-Flohé and colleagues asked why our summary of the findings of the review of Ashton (2009) on the use of biomarkers for
seleniummeasurement did not mention singular nucleotide polymorphisms (p34 in our review).We summarised the findings of Ashton
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2009 that were relevant for the discussion of bias and confounding in our review. Genetic polymorphisms were not included in the
analyses of heterogeneity between study results by Ashton (2009). Instead, Ashton et al. proposed singular nucleotide polymorphisms in
their discussion as an area for future research and stated: “Also, for all potential biomarkers, more information is needed to understand
the limitations of applicability for different population groups, the possible effects of genotype, supplementation doses, duration,
baseline status, etc” (p2037S).
The criticism that we failed to distinguish between significant and non-significant findings in epidemiological studies points to
a fundamental difference in the interpretation of epidemiological study results. Indeed, we consider ‘statistical’ significance as an
inappropriate approach to data analysis and interpretation with regard to observational studies, as has been long recognised (RothmanKJ
1978; Sterne/Davey Smith 2001; Greenland 2011), with no connection with ‘biological significance’. Pitfalls of statistical significance
testing encompass dismissing so called ‘non-significant values´ in small studies or putting undue emphasis on ‘statistically significant’
results without attempting to integrate potential biases for a study finding that would affect the estimates from that study (see: e.g.,
Rothman, Greenland & Lash 2008; Stang/Poole/Kuss 2010). This may lead to confusion between the validity of an investigation and
its statistical stability.
Analysis and interpretation of results in biomedical research must be based on a number of considerations, comprising both study
design and data analysis. We made a conscious effort in our selenium review to avoid use of an approach that dichotomised study results
according to which were statistically significant and which were not. We consider this effort a major strength of our review.
We have attempted to be prudent with our conclusions by highlighting important considerations associated with the results of
epidemiological studies that we reported. Both the current literature and our review indicate that although some associations have been
noted between selenium levels and risk of cancer at certain body sites (e.g., prostate, bladder), more research and information are clearly
required before it can be concluded that these results are “convincing” for a protective effect of selenium. The World Cancer Research
Fund’s Second Expert Report (2007) also suggests the possibility of residual confounding between selenium levels and healthy lifestyles
(p109).
We admit that the sentence about themarketing situationof selenium in our discussion section expresses a valuation, andwe acknowledge
that other colleagues might assess the marketing situation differently and as such might disagree with this sentence.
In the last part of our reply, we will address the concerns by Dr Brigelius-Flohé and colleagues regarding the content of the background
section of the review.
The reference Rodriguez 1995, which is listed in the MEDLINE database, in contrast to what our colleagues stated (please refer to
PubMed ID 7605824), is an early study that investigated urinary selenium in healthymen and women and addressed the study question
of the relationship between factors such as gender/sex, etc., and urinary selenium. It found gender/sex differences in urinary selenium
excretion, as well as influences of health behaviours (physical activity), as stated in our background text.
We do not agree that studies investigating primarily the relationship between selenium status, thyroid volume and gland echostructure
(Derumeaux 2003) or the relationship between baseline plasma selenium concentration and occurrence of dysglycaemia (Akbaraly
2010) would have been more suitable references for the statement that we made regarding gender differences.
We also would like to recapitulate the Vinceti et al. (2000a) paper because we feel that Dr Brigelius-Flohé and colleagues misreported
the methods and findings of this study. The Vinceti et al. studies in an unusual Northern Italy setting evaluated the health effects
of selenium in its inorganic hexavalent form-the one usually found in underground and drinking water-together with the tetravalent
species (Vinceti 2010). This study was a ‘natural experiment’, considered to be ‘the paradigm of non-experimental epidemiologic
research’, as in this type of study, ‘nature emulates the sort of experiment the investigator might have conducted, but for ethical and
cost constraints’ (p94, Rothman/Greenland/Lash 2008). Study authors assessed the potential for confounding by lifestyle by assessing
the socioeconomic status of exposed and unexposed cohorts, and labeling this study as a natural experiment was allowed only after the
similarity of the two populations was confirmed. Dr Brigelius-Flohé stated that Vinceti et al. admitted that their results are consistent
with “no effect”, as standardised mortality ratios were generally inconsistent between men and women at most sites, and most site-
specific estimates had limited precision. The citation in the original publication reads: “The results of our study are consistent with either
no effect or, particularly among the elderly, unfavourable effects of long-term exposure to inorganic selenium on cancer mortality”.
Then Vinceti et al. analyzed the strengths and limitations of their study, both for the melanoma association and more generally for the
effects on cancer risk. Excess melanoma risk, despite different study designs and strengths of association, has been documented to be
associated with selenium exposure in a number of studies (Garland 1995; Vinceti 1998; Duffield-Lillico 2002; Vinceti et al., in press)
and has been causally associated with administration of selenium in combination with zinc and vitamins in SU.VI.MAX (Hercberg
2007). In general, we would like to propose caution when dealing with the possible selenium-melanoma association.
In conclusion, we express our appreciation to our commentators for scrutinising our review, offering their criticisms and supporting the
scientific endeavour of enclosing epidemiological as well as intervention studies in a Cochrane review. We are hopeful that the review
and the commentary of our colleagues will contribute to the important and continuing discussion about the health effects of selenium
and selenium supplements globally and in diverse populations.
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Further discussion on ’Selenium for preventing cancer’
Summary
We are pleased with your positive response to our concerns and the expressed willingness of the review authors to make changes as
appropriate. In particular, we welcome the following proposed modifications.
• A more accurate (and longer) abstract and plain language summary to take account of the concerns we specified in our letter and
in the first of our “General criticisms”.
• Modification of the review by ensuring that differences in baseline selenium exposure between trials are clarified and placed in
the proper context.
• More careful use of language in relation to statistical significance, as, for instance, in the two examples you cite in your letter.
The preferred form you quote is much better than the misleading use of “lower” or “higher” for “non-significant” effects, as occurred
frequently in the review.
• Removal of constraints on the use of section headings so that more appropriate headings can be used.
There is little point in revisiting all of our criticisms as they were clearly set out in our original letter and document, and most still
stand. We would like to see the review amended as soon as possible to take account of those criticisms and specifically to correct the
inaccuracies that we have noted. The review authors have replied with a number of points that we would like to challenge.
• p2: Re the suggestion of an upper safe limit of organic selenium of 20 µg/d by Vinceti et al., the authors now justify the original
inclusion of that statement on the basis of a study (ORDET) based on a semiquantitative FFQ at baseline and follow-up for
development of type 2 diabetes 16 years later. Based on that same study (p4), the authors refer to “Such a diabetogenic effect of
selenium…”. A prospective study, especially one with a very weak study design such as ORDET, can only show an association-hardly
a good basis for making such a statement in a Cochrane review. Furthermore, an upper safe limit of organic selenium of 20 µg/d
would be just above that at which Keshan disease is seen-11 µg/d in a Chinese man, which translates to 14 µg/d in a man of Western
body weight.[1]
• p2: The authors say, “The recent availability of new data about endocrine (Lippman 2009; Stranges 2007) and dermatologic
(Lippman 2009) toxicity of low doses of organic selenium adds new findings which support the recommendations by the WHO
group.” The authors seem still not to have taken on board the fact that Lippman et al. 2009 doesnot show any endocrine toxicity of
selenium. Furthermore, the dose given-200 µg/d-was not low.
• p4: Diminution of the effect on type 2 diabetes over time. Proper interpretation of SELECT is that there was a null result during
the trial (RR 1.07, P value 0.16) and a similarly null result with postintervention follow-up time included (RR 1.04, P value 0.34). If
trial-only data versus post-trial-only data were compared, it is probably unlikely that there would be any difference statistically.
However, we do understand the point the review authors make: Interpretation depends on how one thinks selenium acts. If we were
talking about an effect that occurred immediately after starting a drug (e.g. platelet effect of aspirin, blood pressure reduction from
antihypertensive) and stopped more or less immediately after cessation of the drug, then the review authors’ interpretation would
have better credibility.
• In contrast to the week or so that the effect of aspirin on platelets lasts, selenomethionine has a long half-life of 252 d [363 d
(turnover time) × 0.693 (from kinetic modelling)] (Swanson et al. AJCN 1991, 54:917-26). In medicine, when calculating dosing
intervals for drugs, it is typical to give doses every five to six half-lives. When first-order kinetics is applied, five half-lives for total
body selenium is 1260 days (3.45 years), and six half-lives is 1512 days (4.14 years). Although it is true that the amount of the
original dose still remaining is small after five (6.25%) or six (3.13%) half-lives, excess residual selenium remains from the
supplementation. So, on the basis of both observed effects with cancer and pharmacokinetic data, the events that occurred in the
post-trial period for SELECT participants (34 additional months) should still be considered a period of selenium exposure and
thereforeincompatible with the review authors’ hypothesis.
• p6: We hotly dispute the assertion of the review authors (none of whom is a nutritionist) that “The assessment of selenium
intake, despite the difficulties associated to its variability and the possible individual variability in absorption, in some cases might
even yield better estimates of actual exposure compared with biomarkers”.
• p7: Gender differences: The Schomburg references would have been preferable; Schomburg is the accepted authority in this area.
We very much hope that our original comments and those contained in this letter will help the review authors, guided by the editors,
to revise the review, so that it sits more comfortably with the opinion of experienced investigators in the selenium-cancer field.
Yours sincerely,
Professor Regina Brigelius-Flohé, University of Potsdam, German Institute of Human Nutrition
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Professor GF Combs Jr, Grand Forks Human Nutrition Research Center, ARS/USDA, USA
Dr Cindy D Davis, Office of Dietary Supplements, NIH, USA
Dr Fiona R Green, Reader in Functional Genomics, University of Surrey, UK
Professor John Hesketh, Institute for Cell & Molecular Biosciences, University of Newcastle, UK
Professor Josef Köhrle, Charité Universitätsmedizin Berlin, Germany
Dr Alan Kristal, Fred Hutchinson Cancer Research Center, Seattle, USA
Professor Margaret P Rayman, Faculty of Health and Medical Sciences, University of Surrey, UK
Professor Lutz Schomburg, Charité Universitätsmedizin Berlin, Germany
Dr Phil Taylor, Division of Cancer Epidemiology and Genetics, NCI, USA
Professor Piet van den Brandt, Department of Epidemiology, Maastricht University, The Netherlands
Professor David J Waters, Purdue University, USA
Professor Phil Whanger, Oregon State University, USA
[1] National Academy of Sciences, Institute ofMedicine’s Food and Nutrition Board, Dietary Reference Intakes for Vitamin C, Vitamin
E, Selenium and Carotenoids.
http://fnic.nal.usda.gov/nal˙display/index.php?info˙center=4&tax˙level=4&tax˙subject=256&topic˙id=1342&level3˙id=5141&
level4˙id=10591.
Reply
We would like to thank Drs Brigelius-Flohé and colleagues for their continuing interest in our research activity on selenium.
We decided to shortly respond to some of their discussion points (citations from Dr Brigelius-Flohé et al are provided in italics):
• “more careful use of language in relation to statistical significance as, for instance, in the two examples you cite in your letter. The
preferred form you quote is much better than the misleading use of “lower” or “higher” for “non-significant” effects as occurred frequently in
the review”
Dr Brigelius-Flohé and colleagues do not acknowledge the limitations of their approach based on ‘statistical significance’ (please refer to
the references provided in our previous reply). Their approach appears to have had major consequences for a number of considerations
and statements in their two letters. It is of interest to note that even the SELECT “Data and Safety Monitoring Committee” expressed
its concern “over a non-significant increase in diabetes mellitus associated with selenium (P = 0.08 per interim data of August 1, 2008)”
(cited from Lippman et al., JAMA 2009), which we consider a very correct approach given the decision-making responsibility of such
a Committee.
“The authors have replied with a number of points that we would like to challenge“
• p2: ”Re the suggestion of an upper safe limit of organic selenium of 20 µg/d by Vinceti et al., the authors now justify the original
inclusion of that statement on the basis of a study (ORDET) based on a semi-quantitative FFQ at baseline and follow-up for development of
type-2 diabetes 16 years later. Based on that same study (p4), the authors refer to “Such a diabetogenic effect of selenium….”. A prospective
study, especially one with a very weak study design such as ORDET, can only show an association-hardly a good basis for making such a
statement in a Cochrane review. Furthermore, an upper safe limit of organic selenium of 20 µg/d would be just above that at which Keshan
Disease is seen-11 mg/d in a Chinese man, which translates to 14 µg/d in a man of Western body weight.
As written in our original response, the suggestion of a safe upper limit of 20 µg/L was based on the ORDET study results already
availableand published as an abstract in Epidemiology in 2009. Stating that theORDET study, one of the first andmost methodologically
sound European prospective studies, started in the 1980s by the Italian National Cancer Institute in Milan, was ‘weak’ is unacceptable.
Its methodological value has been largely recognised in the scientific community and in the epidemiological literature.
Our review, however, never aimed at summarising the large epidemiological and laboratory literature addressing the issue of safe upper
limit of Se exposure in humans, particularly the most recent studies.
• p2: The authors say, “The recent availability of new data about endocrine (Stranges 2007; Lippman 2009) and dermatologic
(Lippman 2009) toxicity of low doses of organic selenium adds new findings which support the recommendations by the WHO group.” The
authors seem still not to have taken on board the fact that Lippman et al. 2009 shows no endocrine toxicity of selenium. Furthermore, the
dose given-200 mg/d-was not low.
The relation between selenium and excess diabetes risk is an extremely important issue that clearly would require extensive review, but
this was not the aim of our Cochrane review;therefore we would like to refer Dr Brigelius-Flohé and colleagues to themost recent studies
and reviews on the topic. It would also be useful to remind Dr Brigelius-Flohé and colleagues that the SELECT trial found an excess
risk of diabetes, which understandably caused concern for its “Data and safety monitoring Committee” (see above) and contributed to
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the anticipated ending of the trial. We took note that Dr Brigelius-Flohé and colleagues do not consider the SELECT supplemental
dose of 200 mg/Se/d to be a ‘low’ dose; actually, it was so high that it could be toxic.
• p6: “We hotly dispute the assertion of the authors (none of whom is a nutritionist) that “The assessment of selenium intake, despite the
difficulties associated to its variability and the possible individual variability in absorption, in some cases might even yield better estimates of
actual exposure compared with biomarkers”.
Different exposure assessment methods have different advantages and disadvantages. What we stated in our review was, “A concern,
which we cannot clarify to date, is that biomarkers do not adequately reflect intake of both organic and inorganic selenium species”.
We still think there is currently no way of clarifying this.
We were very surprised in reading comments such as ‘None of the authors is a nutritionist’, not just because this is incorrect (one of the
review authors, MB, is an accredited and practicing dietician and nutritionist), but also for the underlying and clearly ‘biased’ concept:
that the right to conduct independent research should be determined by subjective value judgements by one’s peers.
Despite the detailed comments made by Dr Brigelius-Flohé et al regarding key statements we have made and details of the studies we
have identified in preparing the review, we remain convinced that the conclusions drawn from the original version of the review remain
valid: We have not demonstrated a protective effect of selenium against cancer in men, women or children.
Contributors
Marco Vinceti, Maree Brinkman, Gabriele Dennert and Marcel Zwahlen on behalf of the review authors.
WH A T ’ S N E W
Last assessed as up-to-date: 8 February 2017.
Date Event Description
22 January 2018 Amended Minor edit to affiliation
18 January 2018 New citation required but conclusions have not changed Addition of some recent references and minor edits.
8 February 2017 New search has been performed New literature search conducted 8 February 2017.
H I S T O R Y
Protocol first published: Issue 2, 2005
Review first published: Issue 5, 2011
Date Event Description
3 February 2015 Feedback has been incorporated Feedback and trial author’s response added
18 March 2014 New citation required but conclusions have not
changed
New trials added. Meta-analysis of data from RCTs ap-
plied when at least 2 studies were available for each out-
come
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(Continued)
15 February 2013 New search has been performed Search strategy updated
14 August 2012 Feedback has been incorporated Additional feedback and trial author’s response incor-
porated
8 March 2012 Feedback has been incorporated Feedback submitted and trial author’s reply added
C O N T R I B U T I O N S O F A U T H O R S
1. MV co-ordinated the current update, commented on the protocol and the review, screened search results, appraised study bias,
and updated the draft in collaboration with the other review authors.
2. TF and CDG extracted data from the added papers, appraised study bias, conducted data analyses, commented on the review,
wrote part of the draft, and provided a methodological perspective.
3. CDG commented on the review, appraised study bias, prepared the ’Summary of findings’ (GRADE) table, wrote part of the
draft, and provided a methodological perspective.
4. GD is the primary author of the first version of the review and was involved in all steps of the present update, including
commenting on the protocol and the manuscript, extracting data from papers, and providing a methodological perspective.
5. MZw commented on the protocol and the review and provided a methodological perspective.
6. MB commented on the protocol and provided feedback at various stages of the review.
7. MZe commented on the protocol and the review and provided feedback on different portions of these documents.
8. MH commented on the protocol, extracted data from papers, and commented on the review text at various stages of the review.
9. RDA commented on the protocol and provided feedback at various stages of the review.
10. CMC commented on the protocol and on the review, wrote part of the draft, and provided a methodological perspective.
All review authors have reviewed and approved the final draft of this update.
D E C L A R A T I O N S O F I N T E R E S T
1. MV: none known.
2. TF: none known.
3. CDG: none known.
4. GD: none known.
5. MZw: none known.
6. MB: none known.
7. MZe: Maurice Zeegers is the first investigator and the coauthor of included observational and experimental studies.
8. MH: none known.
9. RDA: none known.
10. CMC: none known.
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Emilia, Modena. The funding source had no role in designing, conducting, or writing this systematic review. The contents of this
systematic review are solely the responsibility of the review authors and do not necessarily represent the official views of this
Department.
External sources
• Dr. Ernst und Anita Bauer Foundation, Germany.
This work was partially funded by the Dr. Ernst and Anita Bauer Foundation. The funding source had no role in designing,
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of Health.
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designing, conducting, or writing this systematic review. The contents of this systematic review are solely the responsibility of the
review authors and do not necessarily represent the official views of LILT-Reggio Emilia.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the previous Cochrane review, review authors adapted the risk of bias assessment for RCTs, which was introduced by Cochrane after
publication of our protocol; we used the Jadad score and the Delphi list to assess the quality of RCTs, but because the results of these
checklist assessments were of no relevance for this review, we have omitted them.
With respect to the protocol, in this second updated review (as well as in the previous update), we decided to perform meta-analysis of
RCTs when at least two studies were available, and to emphasise the analysis conducted for all RCTs and for RCTs at low risk of bias,
to highlight the most reliable and recent evidence on the selenium and cancer relation, which comes from well-designed experimental
studies. As in the previous version of the review, we included in our analysis both primary and secondary outcomes of RCTs, as well
as adverse effects reported in these studies. Furthermore, we updated the methods section to clarify that the main ‘primary’ analysis
included analyses examining low risk of bias trials only, and ‘sensitivity analyses’ consisted of analyses that included all trials, regardless
of risk of bias.
In this update, we included a ’Summary of findings’ table for RCTs with low risk of bias, and one for observational studies.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Case-Control Studies; Neoplasms [∗prevention & control]; Observational Studies as Topic; Odds Ratio; Randomized Controlled Trials
as Topic; Selenium [∗administration & dosage; adverse effects]; Sex Factors; Trace Elements [∗administration & dosage; adverse effects]
MeSH check words
Female; Humans; Male
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